UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 20-F

(Mark One)

 [  ]REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 [X]

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 20192020

 

OR

 [  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 [  ]SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report

 

Commission file number: 000-55135

 

POET TECHNOLOGIES INC.

(Exact name of Registrant as specified in its charter)

 

Ontario, Canada

(Jurisdiction of incorporation or organization)

 

1107 – 120 Eglinton Avenue East

Toronto, Ontario, M4P 1E2, Canada

(Address of principal executive offices)

 

Suresh Venkatesan, CEO

 

Email: svv@poet-technologies.com

(Name, Telephone, Email and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act: None.

 

Securities registered or to be registered pursuant to Section 12(g) of the Act: Common Stock, no par value.

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: Not Required.

 

The number of outstanding shares of common stock, no par value, as of December 31, 20192020 was 288,363,553294,618,104

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. [  ] Yes [X] No

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

 

Yes [  ] No [X]

 

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

[X] Yes [  ] No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in the Exchange Act.

 

 Large accelerated filer [  ]

Accelerated filer [X]

Emerging Growth Company [X]Non-accelerated filer [  ] 

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S GAAP [  ]

International Financial Reporting Standards as issued

by the International Accounting Standards Board [X]

Other [  ]

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

 

☐ Item 17        ☐ Item 18

[  ] Item 17            [  ] Item 18

 

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ] Yes No

[X]

 

 

 

 

POET TECHNOLOGIES INC.

FORM 20-F ANNUAL REPORT

TABLE OF CONTENTS

 

  Page
   
Introduction1
PART I
  
ITEM 1.Identity of Directors, Senior Management and Advisors45
ITEM 2.Offer Statistics and Expected Timetable45
ITEM 3.Key Information45
ITEM 4.Information on the Company23
ITEM 4A.Unresolved Staff Comments3334
ITEM 5.Operating and Financial Review and Prospects3334
ITEM 6.Directors, Senior Management, and Employees5752
ITEM 7.Major Shareholders and Related Party Transactions7666
ITEM 8.Financial Information7766
ITEM 9.The Offer and Listing7867
ITEM 10.Additional Information7968
ITEM 11.Quantitative and Qualitative Disclosures About Market Risk9079
ITEM 12.Description of Securities Other Than Equity Securities9180
   
PART II
   
ITEM 13.Defaults, Dividend Arrearages and Delinquencies9180
ITEM 14.Material Modifications to the Rights of Security Holders and Use of Proceeds9180
ITEM 15.Controls and Procedures9180
ITEM 16.Reserved9381
ITEM 16A.Audit Committee Financial Expert9381
ITEM 16B.Code Of Ethics9381
ITEM 16C.Principal Accounting Fees and Services9381
ITEM 16D.Exemptions from the Listing Standards for Audit Committees9482
ITEM 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers9482
ITEM 16F.Changes in Registrant’s Certifying Accountants9482
ITEM 16G.Corporate Governance9482
ITEM 16H.Mine Safety Disclosure9482
   
PART III
   
ITEM 17.Financial Statements9482
ITEM 18.Financial Statements9482
ITEM 19.Exhibits9583

 

 

INTRODUCTION

 

POET Technologies Inc. is organized under the Business Corporations Act (Ontario). In this Annual Report, the “Company”, “we”, “our”, “POET” and “us” refer to POET Technologies Inc. and its subsidiaries (unless the context otherwise requires). We refer you to the documents attached as exhibits hereto for more complete information than may be contained in this Annual Report. Our principal Canadian corporate offices are located at Suite 1107, 120 Eglinton Avenue East, Toronto, Ontario M4P 1E2, Canada. Our U.S office is located in the U.S. 1605 N. Cedar Crest Boulevard, Allentown, PA, 18104. Our telephone number in Toronto is (416) 368-9411.

 

We file reports and other information with the Securities and Exchange Commission (“SEC”) located at 100 F Street NE, Washington, D.C. 20549. You may obtain copies of our filings with the SEC by accessing their website located at www.sec.gov. We also file reports under Canadian regulatory requirements on SEDAR; you may access our reports filed on SEDAR by accessing the website www.sedar.com.

 

This Annual Report (including the consolidated audited financial statements for the years ended December 31, 2020, 2019 2018 and 20172018 attached thereto, together with the auditors’ report thereon), and the exhibits thereto shall be deemed to be incorporated by reference as exhibits to the Registration Statement of the Company on Form F- 10, as amended (File No. 333-227873), and to be a part thereof from the date on which this report was filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 


Page 1

 

Business of POET Technologies Inc.

 

POET designs, develops, manufactures and sells integrated opto-electronic solutions for data communications and telecommunications markets. POET has developed and is marketing its proprietary POET Optical InterposerÔTM platform which utilizes a novel waveguide technology that allows the integration of electronic and photonic devices into a single multi-chip module. The integration of devices into a single package is achieved by applying advanced wafer-level semiconductor manufacturing techniques and novel packaging methods developed by POET. POET’s Optical Interposer eliminates costly components, assembly and testing methods employed in conventional photonics solutions. In addition to lowering costs compared to conventional devices, POET’s Optical Interposer provides a flexible and scalable platform for a variety of photonics applications ranging from data centers to consumer products.

 

On November 8, 2019,October 20, 2020, the Company closedsigned a Joint Venture Agreement (“JVA”) establishing a joint venture company, Super Photonics Integrated Circuit Xiamen Co., Ltd (“SPX”) with Xiamen Sanan Integrated Circuit Co. Ltd. (“Sanan IC”) whose purpose is to assemble, test, package and sell cost-effective, high-performance optical engines based on POET’s proprietary Optical Interposer platform technology.

SPX’S capitalization is a combination of committed cash, capital equipment and intellectual property from Sanan IC and intellectual property and know-how from POET, with a combined estimated value of approximately US$50M.

Sanan IC is a world-class wafer foundry service company with an advanced compound semiconductor technology platform, serving the sale of itsoptical, RF microelectronics and power electronics markets. Sanan IC is a wholly owned subsidiary DenseLight Semiconductors Pte.of Sanan Optoelectronics Co., Ltd. (Shanghai Stock Exchange, SSE: 600703), to a consortiumthe leading manufacturer of investors organized under DenseLight Semiconductor Technology (Shanghai) Ltd. (“DL Shanghai”) for $26,000,000. POET shareholders approved the sale with 99% of votes submitted at a Special Meeting held on October 24, 2019, ratifying the Share Sale Agreement (“SSA”) signed by the Company on August 20, 2019. The buyer assumed control of DenseLight upon closing. The sale proceeds are being paid over multiple tranches. The first tranche payment was received on November 8, 2019advanced ultra-high brightness LED epitaxial wafers and chips in the amount of US$8 million. Shares of DenseLight were placed in escrow in the Buyer’s name, to be released by the escrow agent to the Buyer upon receipt of the remaining payments. The second tranche payment was made in two installments, with the first paid on February 19, 2020 consisting of US$4.75 million and the second on March 30, 2020 of US$8.25 million for a total paid to date of US$21.0 million. The remaining payment of US$5 millionworld.

SPX is expected to be made on or before May 31, 2020. Upon closing,assemble, test, package and sell 100G, 200G and 400G optical engines with customized lasers and photodiodes from Sanan IC combined with optical interposer platform technology from POET. Optical engines are a primary components of optical transceivers that transmit data between switches and severs in data centers and between data centers and metro areas. With assembly and test operations built upon the Company recognized a gain on the sale of $8,707,280. The Company received an additional $2,000,000, in excessnon-linear, wafer-scale methods of the sale proceeds,semiconductor industry, compared to the linear scale of conventional photonics assembly, SPX will be able to offer optical engines at dramatically lower cost and higher performance. Device volumes can scale rapidly with marginal investments in capital equipment and labor compared to conventional methods. This ability to manufacture optical engines at the most recently paid two tranches which was immediately paidlarge-scale volumes as needed, offer the opportunity for SPX and POET to Oak Capital on behalf ofpenetrate rapidly the Buyerlarge markets for due diligence, legalhigh-speed data communications applications, including internet data centers and other expenses.5G carrier networks.

 

Although the Company continued to operate as a single entity until the sale was closed, to meet financial reporting standards, the Company was required to report DenseLight as “discontinued operations” separate from the remainder of the Company from January 1, 2020 and until Friday, November 8, 2019. Revenue and expenses, and gains and losses relating to the discontinued operations have been removed from the results of continuing operations and are shown as a single line item on the face of the consolidated statement of comprehensive loss.

Page 2

 

During the yeartwelve months ended December 31, 2019,2020, the Company reported net loss from continuing operations before taxes of $11,727,372.$18,169,070.

 

The net loss from continuing operations included $2,083,815 spent on$6,634,317 incurred for research and development activities directly related to the development and commercialization of the POET Optical Interposer Platform. Research and development included $237,311non-cash costs of non-cash fair value$567,859 related to stock-based compensation. $6,697,387$8,137,998 was spent onincurred for selling, marketing and administration expenses which included non-cash operating costs of $2,650,830$3,045,086 related to the fair value of stock-based compensation and $243,674$813,103 related to depreciation and amortization.

 

The Company incurred $819,911$937,903 of interest expense, and $372,340 of debt issuance costswhich $524,095 was non-cash, related to $7,729,921funds borrowed at various dates and from various lenders during 2019. The Company repaid $4,000,000in 2019 by way of convertible debentures. During the period, $369,545 worth of the borrowed funds on November 8, 2019.

During 2019,convertible debentures were converted into 1,235,000 units of the Company performed an impairment analysis on its goodwillCompany. Each unit consists of one common share and intangible assets related toone common share purchase warrant of the acquisition of BB Photonics in 2016. The Company determined that these assets were impaired and consequently recognized an impairment loss of $1,764,459.


Net income from discontinued operations, net of taxes was $5,481,757. Discontinued operations generated revenue of $4,426,355 from the sale of sensing products and non-recurring engineering (“NRE”). Gross profit was $3,224,982 or 73%. Included in the net income from discontinued operations, net of taxes was $5,677,222 spent on research and development and $1,950,526 spent on selling, marketing and administration. Discontinued operations had other income of $1,251,737 resulting primarily from cash credits either collected or recoverable from the Economic Development Board (“EDB”) of Singapore. The income from discontinued operations, net of taxes included a gain on the sale of discontinued operations, net of taxes of $8,707,280.Company.

 

The Company’s balance sheet as of December 31, 20192020 reflects assets with a book value of $24,077,355$11,636,728 compared to $25,137,903$24,077,355 as of December 31, 2018. Eighty-four2019. Sixty-four percent (84%(64%) of the book value at December 31, 20192020 was in current assets consisting primarily of cash and cash equivalents of $6,872,894 compared to eighty-four percent (84%) of the book value as of December 31, 2019, which consisted primarily of receivable from the sale of discontinued operations of $18,000,000 compared$18,000,000.

On February 11, 2021, subsequent to twenty-seven percent (27%)the year end, the Company completed a brokered private placement offering of 17,647,200 units at a price of $0.67 (CAD$0.85) per unit for gross proceeds of $11,811,118 (CAD$15,000,120). Each unit consists of one common share and one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the book value asCompany at a price of $0.90 (CAD$1.15) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company’s average stock price exceeds $1.81 (CAD$2.30) for a period of 10 consecutive trading days. The broker was paid a cash commission of $708,667 (CAD$900,007) equating to 6% of the gross proceeds and received 1,058,832 broker warrants. Each broker warrant is exercisable into one common share of the Company at a price of $0.67 (CAD$0.85) per broker warrant until February 11, 2023.

In addition to funds received from the brokered private placement, subsequent to December 31, 2018, or $6,888,264, was in current assets consisting primarily2020 the Company received $8,441,240 (CAD$10,714,953) from the exercise of cashstock options and other current assets.warrants. The Company also improved its liquidity by $1,709,526 (CAD$2,170,000) through the conversion of convertible debentures into common shares of the Company.

 

As at December 31, 2019, the Company had a working capital balance of $15,354,149. The Company is satisfied that it will have sufficient funds meet its operating requirements over the next 12 months.

Page 3

 

Financial and Other Information

 

In this Annual Report, unless otherwise specified, all dollar amounts are expressed in United States Dollars (“US$”, “USD” or “$”).

 

Cautionary Statements Regarding Forward-Looking Statements

 

This Annual Report on Form 20-F and other publicly available documents, including the documents incorporated herein and therein by reference contain forward- looking statements and information within the meaning of U.S. and Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward- looking terminology or words, such as, “continues”, “with a view to”, “is designed to”, “pending”, “predict”, “potential”, “plans”, “expects”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, and similar expressions or variations thereon, or statements that events, conditions or results “can”, “might”, “will”, “shall”, “may”, “must”, “would”, “could”, or “should” occur or be achieved and similar expressions in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends. Forward- looking statements and information are based on management’s current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict.

 

Our actual results, performance and achievements may differ materialmaterially from those expressed in, or implied by, the forward-looking statements and information in this Annual Report as a result of various risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the control of the Company, including without limitation:

 

 owe have a limited operating history;

 oour need for additional financing, which may not be available on acceptable terms or at all;

 othe possibility that we will not be able to compete in the highly competitive semiconductor market;

 othe risk that our objectives will not be met within the timelines we expect or at all;

 oresearch and development risks;

 othe risks associated with successfully protecting patents and trademarks and other intellectual property;

 othe need to control costs and the possibility of unanticipated expenses;

 omanufacturing and development risks;

 othe risk that the price of our common stock will be volatile;

othe risk that geopolitical uncertainties may negatively impact our business venture in China;
 othe risk that shareholders’ interests will be diluted through future stock offerings, option and warrant exercises; and

 oother risks and uncertainties described in ITEM 3.D. “Risk Factors”.

 


Page 4

 

For all of the reasons set forth above, investors should not place undue reliance on forward-looking statements. Other than any obligation to disclose material information under applicable securities laws or otherwise as maybe required by law, we undertake no obligation to revise or update any forward-looking statements after the date hereof.

 

Data relevant to estimated market sizes for our technologies under development are presented in this Annual Report. These data have been obtained from a variety of published resources including published scientific literature, websites and information generally available through publicized means. The Company attempts to source reference data from multiple sources whenever possible for confirmatory purposes. However, the Company has not independently verified the accuracy and completeness of this data.

 

PART I

 

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS

 

A. Not Required.

 

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

 

Not Required.

 

ITEM 3. KEY INFORMATION

 

A.Selected Financial Data

 

The selected financial data of the Company for the years ended December 31, 2020, 2019 2018 and 20172018 was derived from the audited annual consolidated financial statements of the Company, which have been audited by Marcum LLP, independent registered public accounting firm. Selected financial data of the Company for the years ended December 31, 20162017 and 20152016 was derived from the consolidated financial statements of the Company, which are not included in this Annual Report.

 

The information contained in the selected financial data for the 2020, 2019 2018 and 20172018 years is qualified in its entirety by reference to the Company’s audited consolidated financial statements and related notes included under the heading “ITEM 17”. Financial Statements” and should be read in conjunction with such financial statements and related notes and with the information appearing under the heading “ITEM 5”.

 

Operating and Financial Review and Prospects.” Except where otherwise indicated, all amounts are presented in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

 

Since its formation, theThe Company has financed its operations from public and private sales of equity securities, issuance of convertible debentures, proceeds received upon the exercise of warrants and stock options, research and development contracts from U.S. government agencies, sales of the Company’s photonic products and, prior to 2012, by sales of solar energy equipment products. The Company has never been profitable, so its ability to finance operations has been dependent on equity financings. Since 2016, through its former subsidiary, DenseLight, the Company generated cash flow from the sale of its photonic sensing products and NRE. We believe, however, that it will need to rely on the sale of equity securities, debt securities or a combination of both, to provide funds for its activities on an ongoing basis until we have concluded the development of the Optical Inter-poser. See ITEM 3.D. “Risk Factors.”

 

The Company has not declared any dividends since incorporation and does not anticipate that it will do so in the foreseeable future.

 


Page 5

 

Consolidated Statements of Operations Under

International Financial Reporting Standards

(US$)

 

   Reclassified (1)         Restated(1)  Restated(1)  Restated(1) 
  2019   2018   2017   2016   2015 
                    
Years Ended December 31, 2020  2019  2018  2017  2016 
Operating Expenses                                        
Selling, marketing and administrative $6,697,387  $6,173,875  $5,887,709  $8,178,901  $8,614,109  $8,137,998  $6,697,387  $6,173,875  $5,887,709  $8,178,901 
Research and development  2,083,815   2,262,476   2,039,421   2,122,983   3,532,492   6,634,317   2,083,815   2,262,476   2,039,421   2,122,983 
Impairment loss  1,764,459   -   -   -   - 
Operating Expenses  14,772,315   8,781,202   8,436,351   7,927,130   10,301,884 
Impairment of long-lived assets  -   1,764,459   -   -   - 
Interest expense  819,911   -   -   63,522   -   937,903   819,911   -   -   63,522 
Amortization of debt issuance costs  372,340   -   -   -   -   -   372,340   -   -   - 
Other income, including interest�� (41,148)  (10,540)  (14,234)  (18,279)  (52,845)
Credit loss on receivable from the sale of discontinued operations  2,500,000                 
Loss on disposal of property and equipment  -   -   -   46,738   -       -   -   -   46,738 
Other income, including interest  (10,540)  (14,234)  (18,279)  (52,845)  (76,431)
Operating Expenses  11,727,372   8,422,117   7,908,851   10,359,299   12,070,170 
Net loss from continuing operations, before taxes  18,169,070   11,727,372   8,422,117   7,908,851   10,359,299 
Income tax recovery  (292,740)  -   -   -   -   -   (292,740)  -   -   - 
Net loss from continuing operations  (11,434,632)  (8,422,117)  (7,908,851)  (10,359,299)  (12,070,170)  (18,169,070)  (11,434,632)  (8,422,117)  (7,908,851)  (10,359,299)
Income (loss) from discontinued operations, net of taxes  5,481,757   (7,900,662)  (4,888,946)  (2,865,385)  -   -   5,481,757   (7,900,662)  (4,888,946)  (2,865,385)
Net loss  (5,952,875)  (16,322,779)  (12,797,797)  (13,224,684)  (12,070,170)  (18,169,070)  (5,952,875)  (16,322,779)  (12,797,797)  (13,224,684)
Deficit, beginning of year  (133,195,932)  (116,873,153)  (104,075,356)  (90,850,672)  (78,780,502)  (139,148,807)  (133,195,932)  (116,873,153)  (104,075,356)  (90,850,672)
Deficit, end of year $(139,148,807) $(133,195,932) $(116,873,153) $(104,075,356) $(90,850,672) $(157,317,877) $(139,148,807) $(133,195,932) $(116,873,153) $(104,075,356)
                                        
Basic and diluted loss per share, continuing operations $(0.04) $(0.03) $(0.03) $(0.05) $(0.07) $(0.06) $(0.04) $(0.03) $(0.03) $(0.05)
Basic and diluted income (loss) per share, discontinued operations $0.02  $(0.03) $(0.02) $(0.01) $0.00   -  $0.02  $(0.03) $(0.02) $(0.01)
Basic and diluted loss per share $(0.02) $(0.06) $(0.05) $(0.06) $(0.07) $(0.06) $(0.02) $(0.06) $(0.05) $(0.06)

 

(1) The information above has been reclassifiedrestated to present DenseLight results as discontinued operations for the years 2016 – 2018.

 


Page 6

 

Consolidated Statements of Discontinued Operations Under

International Financial Reporting Standards

(US$)

 

  

For the Period from

January 1,

2019

to

November 8,

   For the Years Ended December 31,    For the Period from January 1, 2019 to November 8,   For the Years Ended December 31,   
  2019   2018   2017   2016  2020  2019  2018  2017  2016 
                           
Revenue $4,426,355  $3,888,185  $2,794,044  $1,861,747   -  $4,426,355  $3,888,185  $2,794,044  $1,861,747 
Cost of Revenue  1,201,373   1,475,969   1,342,691   946,001   -   1,201,373   1,475,969   1,342,691   946,001 
Gross Margin  3,224,982   2,412,216   1,451,353   915,746   -   3,224,982   2,412,216   1,451,353   915,746 
Operating Expenses                  -                 
Selling, marketing and administrative  1,950,526   5,515,329   4,983,032   3,242,703   -   1,950,526   5,515,329   4,983,032   3,242,703 
Research and development  5,677,222   6,430,328   3,403,452   1,042,842   -   5,677,222   6,430,328   3,403,452   1,042,842 
Operating Expenses      7,627,748   11,945,657   8,386,484   4,285,545 
Interest expense  74,494   -   -   -   -   74,494   -   -   - 
Impairment loss  -   156,717   -   -   -   -   156,717   -   - 
Other income  (1,251,737)  (1,491,556)  (1,748,245)  (14,027)  -   (1,251,737)  (1,491,556)  (1,748,245)  (14,027)
Operating Expenses  6,450,505   10,610,818   6,638,239   4,271,518 
Expenses  -   6,450,505   10,610,818   6,638,239   4,271,518 
Net loss from operations  (3,225,523)  (8,198,602)  (5,186,886)  (3,355,772)  -   (3,225,523)  (8,198,602)  (5,186,886)  (3,355,772)
Change in fair value contingent consideration  -   -   -   283,130   -   -   -   -   283,130 
Gain on sale of discontinued operations, net of taxes  8,707,280   -   -   -   -   8,707,280   -   -   - 
Net income (loss) from discontinued operations  5,481,757   (8,198,602)  (5,186,886)  (3,072,642)  -   5,481,757   (8,198,602)  (5,186,886)  (3,072,642)
Income tax recovery  -   297,940   297,940   207,257   -   -   297,940   297,940   207,257 
Income (loss) from discontinued operations, net of income taxes $5,481,757  $(7,900,662) $(4,888,946) $(2,865,385)  -  $5,481,757  $(7,900,662) $(4,888,946) $(2,865,385)

 

Page 7

 


Consolidated Statements of Financial Position

Under International Financial Reporting Standards

(US$)

  December 31, 
  2020  2019  2018  2017  2016 
Assets               
Cash and cash equivalents $6,872,894  $1,428,129  $2,567,868  $4,974,478  $14,376,282 
Short-term investments  -   -   -   -   589,275 
Accounts receivable  -   -   946,944   493,925   292,849 
Receivable from the sale of discontinued operations  -   18,000,000   -   -   - 
Prepaids and other current assets  618,717   831,265   2,936,619   1,957,727   758,917 
Inventory  -   -   436,833   524,582   1,116,880 
Property and equipment  3,185,754   3,143,060   9,299,513   8,278,170   9,364,210 
Patents and licenses  438,677   452,384   466,714   456,250   449,676 
Right of use asset  520,686   222,517   -   -   - 
Intangible assets  -   -   802,409   839,637   876,865 
Goodwill  -   -   7,681,003   7,681,003   7,681,003 
Total Assets $11,636,728  $24,077,355  $25,137,903  $25,205,772  $35,505,957 
Liabilities                    
Accounts payable and accrued liabilities $1,730,361  $1,725,708  $3,040,422  $810,593  $1,624,344 
Covid-19 government support loans  147,841   -   -   -   - 
Lease liability  172,949   90,504   -   -   - 
Convertible debentures  3,341,246   3,089,033   -   -   - 
Non-current covid-19 government support loans  70,310   -   -   -   - 
Non-current lease liability  359,048   133,254   -   -   - 
Deferred tax liability  -   -   1,000,427   1,298,367   1,596,307 
Deferred rent  -   -   1,814   24,031   42,665 
Total Liabilities  5,821,755   5,038,499   4,042,663   2,132,991   3,263,316 
Shareholders’ Equity                    
Share capital  114,586,260   112,144,172   112,028,194   103,616,221   103,357,862 
Equity component of convertible debentures  565,121   627,511   -   -   - 
Warrants and compensation options  5,557,002   8,525,358   8,303,738   5,985,378   5,985,378 
Contributed surplus  44,407,679   38,799,337   36,042,754   32,102,967   29,062,874 
Accumulated other comprehensive loss  (1,983,212)  (1,908,715)  (2,083,514)  (1,758,632)  (2,088,117)
Deficit  (157,317,877)  (139,148,807)  (133,195,932)  (116,873,153)  (104,075,356)
Total Shareholders’ Equity  5,814,973   19,038,856   21,095,240   23,072,781   32,242,641 
Total Liabilities and Shareholders’ Equity $11,636,728  $24,077,355  $25,137,903  $25,205,772  $35,505,957 

 

  December 31,
   2019   2018   2017   2016   2015 
Assets                    
Cash and cash equivalents $1,428,129  $2,567,868  $4,974,478  $14,376,282  $14,409,996 
Short-term investments  -   -   -   589,275   - 
Accounts receivable  -   946,944   493,925   292,849   - 
Receivable from the sale of discontinued operations  18,000,000   -   -   -   - 
Prepaids and other current assets  831,265   2,936,619   1,957,727   758,917   150923 
Inventory  -   436,833   524,582   1,116,880   - 
Property and equipment  3,143,060   9,299,513   8,278,170   9,364,210   947,107 
Patents and licenses  452,384   466,714   456,250   449,676   426,813 
Right of use asset  222,517   -   -   -   - 
Intangible assets  -   802,409   839,637   876,865   - 
Goodwill  -   7,681,003   7,681,003   7,681,003   - 
Total Assets $24,077,355  $25,137,903  $25,205,772  $35,505,957  $15,934,839 
Liabilities                    
Accounts payable and accrued liabilities $1,725,708  $3,040,422  $810,593  $1,624,344  $515,421 
Convertible debentures  3,089,033   -   -   -   - 
Lease liability  223,758   -   -   -   - 
Deferred tax liability  -   1,000,427   1,298,367   1,596,307   - 
Deferred rent  -   1,814   24,031   42,665   - 
Total Liabilities  5,038,499   4,042,663   2,132,991   3,263,316   515,421 
Shareholders’ Equity                    
Share capital  112,144,172   112,028,194   103,616,221   103,357,862   81,027,171 
Equity component of loan payable  627,511   -   -   -   - 
Warrants  8,525,358   8,303,738   5,985,378   5,985,378   2,013,747 
Contributed surplus  38,799,337   36,042,754   32,102,967   29,062,874   25,618,159 
Accumulated other comprehensive loss  (1,908,715)  (2,083,514)  (1,758,632)  (2,088,117)  (2,388,987)
Deficit  (139,148,807)  (133,195,932)  (116,873,153)  (104,075,356)  (90,850,672)
Total Equity  19,038,856   21,095,240   23,072,781   32,242,641   15,419,418 
Total Liabilities and Equity $24,077,355  $25,137,903  $25,205,772  $35,505,957  $15,934,839 
Page 8


 

B.Capitalization and Indebtedness

 

During 2019 the Company closed five tranches of a private placement of the Convertible Debentures that raised gross proceeds of $3,729,921. The Convertible Debentures, bear interest at 12% per annum, compounded annually with 1% payable at the beginning of each month and mature two years from the date of issue. $3,429,105$2,388,253 was owed on convertible debentures at April 22, 2020.March 13, 2021. All, $1,341,668 that were settled, were settled through conversion into units of the Company. The Company has not paid any cash to settle the convertible debentures.

 

A summary of the Company’s indebtedness at April 22, 2020 is as follows:

 

      Balance 
Issue Date Maturity Date Loan Repayment/Conversion Balance Maturity Date Loan Repayment/Conversion March 31, 2021 December 31, 2020 
03-Apr-19 03-Apr-21 $1,449,752  $-  $1,449,752  03-Apr-21 $1,449,752  $(366,981) $1,082,771  $1,518,613 
03-May-19 03-May-21  1,087,408   (128,788)  958,620  03-May-21  1,087,408   (777,884)  309,524   949,971 
03-Jun-19 03-Jun-21  641,328   (95,105)  546,223  03-Jun-21  641,328   (84,185)  557,143   579,404 
02-Aug-19 02-Aug-21  414,205   (76,923)  337,282  02-Aug-21  414,205   (112,618)  301,587   337,593 
06-Sep-19 06-Sep-21  137,228   -   137,228  06-Sep-21  137,228   -   137,228   142,888 
Balance   $3,729,921  $(300,816) $3,429,105  $3,729,921  $(1,341,668) $2,388,253  $3,528,469 

 

C.Reasons for the Offer and Use of Proceeds

 

Not Required.

 

D.Risk Factors

 

We are subject to various risks, including those described below, which could materially adversely affect our business, financial condition and results of operations and, in turn, the value of our securities. In addition, other risks not presently known to us or that we currently believe to be immaterial may also adversely affect our business, financial condition and results of operations, perhaps materially. The risks discussed below also include forward-looking statements and information within the meaning of U.S. and Canadian securities laws that involve risks and uncertainties. The Company’s actual results may differ materially from the results discussed in the forward-looking statements and information Factors that might cause such differences include those discussed. Before making an investment decision with respect to any of our securities, you should carefully consider the following risks and uncertainties described below and elsewhere in this Annual Report. See also “Cautionary Statement Regarding Forward-Looking Statements.”

 

Risks Related to Our Business

 

We have a history of large operating losses. We may not be able to achieve or sustain profitability in the future and as a result we may not be able to maintain sufficient levels of liquidity.

We have historically incurred losses and negative cash flows from operations since our inception. As of December 31, 2020, we had an accumulated deficit of $157,317,877. For the years ended December 31, 2020, 2019 and 2018, we incurred net losses of 18,169,070, $5,952,875 and $16,322,779, respectively.

As of December 31, 2020, we held $6,872,894 in cash and cash equivalents, and we had working capital of $2,099,214.

Page 9

We divested our major operating asset, adopted a new “fab-light” strategy, and we plan to focus on the Optical Interposer as our main business. Any or all of these decisions if incorrect may have a material adverse effect on the results of our operations, financial position and cash flows, and pose further risks to the successful operation of our business over the short and long-term.

 

There are substantial risks associated with our adoption of a “fab-light” strategy, including the immediate loss of all or a substantial part of our revenue, the loss of control over an internal development asset, and the loss of key technical knowledge available from personnel who will no longer be employed by the Company, many of whom we may have to replace.

 


We have some previous experience with managing development without an internal development resource under a similar “fab-light” strategy which was not successful, and there is no guarantee that our new approach to operating a company with our chosen strategy will be successful. Further, our strategy will be solely dependent on the future market acceptance and sale of Optical Interposer-based solutions, which are either not fully developed or are in qualification stages, and which no customer has yet fully committed to adopting in a production product.

 

We have taken substantial measures to protect POET’s intellectual property in the Optical Interposer, including development and production with a separate third-party company which engaged no DenseLight engineering personnel. We conducted development of component devices separately at our DenseLight facility and took measures to protect POET’s intellectual property on those developments as well. However, we cannot guarantee that all our measures to protect our intellectual property on either the POET Optical Interposer or its component devices have been totally effective. Following divestment, we will have little or no control over any leakage of certain proprietary information or know-how and additional development with the DenseLight operation on component devices may expose our intellectual property to parties that we cannot control. Further, we cannot guarantee that DenseLight or any other third-party that we rely on to perform development, manufacturing, packaging or testing services will perform as expected and produce the devices we will need to grow our Optical Interposer business.

 

There can be no assurance that we will be successful in addressing these or any other significant risks we may encounter in the divestment of DenseLight, the adoption of a “fab-light” strategy or the focus of our business solely on the Optical Interposer.

 

We may not be able to generate sufficient cashobtain additional capital when desired, on favorable terms or at all.

We operate in a market that makes our prospects difficult to service our debt obligations.

Throughout 2019,evaluate and, to remain competitive, we sold unsecured convertible debentures. Our abilitywill be required to make continued payments on our debt will depend on our financialinvestments in capital equipment, facilities and operating performance, which may fluctuate significantly from quarter to quarter, and is subject to prevailing economic conditions and financial, business and other factors, many of which are beyond our control.technology. We cannot assure youexpect that wesubstantial capital will be ablerequired to generate sufficient cash flow or thatcontinue technology and product development, to expand our contract manufacturing capacity if we will be ableneed to borrow funds from another source in amounts sufficientdo so and to enable us to service our debt.fund working capital for anticipated growth. If we aredo not able to generate sufficient cash flow from operations or otherwise have the capital resources to borrow sufficientmeet our future capital needs, we may need additional financing to implement our business strategy.

If we raise additional funds through the issuance of our common stock or convertible securities, the ownership interests of our stockholders could be significantly diluted. These newly issued securities may have rights, preferences or privileges senior to servicethose of existing stockholders. Additional financing may not, however, be available on terms favorable to us, or at all, if and when needed, and our debt,ability to fund our operations, take advantage of unanticipated opportunities, develop or enhance our infrastructure or respond to competitive pressures could be significantly limited. If we cannot raise required capital when needed we may be requiredunable to sell equity or assets, reduce expenditures, refinance all or a portioncontinue technology and product development, meet the demands of existing and prospective customers, adversely affecting our existing debt or obtain additional financing. We cannot assure you that we will be able to refinancesales and market opportunities and consequently our debt, sell assets or equity or borrow more funds on terms acceptable to us, if at all.business, financial condition and results of operations.

 

Page 10

The process of developing new, technologically advanced products in semiconductor manufacturing and photonics products is highly complex and uncertain, and we cannot guarantee a positive result.

 

The development of new, technologically advanced products is a complex and uncertain process requiring frequent innovation, highly-skilled engineering and development personnel and significant capital, as well as the accurate anticipation of technological and market trends. We cannot assure you that we will be able to identify, develop, manufacture, market or support new or enhanced products successfully or on a timely basis. Further, we cannot assure you that our new products will gain market acceptance or that we will be able to respond effectively to product introductions by competitors, technological changes or emerging industry standards. We also may not be able to develop the underlying core technologies necessary to create new products and enhancements, license these technologies from third parties, or remain competitive in our markets.

 

The optical data communications industry in which we have chosen to operate is subject to significant risks, including rapid growth and volatility, dependence on rapidly changing underling technologies, market and political risks and uncertainties and extreme competition. We cannot guarantee that we will be able to anticipate or overcome any or all of these risks and uncertainties, especially as a small company operating in an environment dominated by large, well-capitalized competitors with substantially more resources.

The optical data communications industry is subject to significant operational fluctuations. In order to remain competitive, we incur substantial costs associated with research and development, qualification, prototype production capacity and sales and marketing activities in connection with products that may be purchased, if at all, long after we have incurred such costs. In addition, the rapidly changing industry in which we operate, the length of time between developing and introducing a product to market, frequent changing customer specifications for products, customer cancellations of products and general down cycles in the industry, among other things, make our prospects difficult to evaluate. As a result of these factors, it is possible that we may not (i) generate sufficient positive cash flow from operations; (ii) raise funds through the issuance of equity, equity-linked or convertible debt securities; or (iii) otherwise have sufficient capital resources to meet our future capital or liquidity needs. There are no guarantees we will be able to generate additional financial resources beyond our existing balances.

We have contributed a portion of our intellectual property and exclusive assembly and sales rights for certain key initial products to a joint venture company that we have recently formed in China. Although we believe that the joint venture offers significant opportunities for growth that we might not otherwise have and solves several major known challenges, we also recognize that there are substantial risks and uncertainties associated with executing a major portion of our strategy through a joint venture, regardless of the intentions and capabilities of the parties involved.

On October 22, 2020, the Company signed a Joint Venture Agreement (“JVA”) with Sanan IC to form a joint venture company, Super Photonics Xiamen Co., Ltd. (“SPX”), which will eventually be owned 48% by the Company. SPX will assemble, test, package and sell certain optical engines on an exclusive basis globally and certain others on an exclusive basis in the territory of Greater China. Optical engines based on the POET Optical Interposer are expected to be a primary component of several types of optical transceivers used in data centers. The joint venture is based on the contribution by the Company of certain assembly and test know-how and other intellectual property and cash to be contributed by Sanan IC in stages, subject to meeting certain milestones, to cover all capital and operating expenses of SPX until it is self-sustaining. We cannot guarantee that SPX will meet each milestone or that Sanan IC will or will not contribute capital on schedule when and if such milestones are met, nor can we guarantee that SPX will be successful in assembling and testing optical engines, nor in the marketing and sales once the optical engines are tested and qualified by potential customers.


Page 11

The Company’s investment into “Super Photonics Xiamen” (“SPX”) is into an independent company operating as a true joint venture under the laws of the Peoples Republic of China (“PRC”). There are significant governance and operational risks associated with joint ventures and with companies operating in the PRC, in general. We cannot guarantee that we will be able to anticipate or overcome the risks and uncertainties of operating a joint venture company in China.

Although SPX has its own governance structure to which both parties contribute directors, most major decisions must be unanimous, which means that such decisions will require the support of the management of SPX and both of the JV partners. Although the Company has sought the support of well-known and competent legal and other professional advisors and has had a major role in the recruitment of the senior management team of SPX, the Company has no prior experience with either the operation of a joint venture or with the operation of a JV company under the laws of the PRC, so we cannot guarantee that the joint venture will be successfully managed without substantial investment in time and effort by the Company’s current management team or at all

If our customers do not qualify our products for use on a timely basis, our results of operations may suffer.

 

Prior to the sale of new products, our customers typically require us to “qualify” our products for use in their applications. At the successful completion of this qualification process, we refer to the resulting sales opportunity as a “design win.” Additionally, new customers often audit our manufacturing facilities and perform other evaluations during this qualification process. The qualification process involves product sampling and reliability testing and collaboration with our product management and engineering teams in the design and manufacturing stages. If we are unable to accurately predict the amount of time required to qualify our products with customers, or are unable to qualify our products with certain customers at all, then our ability to generate revenue could be delayed or our revenue would be lower than expected and we may not be able to recover the costs associated with the qualification process or with our product development efforts, which would have an adverse effect on our results of operations.

 

We have limited operating history in the data center market, and our business could be harmed if this market does not develop as we expect.

The initial target market for our Optical Interposer-based optical engine is the data center market for data communications within the data center and beyond. We have limited experience in selling products in this market. We may not be successful in developing a product for this market and even if we do, it may never gain widespread acceptance by large data center operators. If our expectations for the growth of the data center / datacom market are not realized, our financial condition or results of operations may be adversely affected.

Customer demand for paid non-recurring engineering work (NRE) is difficult to forecast accurately and, as a result, we may be unable to match our engineering resourcesproduction with customer engagements.demand.

Much of our revenue during the coming years will be for non-recurring engineering work (NRE) related to demonstrating the functionality of the POET Optical Interposer in various applications. At any given time, we have multiple discussions with potential customers ongoing, some of which mature into proposals and a portion of those into paid development work. It is not possible to estimate in advance which of the multiple discussions is likely to convert into a paid project. Nevertheless, weWe make planning and spending decisions, including determining the levels of NREbusiness that we will seek and accept, based on a variety of factors, including the market position and prestige of the customer, our determination of the likelihood of success of applying our solution and the size and likely success of any products that may result. Our decisions involve internal staffing levels, contracts with vendors and co-development partners, sub-componentproduction schedules, component procurement capital expenditures, commitments, to production schedulespersonnel needs and other resource requirements, based on our estimates of product demand and customer requirements. Our products are typically sold pursuant to individual purchase orders. While our customers may provide us with forecasts of their potential needs,demand forecasts, they are typically not contractually committed to more than initial phasesbuy any quantity of design work, with subsequent work dependent on both the successproducts beyond firm purchase orders. Furthermore, many of our efforts and theirs. Orders for additional engineering workcustomers may increase, decrease, cancel or delay at any timepurchase orders already in place without significant penalty. The short-term nature of commitments by our expected customers and the possibility of unexpected changes in demand reducesfor their products reduce our ability to accurately estimate future NRE revenues and our own resource levels.customer requirements. If any of our estimates of the number and scope of projects undertaken for customers is incorrect, or customers decrease, stop or delay purchasing our services or products for any reason, we will likely have excess manufacturing capacity or inventory and our business and results of our operations would be harmed.

 

Page 12

The markets in which we operate are highly competitive, which could result in lost sales and lower revenues.

 

The market for optical components and modules is highly competitive and this competition could result in our existing customers moving their orders to our competitors. We are aware of a number of companies that have developed or are developing integrated optical component products, including LEDs, lasers,silicon photonics engines, remote light sources, pluggable components, modules and subsystems, photonic integrated circuits, among others, that compete (or may in the future compete) directly with our current and proposed product offerings.

 

Some of our current competitors, as well as some of our potential competitors, have longer operating histories, greater name recognition, broader customer relationships and industry alliances and substantially greater financial, technical and marketing resources than we do. We may not be able to compete successfully with our competitors and aggressive competition in the market may result in lower prices for our products and/or decreased gross margins. Any such development could have a material adverse effect on our business, financial condition and results of operationsoperations.

 


We have limited operating history in the datacom market, and our business could be harmed if this market does not develop as we expect.

The initial target market for our Optical Interposer-based optical engine is the datacom market and we have no experience in selling products in this market. We may not be successful in developing a product for this market and even if we do, it may never gain widespread acceptance by large data center operators. If our expectations for the growth of the datacom market are not realized, our financial condition or results of operations may be adversely affected.

We depend on a limited number of suppliers and key contract manufacturers who could disrupt our business and technology development activities if they stopped, decreased, delayed or were unable to meet our demand for shipments of their products or manufacturing of our products.

 

We depend on a limited number of suppliers of epitaxial wafers and contract manufacturers for our Indium Phosphide (“InP”) and Optical Interposer development and optical interposer production activities. Some of these suppliers are sole source suppliers. We typically have not entered into long-term agreements with our suppliers. As a result, these suppliers generally may stop supplying us materials and other components at any time. Our reliance on a sole supplier or limited number of suppliers could result in delivery problems, reduced control over technology development, product development, pricing and quality, and an inability to identify and qualify another supplier in a timely manner. Some of our suppliers that may be small or under-capitalized may experience financial difficulties that could prevent them from supplying us materials and other components. In addition, our suppliers, including our sole source suppliers, may experience manufacturing delays or shut downsshutdowns due to circumstances beyond their control such as earthquakes, floods, fires, labor unrest, political unrest or other natural disasters. A Changechange in supplier could require technology transfer that could require multiple iterations of test wafers. This could result in significant delays in resumption of production.

 

Any supply deficiencies relating to the quality or quantities of materials or equipment we use to manufacture our products could materially and adversely affect our ability to fulfill customer orders and our results of operations. Lead times for the purchase of certain materials and equipment from suppliers have increased and, in some cases, have limited our ability to rapidly respond to increased demand, and may continue to do so in the future. To the extent we introduce additional contract manufacturing partners, introduce new products with new partners and/or move existing internal or external production lines to new partners, we could experience supply disruptions during the transition process. In addition, due to our customers’ requirements relating to the qualification of our suppliers and contract manufacturing facilities and operations, we cannot quickly enter into alternative supplier relationships, which preventsprevent us from being able to respond immediately to adverse events affecting our suppliers.

 


Our international business and operations expose us to additional risks.

 

We have significant tangible assets located outside Canada and the United States. We have operating facilities are located in Singapore. Conducting business outside Canada and the United States subjects us to a number of additional risks and challenges, including:

 

periodic changes in a specific country's or region's
periodic changes in a specific country’s or region’s economic conditions, such as recession;
licenses and other trade barriers;

Page 13

 

licenses and other trade barriers;

the provision of services may require export licenses;

environmental regulations;

certification requirements;

fluctuations in foreign currency exchange rates;

inadequate protection of intellectual property rights in some countries;

preferences of certain customers for locally produced products;

potential political, legal and economic instability, foreign conflicts, and the impact of regional and global infectious illnesses in the countries in which we and our customers, suppliers and contract manufacturers are located;

Canadian and U. S. and foreign anticorruption laws;

seasonal reductions in business activities in certain countries or regions; and

fluctuations in freight rates and transportation disruptions.
the provision of services may require export licenses;
environmental regulations;
certification requirements;
fluctuations in foreign currency exchange rates;
inadequate protection of intellectual property rights in some countries;
preferences of certain customers for locally produced products;
potential political, legal and economic instability, foreign conflicts, and the impact of regional and global infectious illnesses in the countries in which we and our customers, suppliers and contract manufacturers are located;
Canadian and U. S. and foreign anticorruption laws;
seasonal reductions in business activities in certain countries or regions; and
fluctuations in freight rates and transportation disruptions.

 

These factors, individually or in combination, could impair our ability to effectively operate one or more of our foreign facilities or deliver our products, result in unexpected and material expenses, or cause an unexpected decline in the demand for our products in certain countries or regions. Our failure to manage the risks and challenges associated with our international business and operations could have a material adverse effect on our business.

 

If we fail to attract and retain key personnel, our business could suffer.

 

Our future success depends, in part, on our ability to attract and retain key personnel, including executive management. Competition for highly skilled technical personnel is extremely intense and we may face difficulty identifying and hiring qualified engineers in many areas of our business. We may not be able to hire and retain such personnel at compensation levels consistent with our existing compensation and salary structure. Our future success also depends on the continued contributions of our executive management team and other key management and technical personnel, each of whom would be difficult to replace. The loss of services of these or other executive officers or key personnel or the inability to continue to attract qualified personnel could have a material adverse effect on our business.

 


Our predecessor company received subsidies and other types of funding from government agencies in the locations in which we operate.agencies. Our current company has applied for loans related to COVID-19. The funding agreements stipulate that if we do not comply with various covenants, including eligibility requirements, and/or do not achieve certain pre-defined objectives, those government agencies may reclaim all or a portion of the funding provided. If they find that we were ineligible for such funding, then they may both reclaim the funds and add penalties and interest. If this were to occur, we would either not be in a position to repay the claimed amounts or would have to borrow large sums in order to do so or refinance with dilutive financing, which could adversely affect our financial condition.

Our predecessor company, Opel Solar and itsan affiliated company, ODIS, now a wholly-owned subsidiary, ODIS, received research and development grants from the United States Air Force and from NASA. The rules for eligibility vary widely across government agencies, are complex and may be subject to different interpretations. We cannot guarantee that one or more agencies will not seek repayment of all or a portion of the funds provided or make claims that we were ineligible to receive such funds, and if this were to occur, we could have to borrow large sums or refinance with dilutive financing in order to make the repayments, which would adversely affect our financial condition.

 

Page 14

In March and April of 2020, in response to the financial challenges companies face as a result of the COVID-19 pandemic, the United States and Canadian Governments, both launched financial assistance programs by way of Government backed loans. These loans may either be partially or fully forgiven if recipient companies meet certain spending or repayment criteria. If such criteria are not met, recipients of these government backed loans may be required to repay the loans in full plus a prescribed amount of interest. The Company received $218,151 of such loans. While we are confident that we meet all the criteria for receiving such loans, we cannot guarantee that we may not be required to repay the loans in full plus any incurred interest and or penalties.

If we fail to protect, or incur significant costs in defending, our intellectual property and other proprietary rights, our business and results of operations could be materially harmed.

Our success depends on our ability to protect our intellectual property and other proprietary rights. We rely on a combination of patent, trademark, copyright, trade secret and unfair competition laws, as well as license agreements and other contractual provisions, to establish and protect our intellectual property and other proprietary rights. We have applied for patent registrations in the U.S. and in foreign countries, some of which have been issued. We cannot guarantee that our pending applications will be approved by the applicable governmental authorities. Moreover, our existing and future patents and trademarks may not be sufficiently broad to protect our proprietary rights or may be held invalid or unenforceable in court. A failure to obtain patents or trademark registrations or a successful challenge to our registrations in the U.S. or foreign countries may limit our ability to protect the intellectual property rights that these applications and registrations intended to cover.

Policing unauthorized use of our technology is difficult and we cannot be certain that the steps we have taken will prevent the misappropriation, unauthorized use or other infringement of our intellectual property rights. Further, we may not be able to effectively protect our intellectual property rights from misappropriation or other infringement in foreign countries where we have not applied for patent protections, and where effective patent, trademark, trade secret and other intellectual property laws may be unavailable or may not protect our proprietary rights as fully as Canadian or U.S. law. We may seek to secure comparable intellectual property protections in other countries. However, the level of protection afforded by patent and other laws in other countries may not be comparable to that afforded in Canada and the U.S.

We also attempt to protect our intellectual property, including our trade secrets and know-how, through the use of trade secret and other intellectual property laws, and contractual provisions. We enter into confidentiality and invention assignment agreements with our employees and independent consultants. We also use non-disclosure agreements with other third parties who may have access to our proprietary technologies and information. Such measures, however, provide only limited protection, and there can be no assurance that our confidentiality and non-disclosure agreements will not be breached, especially after our employees end their employment, and that our trade secrets will not otherwise become known by competitors or that we will have adequate remedies in the event of unauthorized use or disclosure of proprietary information. Unauthorized third parties may try to copy or reverse engineer our products or portions of our products, otherwise obtain and use our intellectual property, or may independently develop similar or equivalent trade secrets or know-how. If we fail to protect our intellectual property and other proprietary rights, or if such intellectual property and proprietary rights are infringed or misappropriated, our business, results of operations or financial condition could be materially harmed.

In the future, we may need to take legal actions to prevent third parties from infringing upon or misappropriating our intellectual property or from otherwise gaining access to our technology. Protecting and enforcing our intellectual property rights and determining their validity and scope could result in significant litigation costs and require significant time and attention from our technical and management personnel, which could significantly harm our business. We may not prevail in such proceedings, and an adverse outcome may adversely impact our competitive advantage or otherwise harm our financial condition and our business.

Page 15

We may be involved in intellectual property disputes in the future, which could divert management’s attention, cause us to incur significant costs and prevent us from selling or using the challenged technology.

Participants in the markets in which we sell our products have experienced frequent litigation regarding patent and other intellectual property rights. There can be no assurance that third parties will not assert infringement claims against us, and we cannot be certain that our products would not be found infringing on the intellectual property rights of others. Regardless of their merit, responding to such claims can be time consuming, divert management’s attention and resources and may cause us to incur significant expenses. Intellectual property claims against us could result in a requirement to license technology from others, discontinue manufacturing or selling the infringing products, or pay substantial monetary damages, each of could result in a substantial reduction in our revenue and could result in losses over an extended period of time.

If we fail to obtain the right to use the intellectual property rights of others that are necessary to operate our business, and to protect their intellectual property, our business and results of operations will be adversely affected.

From time to time, we may choose to or be required to license technology or intellectual property from third parties in connection with the development of our products. We cannot assure you that third party licenses will be available to us on commercially reasonable terms, if at all. Generally, a license, if granted, would include payments of up-front fees, ongoing royalties or both. These payments or other terms could have a significant adverse impact on our results of operations. Our inability to obtain a necessary third-party license required for our product offerings or to develop new products and product enhancements could require us to substitute technology of lower quality or performance standards, or of greater cost, either of which could adversely affect our business. If we are not able to obtain licenses from third parties, if necessary, then we may also be subject to litigation to defend against infringement claims from these third parties. Our competitors may be able to obtain licenses or cross-license their technology on better terms than we can, which could put us at a competitive disadvantage.

If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be adversely affected. The requirement to have our internal controls audited under Section 404B of the Sarbanes-Oxley act will be effective for our next fiscal year and each subsequent year thereafter, so will require substantial investment in outside consultants, management’s time and attention and in additional audit fees to prepare for and pass such inspection.

Preparing our consolidated financial statements involves a number of complex manual and automated processes, which are dependent upon individual data input or review and require significant management judgment. One or more of these elements may result in errors that may not be detected and could result in a material misstatement of our consolidated financial statements. The Sarbanes-Oxley Act in the U.S. requires, among other things, that as a publicly traded company we disclose whether our internal control over financial reporting and disclosure controls and procedures are effective. Until the end of 2020 we qualify as an “emerging growth company” under the JOBS Act, so we will not have to provide an auditor’s attestation report on our internal controls. Our “emerging growth company” status is set to expire on December 31, 2021. However, during the course of any evaluation, documentation or attestation, we or our independent registered public accounting firm may identify weaknesses and deficiencies that we may not otherwise identify in a timely manner or at all as a result of the deferred implementation of this additional level of review. In 2021, when we are no longer qualified as an “emerging growth company” our internal controls will be subject to external audit.

Our internal controls cannot guarantee that no accounting errors exist or that all accounting errors, no matter how immaterial, will be detected because a control system, no matter how well designed and operated, can provide only reasonable, but not absolute assurance that the control system’s objectives will be met. If we are unable to implement and maintain effective internal control over financial reporting, our ability to accurately and timely report our financial results could be adversely impacted. This could result in late filings of our annual and quarterly reports under the Securities Act (Ontario) and the Securities Exchange Act of 1934, or the Exchange Act, restatements of our consolidated financial statements, a decline in our stock price, suspension or delisting of our common stock by the TSX Venture Exchange, or other material adverse effects on our business, reputation, results of operations or financial condition.

Page 16

Our ability to use our net operating losses and certain other tax attributes may be limited.

As of December 31, 2020, we had accumulated net operating losses (“NOLs”), of approximately $111 million Varying jurisdictional tax codes have restrictions on the use of NOLs, if a corporation undergoes an “ownership change,” the Company’s ability to use its pre-change NOLs, R&D credits and other pre-change tax attributes to offset its post-change income may be limited. An ownership change is generally defined as a greater than 50% change in equity ownership. Based upon an analysis of our equity ownership, we do not believe that we have experienced such ownership changes and therefore our annual utilization of our NOLs is not limited. However, should we experience additional ownership changes, our NOL carry forwards may be limited.

We are subject to governmental export and import controls that could subject us to liability or impair our ability to compete in international markets. Such controls have recently increased for companies in China under the US government’s “control list”, and may further limit or impair our ability to use certain sub-contractors or to sell directly to companies on the list

We are subject to export and import control laws, trade regulations and other trade requirements that limit which raw materials and technology we can import or export and which products we sell and where and to whom we sell our products. Specifically, the Bureau of Industry and Security of the U.S. Department of Commerce is responsible for regulating the export of most commercial items that are so called dual-use goods that may have both commercial and military applications. A limited number of our products are exported by license under certain classifications. Export Control Classification requirements are dependent upon an item’s technical characteristics, the destination, the end-use, and the end-user, and other activities of the end-user. Should the regulations applicable to our products change, or the restrictions applicable to countries to which we ship our products change, then the export of our products to such countries could be restricted. As a result, our ability to export or sell our products to certain countries could be restricted, which could adversely affect our business, financial condition and results of operations. Changes in our products or any change in export or import regulations or related legislation, shift in approach to the enforcement or scope of existing regulations, or change in the countries, persons or technologies targeted by such regulations, could result in delayed or decreased sales of our products to existing or potential customers. In such event, our business and results of operations could be adversely affected.

Our manufacturing operations are subject to environmental regulation that could limit our growth or impose substantial costs, adversely affecting our financial condition and results of operations.

Our properties, operations and products are subject to the environmental laws and regulations of the jurisdictions in which we operate and sell products. These laws and regulations govern, among other things, air emissions, wastewater discharges, the management and disposal of hazardous materials, the contamination of soil and groundwater, employee health and safety and the content, performance, packaging and disposal of products. Our failure to comply with current and future environmental laws and regulations, or the identification of contamination for which we are liable, could subject us to substantial costs, including fines, cleanup costs, third-party property damages or personal injury claims, and make significant investments to upgrade our facilities or curtail our operations. Identification of presently unidentified environmental conditions, more vigorous enforcement by a governmental authority, enactment of more stringent legal requirements or other unanticipated events could give rise to adverse publicity, restrict our operations, affect the design or marketability of our products or otherwise cause us to incur material environmental costs, adversely affecting our financial condition and results of operations.

Page 17

We are exposed to risks and increased expenses and business risk as a result of Restriction on Hazardous Substances, or RoHS directives, which have been amended but are still in effect.

Following the lead of the European Union, or EU, various governmental agencies have either already put into place or are planning to introduce regulations that regulate the permissible levels of hazardous substances in products sold in various regions of the world. For example, the RoHS directive for EU took effect on July 1, 2006. The labeling provisions of similar legislation in China went into effect on March 1, 2007 and is still in effect, as amended. Consequently, many suppliers of products sold into the EU have required their suppliers to be compliant with the new directive. We anticipate that our customers may adopt this approach and will require our full compliance, which will require a significant amount of resources and effort in planning and executing our RoHS program, it is possible that some of our products might be incompatible with such regulations. In such events, we could experience the following consequences: loss of revenue, damages reputation, diversion of resources, monetary penalties, and legal action.

Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

We are subject to the U.S. Foreign Corrupt Practices Act, which generally prohibits companies operating in the U.S. from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. In addition, we are required to maintain records that accurately and fairly represent our transactions and have an adequate system of internal accounting controls. Non-U.S. companies, including some that may compete with us, may not be subject to these prohibitions, and therefore may have a competitive advantage over us. If we are not successful in implementing and maintaining adequate preventative measures, we may be responsible for acts of our employees or other agents engaging in such conduct. We could suffer severe penalties and other consequences that may have a material adverse effect on our financial condition and results of operations.

Natural disasters or other catastrophic events could harm our operations.

Our operations in the U.S., Canada, Singapore and China could be subject to significant risk of natural disasters, including earthquakes, hurricanes, typhoons, flooding and tornadoes, as well as other catastrophic events, such as epidemics, terrorist attacks or wars. For example, our testing facility in Singapore is in an area that is susceptible to hurricanes. Any disruption in our facilities or those of our contractors and suppliers arising from these and other natural disasters or other catastrophic events could cause significant delays in the production or shipment of our products until we are able to arrange for third parties to manufacture our products. We may not be able to obtain alternate capacity on favorable terms or at all. Our property insurance coverage with respect to natural disaster is limited and is subject to deductible and coverage limits. Such coverage may not be adequate or continue to be available at commercially reasonable rates and terms. The occurrence of any of these circumstances may adversely affect our financial condition and results of operation.

We may be subject to disruptions or failures in information technology systems and network infrastructures that could have a material adverse effect on our business and financial condition.

We rely on the efficient and uninterrupted operation of complex information technology systems and network infrastructures to operate our business. A disruption, infiltration or failure of our information technology systems as a result of software or hardware malfunctions, system implementations or upgrades, computer viruses, third-party security breaches, employee error, theft or misuse, malfeasance, power disruptions, natural disasters or accidents could cause a breach of data security, loss of intellectual property and critical data and the release and misappropriation of sensitive competitive information and partner, customer, and employee personal data. Any of these events could harm our competitive position, result in a loss of customer confidence, cause us to incur significant costs to remedy any damages and ultimately materially adversely affect our business and financial condition.

A significant disruption in, or breach in security of, our information technology systems or violations of data protection laws could materially adversely affect our business and reputation.

 

In the ordinary course of business, we collect and store confidential information, including proprietary business information belonging to us, our customers, suppliers, business partners and other third parties and personally identifiable information of our employees. We rely on information technology systems to protect this information and to keep financial records, process orders, manage inventory, coordinate shipments to customers, and operate other critical functions. Our information technology systems may be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, telecommunication failures and user errors. If we experience a disruption in our information technology systems, it could result in the loss of sales and customers and significant incremental costs, which could materially adversely affect our business. We may also be subject to security breaches caused by computer viruses, illegal break-ins or hacking, sabotage, or acts of vandalism by disgruntled employees or third parties. The risk of a security breach or disruption, particularly through cyberattack or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Our information technology network and systems have been and, we believe, continue to be under constant attack. Accordingly, despite our security measures or those of our third-party service providers, a security breach may occur, including breaches that we may not be able to detect. Security breaches of our information technology systems could result in the misappropriation or unauthorized disclosure of confidential.

 


Page 18

 

We have a history of large operating losses. We may not be able to achieve or sustain profitability in the future and as a result we may not be able to maintain sufficient levels of liquidity.

We have historically incurred losses and negative cash flows from operations since our inception. As of December 31, 2019, we had an accumulated deficit of $139,148,807. For the years ended December 31, 2019 and December 31, 2018, we incurred net losses of $5,952,875 and $16,322,779 respectively.

The Company had working capital of $15,354,149 on December 31, 2019 compared to $3,847,842 on December 31, 2018. The Company’s balance sheet as of December 31, 2019 reflects assets with a book value of $24,077,355 compared to $25,137,903 as of December 31, 2018. Eighty-four percent (84%) of the book value at December 31, 2019 was in current assets consisting primarily of receivable from the sale of discontinued operations of $18,000,000 compared to twenty-seven percent (27%) of the book value as of December 31, 2018, or $6,888,264, was in current assets consisting primarily of cash and other current assets.

The Company is satisfied that it has sufficient working capital to meet its operating requirements over the next 12 months.


The optical communications industry is subject to significant operational fluctuations. In order to remain competitive, we incur substantial costs associated with research and development, qualification, production capacity and sales and marketing activities in connection with products that may be purchased, if at all, long after we have incurred such costs. In addition, the rapidly changing industry in which we operate, the length of time between developing and introducing a product to market, frequent changing customer specifications for products, customer cancellations of products and general down cycles in the industry, among other things, make our prospects difficult to evaluate. As a result of these factors, it is possible that we may not (i) generate sufficient positive cash flow from operations; (ii) raise funds through the issuance of equity, equity-linked or convertible debt securities; or (iii) otherwise have sufficient capital resources to meet our future capital or liquidity needs. There are no guarantees we will be able to generate additional financial resources beyond our existing balances.

We may not be able to obtain additional capital when desired, on favorable terms or at all.

We operate in a market that makes our prospects difficult to evaluate and, to remain competitive, we will be required to make continued investments in capital equipment, facilities and technology. We expect that substantial capital will be required to continue technology and product development, to expand our manufacturing capacity if we need to do so and to fund working capital for anticipated growth. If we do not generate sufficient cash flow from operations or otherwise have the capital resources to meet our future capital needs, we may need additional financing to implement our business strategy.

If we raise additional funds through the issuance of our common stock or convertible securities, the ownership interests of our stockholders could be significantly diluted. These newly issued securities may have rights, preferences or privileges senior to those of existing stockholders. Additional financing may not, however, be available on terms favorable to us, or at all, if and when needed, and our ability to fund our operations, take advantage of unanticipated opportunities, develop or enhance our infrastructure or respond to competitive pressures could be significantly limited. If we cannot raise required capital when needed, including under our Short Form Prospectus filed with the Canadian Securities Exchange and the SEC in October 2016 and refiled in November 2018, we may be unable to continue technology and product development, meet the demands of existing and prospective customers, adversely affecting our sales and market opportunities and consequently our business, financial condition and results of operations.

We may be subject to disruptions or failures in information technology systems and network infrastructures that could have a material adverse effect on our business and financial condition.

We rely on the efficient and uninterrupted operation of complex information technology systems and network infrastructures to operate our business. A disruption, infiltration or failure of our information technology systems as a result of software or hardware malfunctions, system implementations or upgrades, computer viruses, third-party security breaches, employee error, theft or misuse, malfeasance, power disruptions, natural disasters or accidents could cause a breach of data security, loss of intellectual property and critical data and the release and misappropriation of sensitive competitive information and partner, customer, and employee personal data. Any of these events could harm our competitive position, result in a loss of customer confidence, cause us to incur significant costs to remedy any damages and ultimately materially adversely affect our business and financial condition.

If we fail to protect, or incur significant costs in defending, our intellectual property and other proprietary rights, our business and results of operations could be materially harmed.

Our success depends on our ability to protect our intellectual property and other proprietary rights. We rely on a combination of patent, trademark, copyright, trade secret and unfair competition laws, as well as license agreements and other contractual provisions, to establish and protect our intellectual property and other proprietary rights. We have applied for patent registrations in Canada, the U.S. and other countries, some of which have been issued. We cannot guarantee that our pending applications will be approved by the applicable governmental authorities. Moreover, our existing and future patents and trademarks may not be sufficiently broad to protect our proprietary rights or may be held invalid or unenforceable in court. A failure to obtain patents or trademark registrations or a successful challenge to our registrations in Canada, the U.S. or other countries may limit our ability to protect the intellectual property rights that these applications and registrations intended to cover.


Policing unauthorized use of our technology is difficult and we cannot be certain that the steps we have taken will prevent the misappropriation, unauthorized use or other infringement of our intellectual property rights. Further, we may not be able to effectively protect our intellectual property rights from misappropriation or other infringement in foreign countries where we have not applied for patent protections, and where effective patent, trademark, trade secret and other intellectual property laws may be unavailable, or may not protect our proprietary rights as fully as Canadian or U.S. law. We may seek to secure comparable intellectual property protections in other countries. However, the level of protection afforded by patent and other laws in other countries may not be comparable to that afforded in Canada and the U.S.

We also attempt to protect our intellectual property, including our trade secrets and know-how, through the use of trade secret and other intellectual property laws, and contractual provisions. We enter into confidentiality and invention assignment agreements with our employees and independent consultants. We also use non- disclosure agreements with other third parties who may have access to our proprietary technologies and information. Such measures, however, provide only limited protection, and there can be no assurance that our confidentiality and non-disclosure agreements will not be breached, especially after our employees end their employment, and that our trade secrets will not otherwise become known by competitors or that we will have adequate remedies in the event of unauthorized use or disclosure of proprietary information. Unauthorized third parties may try to copy or reverse engineer our products or portions of our products, otherwise obtain and use our intellectual property, or may independently develop similar or equivalent trade secrets or know-how. If we fail to protect our intellectual property and other proprietary rights, or if such intellectual property and proprietary rights are infringed or misappropriated, our business, results of operations or financial condition could be materially harmed.

In the future, we may need to take legal actions to prevent third parties from infringing upon or misappropriating our intellectual property or from otherwise gaining access to our technology. Protecting and enforcing our intellectual property rights and determining their validity and scope could result in significant litigation costs and require significant time and attention from our technical and management personnel, which could significantly harm our business. We may not prevail in such proceedings, and an adverse outcome may adversely impact our competitive advantage or otherwise harm our financial condition and our business.

We may be involved in intellectual property disputes in the future, which could divert management’s attention, cause us to incur significant costs and prevent us from selling or using the challenged technology.

Participants in the markets in which we sell our products have experienced frequent litigation regarding patent and other intellectual property rights. There can be no assurance that third parties will not assert infringement claims against us and we cannot be certain that our products would not be found infringing on the intellectual property rights of others. Regardless of their merit, responding to such claims can be time consuming, divert management’s attention and resources and may cause us to incur significant expenses. Intellectual property claims against us could result in a requirement to license technology from others, discontinue manufacturing or selling the infringing products, or pay substantial monetary damages, each of could result in a substantial reduction in our revenue and could result in losses over an extended period of time.

If we fail to obtain the right to use the intellectual property rights of others that are necessary to operate our business, and to protect their intellectual property, our business and results of operations will be adversely affected.

From time to time we may choose to or be required to license technology or intellectual property from third parties in connection with the development of our products. We cannot assure you that third party licenses will be available to us on commercially reasonable terms, if at all. Generally, a license, if granted, would include payments of up-front fees, ongoing royalties or both. These payments or other terms could have a significant adverse impact on our results of operations. Our inability to obtain a necessary third-party license required for our product offerings or to develop new products and product enhancements could require us to substitute technology of lower quality or performance standards, or of greater cost, either of which could adversely affect our business. If we are not able to obtain licenses from third parties, if necessary, then we may also be subject to litigation to defend against infringement claims from these third parties. Our competitors may be able to obtain licenses or cross-license their technology on better terms than we can, which could put us at a competitive disadvantage.

If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be adversely affected.

Preparing our consolidated financial statements involves a number of complex manual and automated processes, which are dependent upon individual data input or review and require significant management judgment. One or more of these elements may result in errors that may not be detected and could result in a material misstatement of our consolidated financial statements. The Sarbanes-Oxley Act in the U.S. requires, among other things, that as a publicly traded company we disclose whether our internal control over financial reporting and disclosure controls and procedures are effective. As long as we qualify as an “emerging growth company” under the JOBS Act, we will not have to provide an auditor’s attestation report on our internal controls. During the course of any evaluation, documentation or attestation, we or our independent registered public accounting firm may identify weaknesses and deficiencies that we may not otherwise identify in a timely manner or at all as a result of the deferred implementation of this additional level of review.


Our internal controls cannot guarantee that no accounting errors exist or that all accounting errors, no matter how immaterial, will be detected because a control system, no matter how well designed and operated, can provide only reasonable, but not absolute assurance that the control system’s objectives will be met. If we are unable to implement and maintain effective internal control over financial reporting, our ability to accurately and timely report our financial results could be adversely impacted. This could result in late filings of our annual and quarterly reports under the Canadian Securities Act and the Securities Exchange Act of 1934, or the Exchange Act, restatements of our consolidated financial statements, a decline in our stock price, suspension or delisting of our common stock by the TSX Venture Exchange, or other material adverse effects on our business, reputation, results of operations or financial condition.

Our ability to use our net operating losses and certain other tax attributes may be limited.

As of December 31, 2019, we had accumulated net operating losses (NOLs), of approximately $92 million. Varying jurisdictional tax codes have restrictions on the use of NOLs, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change NOLs, R&D credits and other pre-change tax attributes to offset its post-change income may be limited. An ownership change is generally defined as a greater than 50% change in equity ownership. Based upon an analysis of our equity ownership, we do not believe that we have experienced such ownership changes and therefore the annual utilization of our NOLs may not be subject to such limitation at this time. However, should we experience additional ownership changes, our NOL carry forwards may be limited.

We are subject to governmental export and import controls that could subject us to liability or impair our ability to compete in international markets.

We are subject to export and import control laws, trade regulations and other trade requirements that limit which raw materials and technology we can import or export and which products we sell and where and to whom we sell our products. Specifically, the Bureau of Industry and Security of the U.S. Department of Commerce is responsible for regulating the export of most commercial items that are so called dual-use goods that may have both commercial and military applications. A limited number of our products are exported by license under certain classifications. Export Control Classification requirements are dependent upon an item’s technical characteristics, the destination, the end-use, and the end-user, and other activities of the end-user. Should the regulations applicable to our products change, or the restrictions applicable to countries to which we ship our products change, then the export of our products to such countries could be restricted. As a result, our ability to export or sell our products to certain countries could be restricted, which could adversely affect our business, financial condition and results of operations. Changes in our products or any change in export or import regulations or related legislation, shift in approach to the enforcement or scope of existing regulations, or change in the countries, persons or technologies targeted by such regulations, could result in delayed or decreased sales of our products to existing or potential customers. In such event, our business and results of operations could be adversely affected.

We are exposed to risks and increased expenses and business risk as a result of Restriction on Hazardous Substances, or RoHS directives.

Following the lead of the European Union (“EU”), various governmental agencies have either already put into place or are planning to introduce regulations that regulate the permissible levels of hazardous substances in products sold in various regions of the world. For example, the RoHS directive for EU took effect on July 1, 2006. The labeling provisions of similar legislation in China went into effect on March 1, 2007. Consequently, many suppliers of products sold into the EU have required their suppliers to be compliant with the new directive. We anticipate that our customers may adopt this approach and will require our full compliance, which will require a significant amount of resources and effort in planning and executing our RoHS program, it is possible that some of our products might be incompatible with such regulations. In such events, we could experience the following consequences: loss of revenue, damages reputation, diversion of resources, monetary penalties, and legal action.


Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

We are subject to the U.S. Foreign Corrupt Practices Act, which generally prohibits companies operating in the U.S. from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. In addition, we are required to maintain records that accurately and fairly represent our transactions and have an adequate system of internal accounting controls. Non-U.S. companies, including some that may compete with us, may not be subject to these prohibitions, and therefore may have a competitive advantage over us. If we are not successful in implementing and maintaining adequate preventative measures, we may be responsible for acts of our employees or other agents engaging in such conduct. We could suffer severe penalties and other consequences that may have a material adverse effect on our financial condition and results of operations.

Natural disasters or other catastrophic events could harm our operations.

Our operations in the U.S., Canada and Singapore could be subject to significant risk of natural disasters, including earthquakes, hurricanes, typhoons, flooding and tornadoes, as well as other catastrophic events, such as epidemics, terrorist attacks or wars. For example, our wafer fabrication facility in Singapore is in an area that is susceptible to hurricanes. Any disruption in our manufacturing facilities arising from these and other natural disasters or other catastrophic events could cause significant delays in the production or shipment of our products until we are able to arrange for third parties to manufacture our products. We may not be able to obtain alternate capacity on favorable terms or at all. Our property insurance coverage with respect to natural disaster is limited and is subject to deductible and coverage limits. Such coverage may not be adequate or continue to be available at commercially reasonable rates and terms. The occurrence of any of these circumstances may adversely affect our financial condition and results of operation.

We have closed the sale of our DenseLight subsidiary and received $21 million of the $26 million due on the sale. The remaining tranche of $5 million is scheduled to be paid on or before May 31, 2020. If for any reason the holders or our convertible debentures decide to redeem rather than convert their debentures at the time we receive the final payment and provide notice to holders that they are entitled to redeem, we could experience a significant outflow of cash that could interrupt our operating plans, delay new product introduction and cause significant harm to the Company.

We have planned our operation based on receiving the full consideration for the sale of DenseLight, we have decided not to declare the sale “completed” until we receive the final payment. Given the environment that COVID-19 has produced and the likely losses that have been incurred by the holders of our convertible debentures in other investments, we are concerned that once those holders are entitled to redeem that substantial numbers of them may do so, resulting in a significant outflow of cash during a critical period of time for the Company. While we intend to contact all the convertible debentures holders to explain the burden that redemptions would place on the Company, we cannot guarantee that our appeals for restraint in redemptions would be successful.

The outstanding amount owed in connection with the convertible debentures is $3,429,105. If we do not receive the final payment from the Buyer, and if all or a majority of the purchasers of the convertible debentures request redemption, the Company may have to divert its limited cash to these repayments rather than into its operations

The coronavirusCOVID-19 outbreak could delay our development activities and adversely affect our results of operations.

 

The global outbreak of COVID-19 has resulted in Canada, the United States, Singapore and other countries halting or sharply curtailing the movement of people, goods and services. The curtailed activity has negatively affected many businesses, including businesses that operate in our sector. The prolonged economic impact of COVID-19 remains uncertain. At this point, we believe the conditions may have a material adverse impact on our business.business, as our suppliers are experiencing major delays resulting from high backlogs of orders and an inability to operate at full capacity. Such delays have resulted in a 6 – 8 week delay in the Company achieving certain development objectives. Given the rapidly changing developments we cannot accurately predict what effects these conditionsdevelopments will have on our business going forward, which will depend on, among other factors, the ultimate geographic spread of the virus, governmental limitations, the duration of the outbreak, travel restrictions and business closures imposed globally by various governments.closures.

 


The Company may experience these factors in the future and these factors may have a material adverse effect on the Company’s business, operating results and financial condition.

Risks Related to Our Common Stock

 

Our stock price has been and may continue to be volatile.

 

The trading price for our common stock on the TSX Venture Exchange (“TSXV”) has been and is likely to continue to be highly volatile. Although we have registered our stock with the SEC, the U.S. market for our shares has been slow to develop, and if and as such a market develops, prices on that market are also likely to be highly volatile. The market prices for securities of early stageearly-stage technology companies have historically been highly volatile.

 

Factors that could adversely affect our stock price include:

 

• fluctuations in our operating results and our financial condition;

• announcements of new products, partnerships or technological collaborations and announcements of the results or further actions in respect of any products, partnerships or collaborations, including termination of same;

• innovations by us or our competitors;

• governmental regulation;

• developments in patent or other proprietary rights;

• the results of technology and product development testing by us, our partners or our competitors;

• litigation;

• general stock market and economic conditions;

• number of shares available for trading (float); and

• inclusion in or dropping from stock indexes.

fluctuations in our operating results and our financial condition;
announcements of new products, partnerships or technological collaborations and announcements of the results or further actions in respect of any products, partnerships or collaborations, including termination of same;
innovations by us or our competitors;
governmental regulation;
developments in patent or other proprietary rights;
the results of technology and product development testing by us, our partners or our competitors;
litigation;
general stock market and economic conditions;
number of shares available for trading (float); and
inclusion in or dropping from stock indexes.

 

As of April 22, 2020,March 13, 2021, our 52-week high and low closing market prices for our common stock on the TSXV were CA$0.561.49 and CA$0.23.0.22.

 


Page 19

 

We have historically obtained, and expect to continue to obtain, additional financing primarily by way of sales of equity, which may result in significant dilution to existing shareholders.

 

We have not earned profits, so the Company’s ability to finance operations is chiefly dependent on equity financings. Since 2012 weFunds raised approximately US$60.6 million (net of share issue costs) inthrough equity public offerings, financing through private placements or the exercise of stock options and warrants and the conversion of convertible debt into common shares in support of the Company’s business which has resulted in significant dilution to existing shareholders.shareholder dilution. Further equity financings will also result in dilution to existing shareholders, and such dilution could be significant.

 

Future sales of common stock, or warrants, or the prospect of future sales, may depress our stock price. The exercise of share purchase options and warrants will create dilution which could adversely affect the Company’s shareholders.

 

Sales of a substantial number of shares of common stock, or warrants, or the perception that sales could occur, could adversely affect the market price of our common stock. Additionally, as of April 22, 2020,March 13, 2021, there were outstanding options to purchase up to 29,539,15545,704,282 shares of our common stock that are currently exercisable and additional outstanding options to purchase up to 25,047,296 shares of common stock that are exercisable over the next several years.stock. As of April 22, 2020,March 13, 2021, there were outstanding warrants to purchase 45,729,85021,406,816 shares of our stock. The holders of these options and warrants have an opportunity to profit from a rise in the market price of our common stock with a resulting dilution in the interests of the other shareholders. The existence of these options and warrants may adversely affect the terms on which we may be able to obtain additional financing. The weighted average exercise price of issued and outstanding options is CAD$0.65,0.42, the weighted average exercise price of warrants is CAD$0.57,0.51, which compares to the CAD$0.521.17 market price at closing on April 22, 2020.March 13, 2021. If all of these securities were exercised, an additional 99,331,30167,111,098 common shares would become issued and outstanding. This represents an increase of 34.2%19.95% in the number of shares issued and outstanding and would result in significant dilution to current shareholders

 

The risks associated with penny stock classification could affect the marketability of the Company’s common shares and shareholders could find it difficult to sell their shares.

 

The Company’s common shares are subject to “penny stock” rules as defined in Exchange Act Rule 3a51-1. The SEC adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Transaction costs associated with purchases and sales of penny stocks are likely to be higher than those for other securities. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities listed on certain U.S. national securities exchanges, provided that current price and volume information with respect to transactions in such securities is provided by the exchange).

 

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation.

 

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from such rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the Company’s common shares in the United States and shareholders may find it more difficult to sell their shares.

 


Page 20

 

The rights of our shareholders may differ from the rights typically afforded to shareholders of a U.S. corporation.

 

We are incorporated under the Business Corporations Act (Ontario) (the “OBCA”). The rights of holders of our common shares are governed by the laws of the Province of Ontario, including the OBCA, by the applicable laws of Canada, and by our Articles of Continuance and all amendments thereto (collectively, the “Articles”), and our by-laws (the “By-laws”). These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. The principal differences include without limitation the following:

 

Under the OBCA, we have a lien on any common share registered in the name of a shareholder or the shareholder’s legal representative for any debt owed by the shareholder to us. Under U.S. state law, corporations generally are not entitled to any such statutory liens in respect of debts owed by shareholders.

 

With regard to certain matters, we must obtain approval of our shareholders by way of at least 66 2/3% of the votes cast at a meeting of shareholders duly called for such purpose being cast in favor of the proposed matter. Such matters include without limitation: (a) the sale, lease or exchange of all or substantially all of our assets out of the ordinary course of our business; and (b) any amendments to our Articles including, but not limited to, amendments affecting our capital structure such as the creation of new classes of shares, changing any rights, privileges, restrictions or conditions in respect of our shares, or changing the number of issued or authorized shares, as well as amendments changing the minimum or maximum number of directors set forth in the Articles. Under U.S. state law, the sale, lease, exchange or other disposition of all or substantially all of the assets of a corporation generally requires approval by a majority of the outstanding shares, although in some cases approval by a higher percentage of the outstanding shares may be required. In addition, under U.S. state law the vote of a majority of the shares is generally sufficient to amend a company’s certificate of incorporation, including amendments affecting capital structure or the number of directors.

 

Pursuant to our By-laws, two persons present in person or represented by proxy and each entitled to vote thereat shall constitute a quorum for the transaction of business at any meeting of shareholders. Under U.S. state law, a quorum generally requires the presence in person or by proxy of a specified percentage of the shares entitled to vote at a meeting, and such percentage is generally not less than one-third of the number of shares entitled to vote.

 

Under rules of the Ontario Securities Commission, a meeting of shareholders must be called for consideration and approval of certain transactions between a corporation and any “related party” (as defined in such rules). A “related party” is defined to include, among other parties, directors and senior officers of a corporation, holders of more than 10% of the voting securities of a corporation, persons owning a block of securities that is otherwise sufficient to affect materially the control of the corporation, and other persons that manage or direct, to a substantial degree, the affairs or operations of the corporation. At such shareholders’ meeting, votes cast by any related party who holds common shares and has an interest in the transaction may not be counted for the purposes of determining whether the minimum number of required votes have been cast in favor of the transaction. Under U.S. state law, a transaction between a corporation and one or more of its officers or directors can generally be approved either by the shareholders or a by majority of the directors who do not have an interest in the transaction.

 

Neither Canadian law nor our Articles or By-laws limit the right of a non-resident to hold or vote common shares of the Company, other than as provided in the Investment Canada Act (the “Investment Act”), as amended by the World Trade Organization Agreement Implementation Act (the “WTOA Act”). The Investment Act generally prohibits implementation of a direct reviewable investment by an individual, government or agency thereof, corporation, partnership, trust or joint venture that is not a “Canadian,” as defined in the Investment Act (a “non-Canadian”), unless, after review, the minister responsible for the Investment Act is satisfied that the investment is likely to be of net benefit to Canada. An investment in the common shares of the Company by a non-Canadian (other than a “WTO Investor,” as defined below) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company, and the value of the assets of the Company were CA$5.0 million or more (provided that immediately prior to the implementation of the investment the Company was not controlled by WTO Investors). An investment in common shares of the Company by a WTO Investor (or by a non- Canadian other than a WTO Investor if, immediately prior to the implementation of the investment the Company was controlled by WTO Investors) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company and the value of the assets of the Company equaled or exceeded certain threshold amounts determined on an annual basis. The threshold for a pre-closing net benefit review depends on whether the purchaser is: (a) controlled by a person or entity from a member of the WTO; (b) a state- owned enterprise (SOE); or (c) from a country considered a “Trade Agreement Investor” under the Investment Act. A different threshold also applies if the Canadian business carries on a cultural business. The 20202021 threshold for WTO investors that are SOEs will be $428CA$416 million based on the book value of the Canadian business'business’ assets, updown from $416CA$428 million in 2019.2020. The 20202021 thresholds for review for direct acquisitions of control of Canadian businesses by private sector investor WTO investors ($1 billion) and private sector trade- agreement investors ($1.5 billion) remain the same and are both based on the "enterprise value"“enterprise value” of the Canadian business being acquired.

 


Page 21

 

A non-Canadian, whether a WTO Investor or otherwise, would be deemed to acquire control of the Company for purposes of the Investment Act if he or she acquired a majority of the common shares of the Company. The acquisition of less than a majority, but at least one-third of the shares, would be presumed to be an acquisition of control of the Company, unless it could be established that the Company is not controlled in fact by the acquirer through the ownership of the shares. In general, an individual is a WTO Investor if he or she is a “national” of a country (other than Canada) that is a member of the WTO (“WTO Member”) or has a right of permanent residence in a WTO Member. A corporation or other entity will be a “WTO Investor” if it is a “WTO Investor-controlled entity,” pursuant to detailed rules set out in the Investment Act. The U.S. is a WTO Member. Certain transactions involving our common shares would be exempt from the Investment Act, including:

 

• an acquisition of our common shares if the acquisition were made in connection with the person’s business as a trader or dealer in securities;

• an acquisition of control of the Company in connection with the realization of a security interest granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act; and

• an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization, following which the ultimate direct or indirect control of the Company, through the ownership of voting interests, remains unchanged. Under U.S. law, except in limited circumstances, restrictions generally are not imposed on the ability of non- residents to hold a controlling interest in a U.S. corporation.

an acquisition of our common shares if the acquisition were made in connection with the person’s business as a trader or dealer in securities;
an acquisition of control of the Company in connection with the realization of a security interest granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act; and
an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization, following which the ultimate direct or indirect control of the Company, through the ownership of voting interests, remains unchanged. Under U.S. law, except in limited circumstances, restrictions generally are not imposed on the ability of non- residents to hold a controlling interest in a U.S. corporation.

 

As a “foreign private issuer”, the Company is exempt from certain sections of the Exchange Act which results in shareholders having less complete and timely data than if the Company were a domestic U.S. issuer.

 

As a “foreign private issuer,” as defined under the U.S. securities laws, we are exempt from certain sections of the Exchange Act. In particular, we are exempt from Section 14 proxy rules that are applicable to domestic U.S. issuers. The submission of proxy and annual meeting of shareholder information (prepared to Canadian standards) on Form 6-K has typically been more limited than the submissions required of U.S. issuers and results in shareholders having less complete and timely data, including, among others, with respect to disclosure of: (i) personal and corporate relationships and age of directors and officers; (ii) material legal proceedings involving the Company, affiliates of the Company, and directors, officers promoters and control persons; (iii) the identity of principal shareholders and certain significant employees; (iv) related party transactions; (v) audit fees and change of auditors; (vi) voting policies and procedures; (vii) executive compensation; and

(viii) composition of the Compensation Committee. In addition, due to the Company’s status as a foreign private issuer, the officers, directors and principal shareholders of the Company are exempt from the short-swing insider disclosure and profit recovery provisions of Section 16 of the Exchange Act. The foregoing exemption results in shareholders having less data in this regard than is available with respect to U.S. issuers.

 

If the Company is characterized as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences.

 

As more fully described below in ITEM 10.E. “Taxation” — United States Federal Income Tax Considerations — Passive Foreign Investment Company Status”, if for any taxable year our passive income, or the value of our assets that produce (or are held for the production of) passive income, exceed specified levels, we may be characterized as a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes. This characterization could result in adverse U.S. tax consequences to our U.S. shareholders, including gain on the disposition of our common shares being treated as ordinary income and any resulting U.S. federal income tax being increased by an interest charge. Rules similar to those applicable to dispositions generally will apply to certain “excess distributions” in respect of our common shares.

 

Page 22

The actual allocation of proceeds from any financing undertaken may differ from the Company’s initial or current intentions.

 

The Company has discretion in the use of the net proceeds from any offering of equity securities. The Company may elect to allocate proceeds differently from its initial or current intentions. The failure by the Company’s management to apply these funds effectively could have a material adverse effect on its business.

 


Warrants included with financings

 

Warrants offered with financings are not listed on any exchange. Investors may be unable to sell the warrants at the prices desired or at all. There is no existing trading market for the warrants and there can be no assurance that a liquid market will develop or be maintained for the warrants, or that an investor will be able to sell any of the warrants at a particular time (if at all). The liquidity of the trading market in the warrants, and the market price quoted for the warrants, may be adversely affected by, among other things:

 

changes in the overall market for the warrants;

changes in the Corporation's financial performance or prospects;

changes or perceived changes in the Corporation's creditworthiness;

the prospects for companies in the industry generally;

the number of holders of the warrants;

the interest of securities dealers in making a market for the warrants; and

prevailing interest rates.
changes in the overall market for the warrants;
changes in the Corporation’s financial performance or prospects;
changes or perceived changes in the Corporation’s creditworthiness;
the prospects for companies in the industry generally;
the number of holders of the warrants;
the interest of securities dealers in making a market for the warrants; and
prevailing interest rates.

 

ITEM 4. INFORMATION ON THE COMPANY

 

A.History and Development of the Company

 

The legal and commercial name of the Company is POET Technologies Inc. The Company was originally incorporated under the British Columbia Company Act on February 9, 1972 as Tandem Resources Ltd. On November 14, 1985, Tandem Resources Ltd. amalgamated with Stanmar Resources Ltd. and Keezic Resources Ltd., to continue as one company under the name Tandem Resources Ltd. under the British Columbia Company Act. By Articles of Continuance dated January 3, 1997, Tandem Resources Ltd. was continued under the OBCA. By Articles of Amendment dated September 26, 2006, Tandem Resources Ltd. changed its name to OPEL International Inc. By Certificate of Continuance dated January 30, 2007, OPEL International Inc. was continued under the New Brunswick Business Corporations Act. By Articles of Continuance dated November 30, 2010, OPEL International Inc. was continued under the OBCA and changed its name to OPEL Solar International Inc. By Articles of Amendment dated August 25, 2011, OPEL Solar International Inc. changed its name to OPEL Technologies Inc. By Articles of Amendment dated July 23, 2013, OPEL Technologies Inc. changed its name to POET Technologies Inc.

 

On May 11, 2016, in an all-stock transaction, the Company acquired all the issued and outstanding shares of DenseLight Semiconductor Pte. Ltd., a privately held Singapore company that provides optical solutions. DenseLight designs, manufactures and sells optical light source products. DenseLight was acquired for $10,500,000 of the Company’s stock. The Company issued 13,611,150 common shares to the former shareholders of DenseLight.

 

Page 23

On November 8, 2019, the Company sold 100% of the issued and outstanding shares of DenseLight for $26,000,000. The Company recognized a gain on the sale of $8,707,280.

 

On June 22, 2016, in an all-stock transaction, the Company acquired all the issued and outstanding shares of BB Photonics Inc., a privately held US Company with a wholly owned subsidiary, BB Photonics UK Ltd. Both companies design integrated photonics solutions for the data communications market. BB Photonics and its subsidiary were acquired for consideration of $1,550,000. The acquisition was settled with the issuance of 1,996,090 common shares of the Company to the former shareholders of BB Photonics. The Company dissolved BB Photonics UK Ltd. on October 6, 2020.

 


On May 17, 2019, the Company established POET Technologies Pte. Ltd. (“PTS”), a wholly owned subsidiary in Singapore. On August 4, 2020, PTS established POET Optoelectronics Shenzhen Co., Ltd (“POET SZ”), a wholly owned subsidiary in Shenzhen, China.

On October 22, 2020, the Company signed a Joint Venture Agreement establishing a joint venture company, Super Photonics Xiamen Co., Ltd with Xiamen Sanan Integrated Circuit Co. Ltd. Super Photonics Xiamen Co., Ltd was formed on March 12, 2021.

 

The following is a graphic description of the Company and its subsidiaries:

 


 

OPEL Solar Inc. and ODIS Inc.

 

OPEL Solar, Inc. (OPEL)

 

OPEL is a wholly-owned subsidiary of POET Technologies and is the assignee for all patents and patent applications filed by the Company prior to 2019.

 

Page 24

ODIS Inc. (“ODIS”)

 

ODIS is a wholly owned subsidiary of OPEL Solar, Inc. and is the developer of the POET platform semiconductor process IP for fabrication of integrated circuit devices containing both electronic and optical elements in a single package ("(“hybrid integration"integration”).

 

BB Photonics Inc. and BB Photonics UK Ltd.

 

BB Photonics develops photonic integrated components for the datacenter market utilizing embedded waveguide technology that is intended to enable on-chip athermal wavelength control which lowers the total solution cost of datacenter photonic integrated circuits.

 

POET Technologies Pte Ltd. (“PTS”)

 

PTS is a wholly owned subsidiary of POET Technologies Inc. Situated in Singapore, PTS tests and validates the designs of ODISODIS.

POET Optoelectronics Shenzhen Co., Ltd (“POET SZ”)

POET SZ is a wholly owned subsidiary of PTS. Situated in Shenzhen, China, PTS develops optoelectronic products based on the designs of ODIS.

Super Photonics Xiamen Co., Ltd, (“SPX”)

SPX is a joint venture, situated in Shenzhen, China. SPX was established with Sanan IC with a sole purpose to assemble, test, package and sell cost-effective, high-performance optical engines based on POET’s proprietary Optical Interposer platform technology.

 

The Company operates geographically in the United States, Canada, Singapore and SingaporeChina.

 

Capital Expenditures

 

Our capital expenditures for the last three years, which principally consist of purchases of research and development equipment and instrumentation and patents are as follows:

 

Period  Capital Expenditure Purpose Capital Expenditure Purpose
Fiscal 2020 $1,573,863  Instruments, equipment and patents
Fiscal 2019 (1) $2,121,987 Instruments, equipment and patents $2,121,987  Instruments, equipment and patents
Fiscal 2018 $3,785,760 Instruments, equipment and patents $3,785,760  Instruments, equipment and patents
Fiscal 2017 $1,030,340 Instruments, equipment and patents

 

(1)Prior to the sale of DenseLight, the Company spent $1,610,503 in capital expenditures at DenseLight and $511,484 on capital expenditures at POET. The capital items acquired at DenseLight were sold as part of the sale.

 

The Company’s registered office is located at Suite 1107, 120 Eglinton Avenue East, Toronto, Ontario, Canada M4P 1E2 and its phone number is (416) 368-9411. The Company has operations at Suite 308, 1605 N. Cedar Crest Boulevard, Allentown, PA, 18104, and 21 Changi North Way, #04-06, Singapore, 498774.498774 and Unit 02, 10th Floor, A4 Building, Kexing Science Park, No.15 Keyuan Road, Science Park Middle District, Nanshan District, Shenzhen, 518057

 

B.Business Overview

 

Corporate Overview

 

Page 25

Overview

 

We design, develop, manufacture and sell both discrete and integrated opto-electronic solutions for data communications and telecommunications markets. POET has developed and is marketing its proprietary POET Optical InterposerÔ platform. The POET Optical InterposerTM platform which utilizes a novel waveguide technology that allows the integration of electronic and photonic devices into a single multi-chip module. The integration of devices into a single package is achieved by applying advanced wafer-level semiconductor manufacturing techniques and novel packaging methods developed by POET. POET’s Optical Interposer eliminates costly components, assembly and testing methods employed in conventional photonics solutions. In addition to lowering costs compared to conventional devices, POET’s Optical Interposer provides a flexible and scalable platform for a variety of photonics applications ranging from data centers to consumer products.

 


POET’s Optical Interposer is a platform technology upon which multiple applications can be based, including transceivers for data- and tele-communications, integrated photonics on electronic switching devices, low-cost components for the networking and cellular markets, automotive LIDAR and a plethoravariety of sensing and other applications using light as a medium for data transmission. In each case, devices traditionally associated with photonics, such as laser diodes, light emitting diodes, detectors, amplifiers and the associated waveguides and other passive devices are designed specifically in the context of the Optical Interposer to meet the needs and functions of specific applications.

 

POET has targeted as the first application of the Optical Interposer the development of Optical Engines for transceivers used in data centers. Transceivers are used to convert digital electronic signals into light signals and to transmit and receive those light signals via fiber optic cables within datacenters and between datacenters and metropolitan centers in a vast data and tele-communications network. In 2019 we delivered prototypes of certain components designed for our Optical Engines and we expect to continue to do so throughout 2020. These prototypes addressinto 2020, representing a period of technology development in which the emerging high-growth segmentbasic concept of the current marketOptical Interposer was demonstrated. At about mid-year, in connection with certain customers that understood POET’s approach, we began a period of product development, applying our novel technologies to specific products used in specific applications, including transceiver modules, light sources and optical computational platforms used in artificial intelligence applications. This activity requires the production of a different kind of prototype, which we are now engaged in producing for Optical Engines. Continued developmentthese customers. Product prototypes go through various stages of our Optical Enginematurity, including pre-alpha, alpha and beta, all associated with how closely the prototypes is intendedmeet customer specifications. Typically, the last stage of prototypes are the beta samples, which are supplied to add several commonly used communication protocolscustomers in small volumes and data speedsare subjected to increase the functionality of our Optical Enginesrigorous testing and to address broader markets.qualification. Only when prototypes pass qualification, are they ready for mass production.

 

Virtually all of POET'sPOET’s R&D expenditures in recent years have been in some way connected to the Optical Interposer. We expect to continue to spend the majority of our R&D resources for the foreseeable future on Optical Interposer-based components across a variety of potential applications. DenseLight has also incurred R&D expenditures for conventional non-interposer-based products, primarilydevices directed at specific application areas in the area of photonic sensing that represent the majority of the Company’s current product sales.connection with strategic partners already selling to those application areas.

 

As a platform technology, Optical Interposer development does not have a specific end point. Each application of the Optical Interposer requires design and development specific to thethat application. POET’s product roadmap is currently focused on the development of Optical Engines for optical transceivers. Optical Engines include all of the photonics-related components of a transceiver but do not include several of the electronic devices needed for a functioning transceiver module. Nor does it include the external packaging and optical fibers. Nevertheless, Optical Engines represent the majoritya significant portion of the cost and value of most optical transceivers.

The success of the Optical Interposer is derived from the unique and proprietary integration of “active” and “passive” components at the chip level, with all of the processing, assembly, packaging and test done at wafer-level. Wafer-level processing eliminates the complex, high-cost individual alignment steps required in conventional and silicon photonics-based assembly following placement of each photonic device in the package. In addition to eliminating the alignment steps, wafer-level processing also eliminates the capital expense of the equipment typically used to measure the alignment. The Optical Interposer platform allows the use of known-good device components, eliminates multiple points of potential failure in alternative processing methods, and eliminates much of the labor associated with fabrication of photonics devices.

Page 26

 

The “active” components that are included in a POET Optical Engine include lasers, detectors and modulators fabricated on InP or Silicon substrate and specifically designed to be integrated into the Optical Interposer fabric. We have supplemented our active component device development with co-development partners and license agreements, including for certain types of lasers and modulators. This not only reduces the risk to internal development and accelerates time to market, but it also ensures second sources of Optical Interposer-compatible active components, a critical part of our strategy going forward.

 

In parallel to these activities, POET has also directedbeen engaged in development programs in two other areas for the Optical Interposer platform, outside of DenseLight, includingnamely Passive Component design and development and Core Integration process development. Passive devices include filters, mux-demux devices, waveguides and spot size converters, all designed and fabricated using POET’s proprietary materials and processes. The Optical Interposer devices are fabricated at a third-party foundry. We transferred the basic processes for producing our Optical Interposers to our foundry partner in 2018 and since then we have continued to improve those processes in order to make them suitable for high volume manufacturing.

 

Core Integration Process Developmentdevelopment relates primarily to advanced packaging methods that, combined with the unique design of the Optical Interposer, allows true wafer-scale assembly and test. We do not believe that such true wafer-scale integration has yet been demonstrated by any other approach in the photonics industry. We are able to achieve chip-level integration and wafer-scale assembly, test and packaging because all of the active devices are designed to be placed and “matched” to passive device interfaces on the foundational Optical Interposer wafer using pick-and-place assembly techniques. We eliminate the high cost and cumbersome process of testing each component following placement. Once placed and tested at wafer scale, each Optical Interposer device is sealed, the wafer is separated into hundreds of individual die, and the final Optical Engine is ready for shipment to the customer. Each of these process steps, from flip-chipping of devices onto the Optical Interposer, pick and place assembly, hermetic sealing and singulation required substantial innovation and development, including several techniques that are unique in the photonics and compound semiconductor industries. Core Integration development became a top priority once POET entered the product development stage with customers and became critical with the signing of the JVA for the creation of SPX.

 

We are also working with leading industry partners on optical enginesOptical Engines and other components for 400G transceivers, which is the next generation of transceiver modules that are expected to be introduced into data centers in the coming months and years. We believe that the Optical Interposer platform is very relevant to markets beyond data communications, such as telecommunications, Automotiveautomotive LIDAR, and in “Co-Packaged Optics,” which is the integration of optics with Application Specific Integrated Circuits (ASICs), including switches and graphics generators.generators, for both data center application and more self-contained applications of optical computing, which is relevant for artificial intelligence.

 

“G” is an abbreviation for “Giga bits per second”, the rate at which the device transmits or receives data.

 


Page 27

 

Industry Background

 

The explosion in data, storage and information distribution is driving extraordinary growth in internet traffic and cloud services. The expected growth in the networking and data communication market is the result of many factors, among them being, the growth of wireless and mobile traffic (which will account for 71% of total Internet Provider (IP) traffic by 20221), social media activity, the progression of video transmission, the emergence of imaging such as virtual/augmented/mixed reality and 3D video, the continued migration to cloud storage, the propagation of sensors feeding the Internet of Things, and the evolution of big data analytics and machine learning/artificial intelligence. These factors will continue to drive a long-term increased demand for more capacity and higher speeds.

 

Photonics has traditionally been employed to transmit and receive data over long distances because light can carry considerably more content and data at faster speeds than other means of transmission, such as radio waves or copper wires. Optical transmission becomes more energy efficient as compared to electronic alternatives when the transmission length and speed increase. As a natural consequence, optics arehave systematically replacingreplaced copper in many of the data center communication links where speed, bandwidth and energy are at a premium.

 

Data center operators are increasing the size and scale of their facilities, while simultaneously looking to component suppliers for solutions capable of providing higher data transmission rates. Within data centers, data communications over distances 500 m to 2 km have already been transitioned from inherently lower speed copper cable to optical fibers. Furthermore, short reach communications, either rack-to-rack or within the rack as well as those requiring speeds of up to 100G, are now increasingly being converted from copper to optical cables.

 

Outside the Data Centers, future 5G build-out of mobile communications will drive speed and capacity requirements closer to the user with significant reduction in latency. Compared to 4G, 5G technology standard offers much faster download and upload speed, minimum delay in data communication and processing, as well as much higher density in device connections. 5G will enable advances in virtual reality, augmented reality, autonomous driving, high-definition video, and the Internet of Things, among other applications. All of these applications require advanced photonics devices to provide higher speeds and more bandwidth.

 

1 Cisco Visual Networking Index: Forecast and Methodology, 2017-2022, White Paper, Executive Summary, Feb. 27, 2019


Photonics Markets

 

POET’s primary intent is to sell its Optical Interposer-based solutions in the Optical Data Communications market.

 

The Optical Communications Market (which includesglobal optical switchingcommunication and networking equipment fiber optic transmission systems, transceivers, etc. formarket size was valued at US$18.9 billion in 2020 and is projected to reach US$ 27.8 billion by 2025; it is growing at a CAGR of 8.0% from 2020 to 2025. Rising adoption of cloud-based services and virtualization services all industries) is forecasted to grow at about 9% CAGR over the period from 2017world, increasing data traffic due to 2023, to US$24 billion from a current US$15 billion.increased internet usage, and growing number of data centers are the factors driving the optical communication and networking equipment industry growth.2 System

1Cisco Visual Networking Index: Forecast and component growth is driven largely by global Internet Provider (IP) traffic, which is expected to nearly triple from 2017 to 2022, representing a 26% CAGR.Methodology, 2017-2022, White Paper, Executive Summary, Feb. 27, 2019

32 Markets and Markets Research Private Ltd. Optical Communication and Networking Equipment Market, February 2020

Page 28

Within the overall Data Communications market, photonicsales of optical transceivers will representare expected to grow from US$5.7 billion in 2020 to US$ 9.2 billion by 2025, at a $25 billion market opportunity in 2025, according to Oculi, llcCAGR of 10.0%. Increasing the adoption of smart devices and rising data traffic has spurred the growth of the optical transceiver market. Other drivers for the optical transceiver industry growth include growing demand for cloud computing applications and the increasing requirement for compact and energy-efficient transceivers.43

The primary segments for photonicoptical transceivers are Ethernet, wide area network (WAN) and dense wavelength division multiplexing (DWDM), all of which are predominantly addressed by InP-based optical technologies. Ethernet transceivers are forecastedexpected by the Company to grow to $7.4 billion by 2025represent the largest of these three segments, with 100G course wavelength division multiplexing (CWDM) driving a majority of the growth. Within Ethernet, single mode transceivers based on InP devices are forecasted to outgrow multimode transceivers based on GaAs devices by a factor of 6:1. Segmented by distance, the majority of growthThe trend in this segment is expected in the <10km segment ($4.3 billion by 2025).5

Integratedfor integrated photonic transceivers, incorporating approaches such as silicon photonics, which is comparable to that of POET, are expected to overtake thoseovertaking conventional technologies using discrete components by 2021, growing from a current $3.2 billion to $20 billion in 20256. Within this market, POET is focused onwithin the highest growth segments, including Wavelength Division Multiplexing (WDM) for medium-reach (500m – 2km) Ethernet datacom connections and Wide Area Network protocols for long-reach or metro applications (2km – 10km). next few years.

The majority of today’s conventional discrete transceiver suppliers are shipping 100G transceivers in a 4x25G format, having developed assembly methods for placing multiple laser chips on one substrate and coupling the output into one fiber using micro-optic filters and other elements. POET’s approach is to use the Optical Interposer to combine multiple active and passive devices into a single device, or “Optical Engine”, which when combined with control electronics and an outer housing, constitutes a pluggable optical transceiver. We plan to sell our optical engines to manufacturers and assemblers of optical transceiver modules. We believe our Optical Engine solution will behave a significant cost competitive withadvantage over both conventional modules as well as silicon photonics in the <2km data center market, and it should bewhile also being scalable to 10km, and supportsupporting 200G, 400G and 400G800G datacom speeds.

 

WhileDemand for ethernet optical transceivers declined in the first half of 2019 for the first time since 2009, accompanied by a steep drop in prices. In the latter part of the year, demand increased only to be forestalled by the COVID-19 pandemic in early 2020. Nevertheless, the deficiencies in network infrastructure became apparent during crisis, causing a renewed emphasis globally on infrastructure investment which, along with increased growth curve for photonics products has flattened in 2019, especiallyinternet traffic, should translate into renewed growth in 100G datacom applications,2020 and beyond. The life cycles of transceivers at each speed node are exceedingly long, extending 6 – 10 years or more, with multiple generations in each node. As a result, we believe that margin pressuresthe 100G/200G market is a viable market for POET. In addition, during the past year, widespread adoption of 400G has been delayed and the opportunity for Optical Engines based on module makers will create large opportunitiesthe POET Optical Interposer to be designed-in to modules of major suppliers persists.

Our Strategy

Our vision for the Company is to become the global leader in chip-scale photonic solutions by deploying our Optical Interposer technology to enable the seamless integration of electronics and photonics for a low or lowestbroad range of vertical market applications.

Our strategy includes the following key elements:

● Introduce the Optical Interposer approach to suppliers of transceivers and data center operators and form commercial partnerships for product development. Because of the magnitude of the cost provider.savings and performance advantages that may be derived from the use of POET’s Optical Engines for transceiver applications, we expect to generate significant interest among both the suppliers of transceiver modules and their ultimate customers, the data center operators. In addition, in datacom, the overall slowing of growth has the advantage of providing more time for the design and introduction of first generation 400G transceivers, which we have prioritized for our firstPOET Optical Interposer prototypes.provides a straightforward and cost-effective path to higher speed transceivers, including up to 400G and higher, providing a single platform that can span several device generations. We anticipate that several companies will be interested in pursuing commercial partnerships with POET in order to qualify and design-in our Optical Engines.

 

23 Markets and Markets Inc. Optical Transceiver Market, Research Future Optical Communications Market Research Report – Global Forecast to 2023, January 2019

3 Cisco VNI, Forecast Overview, Feb. 27, 2019

4 Oculi, llc, Estimates for 2025 commissioned by POET Technologies, Inc., March 2017

5 Ibid

6 Ibid

2020 

 


Page 29

 

● Promote the POET Optical Interposer as a true platform technology across several photonic applications and markets. The POET Optical Interposer is designed to be a flexible platform for the combination or integration of various photonic and electronic components. The low cost makes it suitable for applications like transceivers and automotive LIDAR. The compatibility of the Optical Interposer manufacturing process with standard silicon CMOS processing and the ability to construct architectures with substantially lower energy consumption opens up large and critical data processing applications where super high-speed processing is essential, such as integration with next generation switches and artificial intelligence.

● Pursue multiple potential sources of non-product revenue and strategic partnerships. In addition to product sales, we have been pursuing Non-Recurring Engineering (“NRE”) revenues from end-use customers and/or from strategic partners. In particular, we believe our 400G transceiver components represent a uniquely attractive opportunity for collaborative development with a strategic partner(s).

● Pursue a “fab-light” strategy. “Fab-light” is a common business model in the semiconductor industry. Such a strategy allows the Company to invest more in design and development of Optical Interposer-based solutions, expand its marketing and sales presence globally and spend less on capital equipment and maintenance of facilities, enabling a faster path to profitability.

● Pursue complementary strategic alliance or acquisition opportunities. We intend to evaluate and selectively pursue strategic alliances or acquisition opportunities that we believe will accelerate our penetration of specific applications or vertical markets with our technology or products.

Our Products

 

·POET has announced its LightBar™ and LightBar-C™ products as fully multiplexed light source products operating in the “O-band” for data communications applications and the “C-band” for sensing and computing applications. Both LightBar products come fully assembled with fiber attached for easy adaptation to existing transceiver module and co-packaging applications.
POET is currently engaged in the development of 100G, 200G and 400G CWDM4, LR4 and FR4 Optical Engines andas components for 400G transceiver assemblies.

 

Competition

 

The photonics market is intensely competitive and we expect experience intense competition from a number of manufacturers with alternative technologies. Many of our competitors will be larger than we are and have significantly greater financial, marketing and other resources.

 

In addition, several of our competitors, especially in the datacom markets, have large market capitalizations or cash reserves and are much better positioned to acquire other companies to gain new technologies or products that may displace our products. Data center equipment providers, who we expect to become our customers, and data center service providers, who are supplied by our customers, may decide to manufacture the optical subsystems that we plan to provide. We may also encounter potential customers that, because of existing relationships, are committed to the products offered by these competitors.

 

We believe the principal competitive factors in our target markets include the following:

 

 ·use of internally manufactured components;

 ·product breadth and functionality;

 

 ·Page 30

timing and pace of new product development;

 ·
breadth of customer base;

 ·
technological expertise;

 ·
reliability of products;

 ·
product pricing; and

 ·
manufacturing efficiency.

 

We believe that we can compete favorably with respect to the above factors based on processes, the projected performance, anticipated inherent reliability of our products, our technical expertise in photonic engine design and manufacture and cost.

 

Intellectual Property

 

We have 6576 issued patents and 1110 patent applications pending, andincluding three provisionals(3) provisional patent applications submitted. There are multiple additional applications in process.various stages of preparation. The patents cover device structures, underlying technology related to the Optical Interposer, applications of the technology and fabrication processes. We believe these patents provide a significant barrier to entry against competition, along with trade secrets and know-how. We intend to continue to apply for additional patents in the future. Currently, we are working on the design of integrated devices, manufacturing processes, assembly and packaging processes and products for data communication applications in the data center market.


Sale of DenseLight Subsidiary

On February 3, 2019, management committed to a plan to sell its subsidiary, DenseLight. The decision was taken in line with a strategy to focus on the Company's opportunities related to its Optical Interposer. Management determined that the divestiture of DenseLight would immediately reduce the Company's operating losses and cash burn, while allowing the Company to pursue a "fab-light" strategy with a less capital-intensive business model that is focused on growing the Optical Interposer business through targeted investments in the design, development and sale of vertical market solutions. Consequently, all saleable assets and liabilities relating to DenseLight were classified as "Non-current assets held for sale" or "disposal group liabilities". An impairment assessment was done on the assets that are held for sale. It was determined that no assets were impaired either on the date management committed to a plan of sale or on November 8, 2019 when the sale was consummated.

 

On November 8, 2019, the Company closed on the sale of its wholly owned subsidiary, DenseLight Semiconductors Pte. Ltd., to a consortium of investors organized under DenseLight Semiconductor Technology (Shanghai) Ltd. (“DL Shanghai”) for $26,000,000. POET shareholders approved the sale with 99% of votes submitted at a Special Meeting held on October 24, 2019, ratifying the Share Sale Agreement (“SSA”) signed by the Company on August 20, 2019. The buyer assumed control of DenseLight upon closing. The sale proceeds are beingwere paid over multiple tranches. The first tranche payment was received on November 8, 2019 in the amount of US$8 million. Shares of DenseLight were placed in escrow in the Buyer’s name, to be released by the escrow agent to the Buyer upon receipt of the remaining payments. The second tranche payment was made in two installments, with the first paid on February 19, 2020 consisting of US$4.75 million$4,750,000 and the second on March 30, 2020 of US$8.25 million for$8,250,000.

The Company received payments of $1,500,000 and $1,000,000 on June 29, 2020 and July 3, 2020 respectively. After taking into consideration the length of time it had taken the Buyer to make the foregoing payments and the Company’s expectations regarding the likelihood of receiving an additional payment, the Company determined that it was in its best interest to accept partial payments as final payment on the Company’s receivable. As a total paid to dateresult, the Company recognized a credit loss of US$21.0 million. The remaining payment of US$5 million is expected to be made on or before May$2,500,000 during the year ended December 31, 2020. 2020 (nil - 2019).

Upon closing the transaction in November 2019, the Company recognized a gain on the sale of $8,707,280. The Company received an additional $2,000,000 in excess of the sale proceeds with the most recently paid two tranches which was immediately paid to Oak Capital on behalf of the Buyer for due diligence, legal and other expenses.

 

Our StrategyAlthough it continued to operate as a single entity until the sale was closed, to meet financial reporting standards, the Company was required to report DenseLight as “discontinued operations” separate from the remainder of the Company through and until November 8, 2019. This MD&A and the associated audited consolidated financial statements for the three and twelve months ended December 31, 2020 and 2019 have reported DenseLight as discontinued operations separate from its parent company, POET Technologies, Inc. Prior periods reported on in this MD&A have been revised to conform with this disclosure.

 

Our vision for the company is to become the global leader in chip-scale photonic solutions by deploying our Optical Interposer technology to enable the seamless integration of electronics and photonics for a broad range of vertical market applications.

Page 31

 

Our strategy includesSince the following key elements:

· Introduceacquisition of DenseLight in mid-2016, all of the Company’s revenues had been derived from its activities in Singapore. The majority of sales since the acquisition were in light source products developed, marketed and sold by DenseLight to customers globally. In addition, the Company accepted contracts from various customers for Non-Recurring Engineering (NRE) work that also formed a portion of its reported sales. During 2019, a significant portion of the Company’s revenues derived from a Non-Recurring Engineering (NRE) contract with a major customer for work directly related to the Optical Interposer. Purchase Orders (“PO’s”) received and accepted by POET were issued to DenseLight, on the basis that the bulk of the contracted development work was performed at the DenseLight facility by DenseLight employees. During the sale process, it was agreed between POET, DenseLight and the Buyer that DenseLight would retain those PO’s already issued and conclude the work, while retaining all of the associated costs. Only newly issued PO’s for additional development work on the Optical Interposer conceptand related components would be issued to suppliersPOET, with POET contracting with DenseLight and other third parties to perform portions of transceivers and data center operators and form commercial partnershipsthose projects.

The Share Sale Agreement included an Earn-Out provision which provided for product development. Becauseadditional consideration in the amount of $4,000,000 to be paid to the Company in the event that the audited revenues of DenseLight for the year ending December 31, 2019 were at least US$9 million with gross margins comparable to prior periods. DenseLight did not meet this revenue target. For more information about the details of the magnitudeSSA and the Buyer, please refer to the Management Information Circular, which can be found on SEDAR (www.sedar.com) and the TMX Trust website (www.tmxtrust.com).

Until November 8, 2019, majority of the cost savingsCompany’s R&D activities were conducted at DenseLight or with third parties under the direction of POET. Upon the sale of DenseLight, the Company retained sole ownership and performance advantages that may be derived from the use of POET’s Optical Engines for transceiver applications, we expectall intellectual property and rights to generate significant interest among both the suppliers of transceiver modules and their ultimate customers, the data center operators. In addition,its principal invention, the POET Optical Interposer provides a straightforward and cost-effective path to higher speed transceivers, including up to 400G and higher, providing a single platform that can span several device generations. We anticipate that several companies will be interested in pursuing commercial partnerships with POET in order to qualify and design-in our Optical Engines.

· Promote the POETTM. The Optical Interposer as a true platform technology across several photonic applications and markets. The POET Optical Interposer is designed to be a flexible platformwill form the basis for the combination or integration of various photonicCompany’s future growth and electronic components. The anticipated low cost makes it suitable for applications like automotive LIDAR. The compatibilityis therefore the focus of the Optical Interposer manufacturing process with standard silicon CMOS processing opens up a wide variety of other applications where high-speed data communications is needed, such as integration with ASICs, graphics generators and high-speed switches.


· Pursue multiple potential sources of non-product revenue and strategic partnerships. In addition to product sales, we have been pursuing Non-Recurring Engineering (“NRE”) revenues from end-use customers and/or from strategic partners. In particular, we believe our 400G transceiver components represent a uniquely attractive opportunity for collaborative development with a strategic partner(s).

· Pursue a “fab-light” strategy. “Fab-light” is a common business model in the semiconductor industry. Such a strategy allows the Company to invest more in design and development of Optical Interposer-based solutions, expand its marketing and sales presence globally and spend less on capital equipment and maintenance of facilities, enabling a faster path to profitability.

· Pursue complementary strategic alliance or acquisition opportunities. We intend to evaluate and selectively pursue strategic alliances or acquisition opportunities that we believe will accelerate our penetration of specific applications or vertical markets with our technology or products.Business Overview.

 

Geographic Distribution of Revenue

 

Revenue and geographic markets in DenseLight for 2020, 2019 2018 and 20172018 were approximately as follows:

 

Region  2019   20182017  2020 2019 2018 
Asia – Pacific $1,271,000 $1,971,0001,593,000  $    -  $1,271,000   1,971,000 
Europe $744,000 $1,191,000866,000  $-  $744,000   1,191,000 
North & South America $2,411,000 $726,000335,000  $-  $2,411,000   726,000 

“Fab-light” does not mean “fab-less”, as significant portions of our Intellectual Property are embedded in the processes that we have developed that are themselves integral to the equipment and functioning of the Optical Interposer. By purchasing our own equipment and placing the equipment in a foundry, for example, we are able to preserve confidentiality and ownership of such critical IP. As a result, even with a “fab-light” strategy, we expect to continue to invest in capital equipment, but not at the same level as owning and supporting an entire InP wafer fabrication facility.

 


 Page 32

C.Organizational Structure

 

The following graphically displays the organizational structure of the Company:

 

(1)There are 28,374,000 Class A Common Shares of OPEL Solar, Inc. issued and outstanding, all of which are held by the Company. There are no other outstanding securities of OPEL Solar, Inc. other than the Class A Common Shares.

 
(2)There are 5 Common Shares of ODIS Inc. issued and outstanding, held by OPEL Solar, Inc.
  
(3)There is 1 Ordinary share of POET Technologies Pte Ltd. issued and outstanding, held by POET Technologies Inc.

 (4)There is 1 Ordinary Share of BB Photonics UK Ltd. issued and outstanding, held by BB Photonics Inc.

(5)(4)There are 1,000,000 Preferred Shares and 1,050,100 Common shares of BB Photonics Inc. issued and outstanding, all of which are held by the Company. There are no other outstanding securities of BB Photonics Inc.
(5)POET Optoelectronics Co, Ltd. is a wholly owned subsidiary of POET Technologies Pte. Ltd with a registered capital of RMB195,997.

 

D.Property, Plants and Equipment

 

The Company’s head Canadian office is located in a 400 sq. ft. leased office space in Toronto, Ontario, Canada. The US based operations are in a leased 3,883 sq. ft. space in Allentown, Pennsylvania. Our testing operations are located in a 4,669 sq. ft leased facility in Singapore. Our product development operation is located in a 2,830 sq. ft leased facility in Shenzhen, China.

 


Page 33

 

ITEM 4A. UNRESOLVED STAFF COMMENTS

 

Not Required.

 

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

 

The following discussion should be read in conjunction with the audited consolidated financial statements of the Company and the related notes for the years ended December 31, 2020, 2019 2018 and 20172018 and the accompanying notes thereto included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated by forward-looking information due to factors discussed under “ITEM 3.D. Risk Factors” and “ITEM 4.B. Business Overview.”

 


A.Operating Results

 

Critical Accounting Policies and Estimates

 

The Company prepares its audited consolidated financial statements in accordance with IFRS as issued by the IASB, which differs from U.S. GAAP. The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting assumptions and estimates. These assumptions are limited by the availability of reliable comparable data and the uncertainty of predictions concerning future events. It also requires management to exercise judgment in applying the Company’s accounting policies. The Company believes that the estimates and assumptions upon which it relies are reasonable based upon information available at the time that these estimates and assumptions are made. Actual results could differ from these estimates. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below.

 

Basis of presentation

 

These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.

 

Financial Instruments

IFRS 9 introduced new classification and measurement models for financial assets. The investment classifications held-to-maturity and available-for-sale are no longer used and financial assets at fair value through other comprehensive income ("FVTOCI") were introduced. Financial assets held with an objective to hold assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest are measured at amortized cost using the effective interest method. Debt investments held with an objective to hold both assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset on the basis of fair value are measured at FVTOCI. All other financial assets are classified and measured at fair value through profit or loss ("FVTPL"). Financial liabilities are classified as either FVTPL or other financial liabilities, and the portion of the change in fair value that relates to the Company's credit risk is presented in other comprehensive income (loss). Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in net income (loss). Other financial liabilities are subsequently measured at amortized cost using the effective interest method.

Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL, are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in consolidated net income (loss).

Derecognition

Financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability.

Financial liabilities

A financial liability is derecognized from the balance sheet when it is extinguished, that is, when the obligation specified in the contract is either discharged, cancelled or expires. Where there has been an exchange between an existing borrower and lender of debt instruments with substantially different terms, or there has been a substantial modification of the terms of an existing financial liability, this transaction is accounted for an extinguishment of the original financial liability and the recognition of a new financial liability. A gain or loss from extinguishment of the original financial liability is recognized in profit or loss.


The Company'sCompany’s financial instruments includeconsist of cash and cash equivalents, short-term investments, accounts receivable, receivable from the sale of discontinued operations, convertible debentures, covid-19 government support loans and accounts payable and accrued liabilities. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest risk arising from these financial instruments. The Company estimates that the fair value of these instruments approximates fair value due to their short-term nature

 

The following table outlines the classification of financial instruments under IAS 39 and the revised classification on the adoption of IFRS 9:

 

Original classificationNew classification
under IAS 39under IFRS 9
Financial Assets  
Cash and cash equivalents Loans and receivablesAmortized cost
Short-term investmentsFVTPL Amortized cost
Accounts receivable Loans and receivablesAmortized cost
   
Financial Liabilities  
Accounts payable and accrued liabilities Amortized costscost
Convertible debenturesAmortized cost
Covid-19 government support loans Amortized cost

Page 34

 

Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is measured at fair value on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the total carrying value of the compound instrument to derive the equity component. The debt component is subsequently measured at amortized cost using the effective interest rate method. Interest expense based on the coupon rate of the debenture and the accretion of the liability component to the amount that will be payable on redemption are recognized through profit or loss as a finance cost.

 


Cash and cash equivalents

 

Cash and cash equivalents consist of cash in current accounts of $722,894 (2019 - $1,278,129, 2018 - $2,267,868) and funds invested in US Term Deposits of $6,150,000 (2019 - $150,000, 2018 - $300,000) earning interest at 1.31% and maturing in less than 90 days.

 

Cash and cash equivalents include restricted funds of $184,569 (2019 - $93,800, 2018 - $218,888) which serves as a bank guarantee for the purchase of certain equipment. A bank guarantee was discharged in 2020 and a new bank guarantee was put in place. The bank guarantee is reduced on a monthly basis by $14,197 (2019 - $10,424, 2018 - $10,424) which is the amount paid monthly in settlement of the outstanding balance on the equipment.

 

Accounts receivable

 

Accounts receivable are amounts due from customers from the sale of products or services in the ordinary course of business. Accounts receivables are classified as current (on the consolidated statements of financial position) if payment is due within one year of the reporting period date, and are initially recognized at fair value and subsequently measured at amortized cost.

In determining a default provision, the Company utilizes a provision matrix, as permitted under the simplified approach to measure expected credit losses. In doing so management considered historical credit losses, forward-looking factors specific to the Company'sCompany’s debtors and other macro-economic factors to arrive at expected default rates. The default rates are then applied to the Company'sCompany’s aging to determine expected credit losses. The carrying amount of trade receivables is reduced by the expected credit losses. If the financial conditions of these customers were to deteriorate and the Company determines that no recovery of a trade receivable is possible, the amount is deemed irrecoverable and subsequently written-off. Accounts receivable at December 31, 2018 and 2017 related to revenue earned by DenseLight. DenseLight was sold on November 8, 2019.2019

 

Inventory

 

Inventory consists of raw material inventory, work in process, and finished goods and are recorded at the lower of cost and net realizable value. Cost is determined on a first in first out basis and includes all costs of purchase, costs of conversion and other costs incurred in bringing the inventory to its present condition.

An assessment is made of the net realizable value of inventory at each reporting period. Net realizable value is the estimated selling price less the estimated cost of completion and the estimated costs necessary to make the sale. When circumstances that previously caused inventories to be written down no longer exist or when there is clear evidence of an increase in net realizable value because of changed economic circumstances, the amount of any write down previously recorded is reversed so that the new carrying amount is the lower of the cost and the revised net realizable value. Raw materials are not written down unless the goods in which they are incorporated are expected to be sold for less than cost, in which case, they are written down by reference to replacement cost of the raw materials, as this is the best indicator of net realizable value. Inventory at December 31, 2018 and 2017 related to inventory held by DenseLight. DenseLight was sold on November 8, 2019.

 

Page 35

 

Property and equipment

Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives:

 

Machinery and equipment Straight Line, 5 years
Leasehold improvements Straight Line, 5 years or life of the lease, whichever is less
Office equipment Straight Line, 3 - 5 years

 


Patents and licenses

 

Patents and licenses are recorded at cost and amortized on a straight-line basis over 12 years. Ongoing maintenance costs are expensed as incurred.

 

Impairment of long-lived assets

 

The Company’s tangible and intangible assets are reviewed for indications of impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. An assessment is made at each reporting date whether there is any indication that an asset may be impaired.

 

An impairment loss is recognized when the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognized in profit and loss for the year. The recoverable amount is the greater of the asset’s fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit ("CGU"(“CGU”) to which the asset belongs.

 

An impairment loss is reversed if there is an indication that there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. The Company reported anno impairment loss of $714,000 for the year ended December 31, 2019.2020 (2019 - $714,000, 2018 - nil).

 


Goodwill

 

Goodwill represents the excess of the cost of an acquired business over the fair value of the identifiable assets acquired net of liabilities assumed. Goodwill is measured at cost less accumulated impairment losses and is not amortized. Goodwill is tested for impairment on an annual basis or whenever facts or circumstances indicate that the carrying amount may exceed its recoverable amount.

 

The Company performedperforms its annual test for goodwill impairment at December 31, 2019.annually in the fourth quarter. The Company utilized a five-year cash flow forecast using the annual budget approved by the Board of Directors as a basis for such forecasts. Cash flow forecasts beyond that of the budget were prepared using a stable growth rate for future periods. These forecasts were based on historical data and future trends expected by the Company. The Company'sCompany’s valuation model also takes into account working capital and capital investments required to maintain the condition of the assets. Forecasted cash flows were discounted using an after-tax rate of 30%.

 

Based on the impairment tests, the value in-use of the CGU to which goodwill is applicable is less than the carrying amount. As a result goodwill of $1,050,459 was impaired in the current year.2019. No provision for impairment of goodwill was made in 20182020 or 2017.2018.

Page 36

 

Income taxes

 

The Company follows the liability method of accounting for income taxes. Under this method, deferred income taxes are provided on differences between the financial reporting and income tax bases of assets and liabilities and on income tax losses available to be carried forward to future years for tax purposes. Deferred income taxes are measured using the substantively enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are only recognized if the amount is expected to be realized in the future.

Recently Enacted U.S. Federal Tax Legislation

Introduced initially as the Tax Cuts and Jobs Act, the Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018 (the “Act”) was enacted on December 22, 2017. The Act applies to corporations generally beginning with taxable years starting after December 31, 2017 and reduces the corporate tax rate from a graduated set of rates with a maximum 35% tax rate to a flat 21% tax rate. Additionally, the Act introduces other changes that impact corporations, including a net operating loss (“NOL”) deduction annual limitation, an interest expense deduction annual limitation, elimination of the alternative minimum tax, and immediate expensing of the full cost of qualified property. The Act also introduces an international tax reform that moves the U.S. toward a territorial system, in which income earned in other countries will generally not be subject to U.S. taxation. However, the accumulated foreign earnings of certain foreign corporations will be subject to a one-time transition tax, which can be elected to be paid over an eight-year tax transition period, using specified percentages, or in one lump sum. NOL and foreign tax credit (“FTC”) carryforwards can be used to offset the transition tax liability. As a result of this new regulation, the Company reduced its deferred tax assets by $9,472,000 in 2017.

 

Revenue recognition

 

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer.

 

Sale of goods

 

Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured.

 

Service revenue

 

The Company provides contract services, primarily in the form of non-recurring revenue ("NRE"(“NRE”) where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method.

 


Other income

 

Interest income

 

Interest income on cash and cash equivalents classified as fair value through profit or loss is recognized as earned using the effective interest method.

 

Research and Development Credits

 

Through DenseLight, the Company was eligible to receive cash credits for certain qualifying research and development expenses based on actual spending over a three year period, with an expectation that the credits willwould not exceed a certain dollar value over a three year period. Recoverable amounts at December 31, 2018 and 2017 related to expenditures at DenseLight. RecoverableThere was no recoverable amount at December 31, 2020 or 2019 was nil because the Company sold DenseLight on November 8, 2019.

Wage subsidies

Wages subsidies received from the Singaporean government are netted against payroll costs on the consolidated statements of operations and deficit.

Page 37

 

Intangible assets

 

Research and development costs

 

Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the Company believes a development project meets IFRS criteria as set out in IAS 38, Intangible Assets, for deferral and amortization. IAS 38 requires all research costs be charged to expense while development costs are capitalizedcapitalised only after technical and commercial feasibility of the asset for sale or use have been established. This means that the entity must intend and be able to complete the intangible asset and either use it or sell it and be able to demonstrate how the asset will generate future economic benefits. Development costs are tested for impairment whenever events or changes indicate that its carrying amount may not be recoverable.

 

In-Process Research and Development

 

Under IFRS, in-process research and development ("(“IPR&D"&D”) acquired in a business combination that meets the definition of an intangible asset is capitalized with amortization commencing when the asset is ready for use (i.e., when development is complete). The Company acquired $714,000 of IPR&D when it acquired BB Photonics Inc. in 2016. During 2019, management observed indicators that suggested that IPR&D may be impaired. IPR&D acquired with BB Photonics was no longer useable with the novel POET Interposer platform. BB Photonics IPR&D would not generate sufficient cash flow to support its value in use. Management completed an assessment of IPR&D and determined that the amount of $714,000 was impaired. An impairment loss of $714,000 was recorded during the year ended December 31, 2019. No impairment was recorded in 20182020 or 2017.2018.

 

Customer relationships

 

Intangible assets include customer relationships acquired with the acquisition of DenseLight. Customer relationships is an externally acquired intangible asset and is measured at cost less accumulated amortization and any accumulated impairment losses. Customer relationships are amortized on a straight-line basis over their estimated useful lives and is tested for impairment whenever events or changes indicate that their carrying amount may not be recoverable. The useful life of customer relationships was determined to be 5 years. Customer relations was nil at December 31, 2020 and 2019 as because the asset was disposed of with the sale of DenseLight on November 8, 2019.

 

Stock-based compensation

 

Stock options and warrants awarded to non-employees are accounted formeasured using the fair value of the instrument awardedgoods or service provided whicheverservices received unless that fair value cannot be estimated reliably, in which case measurement is considered more reliable.based on the fair value of the stock options. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option-pricingoption pricing model with assumptions applicable at the date of grant.

 

LossIncome (loss) per share

 

Basic lossincome (loss) per share is calculated by dividing net lossincome (loss) by the weighted average number of common shares outstanding during the year. Diluted lossincome (loss) per share is calculated by dividing net lossincome (loss) by the weighted average number of common shares outstanding during the year after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method.

 


Recently adopted accounting policy

IFRS 16, Leases (“IFRS 16”) sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract, the customer (lessee) and the supplier (lessor). This replaces IAS 17, Leases (“IAS 17”) and related Interpretations. IFRS 16 provides revised guidance on identifying a lease and for separating lease and non-lease components of a contract. IFRS 16 introduces a single accounting model for all lessees and requires a lessee to recognize right of use assets and lease liabilities for leases with terms of more than 12 months, unless the underlying asset is of low value, and depreciation of lease assets is reported separately from interest on lease liabilities in the income statement. Under IFRS 16, lessor accounting for operating and finance leases will remain substantially unchanged. IFRS 16 is effective for annual periods beginning on or after January 1, 2019, with earlier application permitted for entities that apply IFRS 15, Revenue from Contracts with Customers. The Company adopted this new standard using the modified retrospective method on January 1, 2019. The adoption of IFRS 16, resulted in a right of use asset and liability of $1,127,534. The carrying value of the right of use asset and lease liability relating to Denselight were disposed of upon the sale of DenseLight on November 8, 2019


Selected Annual Data

 

The selected financial data of the Company for the years ended December 31, 2020, 2019 2018 and 20172018 was derived from the audited annual consolidated financial statements of the Company, which have been audited by Marcum LLP, independent registered public accounting firm, as described in their report which is included in this Annual Report.

 

Page 38

The information contained in the selected financial data for the 2020, 2019 2018 and 20172018 years is qualified in its entirety by reference to the Company’s consolidated financial statements and related notes included under the heading ITEM 17. “Financial Statements” and should be read in conjunction with such financial statements and with the information appearing under the heading ITEM 5 “Operating and Financial Review and Prospects”. Except where otherwise indicated, all amounts are presented in accordance with IFRS as issued by IASB.

 

The following table relates to the operating results of the Company.

 

Consolidated Statements of Operations Under International Financial Reporting Standards

(US$)

 

Years Ended December 31.      
       Restated   Restated 
   2019   2018   2017 
             
Operating Expenses            
Selling, marketing and administrative $6,697,387  $6,173,875  $5,887,709 
Research and development  2,083,815   2,262,476   2,039,421 
Impairment loss  1,764,459   -   - 
Interest expense  819,911   -   - 
Amortization of debt issuance costs  372,340   -   - 
Other income, including interest  (10,540)  (14,234)  (18,279)
Operating Expenses  11,727,372   8,422,117   7,908,851 
Income tax recovery  (292,740)  -   - 
Net loss from continuing operations  (11,434,632)  (8,422,117)  (7,908,851)
Income (loss) from discontinued operations, net of taxes(1)  5,481,757   (7,900,662)  (4,888,946)
Net loss  (5,952,875)  (16,322,779)  (12,797,797)
Deficit, beginning of year  (133,195,932)  (116,873,153)  (104,075,356)
Deficit, end of year $(139,148,807) $(133,195,932) $(116,873,153)
             
Basic and diluted loss per share, continuing operations $(0.04) $(0.03) $(0.03)
Basic and diluted income (loss) per share, discontinued operations $0.02  $(0.03) $(0.02)
Basic and diluted loss per share $(0.02) $(0.06) $(0.05)


        Restated 
Years Ended December 31, 2020  2019  2018 
Operating Expenses            
Selling, marketing and administrative $8,137,998  $6,697,387  $6,173,875 
Research and development  6,634,317   2,083,815   2,262,476 
Operating Expenses  14,772,315   8,781,202   8,436,351 
Impairment of long-lived assets  -   1,764,459   - 
Interest expense  937,903   819,911   - 
Amortization of debt issuance costs  -   372,340   - 
Other income, including interest  (41,148)  (10,540)  (14,234)
Credit loss on receivable from the sale of discontinued operations  2,500,000   -   - 
Loss on disposal of property and equipment      -   - 
Net loss from continuing operations, before taxes  18,169,070   11,727,372   8,422,117 
Income tax recovery  -   (292,740)  - 
Net loss from continuing operations  (18,169,070)  (11,434,632)  (8,422,117)
Income (loss) from discontinued operations, net of taxes  -   5,481,757   (7,900,662)
Net loss  (18,169,070)  (5,952,875)  (16,322,779)
Deficit, beginning of year  (139,148,807)  (133,195,932)  (116,873,153)
Deficit, end of year $(157,317,877) $(139,148,807) $(133,195,932)
             
Basic and diluted loss per share, continuing operations $(0.06) $(0.04) $(0.03)
Basic and diluted income (loss) per share, discontinued operations  -  $0.02  $(0.03)
Basic and diluted loss per share $(0.06) $(0.02) $(0.06)

 

(1) Discontinued operations Under International Financial Reporting Standards

 

Page 39

 

Years Ended December 31,

Years Ended December 31,  2019   2018   2017 
             
Revenue $4,426,355  $3,888,185  $2,794,044 
Cost of Revenue  1,201,373   1,475,969   1,342,691 
Gross profit  3,224,982   2,412,216   1,451,353 
Operating Expenses            
Selling, marketing and administrative  1,950,526   5,515,329   4,983,032 
Research and development  5,677,222   6,430,328   3,403,452 
Interest expense  74,494   -   - 
Impairment loss  -   156,717   - 
Other income  (1,251,737)  (1,491,556)  (1,748,245)
Operating Expenses  6,450,505   10,610,818   6,638,239 
Net loss from operations  (3,225,523)  (8,198,602)  (5,186,886)
Gain on sale of discontinued operations, net of taxes  8,707,280   -   - 
Net income (loss) from discontinued operations  5,481,757   (8,198,602)  (5,186,886)
Income tax recovery  -   297,940   297,940 
Income (loss) from discontinued operations, net of income taxes $5,481,757  $(7,900,662) $(4,888,946)

  2020  2019  2018 
          
Revenue  -  $4,426,355  $3,888,185 
Cost of Revenue  -   1,201,373   1,475,969 
Gross Margin  -   3,224,982   2,412,216 
Operating Expenses  -         
Selling, marketing and administrative  -   1,950,526   5,515,329 
Research and development  -   5,677,222   6,430,328 
Operating Expenses      7,627,748   11,945,657 
Interest expense  -   74,494   - 
Impairment loss  -   -   156,717 
Other income  -   (1,251,737)  (1,491,556)
Expenses  -   6,450,505   10,610,818 
Net loss from operations  -   (3,225,523)  (8,198,602)
Change in fair value contingent consideration  -   -   - 
Gain on sale of discontinued operations, net of taxes  -   8,707,280   - 
Net income (loss) from discontinued operations  -   5,481,757   (8,198,602)
Income tax recovery  -   -   297,940 
Income (loss) from discontinued operations, net of income taxes  -  $5,481,757  $(7,900,662)

 

For the Period from January 1, 2019 to November 8, 2019 compared to the Year Ended December 31, 2018

 


Page 40

 

The selected annual information for continuing operations for 2020, 2019 2018 and 20172018 can be further analyzed as follows:

 

Research and development can be analysed as follows:

 

 For the Years Ended December 31, 
  

For the Years Ended December 31,
  2020 2019 2018 
  2019   2018   2017        
Wages and benefits $874,673  $822,258  $703,759  $1,586,900  $874,673  $822,258 
Subcontract fees  834,598   888,566   1,044,936   3,802,919   834,598   888,566 
Stock-based compensation  237,311   395,468   218,896   567,859   237,311   395,468 
Supplies  137,233   156,184   71,830   676,639   137,233   156,184 
 $2,083,815  $2,262,476  $2,039,421  $6,634,317  $2,083,815  $2,262,476 

 

Selling, marketing and administration costs can be analysed as follows:

 

Stock-based compensation $2,650,830  $3,207,411  $2,739,462 
Wages and benefits  1,619,719   1,433,286   1,443,656 
Professional fees  1,120,805   735,604   597,865 
General expenses  813,951   392,901   598,600 
Depreciation and amortization  243,674   153,244   182,252 
Management and consulting fees  154,357   155,169   229,577 
Rent and facility costs  94,051   96,260   96,297 
  $6,697,387  $6,173,875  $5,887,709 

Stock-based compensation $3,045,086  $2,650,830  $3,207,411 
Wages and benefits  2,233,449   1,619,719   1,433,286 
Professional fees  800,551   1,120,805   735,604 
General expenses  1,188,712   813,951   392,901 
Depreciation and amortization  813,103   243,674   153,244 
Management and consulting fees  -   154,357   155,169 
Rent and facility costs  57,097   94,051   96,260 
  $8,137,998  $6,697,387  $6,173,875 

 

Factors Affecting Our Results of Operations

Analysis of Continuing Operations

Year Ended December 31, 2020 compared to Year Ended December 31, 2019

Net loss from continuing operations before taxes for the period was $18,169,070 compared to a net loss of $11,727,372 in 2019, an increase of $6,441,698 (55%). The following discusses the significant variances between the period and 2019.

Total R&D increased by $4,550,502 from $2,083,815 in 2019 to $6,634,317 in 2020. For the purposes of the following R&D analysis, non-cash stock-based compensation of $567,859 (2019 - $237,311) has been excluded and is included with the analysis of non-cash stock-based compensation below.

R&D, excluding non-cash stock-based compensation, increased by $4,219,954 (228%) to $6,066,458 in the period from $1,846,504 in 2019. The increase is a result of a redistribution of R&D activities and costs that were typically accounted for by DenseLight reflected in discontinued operations and are now being accounted for by the Company. Additionally, the Company established a new test and design facilities in Singapore and Allentown, Pennsylvania which became fully operational in late 2019 and early 2020. All such test activities and related costs were incurred at DenseLight in 2019.

Page 41

Interest expense increased by $117,992 (14%) to $937,903 in the period as compared to $819,911 in 2019, The Company raised $6,805,772 in short-term loans and convertible debentures between April 2019 and September 2019. The Company is required to pay monthly interest on the convertible debentures at a rate of 12%. Interest on short-term loans ranged from 15% - 19.25%. The short-term loans were only outstanding for a brief period in 2019, additionally interest incurred on convertible debentures were for the nine months from April 2019 to December 2019. Conversely, interest expense during the period on convertible debentures is for the twelve months of 2020. Interest expense includes non-cash interest of $524,095 in the period and $280,829 in 2019.

Related to the issuance of other debt in 2019 is the amortization of debt issuance cost. The amortized debt issuance cost in 2019 was directly related to the debt that was repaid in Q4 2019, as a result amortized debt issuance cost in the period was nil compared to $372,340 in 2019.

Depreciation and amortization increased by $569,429 (234%) to $813,103 in the period from $243,674 in 2019. With the sale of DenseLight, the Company embarked on a “fab-light” strategy with a required test facility situated in Singapore. The increase in depreciation and amortization was a result of assets acquired for this new facility. Depreciation of assets within the DenseLight subsidiary were previously reflected in discontinued operations in 2019.

Wages and benefits increased by $613,730 (38%) to $2,233,449 in the period from $1,619,719 in 2019. In late 2019, the Company recruited and hired three senior individuals for roles for which there was a need. These roles included a President & General Manager of the Company, a Vice President & General Manager for the new Singapore testing facility and a Vice President of Product Marketing & Business Development. Wages and benefits for the year include the wages and benefits of these three new hires. 2019 only included similar costs for two months of the year.

General expenses and rent and facility increased by $337,807 (37%) to $1,245,809 in the period from $908,002 in 2019. On June 30, 2020, the Company announced the signing of a $50 million joint venture. General expenses include a one-time cost of $328,000 paid to a firm instrumental in introducing the joint venture parties and assisting with negotiations.

Impairment and other loss was $2,500,000 in the period compared to $1,764,459 in 2019. Impairment and other loss in 2020 consisted of a credit loss of $2,500,000 relating to the receivable from the sale of discontinued operations. In Q2 2020, after taking into consideration the length of time it took the Buyer of DenseLight to make the required payments and the Company’s expectations regarding the likelihood of receiving the balance that was due at the time, the Company determined, that it was in the Company’s best interest to accept partial payments as final payment on the outstanding balance. In Q4 2019, the Company performed an impairment analysis on its goodwill and intangible assets related to the acquisition of BB Photonics in 2016. The Company determined that these assets were impaired and consequently recognized an impairment loss of $1,764,459.

Non-cash stock-based compensation increased by $724,804 (25%) to $3,612,945 in the period from $2,888,141. The valuation of stock options is driven by a number of factors including the number of options granted, the strike price and the volatility of the Company’s stock. The stock option expense is dependent on the timing of the stock option grant and the amortization of the options as they vest. The stock options vest in accordance with the policies determined by the Board of Directors at the time of the grant consistent with the provisions of the Plan

Management and consulting fees were nil in 2020 compared to $154,357 in 2019. Before becoming employees of the Company, certain employees provided services on a consulting basis in 2019. The Company did not incur such consulting services in 2020.

The Company earned $41,148 of interest income in 2020 compared to $10,540 in 2019. The increase of $30,608 (290%) was a result of having lump sum cash payments from the sale of DenseLight that the Company was able to invest in low risk interest bearing investments throughout 2020.

 

Due to the sale of DenseLight on November 8, 2019, the Company’s operating activities were re-stated to reflect the activities of the continuing operation. A discussion of the

 

Page 42

Analysis of Continuing Operations

Due to the sale of DenseLight on November 8, 2019, the Company’s operating activities were re-stated to reflect the activities of the continuing operation.

 

Year Ended December 31, 2019 compared to Year Ended December 31, 2018

 

In 2019, the Company had a net loss from continuing operations of $11,727,372. The net loss from continuing operations included $2,083,815 spent on research and development activities directly related to the development and commercialization of the POET Optical Interposer Platform (“POIP”).Platform. Research and development included $237,311 of non-cash fair value stock-based compensation. $6,697,387 was spent on selling, marketing and administration expenses which included non-cash operating costs of $2,650,830 related to the fair value of stock-based compensation and $243,674 related to depreciation and amortization.

 

The Company incurred $819,911 of interest expense and $372,340 of debt issuance costs related to $7,729,921 borrowed at various dates and from various lenders during 2019. The Company repaid $4,000,000 of the borrowed funds on November 8, 2019.

 

The Company is not exposed to hyperinflationary risks as the Company’s investments and operations are occur in geographic regions with stable economies.


 

R&D

 

Total R&D decreased by $178,661 from $2,262,476 in 2018 to $2,083,815 in 2019. For the purposes of the following R&D analysis, non-cash stock-based compensation of $237,311 (2018 - $395,468) has been excluded and is included with the analysis of non-cash stock-based compensation below.

 

R&D, net of stock-based compensation decreased by $20,504 from $1,867,008 in 2018 to $1,846,504 in 2019. The decrease in R&D was the result of a temporary reduction in certain Optical Interposer development programs in favor of component design taking place through the Company’s discontinued operations. R&D efforts in 2018 included consulting and outsourced services directed at developing the Company’s proprietary waveguides. Variances from year to year reflect individual project emphases between the Company and its discontinued operations rather than any implications for the direction of the overall R&D program. The minor change in R&D year over year reflect the consistency of expenses that were accounted for geographically. Most R&D activity was captured in the Company’s discontinued operations.

 

Wages and benefits

 

Wages and benefits increased by $186,433 (13%) to $1,619,719 for 2019 from $1,433,286 in 2018. In late 2019, the Company recruited and hired three senior individuals for roles for which there was a gap. These roles included a President & General Manager of the Company, a Vice President & General Manager for the new Singapore testing facility and a Vice President of Product Marketing & Business Development. Additionally, the Company hired a Senior Vice President of Strategic Marketing in late 2018. The Company reported a full years’ wages for the Senior Vice President of Strategic Marketing in 2019 while only a partial years’ wages were recorded in 2018.

 

Professional fees

 

Professional fees increased by $385,201 (52%) to $1,120,805 in 2019 from $735,604 in 2018. The increase in professional fees was a result of legal and other professional fees incurred relating to the sale of the Company’s DenseLight subsidiary. The services professionals in multiple jurisdictions were required during the due diligence process, drafting the SSA and to assist with negotiations.

 

Page 43

General expenses and rent

 

General expenses and rent increased by $418,841 (86%) to $908,002 in 2019 from $489,161 in 2018. The increase was primarily a result of ancillary costs incurred related to the various financings that occurred in 2019 and certain indenture fees related to maintaining the warrants of a previous equity financing that occurred in 2018. The Company also incurred substantial travel and related costs due to the time and effort required in negotiating and addressing due diligence matters respecting the sale of DenseLight. Additionally, the Company incurred $49,274 of unrealized foreign exchange loss due the weakening of the Canadian dollar in 2019. The Company had an unrealized foreign exchange gain of $142,104 in 2018. The unrealized gains and losses are a result of currency translation for financial reporting purposes.

 

Interest expense and debt issuance cost

 

Interest expense was $819,911 for 2019 as compared to nil in 2018. The Company raised $7,729,921 of debt financing from various lenders at varying times throughout 2019, net of directly related issue costs. The Company is required to pay monthly interest on the debt raised during the period. The Company did not have debt obligations in 2018.

 

Related to the issuance of debt in 2019 is the amortization of debt issuance cost of $372,340 compared to nil in 2018. The Company paid $147,077 in costs related to a bridge loan of $3,100,000 from Espresso Capital Ltd. Additionally, the Company issued 3,289,500 warrants to the lender to purchase common shares at a price of CAD$0.35 per share. The warrants expire on April 18, 2020. The fair value of the warrants was estimated on the date of issue using the Black-Scholes option pricing model with the following assumptions: volatility of 78.91%, interest rate of 1.62% and an expected life of 1 year. The estimated fair value assigned to the warrants was $221,620. There was no debt issuance cost in 2018.

 


Non-cash stock-based compensation

 

Non-cash stock-based compensation decreased by $714,738 (20%) to $2,888,141 in 2019 from $3,602,879 in 2018. The valuation of stock options is driven by a number of factors including the number of options granted, the strike price and the volatility of the Company’s stock. The stock option expense is dependent on the timing of the stock option grant and the amortization of the options as they vest. The stock options vest in accordance with the policies determined by the Board of Directors at the time of the grant consistent with the provisions of the Plan.

 

Impairment loss

 

During 2019, the Company performed an impairment analysis on its goodwill and intangible assets related to the acquisition of BB Photonics in 2016. The Company determined that these assets were impaired and consequently recognized an impairment loss of $1,764,459. No impairment was recognized in 2018.

 

Exchange Rate Risk

 

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk with the Canadian and Singapore dollar. A 10% change in the Canadian and Singapore dollar would increase or decrease other comprehensive loss by $290,950.$229,088.

Page 44

 

Liquidity Risk

 

The Company currently does not maintain credit facilities. The Company'sCompany’s existing cash and cash resources are considered sufficient to fund operating and investing activities beyond one year from the issuance of these consolidated financial statements. The Company may, however, need to seek additional financing in the future.

 

Year Ended December 31, 2018 compared to Year Ended December 31, 2017

Net loss from continuing operations was $8,422,117 for 2018 compared to $7,908,851 for 2017. The following explains the $513,266 (6%) variance in net loss between 2018 and December 31, 2017.

R&D

Total R&D increased by $223,055 from $2,039,421 in 2017 to $2,262,476 in 2018. For the purposes of the following R&D analysis, non-cash stock-based compensation of $395,468 (2017 - $218,896) has been excluded and is included with the analysis of non-cash stock-based compensation below.

R&D, net of stock-based compensation had a marginal increase of $46,483 (3%), increasing from $1,820,525 in 2017 to $1,867,008 in 2018. The minor change in R&D from 2017 to 2018 reflects the consistency of expenses that were accounted for geographically. Most R&D activity was captured in the Company’s discontinued operations.

Professional fees

Professional fees in 2018 increased by $137,739 (23%) to $735,604 from $597,865 in 2017. Professional fees, including legal fees, were required as the Company reviewed internal policies for best practices and initiated co-development partnerships and agreements with several counterparties as disclosed in 2018. The Company also incurred professional fees related to the filing of its final short form prospectus filed in November 2018.


General expenses and rent

General expenses and rent in 2018 decreased by $205,736 (29%) from $694,897 in 2017 to $489,161 in 2018. The Company incurred $6,197 of unrealized foreign exchange loss due the weakening of the Canadian dollar in 2017, conversely, the Company reported a foreign exchange gain of $142,104 in 2018. The unrealized gains and losses are a result of currency translation for financial reporting purposes.

Management and consulting fees

Management and consulting fees decreased by $74,408 (32%) to $155,169 in 2018 from $229,577 in 2017. The decrease was a result of the resignation of the former Executive Chairman of Board in 2017, whose compensation was included in management and consulting fees. Management and consulting fees did not include fees for the newly appointed Executive Chairman in 2018, which were instead charged to wages and benefits.

Non-cash stock-based compensation

Non-cash stock-based compensation increased by $644,521 (22%) to $3,602,879 in 2018 from $2,958,358 in 2017. The valuation of stock options is driven by a number of factors including the number of options granted, the strike price and the volatility of the Company’s stock. The stock option expense is dependent on the timing of the stock option grant and the amortization of the options as they vest. The stock options vest in accordance with the policies determined by the Board of Directors at the time of the grant consistent with the provisions of the Stock Option Plan, as amended (the “Plan”).

Exchange Rate Risk

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk with the Canadian and Singapore dollar. A 10% change in the Canadian and Singapore dollar would increase or decrease other comprehensive loss by $386,391.

Liquidity Risk

The Company currently does not maintain credit facilities. The Company's existing cash and cash resources are not considered sufficient to fund operating and investing activities beyond one year from the issuance of these consolidated financial statements. The Company will need to seek additional financing to continue as a going concern.


Analysis of Discontinued Operations

 

The selected annual information for discontinued operations for 2020, 2019 2018 and 20172018 can be further analyzed as follows:

 

Research and development can be analysed as follows:

 

  

For the Period from

January 1,

2019

to

November 8,

   For the Years Ended December 31,  2020 2019 2018 
  2019   2018   2017        
Wages and benefits $3,565,076  $3,818,980  $2,135,329   -  $3,565,076  $3,818,980 
Supplies  1,412,572   2,070,495   1,118,011   -   1,412,572   2,070,495 
Subcontract fees  728,457   400,000   -   -   728,457   400,000 
Stock-based compensation  (28,883)  140,853   150,112   -   (28,883)  140,853 
 $5,677,222  $6,430,328  $3,403,452   -  $5,677,222  $6,430,328 

 

Selling, marketing and administration costs can be analysed as follows:

 

Wages and benefits $887,860  $1,034,715  $1,131,322   -  $887,860  $1,034,715 
Rent and facility costs  604,442   975,467   1,079,635   -   604,442   975,467 
General expenses  458,465   785,635   585,637   -   458,465   785,635 
Stock-based compensation  (46,725)  278,385   66,454   -   (46,725)  278,385 
Interest expense  -   -   - 
Professional fees  46,484   31,747   27,076   -   46,484   31,747 
Depreciation and amortization  -   2,409,380   2,092,908   -   -   2,409,380 
 $1,950,526  $5,515,329  $4,983,032   -  $1,950,526  $5,515,329 

 

For the Period from January 1, 2019 to November 8, 2019 compared to the Twelve Months Ended December 31, 2018

 

Effective January 1, 2019, the Company is reporting the activities of DenseLight as a discontinued operation. The activities of DenseLight have been consolidated and reported as discontinued operations from January 1, 2019 to November 8, 2019.

 

Financial information related to DenseLight for the year ended December 31, 2018 has also be restated and presented as discontinued operations.

Net income from discontinued operations, net of taxes for 2019 was $5,481,757 compared to a net loss from discontinued operations net of taxes of $7,900,662 in 2018. The following discussion analyses the $13,382,419 variance from 2018 to 2019.

Page 45

 

Gain on sale of discontinued operations

 

The net income in 2019 includes a gain on the sale of discontinued operations of $8,707,280. On November 8, 2019, the Company sold all the issued and outstanding shares of DenseLight for $26,000,000. The sale resulted in the reported gain in 2019 of $8,707,280.

 

Revenue

 

Even with a stub period reporting (January 1, 2019 – November 8, 2019), revenue increased by $538,170 (14%) to $4,426,355 in 2019 compared to revenue of $3,888,185 in 2018. The increase resulted primarily from an increase in NRE revenue that DenseLight started to report in late 2018. The increased NRE contributed to higher gross margin in 2019. Gross margin was $3,224,982 or 73% in 2019 compared to $2,412,216 or 62% in 2018.

 


R&D

 

Total R&D was $5,677,222 in 2019 compared to $6,430,328 in 2018, a decreaseddecrease of $753,106 (12$%(12%). For the purposes of the following R&D analysis, non-cash stock-based compensation of $(28,883) (2018 - $140,853) has been excluded and is included with the analysis of non-cash stock-based compensation below.

 

R&D, net of stock-based compensation decreased by $583,370 (9%) to $5,706,105 in 2019 from $6,289,475 in 2018. The decrease in R&D does not reflect reduced activity but rather the fact that only 10 months of R&D activity are reflected in 2019 compared to 12 months of activity in reported 2018. Had the comparative periods been the same it is estimated that 2019 R&D would have increased marginally due to the effort expended to accelerate certain component developments, and to reach other technical milestones, including the launch of the advanced Integrated Light Module (ILM), designed specifically for high-performance wind LIDAR and other environmentally-stressed applications. The Company also launched a new 1653 DFB laser for targeting the methane gas sensing markets and the 1650nm Fabry-Perot (FP) laser for test and measurement applications, targeting the OTDR (Optical Time-Domain Reflectometer) market where the equipment is used to detect faults and understand the losses along a given length of fiber-optic cable in networking and data communications systems.

 

Wages and benefits

 

Wages and benefits decreased by $146,855 (14%) to $887,860 in 2019 from $1,034,715 in 2018. The decrease is related to the stub period reported in 2019 compared to the 12 months in 2018. Had 12 months of wages and benefits been reported for both years, the variance would have been negligible.

 

Depreciation and amortization

 

IFRS accounting requires that depreciation and amortization cease when reporting discontinued operations. As a consequence, no depreciation and amortization was reported in 2019 for discontinued operations. Depreciation and amortization was $2,409,380 in 2018.

 

General expenses and rent

 

General expenses and rent decreased by $698,195 (40%) to $1,062,907 in 2019 from $1,761,102 in 2018. The decrease is related to the stub period reported in 2019 compared to the 12 months in 2018. Additionally, the application of the new IFRS 16 standard in January 2019 resulted in the re-characterization of rent. Rent expense has now been replaced with interest cost related to a lease liability and amortization related to a right of use asset. Rental payments are now applied against the newly established lease liability. There was a corresponding reduction in rent expense during the year and an increase in interest cost. Due to the cessation of amortization, no amortization was recorded against the right of use asset. All rental payments were charged to rent expense in 2018.

 

Interest expense

 

During the 2019, the Company recorded non-cash interest expense of $74,494 relating to the afore-mentioned lease liability. The Company did not have an interest expense in 2018.

 

Page 46

Impairment

 

Non-cash impairment was nil in 2019 compared to $156,717 recorded in 2018. In 2018, management determined that certain property and equipment would no longer be used to generate future cash flows and committed to plan to dispose of such property and equipment. The Company disposed of assets that were no longer in use. The assets were impaired prior to their disposal. The fair value was less cost to sell was determined to be $3,000 which was greater than its value in use.

 


Credit Risk

 

The Company is exposed to credit risk associated with its accounts receivable. The Company has accounts receivable from both governmental and non-governmental agencies. Credit risk is minimized substantially by ensuring the credit worthiness of the entities with which it carries on business. Credit terms are provided on a case by case basis. The Company has not experienced any significant instances of non-payment from its customers.

 

The Company'sCompany’s accounts receivable ageing at December 31 was as follows:

 

   2019   2018   2017 
Current $-  $892,343  $330,731 
31 - 60 days  -   34,331   56,094 
61 - 90 days  -   60,885   - 
> 90 days  -   -   107,100 
Expected credit losses (1)  -   (40,615)  - 
  $-  $946,944  $493,925 

  2020  2019  2018 
Current $    -  $   -  $892,343 
31 - 60 days  -   -   34,331 
61 - 90 days  -   -   60,885 
> 90 days  -   -   - 
Expected credit losses (1)  -   -   (40,615 
  $-  $-  $946,944 

 

(1) The Company applies IFRS 9 simplified approach to measuring expected credit losses using a lifetime expected credit loss allowance for trade receivables.

 

The allowance is included in selling, general and administrative expenses in the consolidated statements of operations and deficit. Amounts charged to the loss allowance account are generally written off when there is no reasonable expectation of recovery.

 

In prior years, the impairment of trade receivables was assessed based on the incurred loss model and determined by management in accordance with its assessment of recoverability. Receivables for which an impairment provision was recognized were written off against the provision when there was no expectation of recovering additional cash.

 

Year Ended December 31, 2018 compared to Year Ended December 31, 2017

Revenue

During 2018, DenseLight reported revenue of $3,888,185 compared to $2,794,044 in 2017, a 39% increase driven primarily by an increase in product sales and non-recurring engineering (NRE) revenue. In November 2018 the Company received its first orders for POET Optical Interposer-based solutions from leading global networking companies targeting data communication applications, which represented entry into a new served market for the Company’s products. The increase in sales of $1,094,141 contributed to an increase in gross margin from 52% to 62%.

R&D

Total R&D increased by $3,026,876 from $3,403,452 in 2017 to $6,430,328 in 2018. For the purposes of the following R&D analysis, non-cash stock-based compensation of $140,853 (2017 - $150,112) has been excluded and is included with the analysis of non-cash stock-based compensation below.

The largest increase for the comparative periods was R&D which increased by $3,036,135 (93%) to $6,289,475 in 2018 from $3,253,340 in 2017. Since May of 2016, DenseLight has systematically increased its R&D activities in an effort to bring new products to market and expand its product portfolio. The increased R&D activity has contributed to the development of the POET Optical Interposer platform utilizing the Company’s proprietary waveguides. As a result of increased R&D spending in the period, the Company successfully demonstrated the functionality of PIN photodetectors targeting 100G to 400G optical transceivers. New skilled technical human resources, especially in optics and photonics device testing, represent the largest area of increase in R&D. The increase is consistent with the Company’s budgeted R&D activity. Our expectation is that the R&D activity conducted in 2018 will lead to sales of new products in 2019.

Non-cash stock-based compensation

Non-cash stock-based compensation increased by $202,672 (94%) to $419,238 during 2018 from $216,566 in 2017. The valuation of stock options is driven by a number of factors including the number of options granted, the strike price and the volatility of the Company’s stock. The stock option expense is dependent on the timing of the stock option grant and the amortization of the options as they vest. The stock options vest in accordance with the policies determined by the Board of Directors at the time of the grant consistent with the provisions of the Stock Option Plan, as amended (the “Plan”).


Depreciation and amortization

Non-cash depreciation and amortization increased by $316,472 (15%) to $2,409,380 in 2018 from $2,092,908 in 2017. The Company has committed to improving its fabrication facilities in Singapore, and its overall manufacturing capabilities, which includes acquiring new equipment for the Optical Interposer program. The addition of new equipment will result in increased depreciation charges.

Other income

Other income in 2018 decreased by $256,689 (15%) to $1,491,556 in 2018 from $1,748,245 in 2017. The Company is entitled to a recovery of certain qualifying expenses from the EDB in Singapore. The recoverable amount in 2017 was higher than the amount in 2018 in part due to a reduction adjustment in 2018 related to the over accrued recovery for 2017. If the adjustment had not been done, the recovery would have been more comparable year over year.

Impairment

During the year ended December 31, 2018, management determined that certain property and equipment would not be used to generate future cash flows and committed to a plan to dispose of the property and equipment by December 31, 2018. Management used a market approach to determine the property and equipment's fair value less cost to sell. Key assumptions included the cost of similar assets, the impact of customization and unique use. The fair value less cost to sell was determined to be $3,000 which is greater than its value in use. The Company recorded an impairment loss of $156,717 on the property and equipment and reclassified $3,000 from property and equipment to non-current assets held for sale. The property and equipment was sold in December 2018.

Credit Risk

The Company is exposed to credit risk associated with its accounts receivable. The Company has accounts receivable from both governmental and non-governmental agencies. Credit risk is minimized substantially by ensuring the credit worthiness of the entities with which it carries on business. Credit terms are provided on a case by case basis. The Company has not experienced any significant instances of non-payment from its customers.

The Company's accounts receivable ageing at December 31 was as follows:

   2018   2017 
Current $892,343  $330,731 
31 - 60 days  34,331   56,094 
61 - 90 days  60,885   - 
> 90 days  -   107,100 
Expected credit losses (1)  (40,615)  - 
  $946,944  $493,925 

(1) The Company applies IFRS 9 simplified approach to measuring expected credit losses using a lifetime expected credit loss allowance for trade receivables.

The allowance is included in selling, general and administrative expenses in the consolidated statements of operations and deficit. Amounts charged to the loss allowance account are generally written off when there is no reasonable expectation of recovery.

In prior years, the impairment of trade receivables was assessed based on the incurred loss model and determined by management in accordance with its assessment of recoverability. Receivables for which an impairment provision was recognized were written off against the provision when there was no expectation of recovering additional cash.


B.Liquidity and Capital Resources

 

The Company had working capital of $2,099,214 on December 31, 2020 compared to $15,354,149 on December 31, 2019 compared to $3,847,842 on December 31, 2018.2019. The Company’s balance sheet as of December 31, 20192020 reflects assets with a book value of $24,077,355$11,636,728 compared to $25,137,903$24,077,355 as of December 31, 2018. Eighty-four2019. Sixty-four percent (84%(64%) of the book value at December 31, 20192020 was in current assets consisting primarily of cash and cash equivalents of $6,872,894 compared to eighty-four percent (84%) of the book value as of December 31, 2019, which consisted primarily of receivable from the sale of discontinued operations of $18,000,000 compared$18,000,000.

On February 11, 2021, the Company completed a brokered private placement offering of 17,647,200 units at a price of $0.67 (CAD$0.85) per unit for gross proceeds of $11,811,118 (CAD$15,000,120). Each unit consists of one common share and one common share purchase warrant. Each whole warrant entitles the holder to twenty-seven percent (27%)purchase one common share of the book value asCompany at a price of $0.90 (CAD$1.15) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company’s average stock price exceeds $1.81 (CAD$2.30) for a period of 10 consecutive trading days. The broker was paid a cash commission of $708,667 (CAD$900,007) equating to 6% of the gross proceeds and received 1,058,832 broker warrants. Each broker warrant is exercisable into one common share of the Company at a price of $0.67 (CAD$0.85) per broker warrant until February 11, 2023.

Page 47

In addition to funds received from the brokered private placement, subsequent to December 31, 2018, or $6,888,264, was in current assets consisting primarily2020 the Company received $8,441,240 (CAD$10,714,953) from the exercise of cashstock options and other current assets.warrants. The Company also improved its liquidity by $1,709,526 (CAD$2,170,000) through the conversion of convertible debentures into common shares of the Company.

 

The Company is satisfied that it has sufficient working capital to meet its operating requirements over the next 12 months.

 

The following is a summary of Company’s cash flows and working capital:

 

   2019   2018   2017 
   $   $   $ 
Net cash used in operating activities  (9,394,221)  (9,288,588)  (9,163,689)
Net cash from investing activities  5,397,139   (3,535,600)  (441,065)
Net cash from financing activities  3,135,255   10,648,003   123,528 
Effect of exchange rate changes on cash  (277,912)  (230,425   79,422 
Change in cash  (1,139,739)  (2,406,610)  (9,401,804)
Opening cash  2,567,868   4,974,478   14,376,282 
Ending cash  1,428,129   2,567,868   4,974,478 


  2020  2019  2018 
  $  $  $ 
Net cash used in operating activities  (9,437,964)  (9,394,221)  (9,288,588)
Net cash from investing activities  13,926,137   5,397,139   (3,535,600)
Net cash from financing activities  1,162,459   3,135,255   10,648,003 
Effect of exchange rate changes on cash  (205,867)  (277,912)  (230,425)
Change in cash  5,444,765   (1,139,739)  (2,406,610)
Opening cash  1,428,129   2,567,868   4,974,478 
Ending cash  6,872,894   1,428,129   2,567,868 

 

Operating Activities

 

During 2019,2020, the Company had consolidated losses of $5,952,875 (2018$18,169,070 (2019 - $16,322,779, 2017$11,434,632, 2018 - $12,797,797)$8,422,117). Included in the consolidated loss was income (loss) from discontinued operations of nil (2019 - $5,481,757, in 2019. (20182018loss of $7,900,662, 2017 – loss of $4,888,946)$(7,900,662)).

 

The operating activities of the continuing operation included the following non-cash items: non-cash stock-based compensation of $3,612,945 (2019 - $2,888,141, (20182018$3,602,879, 2017 - $2,958,358)$3,602,879), depreciation and amortization of $813,103 (2019 - $243,674, (20182018 - $153,244, 2017 - $182,252)$153,244), impairment of long lived assets and goodwill of nil in 2020 (2019 - $1,764,459, 2018 – nil), amortization of debt issuance cost of nil (2019 - $372,340 (2018 and 2017 – nil) and, accretion of debt discount on convertible debentures of $524,095 (2019 - $280,829, (20182018 – nil), credit loss on receivable from the sale of discontinued operations of $2,500,000 (2019 and 20172018 – nil) and other non-cash operating costs of $1,070,970 (2019 and 2018 – nil).

 

The Company will regularly have high non-cash stock-based compensation as it uses stock options as method of attracting, retaining and motivating directors, employees and consultants of the Company and any of its subsidiaries and to closely align the personal interests of such directors, employees and consultants with those of the shareholders by providing them with the opportunity, through options, to acquire common shares in the capital of the Company while managing compensation through cash.

 

The Company raised $7,729,921 of debt financing from various lenders at varying times throughout 2019, net of directly related issue costs. The issuance cost of debt in 2019 was amortized over the life of the related debt resulting in the amortization of debt issuance cost of $372,340. The related debt was settled in 2019, as a result there was no debt amortization cost in 2020.

 

Included in the debt raised in 2019 were convertible debentures issued at a discount. The discount on the convertible debentures are accreted over the life of the convertible debentures. This non-cash cost of accretion of debt discount on convertible debentures was $280,829. There were no such costs in the prior years because 2019 was the first time the Company issued such debt instruments.$524,095 (2019 – 280,829).

 

Accounts receivable decreased from $946,944 in 2018 to nil in 2019. All sales in the Company were reported through DenseLight as a result all receivables were also collectible in DenseLight. Due the sale of DenseLight and all its assets, the Company had no receivables at December 31, 2019.

Page 48

 

PrepaidsPrepaid and other current assets also decreased from 2018 to 2019. The Company had $2,936,619 of prepaid and other current assets in 2018 and $831,265 in 2019. 98%2019 to $618,717 in 2020. A significant portion of the 2018 prepaid and other current assetsexpense in 2019 related to prepaid R&D activities that were recoverableconsumed in DenseLight including a recoverable amount2020. The success of $1,905,593 due from the Economic Development Board of Singapore. With sale of DenseLight,that R&D activity resulted in the Company no longer has highannouncing multiple milestone achievements in 2020. The prepaid and other current assets.

With the sale of DenseLight, the Company had a substantial reductionexpenses in accounts payable and accrued liabilities which was reduced from $3,040,422 in 20182020 related to $1,725,708 in 2019.

While discontinued operations reported income from discontinued operations of $5,481,757, (2018 – loss of $7,900,662) it had negative cash flows of $2,951,104 (2018 - $4,790,793). The loss was due primarily to deposits on equipment that was ordered prior to the add back of the gain from the sale of discontinued operations of $8,707,280.December 31, 2020.

 

Consolidated negative cash flow from operations was $9,437,964 in 2020 compared to $9,394,221 in 2019 compared to $9,288,588 in 2018.2019.

 

Investing Activities

 

In 2019,2020, the Company had consolidated cash flow from investing activities of $13,926,137 compared to $5,397,139 in 2019. $5,908,623 of which $7,007,642the cash flows from investing activities in 2019 was from thediscontinued operations while continuing operations while discontinued operations spent $1,610,503$511,484 on investing activities.

 


TheIn 2020, the Company received 8,000,000collected $15,500,000 (2019 - $8,000,000) on November 8, 2019its receivable from the sale of DenseLight. TheAfter taking into consideration the length of time it had taken the Buyer to make the foregoing payments and the Company’s expectations regarding the likelihood of receiving an additional payment, the Company hasdetermined that it was in its best interest to accept partial payments as final payment on the Company’s receivable. As a receivableresult, the Company recognized a credit loss of $18,000,000 that remained outstanding from$2,500,000 during the sale onyear ended December 31, 2019, $4,750,000 of which was paid on February 14, 2020 and $8,250,000 was paid on March 30, 2020.

 

The Company spent a cumulative $1,573,863 (2019 - $2,121,987, 2018 - $3,535,600) on capital purchases in 2020. In 2019, withthe Company spent $511,484 spent in the continuing operations and $1,610,503 was spent on capital purchases at DenseLight. Comparatively, in 2018, the Company either spent cash or accrued $3,718,152 on certain critical equipment, primarily consisting of; die pick tool, Omega etch, APM PECVD and C2L Transport. Almost all capital expenditure was incurred at DenseLight in 2018.

 

Financing Activities

During 2020, the Company received $1,088,450 from the exercise of warrants and stock options (2019 - $60,028). In 2018, $10,648,003 was received as the net receipts from a brokered bought deal public offering of 25,090,700 units.

In March and April 2020 the Company received a cumulative $218,151 of covid-19 government support loans from the US and Canadian governments. The loans are repayable based on various criteria in May 2022 and December 2022.

 

During 2019 the Company closed five tranches of a private placement of the Convertible Debentures that raised gross proceeds of $3,729,921. The Convertible Debentures, bear interest at 12% per annum, compounded annually with 1% payable at the beginning of each month and mature two years from the date of issue. The Company paid $373,502 in brokerage fees and other costs related to the closing of these five tranches.

 

The Convertible Debentures are convertible at the option of the holders thereof into units at any time after October 31, 2019 at a conversion price of CAD$0.40 per unit for a total 12,470,73012,457,500 units of the Company. Each unit will consist of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share of the Company at a price of CAD$0.50 per share for a period of two years from the date upon which the convertible debenture is converted into units. Upon completing the sale of DenseLight and receiving the full sale proceeds of $26,000,000, holders of Convertible Debentures have the right to cause the Company to repurchase the Convertible Debentures at face value, subject to certain restrictions. The Convertible Debentures are governed by a trust indenture between the Company and TSX Trust Company as trustee. The Company has not notified the trustee or the holders of the debentures that the sale of DenseLight has been completed and will not do so until the final payment of $5,000,000 is received from the Buyers, which is expected on or before May 31, 2020.

 

Insiders of the Company subscribed for 14.3% or $535,000 of the Convertible Debentures, including the Company’s board of directors and senior management team. Insiders of IBK Capital subscribed for 4% or $146,000 of the Convertible Debentures.

 

In addition to issuing convertible debentures, the Company was advanced $3,100,000 in various increments from Espresso Capital Ltd as part of a $5,000,000 credit facility. The Company paid 19.25% in interest on the funds advanced from the date of each advance until November 8, 2019 when the advance was repaid. The Company paid $147,077 in costs related to the Bridge Loan. Additionally, the Company issued to Espresso Capital Ltd, warrants for the purchase of 3,289,500 common shares at a price of CAD$0.35 per share. The Warrants expire on April 18, 2020. The fair value of the warrants was estimated on the date of issue using the Black-Scholes option pricing model with the following assumptions: volatility of 78.91%, interest rate of 1.62% and an expected life of 1 year. The estimated fair value assigned to the warrants was $221,620. The total cost of $368,697 along with the foreign exchange impact of $3,543 was deferred and charged against the Bridge Loan and subsequently amortized over the life of the Bridge Loan. The Bridge loan was repaid on November 8, 2019.

 

Page 49

The Company was also advanced $900,000 of a $1,000,000 promissory note on August 30, 2019 at 15% interest per annum. The $900,000 advance and accrued interest were repaid on November 8, 2019.

 

The financing in 2018 was through the issuance of common shares when the Company completed a brokered "bought deal" public offering of 25,090,700 units at a price of $0.425 (CAD$0.55) per unit for gross proceeds of $10,663,548 (CAD$13,799,885). Each unit consists of one common share and one-half common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $0.58 (CAD$0.75) per share until March 21, 2020. The broker was paid a cash commission of $639,813 (6%) of the gross proceeds and received 1,505,442 compensation options. Each compensation option is exercisable into one compensation unit of the Company at a price of $0.425 (CAD$0.55) per compensation unit until March 21, 2020 with each compensation unit comprising one common share and one-half compensation share purchase warrant. Each whole compensation share purchase warrant entitles the broker to purchase one common share of the Company at a price of $0.425 (CAD$0.55) per share until March 21, 2020. The Company paid an additional $492,177 in other costs related to this financing.

Capital Expenditures

 

The Company has an approved capital budget of $1,044,926$1,167,286 for the 20202021 fiscal year related to research and development equipment, manufacturing equipment and patent registration. In 2019, $2,121,9872020, $1,573,863 (2018 - $3,785,760, 2017 - $1,030,340$3,535,600) was either spent in cash or accrued for acquiring development and manufacturing equipment and new patents.

 


C.Research and Development

 

Virtually all of POET'sPOET’s R&D expenditures in recent years have been in some way connected to the Optical Interposer. We expect to continue to spend the majority of our R&D resources for the foreseeable future on Optical Interposer-based components across a variety of potential applications. DenseLight has also incurred R&D expenditures for conventional non-interposer-based products, primarily in the area of photonic sensing that represent the majority of the Company’s current product sales.

 

As a platform technology, Optical Interposer development does not have a specific end point. Each application of the Optical Interposer requires design and development specific to thethat application. POET’s product roadmap is currently focused on the development of Optical Engines for optical transceivers. Optical Engines include all of the photonics-related components of a transceiver but do not include several of the electronic devices needed for a functioning transceiver module. Nor does it include the external packaging and optical fibers. Nevertheless, Optical Engines represent the majoritya significant portion of the cost and value of most optical transceivers.

The success of the Optical Interposer is derived from the unique and proprietary integration of “active” and “passive” components at the chip level, with all of the processing, assembly, packaging and test done at wafer-level. Wafer-level processing eliminates the complex, high-cost individual alignment steps required in conventional and silicon photonics-based assembly following placement of each photonic device in the package. In addition to eliminating the alignment steps, wafer-level processing also eliminates the capital expense of the equipment typically used to measure the alignment. The Optical Interposer platform allows the use of known-good device components, eliminates multiple points of potential failure in alternative processing methods, and eliminates much of the labor associated with fabrication of photonics devices.

 

The “active” components that are included in a POET Optical Engine include lasers, detectors and modulators fabricated on InP or Silicon substrate and specifically designed to be integrated into the Optical Interposer fabric. We have supplemented our active component device development with co-development partners and license agreements, including for certain types of lasers and modulators. This not only reduces the risk to internal development and accelerates time to market, but it also ensures second sources of Optical Interposer-compatible active components, a critical part of our strategy going forward.

 

In parallel to these activities, POET has also directedbeen engaged in development programs in two other areas for the Optical Interposer platform, outside of DenseLight, includingnamely Passive Component design and development and Core Integration process development. Passive devices include filters, mux-demux devices, waveguides and spot size converters, all designed and fabricated using POET’s proprietary materials and processes. The Optical Interposer devices are fabricated at a third-party foundry. We transferred the basic processes for producing our Optical Interposers to our foundry partner in 2018 and since then we have continued to improve those processes in order to make them suitable for high volume manufacturing.

 

Page 50

Core Integration Process Developmentdevelopment relates primarily to advanced packaging methods that, combined with the unique design of the Optical Interposer, allows true wafer-scale assembly and test. We do not believe that such true wafer-scale integration has yet been demonstrated by any other approach in the photonics industry. We are able to achieve chip-level integration and wafer-scale assembly, test and packaging because all of the active devices are designed to be placed and “matched” to passive device interfaces on the foundational Optical Interposer wafer using pick-and-place assembly techniques. We eliminate the high cost and cumbersome process of testing each component following placement. Once placed and tested at wafer scale, each Optical Interposer device is sealed, the wafer is separated into hundreds of individual die, and the final Optical Engine is ready for shipment to the customer. Each of these process steps, from flip-chipping of devices onto the Optical Interposer, pick and place assembly, hermetic sealing and singulation required substantial innovation and development, including several techniques that are unique in the photonics and compound semiconductor industries. Core Integration development became a top priority once POET entered the product development stage with customers and became critical with the signing of the JVA for the creation of SPX.

 

We are also working with leading industry partners on optical enginesOptical Engines and other components for 400G transceivers, which is the next generation of transceiver modules that are expected to be introduced into data centers in the coming months and years. We believe that the Optical Interposer platform is very relevant to markets beyond data communications, such as telecommunications, Automotiveautomotive LIDAR, and in “Co-Packaged Optics,” which is the integration of optics with Application Specific Integrated Circuits (ASICs), including switches and graphics generators.generators, for both data center application and more self-contained applications of optical computing, which is relevant for artificial intelligence.

 


Internally generated research costs, including the costs of developing intellectual property and maintaining patents are expensed as incurred. Internal development costs are expensed as incurred unless such costs meet the criteria for deferralcapitalization and amortization under IFRS, which to date has not occurred.

 

We incurred a cumulative $6,634,317, $7,761,037 $8,692,804 and $5,442,873$8,692,804 of research and development expenses in 2020, 2019 2018 and 2017,2018, which includes non-cash stock-based compensation of $208,421,$567,859, $208,428 and $536,321 and $369,007 respectively. Other expenses related to research and development expenditures in the semiconductor business include costs associated with salaries, material costs, license fees, consulting services and third-party contract manufacturing. The expenses in all years presented can be analyzed for continuing and discontinuing operations as follows:

 

R&D for Continuing Operations

 

  

For the Years Ended December 31,
  For the Years Ended December 31, 
  2019   2018   2017  2020 2019 2018 
Wages and benefits $874,673  $822,258  $703,759  $1,586,900  $874,673  $822,258 
Subcontract fees  834,598   888,566   1,044,936   3,802,919   834,598   888,566 
Stock-based compensation  237,311   395,468   218,896   567,859   237,311   395,468 
Supplies  137,233   156,184   71,830   676,639   137,233   156,184 
 $2,083,815  $2,262,476  $2,039,421  $6,634,317  $2,083,815  $2,262,476 

 

R&D for Discontinued Operations

 

  

For the Period from

January 1, 2019

to

November 8,

   For the Years Ended December 31, 
  2019   2018   2017  2020 2019 2018 
Wages and benefits $3,565,076  $3,818,980  $2,135,329   -  $3,565,076  $3,818,980 
Supplies  1,412,572   2,070,495   1,118,011   -   1,412,572   2,070,495 
Subcontract fees  728,457   400,000   -   -   728,457   400,000 
Stock-based compensation  (28,883)  140,853   150,112   -   (28,883)  140,853 
 $5,677,222  $6,430,328  $3,403,452   -  $5,677,222  $6,430,328 

For the Period from January 1, 2019 to November 8, 2019 compared to the Twelve Months Ended December 31, 2018

Page 51

 

D.Trend Information

 

Other than as may be disclosed elsewhere in this annual report and specifically in ITEM 4.B. “Business Overview,” we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net revenues, income from operations, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial condition.

 

E.Off-Balance Sheet Arrangements

 

The Company has no material off-balance sheet arrangements in place at this time.

 


F.Tabular Disclosures of Contractual Obligations

 

The following table sets forth our contractual obligations and commercial commitments as of December 31, 2019:

2020:

 

   Payments due by period (US$) 
Contractual Obligations  Total   <1 year   1-3 years   3-5 years   >5 years 
Lease Obligations $665,491  $170,759  $494,732  $-  $- 

  Payments due by period (US$) 
Contractual Obligations Total  <1 year  1-3 years  3-5 years  >5 years 
Lease Obligations $679,452  $238,002  $441,450  $-  $- 
Convertible Debentures (1) $3,528,469  $3,528,469  $-  $-  $- 

(1) Refer to Item 3(b) for details

 

G.Safe Harbor

 

See “Forward Looking Statements” on page 1 of this Annual Report.


 

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

 

A.Directors and Senior Management

 

The following table sets forth information regarding our Directors and Officers for the most recent financial year.

 

Name Positions Age Date First Elected or Appointed a Director or Officer
Jean-Louis Malinge (3) Director  6667  September 5, 2017
Peter Charbonneau (1)(3) Corporate Governance and Nominating Committee Chair and Director  6667  March 28, 2018
Dr. Suresh Venkatesan Chief Executive Officer and Chairman  5354  June 11, 2015
Kevin Barnes Corporate Controller and Treasurer  4849  December 1, 2012
Thomas R. Mika Chief Financial Officer  6869  November 2, 2016
Don Listwin (2) Chair of Compensation Committee and Director,  6162  January 22, 2018
Vivek Rajgarhia President and General Manager  5253  November 4, 2019
Chris Tsiofas (1)(2) Audit Committee Chair and Director  5253  August 21, 2012
James Lee General Manager – POET Technologies Pte Ltd.  4849  September 2, 2019
David E. LazovskyGlen Riley (2)(5) Director  4858  April 8, 2015December 7, 2020
Mohandas Warrior (1) Director  5960  June 15, 2015
Rajan Rajgopal (4)President – DenseLight Semiconductor Pte. Ltd.55January 23, 2017
Richard ZoccolilloSenior Vice President – Strategic Marketing and Product Management57September 20, 2018

 

 (1)Member of Audit Committee

 

 (2)Member of Compensation Committee

 

 (3)Member of Corporate Governance and Nominating Committee

Page 52
   
(4)Transferred as part of Sale of DenseLight.
(5)Resigned as Executive Chairman during 2019 but remained a director

 


Dr. Suresh Venkatesan as CEO. Dr. Venkatesan was most recently Senior Vice President, Technology Development at Global Foundries and was responsible for the Company'sCompany’s Technology Research and Development. Dr. Venkatesan joined Global Foundries in 2009, where he led the development and ramp up of the 28nm node and was instrumental in the technology transfer and qualification of 14nm. In addition, he was responsible for the qualification and ramp up of multiple mainstream value-added technology nodes.

 

Mr. Thomas Mika as EVP & CFO. Prior to joining POET, Mika served for one year as the Executive Chairman of Rennova Health, Inc., the successor company to CollabRx and its predecessor, Tegal Corporation, a semiconductor capital equipment company (NASDAQ: TGAL). On the Board of Directors of Tegal since its spin-out from Motorola in 1989, Mika assumed the roles of Chief Financial Officer in 2002, CEO in 2005 and Chairman & CEO in 2006, positions which he held until 2015. In 2015, Tegal merged with Rennova Health with Mika retaining the position of Chairman until joining POET in November 2016. In 1980, Mika co-founded IMTEC, a boutique M&A, investment and consulting firm, serving clients in the U.S., Europe and Japan over a period of 20 years, taking on the role of CEO in several ventures. Earlier in his career, Mika was a managing consultant with Cresap, McCormick & Paget and a policy analyst for the National Science Foundation. He holds a Bachelor of Science in Microbiology from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Harvard Graduate School of Business.

 

Mr. Kevin Barnes has been serving as Corporate Controller and Treasurer since 2008 and briefly as Chief Financial Officer (2016(2012 – 2016). Mr. Barnes holds a Master of Business Administration and is a member of the Institute of the Certified Management Accountants of Australia and an Accredited Chartered Secretary. Mr. Barnes served as a Corporate Controller and Business Performance Manager for EC English, one of the world’s largest language training institutes between 2006 and 2014. Mr. Barnes also serves as Chief Financial Officer of VVC Exploration Corporation, a minerals exploration company since 2006. From 2000 to 2006, he was a reporting manager with Duguay and Ringler Corporate Services, which specializes in financial reporting for publicly traded companies.

 


Mr. Chris Tsiofas, CA, CPA, earned a Bachelor’s of Commerce Degree from the University of Toronto and is a member of the Chartered Professional Accountants of Canada and the Canadian Tax Foundation. He has been on the Board of Directors since August of 2012. He is the president of MTN Chartered Professional Accountant Professional Corporation, a public accountancy firm.

David E. Lazovsky is the founder of Intermolecular and He sits on various private company boards. He has also served as that company’s President and Chief Executive Officer and asin a member of the board of directors from September 2004 to October 2014. Mr. Lazovsky has an in-depth knowledge of the semiconductor industry, technology and markets. Prior to founding Intermolecular, Mr. Lazovsky held several senior management positions at Applied Materials (NASDAQ: AMAT). From 1996 through August 2004, Mr. Lazovsky held management positionsprincipal capacity in the Metal Deposition and Thin Films Product Business Group where he was responsible for managing more than $1 billionvarious entrepreneurial ventures resulting in Applied Materials’ semiconductor manufacturing equipment business. Mr. Lazovsky holds a B.S. in mechanical engineering from Ohio University and, as of March 31, 2014, held 41 pending or issued U.S. patents. Mr. Lazovsky was appointed as the Chairman of the Board on February 1, 2017.successful divestitures.

 

Mr. Mohan Warrior has been an Angel Investor for early stage technology companies since Jan 2017 and serves as an Adviser to many of them. Mr. Warrior was president and chief executive officer (CEO) of Alfalight Inc. (“Alfalight”) from February 2004 to Sep 2016. Alfalight is a GaAs based high power diode laser manufacturing company with headquarters in Madison, Wisconsin. Alfalight serves military, telecom and industrial customers. Mr. Warrior established Alfalight as a leading provider of high-powered laser diode solutions in both commercial and defense segments. Alfalight was sold to Gooch and Housego in 2016. Prior to joining Alfalight, Mr. Warrior'sWarrior’s career included 15 years at Motorola Semiconductors (now Freescale) where he led the test and assembly operations, a group of 3500 employees, in the US, Scotland and Korea. Mr Warrior earned his Bachelor’s degree in Chemical Engineering from Indian Institute of Technology, Delhi, a Master’s degree in Chemical Engineering from Syracuse University, New York and an MBA from the Kellogg School of Management at Northwestern University

 

Page 53

Mr. Jean-Louis Malinge servesrecently retired as partner with ARCH Venture Partners, an early-stage venture capital firm with nearly $2 billion under management. Additionally, he is a board member of EGIDE SA, CAILabs and Aeponyx. EGIDE SA is a public French company which designs, manufactures and sells hermetic packages for the protection and interconnection of several types of electronic and photonic chips. CAIlabs is a venture-backed French innovative start-up founded in 2013 which has developed a unique spatial multiplexing platform. Aeponyx is a venture-backed Canadian innovative start-up which develops a platform combining Silicon Nitride waveguides with planar MEMS for photonics components. From 2004 to 2013 Jean- Louis was President and CEO of Kotura, a Silicon Photonics pioneer which was acquired in 2013 by Mellanox Technologies. Prior to Kotura Mr. Malinge was an executive with Corning Inc for 15 years. Jean-Louis hold an Executive M.B.A. from MIT Sloan School in Boston, Massachusetts. He also holds an engineering degree from the Institut National des Sciences Appliquées in Rennes, France.

 

Mr. Don Listwin has over 30 years of technology investing and management experience, highlighted by a decade at Cisco Systems, where he served as executive vice president. During his tenure at Cisco, he built several multi-billion-dollar lines of business, including the company'scompany’s Service Provider line of business that underpins much of today'stoday’s global Internet infrastructure. More recently, Listwin served as chief executive officer of both Sana Security and Openwave Systems. In addition, Listwin founded and holds the role of chief executive officer of the Canary Foundation, a non-profit research organization focused on the early detection of cancer. He also serves as a director on the boards of AwareX, Calix, iSchemaView, Robin Systems and Teradici. Previously, he also served on the boards or was an advisor to JDS Uniphase, PLUMgrid, Redback Networks, E-TEK Dynamics, the Cellular Telecommunications & Internet Association (CTIA) and the Business Development Bank of Canada (BDC).

 


Mr. Charbonneau was a general partner at Skypoint Capital Corporation for almost 15 years, where he was jointly responsible for the placement of $100 million of capital in early-stage telecommunications and data communication companies. Charbonneau currently serves on the board of directors of Teradici Corporation, a collaboration solutions Company and the creator of PCoIP protocol technology and Cloud Access Software. He serves on the Board of Surgical Safety Technologies Inc. a early stage start up that uses clinically trained deep learning systems to perform advanced analytics on hospital data. He recently served on the Board of Mitel Networks Corporation, a leading global provider of cloud and on-site business communications until November 2018 when it was sold to a private equity firm. He served as Lead Director, Chair of the Nominating and Governance Committee and Chair of the Audit Committee. He previously served as Chairman of the Board of Trustees for the CBC Pension Board and a director on the board of the Canadian Broadcasting Corporation as well as many technology and networking companies, including March Networks Corporation, TELUS Corporation, Breconridge Corporation and Dragonwave Incorporated.

Mr. Zoccolillo joined the Company with extensive experience in the photonics industry, including senior management roles at Infinera, Opnext and Lucent Technology’s optical networking business.  He has held senior management roles in Operations as well as General Management roles executing on growth-oriented business strategies.  Mr. Zoccolillo has served on the Advisory Board for Kaiam Corporation and the School of Science and Technology of Monmouth University.

Mr. Rajgarhia was Senior Vice President & General Manager of the Lightwave Business Unit of MACOM. Mr. Rajgarhia joined MACOM through the acquisition of Optomai Inc., where he was the Co-Founder and CEO, representing MACOM’s initial entry into the optical business. He was then instrumental in identifying and leading several strategic acquisitions to build an extensive portfolio of optical and photonic businesses, which formed MACOM’s Lightwave Business Unit. Mr. Rajgarhia has held senior management positions during his 30 years in the optical communications industry. He was the Director of Sales & Marketing (Asia) for Lucent Technologies’ (now Nokia) optical components, where he started its Asia business; Vice President of Product Marketing and Business Development for OpNext (formerly Hitachi’s Fiber Optics Division), where he was part of the team to spin-off the optical business from Hitachi; Director of Product Management & Marketing for JDS Uniphase (now Viavi), and VP of Global Sales for GigOptix. Mr. Rajgarhia has been a successful entrepreneur, founding two optical companies, and has held international assignments in Hong Kong, Germany and India. He holds a Bachelor of Engineering (Electrical) degree from Stevens Institute of Technology in New Jersey.

 

Mr. Lee was Vice President of Logic Technology at IMEC where he was responsible for defining the logic roadmap and developing the technology elements necessary to extend scaling with ultra-scaled FinFET, GAA devices, advanced metallization as well novel materials for emerging devices and quantum computing. Mr. Lee joined IMEC in 2015 where he was instrumental in driving collaborations with the foundries in China and was responsible for bringing in >100M euros of research partnership. Prior to IMEC, Mr. Lee had a 19-year career with GLOBALFOUNDRIES where he held various technical and management positions spanning the US and Singapore focused on developing, qualifying and ramping leading edge CMOS technology in the foundry. He has over 60 patents and holds a Bachelor of Engineering degree from the University of Illinois at Champaign-Urbana.

 

Mr. Riley has more than 30 years’ experience in leadership roles spanning both the semiconductor and optoelectronics industries. He most recently served as General Manager of the Filter Solutions Business Unit at Qorvo, where he was responsible for developing highly integrated RF modules used in flagship smartphones. Prior to the merger of RFMD and TriQuint that formed Qorvo, he held multiple leadership roles at TriQuint, including Managing Director of international headquarters in Singapore, General Manager of the GaAs foundry business, and General Manager of Optoelectronics. Riley was previously the Chief Executive Officer of Opticalis, an early stage optoelectronics company focused on the development of high-density wavelength division multiplexing products. He also held prior roles as Vice President and General Manager of the Optoelectronic business at Agere Systems, and President of Asia-Pacific Sales and Marketing at Lucent Technologies Microelectronics Group. He graduated as valedictorian with a B.S. degree in Electrical Engineering from the School of Engineering at the University of Maine and completed The General Manager Program at Harvard Business School.

Page 54

The Directors, unless otherwise noted above, have served in their respective capacities since their election and/or appointment, and will serve until the next Company’s annual general meeting or until a successor is duly elected, unless the office is vacated in accordance with the Articles of Continuance.


 

The Board has adopted a written Code of Business Conduct and Ethics to promote a culture of ethical business conduct and relies upon the selection of persons as directors, senior management and employees who they consider to meet the highest ethical standards. The Company’s Code of Business Ethics can be found on the Company’s web site at: www.poet-technologies.com.

 

There are no family relationships between any of our Directors or senior management. There are no arrangements or understandings with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a Director or member of senior management.

 

B.Compensation

 

Fixed Stock Option Plan

 

On September 21, 2007, the Directors approved a fixed 20% vesting Stock Option Plan (the “Plan”) to replace the Rolling Stock Option Plan that had been in effect since May 4, 2005. The Plan was approved by the disinterested shareholders of the Company at the Shareholders’ Meeting of June 19, 2008 and accepted for filing by the TSXV. Under the Plan, the maximum number of shares (the “Maximum Number”) which may be issued pursuant to options granted under the Plan or otherwise granted cannot exceed 20% of the issued and outstanding shares. The shareholders fixed the Maximum Number at 11,930,000. Thereafter, the Plan has been amended by the Directors, and such amendments have been approved by the shareholders in 2009, 2011, 2013, 2014, 2015, 2016, 2018 and 2018.2020. The Maximum Number is currently 57,611,36058,538,554 shares.

 

The purpose of the Plan is to assist the Company in attracting, retaining and motivating directors, employees and consultants of the Company and any of its subsidiaries and to closely align the personal interests of such directors, employees and consultants with those of the shareholders by providing them with the opportunity, through options, to acquire common shares in the capital of the Company.

 

The Plan provides that the number of common shares issuable pursuant to options granted under the Plan and pursuant to other previously granted options is limited to the Maximum Number, currently fixed at 57,611,360.58,538,554. Any subsequent increase in the Maximum Number must be approved by shareholders of the Company and cannot exceed 20% of the issued and outstanding shares of the Company at the time of the shareholders’ approval. There is no other limit to the number of options granted to any individual, except for:

(i) 2% on a yearly basis to any one consultant and (ii) 2% on a yearly basis to any employee providing “Investor Relations Activities.”

 

The following paragraphs summarize some of the terms of the Plan:

 

Eligibility. Options may be granted under the Plan to directors, employees, consultants and consultant companies of the Company and any of its subsidiaries. Options may also be granted to individuals referred to as “Management Company Employees” which are employed by a company providing management services to the Company, except for services involving “Investor Relations Activities.”

 

Plan Administration. The Board of Directors is the plan administrator, subject to the advice and recommendations of our Compensation Committee. The plan administrator will determine the provisions and terms and conditions of each grant.

 


Page 55

 

Exercise Price. The exercise price subject to an option shall be determined by the Board and set forth in the option agreement, but shall be either (i) not less than the last closing price of the Company’s common shares as traded on the TSXV, unless discounted by the Board or (ii) such other price agreed by the Board and accepted by the TSXV. Except in certain circumstance, the Company can amend the other terms of a stock option only where prior TSXV acceptance is obtained and where the following requirements are met:

 

 (i)if the amendment is in respect of an option held by an insider of the Company, but excluding amendments to extend the length of the stock option term, the Company obtains disinterested shareholder approval;

 

 (ii)if the option exercise price is amended, at least six months have elapsed since the later of the date of commencement of the term, the date the Company’s shares commenced trading, or the date the option exercise price was last amended;

 

 (iii)if the option price is amended to the discounted market price, the exchange hold period is applied from the date of the amendment (and for more certainty where the option price is amended to the market price, the exchange hold period will not apply); and

 

 (iv)if the length of the stock option term is amended, any extension of the length of the term of the stock option is treated as a grant of a new option, and therefore the amended option must comply with the pricing and other requirements of the policy as if it were a newly granted option. The term of an option cannot be extended so that the effective term of the option exceeds 10 years in total. An option must be outstanding for at least one year before the Company can extend its term.

 

The TSXV must accept a proposed amendment before the option may be exercised as amended. If the Company cancels a stock option and within one year grants new options to the same individual, the new options will be subject to the requirements in sections (i) to (iv) above.

 


Option Agreement. Options granted under the plan are evidenced by an option agreement that sets forth the terms, conditions and limitations for each grant.

 

Term of the Awards. At the meeting of the Board of Directors held on February 25, 2016, based on the report of Compensia, it was determined that stock options should generally have a term of 10 years.

 

Vesting Schedule. In general, options granted under the Plan vest 25% immediately and 25% every six months from the date of issue, until fully vested. The directors may, at their discretion, specify a different vesting period, provided that options granted to consultants performing “Investor Relations Activities” must vest in stages over 12 months with no more than 25% of the options vesting in any three-month period. At the meeting of the Board of Directors held on February 25, 2016, based on the report of Compensia, it was determined that stock options should vest 25% at the end of one year from the date of issue with the remaining 75% vesting equally on a quarterly basis over the remaining 3 years for a total vesting period of 4 years. At a meeting of the Board of Directors held on March 30, 2017, the board approved a revised one-year vesting schedule for options granted for service on the board to conform to the term for which a director is elected. Such options will vest 25% at the end of each quarter served in office.

 

Transfer Restrictions. Options granted under the Plan may not be transferred in any manner by the option holder other than by will or the laws of succession and may be exercised during the lifetime of the option holder only by the option holder. Securities that are subject to restrictions may not be transferred during the period of restriction.

 

Change of Control and Alteration of Capital. The Plan provides that if a Change of Control, as defined herein, occurs, the shares subject to option shall immediately become vested and may thereupon be exercised in whole or in part by the option holder. The Plan also provides for automatic adjustments in the number of optioned shares and/or the exercised price, in the event of an alteration in the share capital of the Company.

 

Page 56

Termination of Options. In the event that the award recipient ceases employment with us or ceases to provide services to us, the options will terminate after a period of time following the termination of employment. Our Board of Directors has the authority to amend or terminate the plan subject to shareholder approval with respect to certain amendments. However, no such action may adversely affect in any material way any awards previously granted unless agreed upon by the recipient.

 

Officer Compensation

 

Total cash compensation accrued and/or paid (directly and/or indirectly) to all of our Officers during fiscal year 20192020 was $1,595,551$1,501,058 (refer to ITEM 7. “Major Shareholders and Related Party Transactions” for information regarding indirect payments)

 

In order to assist the Board of Directors in fulfilling its oversight responsibilities with respect to human resources matters, the Board established a Compensation Committee. The Compensation Committee reviews and makes determinations with respect to senior officer compensation on a regular basis with any discretionary compensation used only for extraordinary projects or significant milestone results that advance the Company’s growth potential. When determining Executive Officers’ compensation, the Compensation Committee receives input and guidance from the Executive Chairman of the Board and the Chief Executive Officer of the Company. In the past, the Compensation Committee has engaged an outside consultant to conduct a peer group review to provide guidance to the Compensation Committee with respect to appropriate comparative terms for executive compensation and stock option grants. The Company also utilizes peer group comparisons from subsidiary locations to assist in its salary review of various positions in those locations. The Compensation Committee utilizes such comparative reviews to assist it in making appropriate recommendations to the Board.

 

In addition to his or her fixed base salary, each officer may be eligible to receive variable pay compensation or bonus meant to motivate him or her to achieve short- term goals. Currently, the Company does not have in place established procedures for determining variable pay compensation. Stock options are an important element of the variable pay compensation and do not require cash disbursement from the Company. Stock options are also generally awarded to officers, qualifying employees and consultants at the time of hire and are used as a recruitment tool to attract highly qualified and experienced executives, employees and consultants to the Company. Stock options are also granted at other times during the year. As the Company is continuing to develop its Optical Interposer technology, it must conserve its limited financial resources and control costs to ensure that funds are available when needed to complete its scheduled developments. As a result, the Compensation Committee generally considers not only the financial situation of the Company at the time of the determination of the compensation, but also the estimated financial situation in the mid- and long-term. The use of stock options encourages and rewards performance by aligning an increase in each officer’s compensation with increases in the Company’s performance and in shareholder value.

 


The following table sets forth all annual and long-term compensation for services in all capacities to the Company for fiscal year 20192020 of the Company.

 

       Options Based Awards (1)(2)   Non-Equity Incentive Plan Compensation           Share- Options Based Awards (1)(2)   Non-Equity Incentive Plan Compensation       
Name and Principal Position Fiscal Year Salary (2) Share-Based Awards (1) (2) No. of Options Value of Options (1) (2) Annual Incentive Plans Long-term Incentive Plans Pension Value All other Comp. Total Comp. Fiscal Year Salary (2) Based Awards (1) (2) No. of Options Value of Options (1) (2) Annual Incentive Plans Long-term Incentive Plans Pension Value All other Comp. Total Comp. 
David Lazovsky  2019   166,667   -   900,000   256,363   -   -   -   -   423,030 
Dr. Suresh Venkatesan  2019   440,000   -   4,500,000   1,281,816   -   -   -   -   1,721,816  2020   440,000        -   2,500,000   875,825        -          -        -        -   1,315,825 
Richard Zoccolillo  2019   250,000   -   500,000   142,424   -   -   -   -   392,424  2020   62,500   -   -   -   -   -   -   -   62,500 
Kevin Barnes  2019   124,357   -   500,000   142,424   -   -   -   -   266,781  2020   143,000   -   800,000   280,264   -   -   -   -   423,264 
Thomas Mika  2019   300,000   -   1,000,000   284,848   -   -   -   -   584,848  2020   300,000   -   600,000   210,198   -   -   -   -   510,198 
Rajan Rajgopal  2019   219,917   -   -   -   -   -   -   -   219,917 
Vivek Rajgarhia  2019   60,833   -   3,200,000   815,529   -   -   -   -   876,362  2020   365,000   -   1,250,000   437,913   -   -   -   -   802,913 
James Lee  2019   33,777   -   1,000,000   250,932   -   -   -   -   284,709  2020   190,554   -   200,000   70,066   -   -   -   -   260,620 

 

Page 57

 (1)The Company used the Black-Scholes model as the methodology to calculate the grant date fair value. The fair value will be recorded as an operating expense as the options vest based on the stock options vesting schedule from the date of grant.

 

 (2)The exchange rate used in these calculations to convert CAD to USD is based on the exchange rate applicable at the date of grant.

 


The following table sets forth information concerning all awards outstanding under a stock option plan to each of the current officers, as of December 31, 2019:2020:

             
  Option-Based Awards   Share-Based Awards
Name No. of Shares Underlying Unexercised Shares Option Exercise Price (CA$/share) Option Expiration Date Value of Unexercised in-the Money Options (1) (US$) Number of Shares or Units of Shares That Have Not Vested Market or Payout Value of Share-Based Awards That Have Not Vested (US$)
David Lazovsky  250,000  $1.99  08-Apr-2020  -  N/A N/A
   25,000  $1.54  12-Jun-2020  -  N/A N/A
   150,000  $0.86  07-Jul-2026  -  N/A N/A
   3,000,000  $0.39  01-Feb-2027  -  N/A N/A
   950,000  $0.52  28-Mar-2028  -  N/A N/A
   900,000  $0.38  29-May-2029  -  N/A N/A
Kevin Barnes  50,000  $0.76  28-Feb-2021  -  N/A N/A
   25,000  $0.51  28-Sep-2021  -  N/A N/A
   25,000  $0.23  16-Feb-2022  2,788  N/A N/A
   50,000  $1.54  12-Jun-2020  -  N/A N/A
   25,000  $1.08  13-Aug-2020  -  N/A N/A
   100,000  $0.86  07-Jul-2026  -  N/A N/A
   250,000  $0.28  13-Jul-2027  18,269  N/A N/A
   150,000  $0.52  28-Mar-2028  -  N/A N/A
   500,000  $0.38  29-May-2029  -  N/A N/A
Rajan Rajgopal  343,750  $0.36  23-Jan-2027  3,966  N/A N/A
   281,250  $0.28  13-Jul-2027  20,553  N/A N/A
   93,750  $0.52  28-Mar-2028  -  N/A N/A
Richard Zoccolillo  1,750,000  $0.39  24-Sep-2028  -  N/A N/A
   500,000  $0.38  29-May-2029  -  N/A N/A
Suresh Venkatesan  6,357,000  $1.40  10-Jun-2020  -  N/A N/A
   300,000  $0.86  07-Jul-2026  -  N/A N/A
   3,000,000  $0.28  13-Jul-2027  219,231  N/A N/A
   3,900,000  $0.52  28-Mar-2028  -  N/A N/A
   4,500,000  $0.38  29-May-2029  -  N/A N/A
Thomas Mika  1,000,000  $0.62  02-Nov-2026  -  N/A N/A
   500,000  $0.385  16-Jan-2027  -  N/A N/A
   1,000,000  $0.28  13-Jul-2027  73,077  N/A N/A
   950,000  $0.52  28-Mar-2028  -  N/A N/A
   1,000,000  $0.38  29-May-2029  -  N/A N/A
Vivek Rajgarhia  3,250,000  $0.33  04-Nov-2029  112,500  N/A N/A
Yong Lee  1,000,000  $0.33  04-Nov-2029  34,615  N/A N/A

 

      Option-based Awards  Share-based Awards
First Name  Last Name  Number of Securities Underlying Unexercised Options  Option Exercise Price CAD  Option Expiration Date Value of Unexercised in-the-money Options USD  Number of Shares or Units of Shares that have not Vested Market or Payout Value of Shares or Units of Shares that have not Vested
Kevin  Barnes   25,000  $0.23  16-Feb-2022 $11,383.95  N/A N/A
Kevin  Barnes   220,000  $0.28  13-Jul-2027 $91,542.66  N/A N/A
Kevin  Barnes   500,000  $0.37  15-Jan-2030 $172,722.00  N/A N/A
Kevin  Barnes   500,000  $0.38  29-May-2029 $168,796.50  N/A N/A
Kevin  Barnes   25,000  $0.51  28-Sep-2021 $5,888.25  N/A N/A
Kevin  Barnes   150,000  $0.52  28-Mar-2028 $34,151.85  N/A N/A
Kevin  Barnes   300,000  $0.53  11-Jun-2030 $65,948.40  N/A N/A
Kevin  Barnes   50,000  $0.76  28-Feb-2021 $1,962.75  N/A N/A
Kevin  Barnes   100,000  $0.86  07-Jul-2026 $0.00  N/A N/A
Yong  Lee   1,000,000  $0.33  04-Nov-2029 $376,848.00  N/A N/A
Yong  Lee   200,000  $0.53  11-Jun-2030 $43,965.60  N/A N/A
Thomas  Mika   1,000,000  $0.28  13-Jul-2027 $416,103.00  N/A N/A
Thomas  Mika   1,000,000  $0.38  29-May-2029 $337,593.00  N/A N/A
Thomas  Mika   500,000  $0.385  16-Jan-2027 $166,833.75  N/A N/A
Thomas  Mika   950,000  $0.52  28-Mar-2028 $216,295.05  N/A N/A
Thomas  Mika   600,000  $0.53  11-Jun-2030 $131,896.80  N/A N/A
Thomas  Mika   1,000,000  $0.62  02-Nov-2026 $149,169.00  N/A N/A
Vivek  Rajgarhia   3,250,000  $0.33  04-Nov-2029 $1,224,756.00  N/A N/A
Vivek  Rajgarhia   1,250,000  $0.53  11-Jun-2030 $274,785.00  N/A N/A
Suresh  Venkatesan   3,000,000  $0.28  13-Jul-2027 $1,248,309.00  N/A N/A
Suresh  Venkatesan   4,500,000  $0.38  29-May-2029 $1,519,168.50  N/A N/A
Suresh  Venkatesan   3,900,000  $0.52  28-Mar-2028 $887,948.10  N/A N/A
Suresh  Venkatesan   2,500,000  $0.53  11-Jun-2030 $549,570.00  N/A N/A
Suresh  Venkatesan   300,000  $0.86  07-Jul-2026 $0.00  N/A N/A

(1) This amount is calculated based on the difference between the market value of the shares underlying the options as of December 31, 2019, being CAD $0.375 (US$0.29), and the exercise or base price of the option. The exchange rate used in these calculations to convert CAD to USD was 0.7682, being the closing exchange rate at December 31, 2019.

(1)This amount is calculated based on the difference between the market value of the shares underlying the options as of December 31, 2020, being CAD $0.81 (US$0.64), and the exercise or base price of the option. The exchange rate used in these calculations to convert CAD to USD was 0.7851, being the closing exchange rate at December 31, 2020.

 


Page 58

The value vested or earned during fiscal year 20192020 of incentive plan awards granted to NEOs are as follows:

 

    Option-based Awards  Share-based Awards Non-equity
First Name Last Name 

Number of

Securities

Underlying

Options

Vested

  

Value Vested

During the

Year USD

  

Number of

Shares or

Units of

Shares Vested

 

Value Vested

During the

Year

 

Incentive Plan

Compensation

- Value Earned

During The

Year

Kevin Barnes  306,250  $31,968.29  N/A N/A N/A
Yong Lee  250,000  $41,217.75  N/A N/A N/A
Thomas Mika  1,237,500  $108,294.73  N/A N/A N/A
Vivek Rajgarhia  812,500  $133,957.69  N/A N/A N/A
Suresh Venkatesan  3,468,750  $359,624.87  N/A N/A N/A

(1)Option-Based Awards – ValueShare-Based Awards – Value VestedNon-Equity Incentive Plan Compensation – Value Earned
NEO NameVested DuringThis amount is the Year (1) (US$)Duringdollar value that would have been realized and is computed by obtaining the Year (US$)Duringdifference between the Year (US$)
Richard Zoccolillo-N/AN/A
Kevin Barnes3,606N/AN/A
Suresh Venkatesan43,269N/AN/A
Thomas Mika15,024N/AN/A
Rajan Rajgopal7,452N/AN/A
David Lazovsky3,606N/AN/Amarket price of the underlying securities on the vesting date and the exercise or base price of the options under the option-based award. For the named executive officers to realize this value, they would have had to exercise their options and sell the shares on the day of vesting. The exchange rates used in these calculations to convert CAD to USD were the rates applicable on the vesting dates.

 

(1) This amount is the dollar value that would have been realized and is computed by obtaining the difference between the market price of the underlying securities on the vesting date and the exercise or base price of the options under the option-based award. For the named executive officers to realize this value, they would have had to exercise their options and sell the shares on the day of vesting. The exchange rates used in these calculations to convert CAD to USD were the rates applicable on the vesting dates.


Director Compensation

 

The following table details compensation paid/accrued for fiscal year 20192020 for each director who is not also an officer.

 

       Options-Based Non-Equity
Incentive Plan
      
       Awards(1)(2) Compensation   All       Share- Options Based Awards (1)(2)   Non-Equity Incentive Plan Compensation       
Name and Principal Position Fiscal
Year
 Salary (cash)
(2)
(US$)
 Share-Based Awards (1)(US$) No. of Shares (US$) Annual
Incentive
 Long-term Pension Other Total 

Fiscal

Year

 

Salary

(2)

 

Based

Awards

(1) (2)

 

No. of

Options

 

Value of

Options

(1) (2)

 

Annual

Incentive

Plans

 

Long-term

Incentive

Plans

 

Pension

Value

 

All

other

Comp.

 

Total

Comp.

 
Chris Tsiofas 2020   40,000        -   293,135   102,694        -          -       -        -   142,694 
Peter Charbonneau 2020   51,250   -   372,593   130,531   -   -   -   -   181,781 
David Lazovsky (3) 2020   30,000   -   263,821   92,424   -   -   -   -   122,424 
Mohandas Warrior 2020   30,000   -   263,821   92,424   -   -   -   -   122,424 
Jean-Louis Malinge 2020   30,000   -   263,821   92,424   -   -   -   -   122,424 
Don Listwin  2019   32,500      383,356   106,424               138,924  2020   40,000   -   293,135   102,694   -   -   -   -��  142,694 
Chris Tsiofas  2019   47,500      440,653   125,519               173,019 
Mohan Warrior  2019   30,000      360,534   102,697               132,697 
Peter Charbonneau  2019   40,000      400,593   114,108               154,108 
Jean-Louis Malinge  2019   30,000      360,534   102,697               132,697 
Glen Riley 2020   -   -   224,600   78,684   -   -   -   -   78,684 

 

(1)The Company used the Black-Scholes model as the methodology to calculate the grant date fair value. The fair value will be recorded as an operating expense as the stock options vest from the date of grant.

 

(2)The exchange rate used in these calculations to convert CAD to USD was the rate of exchange applicable on the date of grant.
(3)David Lazovsky resigned from the Board of Directors on November 30, 2020

 

The following table sets forth information concerning all awards outstanding under the stock option plans to each of the current Directors who are not also named executive officers as of December 31, 2019:2020:

 

      Option-based Awards  Share-based Awards
First Name  First Name  Number of Securities Underlying Unexercised Options  Option Exercise Price CAD  Option Expiration Date Value of Unexercised in-the-money Options USD  Number of Shares or Units of Shares that have not Vested Market or Payout Value of Shares or Units of Shares that have not Vested
Peter  Charbonneau   399,000  $0.33  21-Jun-2028 $150,362.35  N/A N/A
Peter  Charbonneau   400,593  $0.38  29-May-2029 $135,237.39  N/A N/A
Peter  Charbonneau   35,488  $0.42  06-Feb-2030 $10,866.04  N/A N/A
Peter  Charbonneau   154,730  $0.52  28-Mar-2028 $35,228.77  N/A N/A
Peter  Charbonneau   337,105  $0.53  11-Jun-2030 $74,105.12  N/A N/A
Don  Listwin   468,750  $0.22  22-Jan-2028 $217,129.22  N/A N/A
Don  Listwin   399,000  $0.33  21-Jun-2028 $150,362.35  N/A N/A
Don  Listwin   22,822  $0.33  04-Nov-2029 $8,600.43  N/A N/A
Don  Listwin   360,534  $0.38  29-May-2029 $121,713.75  N/A N/A
Don  Listwin   293,135  $0.53  11-Jun-2030 $64,439.28  N/A N/A
Jean-Louis  Malinge   525,000  $0.30  05-Sep-2027 $210,210.53  N/A N/A
Jean-Louis  Malinge   399,000  $0.33  21-Jun-2028 $150,362.35  N/A N/A
Jean-Louis  Malinge   360,534  $0.38  29-May-2029 $121,713.75  N/A N/A
Jean-Louis  Malinge   263,821  $0.53  11-Jun-2030 $57,995.24  N/A N/A
Glen  Riley   224,600  $0.50  04-Dec-2030 $54,663.37  N/A N/A
Chris  Tsiofas   687,500  $0.28  13-Jul-2027 $286,070.81  N/A N/A
Chris  Tsiofas   487,666  $0.33  21-Jun-2028 $183,775.96  N/A N/A
Chris  Tsiofas   440,653  $0.38  29-May-2029 $148,761.37  N/A N/A
Chris  Tsiofas   293,135  $0.53  11-Jun-2030 $64,439.28  N/A N/A
Chris  Tsiofas   150,000  $0.86  07-Jul-2026 $0.00  N/A N/A
Mohandas  Warrior   562,500  $0.28  13-Jul-2027 $234,057.94  N/A N/A
Mohandas  Warrior   399,000  $0.33  21-Jun-2028 $150,362.35  N/A N/A
Mohandas  Warrior   360,534  $0.38  29-May-2029 $121,713.75  N/A N/A

Mohandas

  Warrior   263,821  $0.53  11-Jun-2030 $57,995.24  N/A N/A

Mohandas

  Warrior   150,000  $0.86  07-Jul-2026 $0.00  N/A N/A

 


   Option-Based Awards        Share-Based Awards
Name  No. of Shares Underlying Unexercised Shares   Option Exercise Price (CA$/share)  Option Expiration Date  Value of Unexercised in-the Money Options (1) (US$)  Number of Shares or Units of Shares That Have Not Vested Market or Payout Value of Share-Based Awards That Have Not Vested (US$)
Chris Tsiofas  300,000  $1.54  12-Jun-2020  -  N/A N/A
   150,000  $0.86  07-Jul-2026  -  N/A N/A
   687,500  $0.28  13-Jul-2027  50,240  N/A N/A
   487,666  $0.33  21-Jun-2028  16,881  N/A N/A
   440,653  $0.38  29-May-2029  -  N/A N/A
Don Listwin  468,750  $0.22  22-Jan-2028  55,889  N/A N/A
   399,000  $0.33  21-Jun-2028  13,812  N/A N/A
   360,534  $0.38  29-May-2029  -  N/A N/A
   22,822  $0.33  04-Nov-2029  790  N/A N/A
Jean-Louis Malinge  525,000  $0.30  05-Sep-2027  30,288  N/A N/A
   399,000  $0.33  21-Jun-2028  13,812  N/A N/A
   360,534  $0.38  29-May-2029  -  N/A N/A
Mohandas Warrior  250,000  $1.54  12-Jun-2020  -  N/A N/A
   150,000  $0.86  07-Jul-2026  -  N/A N/A
   562,500  $0.28  13-Jul-2027  41,106  N/A N/A
   399,000  $0.33  21-Jun-2028  13,812  N/A N/A
   360,534  $0.38  29-May-2029  -  N/A N/A
Peter Charbonneau  154,730  $0.52  28-Mar-2028  -  N/A N/A
   399,000  $0.33  21-Jun-2028  13,812  N/A N/A
   400,593  $0.38  29-May-2029  -  N/A N/A

(1)This amount is calculated based on the difference between the market value of the shares underlying the options as of December 31, 2019,2020, being CAD $0.375$0.81 (US$0.29)0.64), and the exercise or base price of the option. The exchange rate used in these calculations to convert CAD to USD was 0.7682,0.7851, being the closing exchange rate at December 31, 20192020.

 


Page 59

 

The value vested or earned during fiscal year 20192020 of incentive plan awards granted to Directors who are not also named executive officers are as follows:

 

      Option-based Awards  Share-based Awards Non-equity
First Name  Last Name  

Number of

Securities

Underlying

Options

Vested

  

Value Vested

During the

Year

  

Number of

Shares or Units

of Shares Vested

 

Value Vested

During the

Year

 

Incentive Plan

Compensation

- Value Earned

During The

Year

Peter  Charbonneau   395,465  $26,163.43  N/A N/A N/A
Don  Listwin   349,657  $23,790.10  N/A N/A N/A
Jean-Louis  Malinge   312,178  $20,418.21  N/A N/A N/A
Chris  Tsiofas   395,019  $24,495.28  N/A N/A N/A
Mohandas  Warrior   340,303  $20,418.21  N/A N/A N/A

(1)Option-Based Awards – ValueShare-Based Awards – Value VestedNon-Equity Incentive Plan Compensation – Value Earned
Director NameVested DuringThis amount is the Year (1) (US$)Duringdollar value that would have been realized and is computed by obtaining the Year (US$)Duringdifference between the Year (US$)
Peter Charbonneau6,138N/AN/A
Jean-Louis Malinge6,138N/AN/A
Chris Tsiofas7,503N/AN/A
Don Listwin12,449N/AN/A
Mohan Warrior6,138N/AN/Amarket price of the underlying securities on the vesting date and the exercise or base price of the options under the option- based award.

(1) This amount is the dollar value that would have been realized and is computed by obtaining the difference between the market price of the underlying securities on the vesting date and the exercise or base price of the options under the option- based award.

 

Termination and Change of Control Benefits

 

Other than disclosed belowas described in “Written Management Agreements,”their individual management agreements, the Company has no plans or arrangements in respect of remuneration received or that may be received by the Officers the Company to compensate such Officers, in the event of termination of employment (as a result of resignation, retirement, change of control) or a change of responsibilities following a change of control.

 


Pension Plan Benefits

 

The Company does not provide a defined benefit plan to the Officers or any of its employees.

 

The Company offers a defined contribution plan that is a 401k Plan but does not contribute toward such plan. The Company does not have any deferred compensation plans other than that described above.

 

Written Management AgreementsThe following individuals were executives of the Company in 2020:

 

The Company and/or its subsidiaries have employment contracts with the following current and former Officers as follows:

Dr. Venkatesan entered into an Executive Employment Agreement with an effective date of June 10, 2015 wherein (i) he will be paid US$550,000 per year under at- will terms of employment; (ii) he will be eligible for annual and special bonuses as determined by the Board of Directors; (iii) he was granted 6,357,000 stock options vesting over 4 years; (iv) he became eligible for a signing bonus of US $450,000 payable on the first anniversary of the effective date; (v) he will receive a severance of twelve months on termination of employment by the Company, other than for cause. Mr. Venkatesan agreed to a permanent reduction of his cash compensation by 20% effective October 2016, reducing his compensation from US$550,000 to US$440,000 per year. 

Mr. Mika entered into an Executive Employment Agreement with an effective date of November 2, 2016 wherein (i) he will be paid US$250,000 per year under at- will terms of employment (ii) he will be eligible for annual and special bonuses as determined by the Board of Directors; (iii) he was granted 1,000,000 stock options vesting over 4 years; (iv) he will receive an additional 500,000 stock options vesting over 4 years in Q1 2017 (v) he will be entitled to compensation of three months’ salary on termination of employment by the Company, if termination is other than for cause. Mr. Mika’s compensation was adjusted to US$300,000 on May 1, 2018.

On July 1, 2016, Mr. Lazovsky entered into a Consulting Agreement with the Company to provide strategic, technological, integration and other general consulting services. For his services, Mr. Lazovsky was paid $150,000 for the term from July 1, 2016 to December 31, 2016.

Mr. Lazovsky entered into an Executive Employment Agreement to provide services as the Executive Chairman of the Board, with an effective date of February 1, 2017. He will (i) be paid US$200,000 per year under at-will terms of employment (ii) be eligible for annual and special bonuses as determined by the Board of Directors; (iii) granted 3,000,000 stock options vesting over 4 years; (iv) be entitled to compensation of six months’ salary on termination prior to 2 years of employment by the Company, if termination is other than for cause. Mr. Lazovsky resigned as Executive Chairman of the Board on November 6, 2019.

Mr. Barnes had an arrangement with the Company to provide consulting services starting January 1, 2013 for a period of one year with an automatic one-year renewal. His consulting agreement was converted to an employment agreement and is paid CA$190,000 annually.

Effective December 30, 2016, Mr. Rajan Rajgopal entered into an employment agreement with DenseLight to provide services as the President and General Manager of DenseLight. As per the agreement, Mr. Rajgopal will (i) be paid be paid US$220,000 per year (ii) be eligible for annual and special bonuses as determined by the Board of Directors; (iii) be granted 500,000 stock options vesting over 4 years; (iv) be granted an additional 500,000 stock options no later than June 30, 2017 (v) be entitled to compensation of one month salary on termination of employment by the Company, if termination is other than for cause.

Effective September 10, 2018, Mr. Zoccolillo entered into an employment agreement to provide services as the Senior Vice President Strategic Marketing and Product Management. As per the agreement, Mr. Zoccolillo will (i) be paid be paid US$250,000 per year (ii) be eligible for annual and special bonuses as determined by the Board of Directors; and (iii) be granted 1,750,000 stock options vesting over 4 years.

Mr. Rajgarhia entered into an Executive Employment Agreement with an effective date of November 4, 2019 wherein (i) he will be paid US$365,000 per year under at- will terms of employment (ii) he will be eligible for annual and special bonuses as determined by the Board of Directors; (iii) he was granted 3,250,000 stock options vesting over 4 years.

Effective September 2, 2019, Mr. Lee entered into an employment agreement with POET Technologies Pte. Ltd. to provide services as the Vice President and General Manager of POET Technologies Pte. Ltd. As per the agreement, Mr. Lee will (i) be paid be paid US$240,000 per year (ii) be eligible for annual and special bonuses as determined by the Board of Directors; (iii) be granted 1,000,000 stock options vesting over 4 years; (iv) be entitled to compensation of one month salary on termination of employment by the Company, if termination is other than for cause.

NameTitle
Suresh VenkatesanCEO
Vivek RajgarhiaPresident
Thomas MikaExecutive Vice President and CFO
Yong Meng (James) LeeGeneral Manager, POET Technologies Pte Ltd
Kevin BarnesTreasurer, Corporate Controller

 


 Page 60

C.Board Practices

 

Our Board of Directors currently consists of seven (7) directors including the CEO, of which, six (6) are independent directors. Each director holds office until the next annual general meeting of the Company or until his successor is elected or appointed, unless his office is earlier vacated in accordance with the Articles of Amalgamation and all amendments thereto (the “Articles”), or with the provisions of the OBCA. The Company’s Officers are appointed to serve at the discretion of the Board, subject to the terms of the employment agreements described above.

 

Lead independent director

Our independent directors have selected Peter Charbonneau to serve as the lead independent director. The lead independent director’s primary role is to facilitate the functioning of the board, and to maintain and enhance the quality of our corporate governance practices. The lead independent director presides over the private sessions of our independent directors that take place following each meeting of the board and conveys the results of these meetings to the chair of the board.

The Board and committees of the Board schedule regular meetings over the course of the year.

 

During fiscal 2019,2020, the Board held 1216 regularly scheduled meetings, including committee meetings. If for various reasons, Board members may not be able to attend a Board meeting, all Board members are provided information related to each of the agenda items before each meeting, and, therefore, can provide counsel outside the confines of regularly scheduled meetings.

 

The Board has adopted standards for determining whether a director is independent from management. The Board reviews, consistent with the Company’s corporate governance guidelines, whether a director has any material relationship with the Company that would impair the director’s independent judgment. The Board has affirmatively determined, that as of the filing of this Form 20-F, based on its standards, that Messrs. Tsiofas, Malinge, Charbonneau, Listwin, LazovskyRiley and Warrior are independent.

 

Directors’ Service Contracts

 

Mr. Venkatesan entered intohas an employment contract as explained above in “Written Management Agreements.”with the Company.

 

Audit and Compensation Committees of the Board of Directors

 

We currently have four board committees; (1) an Audit Committee; (2) a Compensation Committee, (3) a Strategy Committee and (4) a Corporate Governance and Nominating Committee. Committee charters for the Audit, Compensation and Corporate Governance and Nominating Committees can be found on the Company’s website (poet-technologies.com). The Strategy Committee is an ad-hoc committee and therefore does not have a charter. The names of the members and a summary of the terms of the charter for each the Audit Committee and the Compensation Committee is provided below.

 

Audit Committee

 

The Audit Committee is currently comprised of three members: Chris Tsiofas (Chair), Peter Charbonneau and Mohandas Warrior. All three members are independent directors of the Company. Mr. Tsiofas was appointed chair of the Audit Committee on August 21, 2012. The Board has determined that Mr. Tsiofas satisfies the criteria of “audit committee financial expert” within the meaning of Item 401(h) of Regulation S-K and is independent in accordance with Rule 4200 of the NASDAQ Marketplace Rules. All members of the audit committee are financially literate, meaning they have the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company’s financial statements.

 

Page 61

The Audit Committee is responsible for reviewing the Company’s financial reporting procedures, internal controls and the performance of the Company’s external auditors. The Audit Committee is also responsible for reviewing the annual and quarterly financial statements and accompanying Management’s Discussion and Analysis prior to their approval by the full Board. The Audit Committee also reviews the Company’s financial controls with the auditors of the Company on an annual basis.

 

The Company’s independent auditor is accountable to the Board and to the Audit Committee. The Board, through the Audit Committee, has the ultimate responsibility to evaluate the performance of the independent auditor, and through the shareholders, to appoint, replace and compensate the independent auditor. Any non-audit services must be pre- approved by the Audit Committee.

 


Compensation Committee

 

The Compensation Committee is currently comprised of three members: Don Listwin (Chair), Chris Tsiofas and David Lazovsky.Glen Riley. Mr. Listwin was appointed chair of the Compensation Committee on August 8, 2019. All three members are independent directors. The Board has determined that all members of the Compensation Committee are qualified as members based on the following:

 

Mr. Don Listwin, Chairman of the Compensation Committee has over 30 years of technology investing and management experience, highlighted by a decade at Cisco Systems, where he served as its Executive Vice President. Mr. Listwin currently serves as chief executive officer of iSchema ViewRapidAI and in the recent past served as chief executive officer of both Sana Security and Openwave Systems. Mr. Listwin also currently serves as a director on the boards of AwareX, Calix, Robin Systems and Teradici. Previously, he also served on the boards or was an advisor to JDS Uniphase, PLUMgrid, Redback Networks, E-TEK Dynamics, the Cellular Telecommunications & Internet Association (CTIA) and the Business Development Bank of Canada (BDC). In these capacities, Mr. Listwin had extensive direct experience with executive compensation matters as both a chief executive and board member of an assortment of companies, large and small, including companies within industries directly relevant to the Company.

 

Mr. Chris Tsiofas, CA, CPA, earned a Bachelor’s of Commerce Degree from the University of Toronto and is a member of the Institute of Chartered Accountants of Canada and the Canadian Tax Foundation. He has been on the Board of Directors of the Company since August of 2012. Mr. Tsiofas is the president of MTN Chartered Professional Accountant Professional Corporation, a public accountancy firm. He sits on various private company boards. He has also served in a principal capacity in various entrepreneurial ventures resulting in successful divestitures. Tsiofas formerly served as Chairman of the Company’s Compensation Committee and has directed past engagements with the Company’s outside executive compensation consultants. Mr. Tsiofas is also the Chairman of the Audit Committee of the Board of Directors. He brings to the Compensation Committee specialized knowledge regarding the tax impact of certain compensation policies and practices on individuals and on the Company.

 


Mr. David E. Lazovsky isRiley has more than 30 years’ experience in leadership roles spanning both the foundersemiconductor and optoelectronics industries. He has been on the Board of Intermolecular andDirectors of the Company since December 2020. Mr. Riley most recently served as General Manager of the Filter Solutions Business Unit at Qorvo. Prior to the merger of RFMD and TriQuint that company’s Presidentformed Qorvo, he held multiple senior leadership roles at the vice-presidential level with TriQuint, including Managing Director of TriQuint’s international headquarters in Singapore, General Manager of the GaAs foundry business, and General Manager of Optoelectronics. Prior to TriQuint he was the Chief Executive Officer of privately held Opticalis, an early stage optoelectronics company. He has also held roles as Vice President and as a memberGeneral Manager of the boardOptoelectronic business at Agere Systems, and President of directorsAsia-Pacific Sales and Marketing at Lucent Technologies Microelectronics Group. Mr. Riley has extensive direct experience with executive compensation from September 2004these prior senior level executive roles with these companies in technology industries related to October 2014. Mr. Lazovsky has an in-depth knowledge of the semiconductor industry, technology and markets. Prior to founding Intermolecular, Mr. Lazovsky held several senior management positions at Applied Materials (NASDAQ: AMAT). From 1996 through August 2004, Mr. Lazovsky held management positions in the Metal Deposition and Thin Films Product Business Group where he was responsible for managing more than $1 billion in Applied Materials’ semiconductor manufacturing equipment business. Mr. Lazovsky holds a B.S. in mechanical engineering from Ohio University and, as of March 31, 2014, held 41 pending or issued U.S. patents.Company.

Page 62

 

The Compensation Committee has extensive direct relevant experience in determining executive compensation policies and practices on behalf of the Company. In addition to being supported by outside compensation consultants on a periodic basis for peer group review, the members of the Committee are professional executives familiar with best practices associated with executive compensation, are knowledgeable about the tax implications to the Company and its executive officers of changes in the tax laws pertaining to executive compensation and have direct relevant experience with the incentives used throughout the Company’s industry to align the interests of executive management with company and shareholder interests. This gives these individuals strong insight as to the incentive structures and programs appropriate for companies of a comparable size. The seniority, experience and level of achievement of the three current members of the Compensation Committee speak to the independent judgement exercised in making decisions about the suitability of the Company’s compensation policies and practices.

 

The Compensation Committee discusses and makes recommendations to the Board for approval of compensation issues that pertain to the senior executives of the Company, and on issues involving employment company-wide compensation policies and practices. In general, the compensation programs of the Company are designed to reward performance and to be competitive with the compensation agreements of other comparable semiconductor companies. The Compensation Committee is responsible for evaluating the compensation of the senior management of the Company and assuring that they are compensated effectively in a manner consistent with the Company’s business, stage of development, financial condition and prospects, and the competitive environment. Specifically, the Compensation Committee is responsible for: (i) reviewing the compensation practices and policies of the Company to ensure that they are competitive and that they provide appropriate motivation for corporate performance and increased shareholder value; (ii) overseeing the administration of the Company’s compensation programs, and reviewing and approving the employees who receive compensation and the nature of the compensation provided under such programs, and ensuring that all management compensation programs are linked to meaningful and measurable performance targets; (iii) making recommendations to the Board regarding the adoption, amendment or termination of compensation programs and the approval of the adoption, amendment and termination of compensation programs of the Company, including for greater certainty, ensuring that if any equity- based compensation plan is subject to shareholder approval, and that such approval is sought; (iv) periodically surveying the executive compensation practices of other comparable companies; (v) establishing and ensuring the satisfaction of performance goals for performance-based compensation; (vi) annually reviewing and approving the annual base salary and bonus targets for the senior executives of the Company, other than the Chief Executive Officer (the “CEO”); (vii) reviewing and approving annual corporate goals and objectives for the CEO and evaluating the CEO’s performance against such goals and objectives; (viii) annually reviewing and approving, based on the Compensation Committee’s evaluation of the CEO, the CEO’s annual base salary, the CEO’s bonus, and any stock option grants and other awards to the CEO under the Company’s compensation programs (in determining the CEO’s compensation, the Compensation Committee will consider the Company’s performance and relative shareholder return, the compensation of CEOs at other companies, and the CEO’s compensation in past years); and (ix) reviewing the annual report on executive compensation required to be prepared under applicable corporate and securities legislation and regulation including the disclosure concerning members of the Compensation Committee and settling the reports required to be made by the Compensation Committee in any document required to be filed with a regulatory authority and/or distributed to shareholders.

 

In 2016, the Compensation Committee contracted with Compensia to perform an executive compensation review (the “Review”) of certain senior positions within the then-current executive management team. Base salaries and annual and long-term incentives were benchmarked against a group of public companies in the communications equipment, semiconductor, and electronic component industries. The data provided was one of the elements considered by the Compensation Committee, with adjustments made for the differences in stage of development, revenues, profitability and other characteristics that distinguished the Company from the benchmarks.


The benchmarks comprised the following companies: Alliance Fiber Optic Product, Amtech Systems, Applied Optoelectronics, Clearfield, CyberOptics, Dynasil, EMCORE, Exar, GigPeak, GSI Technology, Intermolecular, LightPath Technologies, Micropac Industries, Nanometrics, PDF Solutions, QuickLogic and Ultratech. The data came from each company’s public filings available as of April 2016. The positions benchmarked were CEO, COO, CTO, VP-Product Development and VP-Design Enablement. Due to cost and relevance, the Company elected not to repeat the Review with Compensia for its consideration of executive compensation for fiscal years subsequent to December 31, 2016.

Code of Ethics

 

The Board has adopted a written code of business conduct and ethics. All transgressions of the code of business conduct and ethics are required to be promptly reported to the Chair of the Board or of any committee, who in turn, reports them to the Corporate Governance and Nominating Committee. The Corporate Governance and Nominating Committee is charged with investigating alleged violations of the code of business conduct and ethics. Any findings of the Corporate Governance and Nominating Committee are then reported to the full Board, which will take such action as it deems appropriate. The Company’s Code of Ethics may be inspected on the Company’s website (poet-technologies.com) and is filed as an Exhibit to this Annual Report.

 

 Page 63

D.Employees

As of December 31, 2020, the Company had twenty-five (25) full-time employees and three (4) consultants, Eight (8) employees and one (1) consultant work at our lab facility either as support staff or are engaged in research and development initiatives; two (2) employees and one (1) consultant are employed at the Canadian office; Thirteen (13) employees are employed at our fabrication facility in Singapore; Two (2) employees are employed at our product development facility in China; One (1) consultant is located in in Italy; and One (1) consultant is located in Japan. None of the Company’s employees are covered by collective bargaining agreements.

 

As of December 31, 2019, the Company had sixteen (16) full-time employees, one (1) part-time employee and three (3) consultants, including one (1) in a senior management position. Eight (8) employees and one (1) consultant work at our lab facility either as support staff or are engaged in research and development initiatives; two (2) employees and one (1) consultant are employed at the Canadian office; Seven (7) employees are employed at our fabrication facility in Singapore. None of the Company’s employees are covered by collective bargaining agreements.

 

As of December 31, 2018, the Company had ninety-nine (99) full-time employees and four (4) consultants, including one (1) in a senior management position. Seven (7) employees and one (1) consultant work at our lab facility either as support staff or are engaged in research and development initiatives; one (1) employee and three (3) consultants are employed at the Canadian office; ninety-one (91) employees are employed at our fabrication facility in Singapore. None of the Company’s employees are covered by collective bargaining agreements.

 

As of December 31, 2017, the Company had sixty-eight (68) full-time employees and five (5) consultants, including senior management. Five (5) employees and one (1) consultant worked at our lab facility either as support staff or were engaged in research and development initiatives; One (1) employee and three (3) consultants were employed at the Canadian office; sixty-three (63) employees were employed at our fabrication facility in Singapore. None of the Company’s employees were covered by collective bargaining agreements.

E.Share Ownership and Other Securities

 

The following table sets forth certain information regarding the beneficial ownership of our outstanding common shares for: (i) each of our Directors and Officers individually; (ii) all of our Directors and Officers as a group; and (iii) each other person known to us to own beneficially more than 5% of our common shares as of April 22, 2020.March 13, 2021. Beneficial ownership of shares is determined under rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power. The table also includes the number of shares underlying options that are exercisable within sixty (60) days of April 22, 2020.March 13, 2021. Ordinary shares subject to these options are deemed to be outstanding for the purpose of computing the ownership percentage of the person holding these options, but are not deemed to be outstanding for the purpose of computing the ownership percentage of any other person.

 


The shareholders listed below do not have any different voting rights from our other shareholders.

 

 Number of Shares Beneficially Owned (1) Percent of Class 

Number of Shares Beneficially

Owned (1)

 Percent of Class 
Directors and Officers:                
Chris Tsiofas  25,000   0%  25,000   0%
Thomas Mika  100,000   0%  100,000   0%
Kevin Barnes  17,463   0%  17,463   0%
David Lazovsky  181,000   0%
Mohandas Warrior  262,500   0%
Suresh Venkatesan  115,000   0%  115,000   0%
Don Listwin  632,250   0%  2,103,207   0%
Directors and Officers Subtotal  1,070,713   0.36%  2,623,170   0.7%
Major Shareholders:                
None that we are aware of.                

 

 (1)The number of shares set forth for each Director, Officer and Major Shareholder is determined in accordance with Rule 13d-3 of the General Rules and Regulations under the Exchange Act.

 

Page 64

See “ITEM 6.B. Compensation” for the exercise prices of options.

 

 

Number of Options exercisable

within 60 days

 Percent of class 

Number of

options exercisable

within 60 days

 

Percent of

class

 
Glen Riley  56,150   0%
James Lee  375,000   1%
Kevin Barnes  484,375   0.92%  763,750   2%
Vivek Rajgarhia  1,218,750   3%
Peter Charbonneau  854,175   1.62%  1,280,140   3%
David Lazovsky  3,071,875   5.85%
Don Listwin  1,149,562   2.19%
Jean- Louis Malinge  1,194,401   2.27%
Mohandas Warrior  1,407,400   3%
Jean-Louis Malinge  1,482,400   3%
Chris Tsiofas  1,985,670   4%
Thomas Mika  2,228,125   4.24%  3,587,500   8%
Chris Tsiofas  1,936,906   3.69%
Suresh Venkatesan  10,200,750   19.45%  8,006,250   18%
Mohandas Warrior  1,613,151   3.07%
Richard Zoccolillo  546,875   1.04%
  24,008,945   45.78%  24,750,404   54%

  Number of Warrants exercisable
within 60 days
  Exercise price CA$  

Percent of

class

 
Suresh Venkatesan  37,500   0.52   0%

  Beneficially owned convertible debentures 
Kevin Barnes $15,702 
Peter Charbonneau $78,510 
Mohandas Warrior $54,957 
Jean-Louis Malinge $54,957 
Chris Tsiofas $78,510 
Thomas Mika $23,553 
Suresh Venkatesan $78,510 
Don Listwin $78,510 
  $463,209 

 

The Convertible Debentures are convertible at the option of the holders thereof into units at any time after October 31, 2019 at a conversion price of CAD$0.40 per unit into units of the Company. Each unit consists of one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share of the Company at a price of CAD$0.50 per share for a period of four years from the date upon which the convertible debenture was issued.

  

Number of Warrants exercisable

within 60 days

 Exercise price CA$ Percent of class
 Suresh Venkatesan  37,500   0.52   0%
 David Lazovsky  90,500   0.52   0%
   128,000       0.002%

 


Page 65

 

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

 

A.Major Shareholders

 

Holdings by Major Shareholders

 

Please refer to ITEM 6.E. “Share Ownership” for details regarding securities held by Directors, Officers and Major Shareholders. The Company’s major shareholders do not have any different or special voting rights.

 

U.S. Share Ownership

 

As of April 22, 2020,March 13, 2021, there were a total of 445 holders of record of our common shares with addresses in the U.S. We believe that the number of U.S beneficial owners is substantially greater than the number of U.S record holders, because a large portion of our common shares are held in broker “street names.” As of April 22, 2020,March 13, 2021, U.S. holders of record held approximately 0.65% of our outstanding common shares.

 

Control of Company

 

The Company is a publicly owned Ontario corporation, the shares of which are owned by Canadian residents, U.S. residents and other foreign residents. The Company is not controlled by any foreign government or other person(s) except as described in ITEM 4.A. “History and Progress of the Company” and ITEM 6.E. “Share Ownership.”

 

Change of Control of Company Arrangements

 

None

 

B.Major Shareholders and Related Party Transactions

 

No shareholder beneficially owns 5% or more of the Company’s common shares.

 

Compensation to key management personnel (Executive Chairman, CEO,(CEO, CFO, President, and General Manager of POET andGM POET Technologies Pte Ltd)Ltd, Treasurer) was as follows:

 

 2019 2018 2017 2020  2019 2018 
             
Salaries $1,251,277  $1,216,250  $932,133  $1,501,058  $1,251,277  $1,216,250 
Share-based payments (1)  2,135,579   2,449,683   2,110,773   2,144,930   2,135,579   2,449,683 
                        
Total $3,386,856  $3,665,933  $3,042,906  $3,645,988  $3,386,856  $3,665,933 

 

(1) Share-based payments are the fair value of options granted to key management personnel and expensed during the various years as calculated using the Black-Scholes model.

 

C. Interests of Experts and Counsel

C.Interests of Experts and Counsel

 

Not applicable.


ITEM 8. FINANCIAL INFORMATION

 

A.Consolidated Statements and Other Financial Information

 

The Company’s financial statements are stated in U.S. dollars and are prepared in accordance with IFRS as issued by the IASB.

Page 66

 

The financial statements as required under “ITEM 17. Financial Statements” are attached hereto and found immediately following the text of this Annual Report. The audit report of Marcum LLP, independent registered public accounting firm, is included herein immediately preceding the consolidated financial statements.

 

Legal Proceedings

 

The directors and the senior management of the Company do not know of any material, either active or pending, legal proceedings against them, nor is the Company involved as a plaintiff in any material proceeding or pending litigation.

 

The directors and the senior management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest in the Company.

 

Dividend Policy

 

The Company has not paid, and has no current plans to pay, dividends on its common shares. We currently intend to retain future earnings, if any, to finance the development of our business. Any future dividend policy will be determined by the Board, and will depend upon, among other factors, our earnings, if any, financial condition, capital requirements, any contractual restrictions with respect to the payment of dividends, the impact of the distribution of dividends on our financial condition, tax liabilities, and such economic and other conditions as the Board may deem relevant.

 


B.Significant Changes

 

On February 14, 202011, 2021, the Company completed a brokered private placement offering of 17,647,200 units at a price of $0.67 (CAD$0.85) per unit for gross proceeds of $11,811,118 (CAD$15,000,120). Each unit consists of one common share and March 30,one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $0.90 (CAD$1.15) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company’s average stock price exceeds $1.81 (CAD$2.30) for a period of 10 consecutive trading days. The broker was paid a cash commission of $708,667 (CAD$900,007) equating to 6% of the gross proceeds and received 1,058,832 broker warrants. Each broker warrant is exercisable into one common share of the Company at a price of $0.67 (CAD$0.85) per broker warrant until February 11, 2023.

In addition to funds received from the brokered private placement, subsequent to December 31, 2020 the Company collected $4,750,000 and $8,250,000 respectively for a cumulative $13,000,000 representing two tranches of an agreed three tranche payment plan for the outstanding balance due from DL Shanghaireceived $8,441,240 (CAD$10,714,953) from the saleexercise of DenseLight.stock options and warrants. The Company collected an additional $2,000,000 which was immediately paid to Oak Capital on behalfalso improved its liquidity by $1,709,526 (CAD$2,170,000) through the conversion of convertible debentures into common shares of the DL Shanghai for due diligence, legal and other expenses.Company.

 

ITEM 9. THE OFFER AND LISTING

 

A. Offer and Listing Details

A.Offer and Listing Details

 

The Company’s common shares began trading on the TSXV in Toronto, Ontario, Canada, on June 25, 2007. The current Stock symbol is “PTK”. The CUSIP/ISN numbers are 73044W104 / 73044W1041.

 

The following table lists the high and low sales price on the TSXV for the Company’s common shares for: the last six months; the last ten fiscal quarters; and the last five fiscal years.

 

Period Ended High (CA$) Low (CA$)
MONTHLY    
March 31, 2020  0.56   0.25 
February 28, 2020  0.54   0.365 
January 31, 2020  0.415   0.365 
December 31, 2019  0.435   0.31 
November 30, 2019  0.34   0.245 
October 31, 2019  0.345   0.30 
QUARTERLY        
March 31, 2020  0.56   0.25 
December 31, 2019  0.44   0.30 
September 30, 2019  0.46   0.30 
June 30, 2019  0.42   0.31 
March 31, 2019  0.46   0.27 
December 31, 2018  0.40   0.24 
September 30, 2018  0.44   0.23 
June 30, 2018  0.44   0.27 
March 31, 2018  0.79   0.19 
December 31, 2017  0.36   0.28 
YEARLY        
December 31, 2019  0.46   0.27 
December 31, 2018  0.79   0.19 
December 31, 2017  0.51   0.17 
December 31, 2016  1.44   0.27 
December 31, 2015  2.00   0.62 
Page 67

Period Ended  High (CA$)  Low (CA$) 
MONTHLY         
February 28, 2021   1.49   1.02 
January 31, 2021   1.11   0.71 
December 31, 2021   0.87   0.46 
November 30, 2020   0.56   0.46 
October 31, 2020   0.64   0.51 
September 30, 2020   0.58   0.49 
QUARTERLY         
February 28, 2021   1.49   0.46 
November 30, 2020   0.64   0.46 
August 31, 2020   0.71   0.48 
May 31, 2020   0.62   0.22 
February 28, 2020   0.55   0.34 
November 30, 2019   0.43   0.30 
August 31, 2019   0.46   0.35 
May 31, 2019   0.40   0.31 
February 28, 2019   0.46   0.25 
November 30, 2018   0.44   0.24 
YEARLY         
December 31, 2020   0.71   0.22 
December 31, 2019   0.46   0.27 
December 31, 2018   0.79   0.19 
December 31, 2017   0.51   0.17 
December 31, 2016   1.44   0.27 

 

B.Plan of Distribution

 

Not Required.

 

C.Markets

 

The Company’s common shares trade on the TSXV in Canada under the symbol “PTK”. The Company’s common shares also trade on the OTCQX International Marketplace under the symbol “POETF”.

 

D.Selling Shareholders

 

Not Required.

 


E.Dilution

 

Not Required.

 

F.Expenses of the Issue

 

Not Required.

 

ITEM 10. ADDITIONAL INFORMATION

 

A.Share Capital

 

Not Required.

 

B.Memorandum and articles of association

 

The Company was originally formed under the British Columbia Company Act on February 9, 1972 as Tandem Resources Ltd. (“Tandem”). The Company took its current form after Tandem amalgamated with Stanmar Resources Ltd. and Keezic Resources Ltd. pursuant to Articles of Amalgamation on November 14, 1985. Tandem moved to Ontario by Articles of Continuance on January 3, 1997. Tandem changed its name to OPEL International Inc. by Articles of Amendment on September 26, 2006. OPEL International Inc. was continued under the New Brunswick Business Corporations Act on January 30, 2007, then back to Ontario by Articles of Continuance on November 30, 2010, changing its name to OPEL Solar International Inc. By Articles of Amendment on August 25, 2011, OPEL Solar International Inc. changed its name to OPEL Technologies, Inc. By Articles of Amendment on July 23, 2013, OPEL Technologies Inc. changed its name to POET Technologies Inc. Today, the Company is an Ontario corporation governed by the OBCA. The following are summaries of material provisions of our Articles of Continuance, as amended from time to time (the “Articles”), in effect as of the date of this Annual Report insofar as they relate to the material terms of our ordinary shares.

Page 68

 

Register, Entry Number and Purposes

 

Our Articles of Continuance became effective on November 30, 2010. Our corporation number in Ontario is 641402. The Articles of Continuance do not contain a statement of the Company’s objects and purposes. However, the Articles of Continuance provide that there are no restrictions on business that the Company may carry on or the powers the Company may exercise as permitted under the OBCA.

 

Board of Directors

 

Pursuant to our By-laws and the OBCA, a director or officer who is a party to, or who is a director or officer of, or has a material interest in, any person who is a party to, a material contract or proposed material contract with the Company, shall disclose the nature and extent of his interest at the time and in the manner provided by the OBCA. Any such contract or proposed contract shall be referred to the Board or shareholders for approval even if such contract is one that in the ordinary course of the Company’s business would not require approval by the Board or shareholders, and a director interested in a contract so referred to the Board shall not vote on any resolution to approve the same unless the contract or transaction: (i) relates primarily to his or her remuneration as a director of the Company or an affiliate; (ii) is for indemnity or insurance of or for the director or officer as permitted by the OBCA; or (iii) is with an affiliate.

 

Directors shall be paid such remuneration for their services as the Board may determine by resolution from time to time, and will be entitled to reimbursement for traveling and other expenses properly incurred by them in attending meetings of the Board or any committee thereof. Neither the Company’s Articles nor By-laws require an independent quorum for voting on director compensation. Directors are not precluded from serving the Company in any other capacity and receiving remuneration therefor. A director is not required to hold shares of the Company. There is no age limit requirement respecting the retirement or non-retirement of directors.

 


The directors may sign the name and on behalf of the Company, or appoint any officer or officers or any other person or persons on behalf of the Corporation either to sign on behalf of the Company, all instruments in writing and any instruments in writing so signed shall be binding upon the Company without further authorization or formality. The term “instruments in writing” includes contracts, documents, powers of attorney, deeds, mortgages, hypothecs, charges, conveyances, transfers and assignments of property (real or personal, immovable or movable), agreements, tenders, releases, receipts and discharges for the payment of money or other obligations, conveyances, transfers and assignments of shares, stocks, bonds, debentures or other securities, instruments of proxy and all paper writing.

 

Nothing in the Company’s By-laws limits or restricts the borrowing of money by the Company on bills of exchange or promissory notes made, drawn, accepted or endorsed by or on behalf of the Company.


 

Rights, Preferences and Restrictions Attaching to Common Shares

 

The holders of common shares are entitled to vote at all meetings of the shareholders, except meetings at which only holders of a specified class of shares are entitled to vote. Each common share carries with it the right to one vote. Subject to the rights, privileges, restrictions and conditions attaching to any other class or series of shares of the Company, the holders of the common shares are entitled to receive any dividends declared and payable by the Company on the common shares. Dividends may be paid in money or property or by issuing fully paid shares of the Company. Subject to the rights, privileges, restrictions and conditions attaching to any other class or series of shares of the Company, the holders of the common shares are entitled to receive the remaining property of the Company upon dissolution.

 

No shares have been issued subject to call or assessment. There are no pre-emptive or conversion rights and no provisions for redemption or purchase for cancellation, surrender, or sinking or purchase funds. The common shares must be issued as fully-paid and non-assessable, and are not subject to further capital calls by the Company. The common shares are without par value. All of the common shares rank equally as to voting rights, participation in a distribution of the assets of the Company on a liquidation, dissolution or winding-up of the Company and the entitlement to dividends.

Page 69

 

The Company does not currently have any preferred shares outstanding.

 

Ordinary and Special Shareholders’ Meetings

 

The OBCA provides that the directors of a corporation shall call an annual meeting of shareholders not later than 15 months after holding the last preceding annual meeting. The OBCA also provides that, in the case of an offering corporation, the directors shall place before each annual meeting of shareholders, the financial statements required to be filed under the Ontario Securities Act and the regulation thereunder relating to the period that began immediately after the end of the last completed financial year and ended not more than six months before the annual meeting and the immediately preceding financial year, if any.

 

The Board has the power to call a special meeting of shareholders at any time.

 

Notice of the date, time and location of each meeting of shareholders must be given not less than 21 days or more than 50 days before the date of each meeting to each director, to the auditor of the Company and to each shareholder who at the close of business on the record date for notice is entered in the securities register as the holder of one or more shares carrying the right to vote at the meeting.

 

Notice of a meeting of shareholders called for any other purpose other than consideration of the minutes of an earlier meeting, financial statements, reports of the directors or auditor, setting or changing the number of directors, the election of directors and reappointment of the incumbent auditor, must state the general nature of the special business in sufficient detail to permit the shareholder to form a reasoned judgment on such business, must state the text of any special resolution to be submitted to the meeting, and must, if the special business includes considering, approving, ratifying, adopting or authorizing any document or the signing of or giving of effect to any document, have attached to it, a copy of the document or state that a copy of the document will be available for inspection by shareholders at the Company’s records office or another accessible location.

 

The only persons entitled to be present at a meeting of shareholders are those entitled to vote, the directors of the Company and the auditor of the Company. Any other person may be admitted only on the invitation of the chairman of the meeting or with the consent of the meeting. In circumstances where a court orders a meeting of shareholders, the court may direct how the meeting may be held, including who may attend the meeting.

 

Limitations on Rights to Own Securities

 

No share may be issued until it is fully paid.

 

Neither Canadian law nor our Articles or By-laws limit the right of a non-resident to hold or vote common shares of the Company, other than as provided in the Investment Canada Act (the “Investment Act”), as amended by the World Trade Organization Agreement Implementation Act (the “WTOA Act”). The Investment Act generally prohibits implementation of a direct reviewable investment by an individual, government or agency thereof, corporation, partnership, trust or joint venture that is not a “Canadian,” as defined in the Investment Act (a “non-Canadian”), unless, after review, the minister responsible for the Investment Act is satisfied that the investment is likely to be of net benefit to Canada. An investment in the common shares of the Company by a non-Canadian (other than a “WTO Investor,” as defined below) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company, and the value of the assets of the Company were CA$5.0 million or more (provided that immediately prior to the implementation of the investment the Company was not controlled by WTO Investors). An investment in common shares of the Company by a WTO Investor (or by a non- Canadian other than a WTO Investor if, immediately prior to the implementation of the investment the Company was controlled by WTO Investors) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company and the value of the assets of the Company equaled or exceeded certain threshold amounts determined on an annual basis.

 


Page 70

 

The threshold for a pre-closing net benefit review depends on whether the purchaser is: (a) controlled by a person or entity from a member of the WTO; (b) a state- owned enterprise (SOE); or (c) from a country considered a “Trade Agreement Investor” under the Investment Act. A different threshold also applies if the Canadian business carries on a cultural business. The 20202021 threshold for WTO investors that are SOEs will be $428$416 million based on the book value of the Canadian business'business’ assets, updown from $416$428 million in 2019.2020. The 20202021 thresholds for review for direct acquisitions of control of Canadian businesses by private sector investor WTO investors ($1 billion) and private sector trade- agreement investors ($1.5 billion) remain the same and are both based on the "enterprise value"“enterprise value” of the Canadian business being acquired.

 

A non-Canadian, whether a WTO Investor or otherwise, would be deemed to acquire control of the Company for purposes of the Investment Act if he or she acquired a majority of the common shares of the Company. The acquisition of less than a majority, but at least one-third of the shares, would be presumed to be an acquisition of control of the Company, unless it could be established that the Company is not controlled in fact by the acquirer through the ownership of the shares. In general, an individual is a WTO Investor if he or she is a “national” of a country (other than Canada) that is a member of the WTO (“WTO Member”) or has a right of permanent residence in a WTO Member. A corporation or other entity will be a “WTO Investor” if it is a “WTO Investor-controlled entity,” pursuant to detailed rules set out in the Investment Act. The U.S. is a WTO Member. Certain transactions involving our common shares would be exempt from the Investment Act, including:

 

• an acquisition of the shares if the acquisition were made in the ordinary course of that person’s business as a trader or dealer in securities;

• an acquisition of control of the Company in connection with the realization of a security interest granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act; and

• an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization, following which the ultimate direct or indirect control in fact of the Company, through the ownership of voting interests, remains unchanged.

an acquisition of the shares if the acquisition were made in the ordinary course of that person’s business as a trader or dealer in securities;
an acquisition of control of the Company in connection with the realization of a security interest granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act; and
an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization, following which the ultimate direct or indirect control in fact of the Company, through the ownership of voting interests, remains unchanged.

 

Procedures to Change the Rights of Shareholders

 

In order to change the rights of our shareholders with respect to certain fundamental changes as described in Section 168 of the OBCA, the Company would need to amend our Articles to effect the change. Such an amendment would require the approval of holders of two-thirds of the votes of the Company’s common shares, and any other shares carrying the right to vote at any general meeting of the shareholders of the Company, cast at a duly called special meeting. The OBCA also provides that a sale, lease or exchange of all or substantially all of the property of a corporation other than in the ordinary course of business of the corporation likewise requires the approval of the shareholders at a duly called special meeting. For such fundamental changes and sale, lease and exchange, a shareholder is entitled under the OBCA to dissent in respect of such a resolution amending the Articles and, if the resolution is adopted and the Company implements such changes, demand payment of the fair value of the shareholder’s common shares.

 

Impediments to Change of Control

 

In 2016, the Canadian Securities Administrators (the “CSA”) enacted amendments (the “Bid Amendments”) to the Take-Over Bid Regime. The Bid Amendments, which are very significant, are contained in National Instrument (NI) 62-104.

 

The Bid Amendments were intended to enhance the quality and integrity of the take-over bid regime and rebalance the current dynamics among offerors, offeree issuer boards of directors (“Offeree Boards”), and offeree issuer security holders by (i) facilitating the ability of offeree issuer security holders to make voluntary, informed and coordinated tender decisions, and (ii) providing the Offeree Board with additional time and discretion when responding to a take-over bid.

 

Specifically, the Bid Amendments require that all non-exempt take-over bids

Page 71

(1) receive tenders of more than 50% of the outstanding securities of the class that are subject to the bid, excluding securities beneficially owned, or over which control or direction is exercised, by the offeror or by any person acting jointly or in concert with the offeror (the Minimum Tender Requirement);

(2) be extended by the offeror for an additional 10 days after the Minimum Tender Requirement has been achieved and all other terms and conditions of the bid have been complied with or waived (the 10 Day Extension Requirement); and

 


(3) remain open for a minimum deposit period of 105 days (the Minimum 105 Day Bid Period) unless

(3)  remain open for a minimum deposit period of 105 days (the Minimum 105 Day Bid Period) unless

 

(a) the offeree board states in a news release a shorter deposit period for the bid of not less than 35 days, in which case all contemporaneous take-over bids must remain open for at least the stated shorter deposit period, or

 

(b) the issuer issues a news release that it intends to effect, pursuant to an agreement or otherwise, a specified alternative transaction, in which case all contemporaneous take-over bids must remain open for a deposit period of at least 35 days.

 

The Bid Amendments involved fundamental changes to the bid regime to establish a majority acceptance standard for all non-exempt take-over bids, a mandatory extension period to alleviate offeree security holder coercion concerns, and a 105 day minimum deposit period to address concerns that offeree boards did not have enough time to respond to an unsolicited take-over bid. The CSA determined not to amend National Policy 62-202 Defensive Tactics (NP 62-202) in connection with these amendments. They reminded participants in the capital markets of the continued applicability of NP 62-202, which means that securities regulators will be prepared to examine the actions of offeree boards in specific cases, and in light of the amended bid regime, to determine whether they are abusive of security holder rights.

 

After canvassing several commentaries concerning the new regime, we have concluded that:

 

It will be much more difficult for hostile bidders as a result of target issuers having a much longer period of time to respond, concurrent with the added risk and cost to such bidders.
It will be much more difficult for hostile bidders as a result of target issuers having a much longer period of time to respond, concurrent with the added risk and cost to such bidders.

 

There is good reason to expect that, except in unusual circumstances, regulators will not permit SRPs to remain in effect after a 105 day bidding period.
There is good reason to expect that, except in unusual circumstances, regulators will not permit SRPs to remain in effect after a 105 day bidding period.

 

A significant number of reporting issuers have not sought re-approval of their SRPs since the amendments were introduced and those that have sought to renew their SRPs have been required to amend the plans to comply with the new rules.
A significant number of reporting issuers have not sought re-approval of their SRPs since the amendments were introduced and those that have sought to renew their SRPs have been required to amend the plans to comply with the new rules.

 

A large part of the traditional rationale for adopting SRPs has now been eliminated.
A large part of the traditional rationale for adopting SRPs has now been eliminated.

 

We believe that the amended take-over bid rules provide adequate protection against hostile bids. Having said that, it has been suggested that the new rules do not protect against creeping take-over bids for control which are exempt from the rules (such as the accumulation of 20% or more of the issuer’s shares through market transactions or the acquisition of a control block through private agreements with a few large shareholders). These activities would however be identifiable through the early warning filing requirements. If, prior to making a determination that the Company ought to adopt a “strategic” SRP at an annual or special meeting of shareholders, the Company were faced with a hostile bid that we believed was not in the best interests of the Company and its shareholders, the directors could adopt a “tactical” plan which we could take to the shareholders for approval. Nevertheless, at this point in time, we are of the opinion that such action is not necessary and the shareholders should be the best arbiters of when “the pill must go”.

 

Stockholder Ownership Disclosure Threshold in Bylaws

 

Neither our Articles nor By-laws contain a provision governing the ownership threshold above which shareholder ownership must be disclosed. Pursuant to securities legislation, an Early Warning Report and an Insider Report must be filed if a shareholder obtains ownership on a partially diluted basis of 10% or greater of the Company.

 

Page 72

Special Conditions for Changes in Capital

 

The conditions imposed by the Company’s Articles are not more stringent than required under the OBCA.

 

C.Material Contracts

 

In addition to any contracts described in “ITEM 7.B. Related Party Transactions” or “ITEM 4. Business Overview”, below is a summary of material contracts, other than those entered into by the Company in the ordinary course of business, to which we are or have been a party during the two years immediately preceding the date of this document. Other than contracts entered into in the ordinary course of business, we have not been a party to any other material contract within such two-year period.


 

 1.On May 11, 2016 the Company acquired all the issued and outstanding shares of DenseLight Semiconductor Pte. Ltd. in an all-stock acquisition for $10,500,000 satisfied through the issuance of 13,611,150 common shares.

 

 2.On June 22, 2016, the Company acquired all the issued and outstanding shares of BB Photonics, a New Jersey company and its subsidiary BB Photonics UK Ltd, collectively BB Photonics, a designer of integrated photonic solutions for the data communications market for consideration of $1,550,000. The all-stock purchase was accomplished with the issuance of 1,996,090 common share of the Company at a price of $0.777 per share.

 

 3.On October 19, 2016, the Company announced that it had entered into an agreement with Singapore’s Economic Development Board (EDB) to expand the Company’s research and development operations in Singapore. Under this agreement, the Company is eligible to receive support up to a maximum of S$10.7 million (US$7.7 million) over five years subject to certain expenditure, capital acquisition and head count thresholds.

 

 4.On April 18, 2019, the Company signed loan and security agreements for a senior secured credit facility (the “Bridge Loan”) to be provided by Espresso Capital Ltd which grants the Company access to a maximum US$5,000,000. On April 23, 2019 the Company received the initial advance against the credit facility in the amount of US$2,000,000. In partial consideration of the US$5,000,000 gross credit facility available to the Company, and in connection with the initial advance, the Company issued to Espresso Capital warrants for the purchase of 3,289,500 common shares at a price of C$0.35 per share. The Warrants expire on April 18, 2020.
   
 5.On August 20, 2019, the Company signed a definitive agreement with respect to the sale of DenseLight for $26,000,000. The Share Sale Agreement was signed on November 8, 2019 when the sale was consummated.
6.On June 30, 2020, the Company announced that it signed a Letter of Intent to establish a joint venture with Xiamen Sanan Integrated Circuit Co. Ltd. (“Sanan IC”) to manufacture cost-effective, high-performance optical engines based on POET’s proprietary CMOS compatible Optical Interposer platform technology. The definitive joint venture agreement was signed on October 21, 2020.

 

D.Exchange Controls

 

Canada has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of the Company’s securities, except as discussed in “ITEM 10.E. Taxation” below.

 

 Page 73

E.Taxation

The following summary discusses certain material U.S. and Canadian tax considerations related to the holding and disposition of common stock as of the hereof. Prospective purchasers of our common stock are advised to consult their own tax advisers concerning the consequences under the tax laws of the country of which they are resident or in which they are otherwise subject to tax of making an investment in our common stock.

 

Canadian Federal Income Tax Considerations

 

The Company believes the following is a brief summary of the material principal Canadian federal income tax consequences to a U.S. Holder (as defined below) of common shares of the Company who deals at arm’s length with the Company, holds the shares as capital property and who, for the purposes of the Income Tax Act (Canada) (the “Tax Act”) and the Canada — U.S. Income Tax Convention (1980) (the “Treaty”), is at all relevant times resident in the U.S., is not and is not deemed to be resident in Canada and does not use or hold and is not deemed to use or hold the shares in carrying on a business in Canada. Special rules, which are not discussed below, may apply to a U.S. Holder that is an insurer that carries on business in Canada and elsewhere. U.S. Holders are urged to consult their own tax advisors with respect to their particular circumstances.

 

This summary is based upon the current provisions of the Tax Act, the regulations thereunder in force at the date hereof, all specific proposals to amend such regulations and the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof and the current provisions of the Convention and the current administrative practices of the Canada Revenue Agency published in writing prior to the date hereof. This summary does not otherwise take into account or anticipate any changes in law or administrative practices whether by legislative, governmental or judicial decision or action, nor does it take into account tax laws of any province or territory of Canada or of the U.S. or of any other jurisdiction outside Canada.

 


For the purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the common shares must be converted into Canadian dollars based on the relevant exchange rate applicable thereto.

 

This summary does not address all aspects of Canadian federal income taxation that may be relevant to any particular U.S. Holder in light of such holder’s individual circumstances. Accordingly, U.S. Holders should consult with their own tax advisors for advice with respect to their own particular circumstances.

 

Under the Tax Act and the Treaty, a U.S. Holder of common shares will generally be subject to a 15% withholding tax on dividends paid or credited or deemed by the Tax Act to have been paid or credited on such shares. The withholding tax rate is 5% where the U.S. Holder is a corporation that beneficially owns at least 10% of the voting shares of the Company and the dividends may be exempt from such withholding in the case of some U.S. Holders such as qualifying pension funds and charities.

 

A U.S. Holder will generally not be subject to tax under the Tax Act on any capital gain realized on a disposition of common shares, provided that the shares do not constitute “taxable Canadian property” to the U.S. Holder at the time of disposition. Generally, common shares will not constitute taxable Canadian property to a U.S. Holder provided that such shares are listed on a designated stock exchange (which currently includes the TSXV) at the time of the disposition and, during the 60- month period immediately preceding the disposition, the U.S. Holder, persons with whom the U.S. Holder does not deal at arm’s length, or the U.S. Holder together with all such persons has not owned 25% or more of the issued shares of any series or class of the Company’s capital stock. If the common shares constitute taxable Canadian property to a particular U.S. Holder, any capital gain arising on their disposition may be exempt from Canadian tax under the Convention if at the time of disposition the common shares do not derive their value principally from real property situated in Canada.

 

U.S. Federal Income Tax Considerations

 

Subject to the limitations described herein, the following discussion summarizes certain U.S. federal income tax consequences to a U.S. Holder of our common shares. A “U.S. Holder” means a holder of our common shares who is:

 

an individual who is a citizen or resident of the U.S. for U.S. federal income tax purposes;

Page 74

a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the U.S. or under the laws of the U.S. or any political subdivision thereof, or the District of Columbia;

an estate, the income of which is subject to U.S. federal income tax regardless of its source; or

a trust (i) if, in general, a court within the U.S. is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions, or (ii) that has in effect a valid election under applicable U.S. Treasury Regulations to be treated as a U.S. person.

 

Unless otherwise specifically indicated, this discussion does not consider the U.S. tax consequences to a person that is not a U.S. Holder (a “Non-U.S. Holder”). This discussion considers only U.S. Holders that will own our common shares as capital assets (generally, for investment) and does not purport to be a comprehensive description of all of the tax considerations that may be relevant to each U.S. Holder’s decision to purchase our common shares.

 


This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended (the “Code”), current and proposed Treasury Regulations promulgated thereunder, and administrative and judicial decisions as of the date hereof, all of which are subject to change, possibly on a retroactive basis. This discussion does not address all aspects of U.S. federal income taxation that may be relevant to any particular U.S. Holder in light of such holder’s individual circumstances. In particular, this discussion does not address the potential application of the alternative minimum tax or the U.S. federal income tax consequences to U.S. Holders that are subject to special treatment, including U.S. Holders that:

 

are broker-dealers or insurance companies;

have elected market-to-market accounting;

are tax-exempt organizations or retirement plans;

are financial institutions or “financial services entities”;

hold our common shares as part of a straddle, “hedge” or “conversion transaction” with other investments;

acquired our common shares upon the exercise of employee stock options or otherwise as compensation;

own directly, indirectly or by attribution at least 10% of our voting power;

have a functional currency that is not the U.S. Dollar;

are grantor trusts;

are certain former citizens or long-term residents of the U.S.; or

are real estate trusts or regulated investment companies.


 

If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our common shares, the tax treatment of the partnership and a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner or partnership should consult its own tax advisor as to its tax consequences.

 

In addition, this discussion does not address any aspect of state, local or non-U.S. laws or the possible application of U.S. federal gift or estate taxes.

 

Each potential U.S Holder of our common shares is advised to consult its own tax advisor with respect to the specific tax consequences to it of purchasing, holding or disposing of our common shares, including the applicability and effect of federal, state, local and foreign income tax and other laws to its particular circumstances.

 

Distributions

 

Subject to the discussion below under “Passive Foreign Investment Company Status,” a U.S. Holder will be required to include in gross income as ordinary dividend income the amount of any distribution paid on our common shares, including any non-U.S. taxes withheld from the amount paid, to the extent the distribution is paid out of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Distributions in excess of such earnings and profits will be applied against and will reduce the U.S. Holder’s basis in our common shares and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of our common shares. The dividend portion of such distributions generally will not qualify for the dividends received deduction available to corporations.

Page 75

 

Subject to the discussion below under “Passive Foreign Investment Company Status,” dividends that are received by U.S. Holders that are individuals, estates or trusts may qualify for taxation at the rate applicable to long-term capital gains (a maximum marginal federal income tax rate of 20%), provided that such U.S. Holders satisfy certain holding period requirements and such dividends meet the requirements of “qualified dividend income.” For this purpose, dividends paid by a non-U.S. corporation may qualify if the non-U.S. corporation is eligible for benefits of a comprehensive income tax treaty with the U.S., which benefits include an information exchange program and is determined to be satisfactory by the U.S. Secretary of the Treasury. The IRS has determined that the U.S.- Canada Tax Treaty is satisfactory for this purpose. Dividends that fail to meet such requirements, and dividends received by corporate U.S. Holders, are taxed at ordinary income rates.

 

Distributions of current or accumulated earnings and profits paid in foreign currency to a U.S. Holder (including any non-U.S. taxes withheld therefrom) will be includible in the income of a U.S. Holder in a U.S. Dollar amount calculated by reference to the exchange rate on the day the distribution is received. A U.S. Holder that receives a foreign currency distribution and converts the foreign currency into U.S. dollars subsequent to receipt may have foreign exchange gain or loss based on any appreciation or depreciation in the value of the foreign currency against the U.S. dollar, which will generally be U.S. source ordinary income or loss. A loss might not be deductible due to certain limitation.

 

U.S. Holders will have the option of claiming the amount of any non-U.S. income taxes withheld at source either as a deduction from gross income or as a dollar-for- dollar credit against their U.S. federal income tax liability. Individuals who do not claim itemized deductions, but instead utilize the standard deduction, may not claim a deduction for the amount of the non-U.S. income taxes withheld, but such amount may be claimed as a credit against the individual’s U.S. federal income tax liability. The amount of non-U.S. income taxes which may be claimed as a credit in any taxable year is subject to complex limitations and restrictions, which must be determined on an individual basis by each shareholder. These limitations include, among others, rules that limit foreign tax credits allowable with respect to specific classes of income to the U.S. federal income taxes otherwise payable with respect to each such class of income. A U.S. Holder will be denied a foreign tax credit with respect to non-U.S. income tax withheld from a dividend received on the common shares if such U.S. Holder does not satisfy certain holding period requirements.

 

Distributions of current or accumulated earnings and profits generally will be foreign source income for U.S. foreign tax credit purposes.

 


Disposition of Common Shares

 

Subject to the discussion below under “Passive Foreign Investment Company Status,” upon the sale, exchange or other taxable disposition of our common shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder’s basis in such common shares, which is usually the cost of such shares, and the amount realized on the disposition. Capital gain from the sale, exchange or other disposition of common shares held more than one year is long-term capital gain, and is eligible for a reduced rate of taxation for individuals (currently a maximum marginal federal income tax rate of 20%). Gains recognized by a U.S. Holder on a sale, exchange or other disposition of common shares generally will be treated as U.S. source income for U.S. foreign tax credit purposes. A loss recognized by a U.S. Holder on the sale, exchange or other taxable disposition of common shares generally is allocated to U.S. source income. The deductibility of capital losses recognized on the sale, exchange or other taxable disposition of common shares is subject to limitations. A U.S. Holder that receives foreign currency upon disposition of common shares and converts the foreign currency into U.S. dollars subsequent to the settlement date or trade date (whichever date the taxpayer was required to use to calculate the value of the proceeds of sale) may have foreign exchange gain or loss based on any appreciation or depreciation in the value of the foreign currency against the U.S. Dollar, which will generally be U.S. source ordinary income or loss. Such loss may not be deductible due to certain limitations.

 

Page 76

Passive Foreign Investment Company Status

 

We would be a passive foreign investment company (a “PFIC”) if (taking into account certain “look-through” rules with respect to the income and assets of our corporate subsidiaries in which we own 25 percent (by value) of the stock) either (i) 75 percent or more of our gross income for the taxable year was passive income or (ii) the average percentage (by value) of our total assets that are passive assets during the taxable year was at least 50 percent.

 

If we were a PFIC, each U.S. Holder would (unless it made one of the elections discussed below on a timely basis) be taxable on gain recognized from the disposition of our common shares (including gain deemed recognized if the common shares are used as security for a loan) and upon receipt of certain “excess distributions” (generally, distributions that exceed 125% of the average amount of distributions in respect to such common shares received during the preceding three taxable years or, if shorter, during the U.S. Holder’s holding period prior to the distribution year) with respect to our common shares as if such income had been recognized ratably over the U.S. Holder’s holding period for the common shares. The U.S. Holder’s income for the current taxable year would include (as ordinary income) amounts allocated to the current taxable year and to any taxable year period prior to the first day of the first taxable year for which we were a PFIC. Tax would also be computed at the highest ordinary income tax rate in effect for each other taxable year period to which income is allocated, and an interest charge on the tax as so computed would also apply. Additionally, if we were a PFIC, U.S. Holders who acquire our common shares from decedents (other than non resident aliens) would be denied the normally available step-up in basis for such shares to fair market value at the date of death and, instead, would have a tax basis in such shares equal to the decedent’s basis, if lower.

 

As an alternative to the tax treatment described above, a U.S. Holder could elect to treat us as a “qualified electing fund” (a “QEF”), in which case the U.S. Holder would be taxed currently, for each taxable year that we are a PFIC, on its pro rata share of our ordinary earnings and net capital gain (subject to a separate election to defer payment of taxes, which deferral is subject to an interest charge). Special rules apply if a U.S. Holder makes a QEF election after the first taxable year in its holding period in which we are a PFIC. In the event that we conclude that we will be classified as a PFIC, we will make a determination at such time as to whether we will be able to provide U.S. Holders with the information that is necessary to make a QEF election. Amounts includable in income as a result of a QEF election will be determined without regard to our prior year losses or the amount of cash distributions, if any, received from us. A U.S. Holder’s basis in its common shares will increase by any amount included in income and decrease by any amounts not included in income when distributed because such amounts were previously taxed under the QEF rules. So long as a U.S. Holder’s QEF election is in effect with respect to the entire holding period for its common shares, any gain or loss realized by such holder on the disposition of its common shares held as a capital asset ordinarily will be capital gain or loss.

 


As an alternative to making the QEF election, a U.S. Holder of PFIC stock which is regularly traded on a qualified exchange may avoid the negative effects of the PFIC rules by electing to mark the stock to market and recognizing as ordinary income or loss, each taxable year that we are a PFIC, an amount equal to the difference as of the close of the taxable year between the fair market value of the PFIC stock and the U.S. Holder’s adjusted tax basis in the PFIC stock. Losses would be allowed only to the extent of net mark-to-market gain previously included by the U.S. Holder under the election for prior taxable years. This election is available for so long as the Company’s common shares constitute “marketable stock,” which includes stock of a PFIC that is “regularly traded” on a “qualified exchange or other market.” Generally, a “qualified exchange or other market” includes a national market system established pursuant to Section 11A of the Exchange Act, or a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located and that has certain characteristics. A class of stock that is traded on one or more qualified exchanges or other markets is “regularly traded” on an exchange or market for any calendar year during which that class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter, subject to special rules relating to an initial public offering. It is not entirely clear whether either the OTCBB or TSXV are qualified exchanges or other markets, or whether there will be sufficient trading volume with respect to the Company’s common shares, and accordingly, whether the common shares will be “marketable stock” for these purposes. Furthermore, there can be no assurances that the Company’s common shares will continue to trade on any of the exchanges listed above.

 

Page 77

We believe we were not a PFIC for the year ending December 31, 20182020 and do not expect to be classified as a PFIC for the year ending December 31, 2019.2021. However, PFIC status is determined as of the end of each taxable year and is dependent on a number of factors, including the value of our passive assets, the amount and type of our gross income, and our market capitalization. Therefore, there can be no assurance that we will not become a PFIC for the current taxable year ending December 31, 20192020 or in a future taxable year. U.S. Holders which are individuals, estates and trusts and whose income exceeds certain thresholds will be required to pay a 38% surtax on “net investment income” including, among other things, dividends (if any) and net gain realized from our common shares. U.S. Holders should consult with their own tax advisors regarding the application of this tax. We will notify U.S. Holders in the event we conclude that we will be treated as a PFIC for any taxable year.

 

Information Reporting and Backup Withholding

 

U.S. Holders (other than exempt recipients, such as corporations) generally are subject to information reporting requirements with respect to dividends paid on, or proceeds from the disposition of, our common shares. U.S. Holders are also generally subject to backup withholding (currently at a rate of 28%) on dividends paid on, or proceeds from the disposition of, our common shares unless the U.S. Holder provides IRS Form W-9 or otherwise establishes an exemption.

 

The amount of any backup withholding will be allowed as a credit against a U.S. or Non-U.S. Holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided that certain required information is furnished to the IRS.

 

F.Dividends and Paying Agents

 

Not Required.

 

G.Statements by Experts

 

The consolidated financial statements of POET Technologies Inc. as of December 31, 2020, 2019 2018 and 20172018 included herein, have been audited by Marcum LLP, our independent registered accounting firm for that period, 555 Long Wharf Drive, 8th Floor, New Haven, CT 06511, USA, as stated in their report appearing herein, and are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

 

H.Documents on Display

 

The Company’s documents can be viewed at its Canadian office, located at: Suite 1107, 120 Eglinton Avenue East, Toronto, Ontario M4P 1E2, Canada. Further, we file reports under Canadian regulatory requirements on SEDAR; you may access our reports filed on SEDAR by accessing their website at www.sedar.com. The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act), and files reports, Annual Reports and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The Company’s reports, Annual Reports and other information can be inspected on the SEC’s website.


 

As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, and other reports and financial statements with the SEC as frequently or as promptly as United States domestic companies whose securities are registered under the Exchange Act.

 

We maintain a corporate website at www.poet-technologies.com. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.

 

 Page 78

I.Subsidiary information

 

Not Required.

 

ITEM 11. Quantitative and Qualitative Disclosures About Market Risk

 

Interest Rate Risk

 

Short-term investments bear interest at fixed rates, and as such, are subject to interest rate risk resulting from changes in fair value from market fluctuations in interest rates. The Company does not depend on interest from its investments to fund its operations.

 

Exchange Rate Risk

 

The Company is exposed to foreign currency risk with the Canadian and Singapore dollar. The Company maintains bank accounts and cash reserves in US, Canadian and Singapore dollars with the majority of reserves currently split between Canadian and US dollars. The Canadian dollar reserves are exposed to currency fluctuations. Most of the company’s operations are transacted in US and Singapore dollars. A 10% change in the Canadian and Singapore dollar would have increased or decreased other comprehensive loss by $290,950.$229,088.

 

The following table shows exchange rates, from CAD to USD, for the past six months:

 

Period High (1) Low (1) Average (2)
March 2020  0.7501   0.6891   0.7181 
February 2020  0.7573   0.7458   0.7529 
January 2020  0.7714   0.7555   0.7645 
December 2019  0.7655   0.7506   0.7580 
November 2019  0.7620   0.7503   0.7561 
October 2019  0.7667   0.7479   0.7573 
October 2019 — March 31, 2020  0.8163   0.7629   0.7544 
Period  High (1)  Low (1)  Average (2) 
February 2021   0.8021   0.7770   0.7874 
January 2021   0.7943   0.7767   0.7857 
December 2020   0.7887   0.7705   0.7588 
November 2020   0.7738   0.7491   0.7557 
October 2020   0.7638   0.7467   0.7581 
September 2020   0.7687   0.7451   0.7551 
September 2020 — February 28, 2021   0.8021   0.7451   0.7736 

 

(1)

(1)    Bank of Canada monthly average rates

(2)Bank of Canada daily closing average rates

 

The following table shows exchange rates, from SGD to USD, for the past six months:

The following table shows exchange rates, from SGD to USD, for the past six months:

 

Period High (1) Low (1) Average (2)
March 2020  0.7254   0.6840   0.7056 
February 2020  0.7324   0.7135   0.7196 
January 2020  0.7432   0.7323   0.7400 
December 2019  0.7399   0.7316   0.7357 
November 2019  0.7369   0.7309   0.7339 
October 2019  0.7346   0.7230   0.7288 
October 2019 — March 31, 2020  0.7432   0.7213   0.7325 
Period  High (1)  Low (1)  Average (2) 
February 2021   0.7581   0.7465   0.7523 
January 2021   0.7590   0.7504   0.7547 
December 2020   0.7566   0.7450   0.7508 
November 2020   0.7479   0.7291   0.7385 
October 2020   0.7392   0.7306   0.7349 
September 2020   0.7384   0.7248   0.7316 
September 2020 — February 28, 2021   0.7590   0.7248   0.7419 

 

(1)

(1)    Bank of Singapore monthly average rates

(2)Bank of Singapore daily closing average rates

Page 79
   


 

Market Risk

 

Market risk arises from the possibility that changes in market prices will affect the value of the financial instruments of the Company. The Company is exposed to fair value fluctuations on its cash equivalents. The Company’s other financial instruments (cash and accounts payable and accrued liabilities) are not subject to market risk, due to the short- term nature of these instruments. The Company manages market risk through its investment policy where surplus funds are only invested in a manner that will provide the optimal blend of investment returns and principal protection while meeting its daily cash flow and liquidity demands.

 

ITEM 12. Description of Securities Other than Equity Securities

 

A.Debt Securities

 

Not Required.

 

B.Warrants and Rights

 

Not Required.

 

C.Other Securities

 

Not Required.

 

D.American Depositary Shares

 

Not Required.

 

PART II

 

ITEM 13. Defaults, Dividend Arrearages and Delinquencies

 

Not Required.

 

ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds

 

Not Required.

 

ITEM 15. Controls and Procedures

 

 (a)Disclosure Controls and Procedures

 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and within the time frames specified in the SEC'sSEC’s rules and forms and accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Notwithstanding the foregoing, there can be no assurance that our disclosure controls and procedures will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be set forth in our reports.

 


Page 80

 

 (b)Management’s Annual Report on Internal Control over Financial Reporting

 

The Company’s Board of Directors and management are responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control system was designed to provide reasonable assurance to management and the Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of its published consolidated financial statements.

 

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 


Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2019.2020. In making this assessment, it used the criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that assessment and those criteria, management concluded that, as of December 31, 2019,2020, the Company’s internal control over financial reporting was effective.

 

 (c)Attestation Report of Registered Public Accounting Firm

 

Not applicable.

 

 (d)Changes in Internal Controls over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the year ended December 31, 20192020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 16. [RESERVED]

 

ITEM 16A. Audit Committee Financial Expert

 

Our Board of Directors has determined that Chris Tsiofas is an audit committee financial expert. The Board has determined that Mr. Tsiofas satisfies the criteria of “audit committee financial expert” set forth in Item 16A of Form 20-F and is independent in accordance with Rule 4200 of the Nasdaq Marketplace Rules.

 

ITEM 16B. Code of Ethics

 

In December 2007,As amended in March 2021, our Board of Directors adopted a Code of Business Conduct and Ethics (the “Code”) that applies to all our employees, including without limitation our chief executive officer, chief financial officer and principal accounting officer. Our Code may be viewed on our website at www.poet-technologies.com and is filed as an Exhibit to this Annual Report. A copy of our Code may be obtained, without charge, upon a written request addressed to our office at, 120 Eglinton Avenue East, Suite 1107, Toronto, Ontario M4P 1E2, Canada.

 

ITEM 16C. Principal Accountant Fees and Services Fees Paid to Independent Registered Public Accounting Firm

 

The following table sets forth, for each of the years indicated, the fees billed by our independent registered public accounting firm, Marcum LLP.

 

   Year Ended December 31, 
Services Rendered  2019   2018 
  (in US$) 
Audit Fees (1) $175,000  $189,500 
Tax Fees (2)  17,200   11,700 
Total $192,200  $201,200 
Page 81

 

  Year Ended December 31, 
Services Rendered 2020  2019 
    
Audit Fees (1) $170,500  $175,000 
All Other Fees (2)  17,200   17,200 
Total $187,700  $192,200 

 

(1)Audit fees consistincluded fees for the audit of the Company’s annual consolidated financial statements and services that would normally be providedrendered in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.filing of registration statements.

 

(2)Tax fees relate to tax compliance planning and advice.services for our US-based entities.


 

Our Audit Committee, in accordance with its charter, reviews and pre-approves all audit services and permitted non-audit services (including the fees and other terms) to be provided by our independent auditors. All of the services provided by Marcum LLP over the past two years were pre-approved by the Audit Committee.

 

ITEM 16D. Exemptions from the Listing Standards for Audit Committees

 

Not Required.

 

ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

Not Required.

 

ITEM 16F. Change in Registrant’s Certifying Accountants

 

Not Required.

 

ITEM 16G. Corporate Governance

 

Not Required.

 

ITEM 16H. Mine Safety Disclosure

 

Not Required.

PART III

 

ITEM 17. Financial Statements

 

The Company’s consolidated financial statements are stated in U.S. dollars and are prepared in accordance with IFRS as issued by the International Accounting Standards Board.

 

The consolidated financial statements required under ITEM 17 are attached hereto and found immediately following the text of this Annual Report and are incorporated by reference herein. The audit report of Marcum LLP, independent registered public accounting firm, is included herein immediately preceding the audited consolidated financial statements.

 

 a.Audited Financial Statements — for the years ended December 31, 2020, 2019 2018 and 20172018 and as of December 31, 2020, 2019 2018 and 20172018

 

ITEM 18. Financial Statements

 

The Company has elected to provide financial statements pursuant to ITEM 17.

 


Page 82

 

ITEM 19. Exhibits

 

1.1Certificate and Articles of Continuance (1)
1.2Amended and Restated Bylaws (2)
2.0Description of Securities (6)
4.1License Agreement with the University of Connecticut, dated April 28, 2003, as amended April 15, 2014 (1)
4.2Agency Agreement with IBK Capital Corp., dated February 14, 2013 (1)
4.3Shareholder Rights Plan Agreement between the Company and TMX Equity Transfer Services, Inc.(2)
4.4Employment Agreement with Suresh Venkatesan, dated June 10, 2015 (3)
4.5Employment Agreement with Rajan Rajgopal,Vivek Rajgarhia, dated December 27, 2016 (4)November 4, 2019 (7)
4.6Employment Agreement with Thomas Mika, dated November 2, 2016 (4)
4.7Employment AgreementDefinitive agreement with Dave Lazovsky,Sanan Integrated Circuit Co., Ltd dated February 1, 2017 (4)October 21, 2020 (7)
4.8Sale and Purchase Agreement for DenseLight Semiconductors PTE, LTD, dated April 27, 2016 (4)
4.9Sale and Purchase Agreement for BB Photonics Inc. dated May 16, 2016 (4)
4.1020182020 Stock Option Plan (5)(7)
4.11Form of Option Agreement(1)
4.12Form of Warrant for Purchase of Common Shares (1)
4.13Stock Specimen Certificate (1)
4.14Credit Facility Agreement (5)
4.15Share Sale Agreement for DenseLight Semiconductors PTE, Ltd dated August 20, 2019 (6)
4.16Employment agreement with Vivek Rajgarhia, dated November 4, 2019 (6)
4.17Convertible Debenture Indenture, dated April 3, 2019 (6)
4.18Warrant Indenture with TSX Trust Company, dated April 3, 2019 (6)
4.19Convertible Debenture Indenture, dated May 3, 2019 (6)
4.20Warrant Indenture with TSX Trust Company, dated May 3, 2019 (6)
4.21Convertible Debenture Indenture, dated June 3, 2019 (6)
4.22Warrant Indenture with TSX Trust Company, dated June 3, 2019 (6)
4.23Convertible Debenture Indenture, dated August 2, 2019 (6)
4.24Warrant Indenture with TSX Trust Company, dated August 2, 2019 (6)
4.25Convertible Debenture Indenture, dated September 19, 2019 (6)
4.26Warrant Indenture with TSX Trust Company, dated September 19, 2019 (6)
4.27Warrant indenture with TSX Trust Company, dated February 11, 2021 (7)
4.28Engagement letter with Cormark Securities Inc, dated January 25, 2021 (7)
4.29Upsize letter with Cormark Securities Inc, dated January 26, 2021 (7)
4.30Form of Subscription for Units of Private Placement, February 11, 2021 (7)
8.1List of Subsidiaries: See ITEM 4.C.
11.1Code of Business Conduct and Ethics (2)(7)
12.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) (6)under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (7)
12.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) (6)under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (7)
13.1Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (6)(7)
13.2Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (6)(7)
23.1Consent of Marcum LLP, independent registered accounting firm (6)(7)
101. INS(**)XBRL Instance Document (7)
101.SCH(**)XBRL Taxonomy Extension Schema Linkbase Document (7)
101. AL(**)XBRL Taxonomy Extension Calculation Linkbase Document (7)
101.DEF(**)XBRL Taxonomy Extension Definition Linkbase Document (7)
101.LAB(**)XBRL Taxonomy Extension Label Linkbase Document (7)
101.PRE(**)XBRL Taxonomy Extension Presentation Linkbase Document (7)
104(*)Cover Page Interactive Data File (embedded within Inline XBRL document) (7)

 

(1) Filed as an exhibit to the Company’s registration statement under the Securities and Exchange Act on Form 20-F/A20-F on May 15, 2014 and incorporated herein by reference.

(2) Filed as an exhibit to the Company’s annual Form 20-F on April 13, 2015 and incorporated herein by reference.

(3) Filed as an exhibit to the Company’s annual Form 20-F on March 18, 2016 and incorporated herein by reference.

(4) Filed as an exhibit to the Company’s annual Form 20-F on April 18, 2017 and incorporated herein by reference.

(5) Filed as an exhibit to the Company’s annual Form 20-F on April 30, 2019 and incorporated herein by reference

(6) Filed as an exhibit to the Company’s annual Form 20-F on April 29, 2020 and incorporated herein by reference.

(7) Filed as an exhibit to this annual Form 20-F.

(**) In accordance with Rule 402 of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Page 83

WHERE TO FIND ADDITIONAL INFORMATION

 

We file reports and other information with the Securities and Exchange Commission; you may obtain copies of our filings with the SEC by accessing their website located at www.sec.gov. Further, we file reports under Canadian regulatory requirements on SEDAR; you may access our reports filed on SEDAR by accessing their website at www.sedar.com.

 


MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL INFORMATION

 

The accompanying consolidated financial statements of the Company and other financial information contained in this Annual Report are the responsibility of management. The consolidated financial statements have been prepared in conformity with IFRS, using management’s best estimates and judgments, where appropriate. In the opinion of management, these consolidated financial statements reflect fairly the financial position and the results of operations and cash flows of the Company within reasonable limits of materiality. The financial information contained elsewhere in this Annual Report has been reviewed to ensure consistency with that in the consolidated financial statements.

 

To assist management in discharging these responsibilities, the Company maintains a system of procedures and internal control which is designed to provide reasonable assurance that its assets are safeguarded against loss from unauthorized use or disposition, that transactions are executed in accordance with management’s authorization and that the financial records form a reliable base for the preparation of accurate and reliable financial information.

 

The Board of Directors endeavors to ensure that management fulfills its responsibilities for the financial reporting and internal control. The Board of Directors exercises this responsibility through its independent Audit Committee comprising a majority of unrelated and outside directors. The Audit Committee meets periodically with management and annually with the external auditors to review audit recommendations and any matters that the auditors believe should be brought to the attention of the Board of Directors. The Audit Committee also reviews the consolidated financial statements and recommends to the Board of Directors that the statements be approved for issuance to the shareholders.

 

The consolidated financial statements for the years ended December 31, 2020, 2019 2018 and 20172018 have been audited by Marcum LLP, independent registered public accounting firm, which has full and unrestricted access to the Audit Committee. Marcum’s report on the consolidated financial statements is presented herein.

 

SIGNATURES

 

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.

 

 POET TECHNOLOGIES INC.
  
 /s/ Suresh Venkatesan
 Suresh Venkatesan
 CEOChief Executive Officer

 

Date: April 29, 202009, 2021

Page 84

 

POET

TECHNOLOGIES INC.

 


Consolidated Financial Statements

For the Year Ended December 31, 2020, 2019 and 2018

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and Board of Directors of

POET Technologies Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated statements of financial position of POET Technologies Inc. (the “Company”) as of December 31, 2020, 2019 2018 and 2017,2018, the related consolidated statements of operations and deficit, comprehensive loss,changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2019,2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, 2019 2018 and 2017,2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019,2020, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company'sCompany’s management. Our responsibility is to express an opinion on the Company'sCompany’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB"(“PCAOB”) and the Canadian Public Accounting Board (“CPAB”) and are required to be independent with respect to the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company'sCompany’s internal control over financial reporting. Accordingly, we express no such opinion.


 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Marcumllp

 

Marcumllp

 

We have served as the Company’s auditor since 2009, such date takes into account the acquisition of a portion of UHY LLP by Marcum LLP in April 2010.

 

New Haven, Connecticut

April 29, 2020

09, 2021

 

 98Page 1
 

 

POET TECHNOLOGIES INC.

 

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Expressed in US Dollars)

 

December 31, 2019  2018 2017  2020  2019 2018 
              
Assets            Assets
Current                   
Cash and cash equivalents $1,428,129  $2,567,868  $4,974,478 
Cash and cash equivalents (Note 2) $6,872,894  $1,428,129  $2,567,868 
Accounts receivable (Notes 2 and 4)  -   946,944   493,925   -   -   946,944 
Receivable from the sale of discontinued operations (Note 23)  18,000,000   -   - 
Receivable from the sale of discontinued operations (Notes 3 and 23)  -   18,000,000   - 
Prepaids and other current assets (Note 5)  831,265   2,936,619   1,957,727   618,717   831,265   2,936,619 
Inventory (Note 6)  -   436,833   524,582   -   -   436,833 
            
  20,259,394   6,888,264   7,950,712   7,491,611   20,259,394   6,888,264 
                        
Property and equipment (Note 7)  3,143,060   9,299,513   8,278,170   3,185,754   3,143,060   9,299,513 
Patents and licenses (Note 8)  452,384   466,714   456,250   438,677   452,384   466,714 
Right of use asset (Note 9)  222,517   -   -   520,686   222,517   - 
Intangible assets (Note 10)  -   802,409   839,637   -   -   802,409 
Goodwill (Note 24)  -   7,681,003   7,681,003   -   -   7,681,003 
 $24,077,355  $25,137,903  $25,205,772             
             $11,636,728  $24,077,355  $25,137,903 
            
Liabilities            Liabilities
                        
Current                        
Accounts payable and accrued liabilities (Note 11) $1,725,708  $3,040,422  $810,593  $1,730,361  $1,725,708  $3,040,422 
Covid-19 government support loans (Note 26)  147,841   -   - 
Lease liability (Note 9)  90,504   -   -   172,949   90,504   - 
Convertible debentures (Note 12)  3,089,033   -   -   3,341,246   3,089,033   - 
  4,905,245   3,040,422   810,593             
              5,392,397   4,905,245   3,040,422 
Lease liability (Note 9)  133,254   -   - 
            
Non-current covid-19 government support loans (Note 26)  70,310   -   - 
Non-current lease liability (Note 9)  359,048   133,254   - 
Deferred tax liability (Note 24)  -   1,000,427   1,298,367   -   -   1,000,427 
Deferred rent  -   1,814   24,031   -   -   1,814 
  5,038,499   4,042,663   2,132,991             
              5,821,755   5,038,499   4,042,663 
Shareholders' Equity            
            
Shareholders’ EquityShareholders’ Equity
                        
Share capital (Note 13(b))  112,144,172   112,028,194   103,616,221   114,586,260   112,144,172   112,028,194 
Equity component of convertible debentures (Note 12)  627,511   -   -   565,121   627,511   - 
Warrants (Note 14)  8,525,358   8,303,738   5,985,378 
Warrants and compensation options (Note 14)  5,557,002   8,525,358   8,303,738 
Contributed surplus (Note 15)  38,799,337   36,042,754   32,102,967   44,407,679   38,799,337   36,042,754 
Accumulated other comprehensive loss  (1,908,715)  (2,083,514)  (1,758,632)  (1,983,212)  (1,908,715)  (2,083,514)
Deficit  (139,148,807)  (133,195,932)  (116,873,153)  (157,317,877)  (139,148,807)  (133,195,932)
  19,038,856   21,095,240   23,072,781             
 $24,077,355  $25,137,903  $25,205,772   5,814,973   19,038,856   21,095,240 
             $11,636,728  $24,077,355  $25,137,903 
Commitments and contingencies (Note 17)            

 

Commitments and contingencies (Note 17)

 

On behalf of the Board of Directors

 

/s/ Suresh Venkatesan /s/ Chris Tsiofas 
Director Director

The accompanying notes are an integral part of these consolidated financial statements.

Page 2

 

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT

(Expressed in US Dollars)

For the Years Ended December 31, 2020  2019  2018 
          
Operating expenses            
Selling, marketing and administration (Note 22)  8,137,998   6,697,387   6,173,875 
Research and development (Note 22)  6,634,317   2,083,815   2,262,476 
             
Operating expenses  14,772,315   8,781,202   8,436,351 
Impairment of long lived assets (Notes 10 and 24)  -   1,764,459   - 
Interest expense (Notes 9 and 12)  937,903   819,911   - 
Amortization of debt issuance costs (Note 12)  -   372,340   - 
Other income, including interest  (41,148)  (10,540)  (14,234)
Credit loss on receivable from sale of            
discontinued operation (Notes 3 and 23)  2,500,000   -   - 
             
Net loss from continuing operations, before taxes  (18,169,070)  (11,727,372)  (8,422,117)
Income tax recovery (Note 25)  -   292,740   - 
             
Net loss from continuing operations  (18,169,070)  (11,434,632)  (8,422,117)
             
Income (loss) from discontinued operations, net of taxes (Notes 23 and 25)  -   5,481,757   (7,900,662)
             
Net loss  (18,169,070)  (5,952,875)  (16,322,779)
             
Deficit, beginning of year  (139,148,807)  (133,195,932)  (116,873,153)
             
Net loss  (18,169,070)  (5,952,875)  (16,322,779)
             
Deficit, end of year $(157,317,877) $(139,148,807) $(133,195,932)
             
Basic and diluted loss per share, continuing operations (Note 16) $(0.06) $(0.04) $(0.03)
Basic and diluted income (loss) per share, discontinued operations (Note 16) $-  $0.02  $(0.03)
Basic and diluted net loss per share (Note 16) $(0.06) $(0.02) $(0.06)
             
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS            
(Expressed in US Dollars)            
For the Years Ended December 31,  2020   2019   2018 
             
Net loss $(18,169,070) $(5,952,875) $(16,322,779)
             
Other comprehensive income (loss) - net of income taxes            
Exchange differences on translating foreign operations, continuing operations  (74,497)  3,109   (543,557)
Exchange differences on translating foreign operations, discontinued operations  -   171,690   218,675 
             
Comprehensive loss $(18,243,567) $(5,778,076) $(16,647,661)

The accompanying notes are an integral part of these consolidated financial statements.

Page 3

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Expressed in US Dollars)

For the Years Ended December 31, 2020  2019  2018 
Share Capital            
Beginning balance $112,144,172  $112,028,194  $103,616,221 
Funds from the exercise of stock options  794,808   60,028   87,974 
Fair value of stock options exercised  768,356   55,950   82,330 
Funds from the exercise of warrants and compensation warrants  293,642   -   1,028,471 
Fair value of warrants and compensation warrants exercised  127,964   -   447,270 
Conversion of convertible debentures  369,545   -   - 
Fair value of warrants issued on conversion of convertible debentures  (146,858)  -   - 
Exercise of warrants issued in conjunction with debt financing  221,620   -   - 
Common shares issued to settle accounts payable  13,011   -   - 
Common shares issued on public offering  -   -   10,663,548 
Share issue costs  -   -   (1,131,990)
Fair value of warrants issued on public offering  -   -   (2,286,426)
Fair value of compensation options issued to brokers  -   -   (479,204)
December 31,  114,586,260   112,144,172   112,028,194 
             
Equity Component of convertible debentures            
Beginning balance  627,511   -   - 
Fair value of equity component of convertible debentures  (62,390)  627,511   - 
December 31,  565,121   627,511   - 
             
Warrants and Compensation Options            
Beginning balance  8,525,358   8,303,738   5,985,378 
Fair value of warrants issued in conjunction with of debt financing  (221,620)  221,620   - 
Fair value of warrants and compensation warrants exercised  (127,964)  -   (447,270)
Fair value of expired warrants and compensation options  (2,765,630)  -   - 
Fair value of warrants issued on the exercise of convertible debentures  146,858   -   - 
Fair value of warrants issued on public offering  -   -   2,286,426 
Fair value of compensation options issued to brokers  -   -   479,204 
December 31,  5,557,002   8,525,358   8,303,738 
             
Contributed Surplus            
Beginning balance  38,799,337   36,042,754   32,102,967 
Stock-based compensation  3,612,945   2,812,533   4,022,117 
Fair value of stock options exercised  (768,356)  (55,950)  (82,330)
Fair value of expired warrants and compensation options  2,765,630   -   - 
Fair value of early conversion of convertible debentures  (1,877)  -   - 
December 31,  44,407,679   38,799,337   36,042,754 
             
Accumulated Other Comprehensive Loss            
Beginning balance  (1,908,715)  (2,083,514)  (1,758,632)
Other comprehensive income (loss) attributable to common            
shareholders - translation adjustment  (74,497)  174,799   (324,882)
December 31,  (1,983,212)  (1,908,715)  (2,083,514)
             
Deficit            
Beginning balance  (139,148,807)  (133,195,932)  (116,873,153)
Net loss  (18,169,070)  (5,952,875)  (16,322,779)
December 31,  (157,317,877)  (139,148,807)  (133,195,932)
             
Total Shareholders’ Equity $5,814,973  $19,038,856  $21,095,240 

The accompanying notes are an integral part of these consolidated financial statements.

Page 4

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Expressed in US Dollars)

For the Years Ended December 31, 2020  2019  2018 
          
CASH AND CASH EQUIVALENTS (USED IN) PROVIDED BY:            
OPERATING ACTIVITIES            
Net loss $(18,169,070) $(5,952,875) $(16,322,779)
Discontinued operations, net of tax  -   (5,481,757)  7,900,662 
             
Net loss, continuing operations  (18,169,070)  (11,434,632)  (8,422,117)
Adjustments for:            
Depreciation of property and equipment (Note 7)  631,263   166,342   96,452 
Amortization of patents and licenses (Note 8)  65,782   61,671   56,792 
Amortization of debt issuance cost (Note 12)  -   372,340   - 
Amortization of right of use asset (Note 9)  116,057   15,683   - 
Impairment of long lived assets (Notes 10 and 24)  -   1,764,459   - 
Accretion of debt discount on convertible debentures (Note 12)  524,095   280,829   - 
Stock-based compensation (Note 15)  3,612,945   2,888,141   3,602,879 
Income tax recovery (Notes 25)  -   (292,740)  - 
Non-cash settled operating costs (Notes 7 and 13)  910,738   -   - 
Credit loss on receivable from the sale of discontinued operations (Note 3)  2,500,000   -   - 
Gain on lease modification (Note 9)  (786)  -   - 
Non-cash foreign exchange  161,000   -   - 
             
   (9,647,976)  (6,177,907)  (4,665,994)
Net change in non-cash working capital accounts:            
Prepaid and other current assets (Note 5)  232,522   (685,667)  (75,855)
Accounts payable and accrued liabilities (Note 11)  (22,510)  420,457   244,054 
             
Cash flows from operating activities, continuing operations  (9,437,964)  (6,443,117)  (4,497,795)
Cash flows from operating activities, discontinued operations  -   (2,951,104)  (4,790,793)
             
   (9,437,964)  (9,394,221)  (9,288,588)
             
INVESTING ACTIVITIES            
Proceeds from the sale of discontinued operations (Note 23)  15,500,000   -   - 
Purchase of property and equipment (Note 7)  (1,521,788)  (445,678)  - 
Purchase of patents and licenses (Note 8)  (52,075)  (65,806)  (67,608)
Cash flows from investing activities, continuing operations  13,926,137   (511,484)  (67,608)
Cash flow from investing activities, discontinued operations  -   5,908,623   (3,467,992)
   13,926,137   5,397,139   (3,535,600)
             
FINANCING ACTIVITIES            
Issue of common shares for cash, net of issue costs (Note 13)  1,088,450   60,028   10,648,003 
Payment of lease liability (Note 9)  (144,142)  (19,162)  - 
Proceeds from covid-19 government support loans (Note 26)  218,151   -   - 
Proceeds from convertible debentures, net of issue costs paid in cash (Note 12)  -   3,352,849   - 
Proceeds from loan payable and promissory note (Note 12)  -   4,000,000   - 
Repayment of loan payable and promissory note (Note 12)  -   (4,000,000)  - 
             
Cash flows from financing activities, continuing operations  1,162,459   3,393,715   10,648,003 
Cash flow from financing activities, discontinued operations  -   (258,460)  - 
             
   1,162,459   3,135,255   10,648,003 
Effect of exchange rate on cash, continuing operations  (205,867)  (263,902)  (256,915)
Effect of exchange rate on cash, discontinued operations  -   (14,010)  26,490 
Effect of exchange rate on cash  (205,867)  (277,912)  (230,425)
Net change in cash and cash equivalents, continuing operations  5,444,765   (3,824,788)  5,825,685 
Net change in cash and cash equivalents, discontinued operations  -   2,685,049   (8,232,295)
Cash and cash equivalents, beginning of year  1,428,129   2,567,868   4,974,478 
Cash and cash equivalents, end of year $6,872,894  $1,428,129  $2,567,868 
             
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES            
Purchase of property and equipment financed through accounts payable $-  $-  $250,160 

The accompanying notes are an integral part of these consolidated financial statements.

Page 5

POET TECHNOLOGIES INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT         
(Expressed in US Dollars)         
For the Years Ended December 31, 2019  2018  2017 
          
Operating expenses            
Selling, marketing and administration (Note 22)  6,697,387   6,173,875   5,887,709 
Research and development (Note 22)  2,083,815   2,262,476   2,039,421 
Impairment of long lived assets (Notes 10 and 24)  1,764,459   -   - 
Interest expense (Notes 9 and 12)  819,911   -   - 
Amortization of debt issuance costs (Note 12)  372,340   -   - 
Other income, including interest  (10,540)  (14,234)  (18,279)
Operating expenses  11,727,372   8,422,117   7,908,851 
Net loss from continuing operations, before taxes  (11,727,372)  (8,422,117)  (7,908,851)
Income tax recovery (Note 25)  (292,740)  -   - 
Net loss from continuing operations  (11,434,632)  (8,422,117)  (7,908,851)
             
Income (loss) from discontinued operations, net of taxes (Notes 23 and 25)  5,481,757   (7,900,662)  (4,888,946)
Net loss  (5,952,875)  (16,322,779)  (12,797,797)
             
Deficit, beginning of year  (133,195,932)  (116,873,153)  (104,075,356)
             
Net loss  (5,952,875)  (16,322,779)  (12,797,797)
Deficit, end of year $(139,148,807) $(133,195,932) $(116,873,153)
             
Basic and diluted loss per share, continuing operations (Note 16) $(0.04) $(0.03) $(0.03)
Basic and diluted income (loss) per share, discontinued operations (Note 16) $0.02  $(0.03) $(0.02)
Basic and diluted net loss per share (Note 16) $(0.02) $(0.06) $(0.05)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS         
(Expressed in US Dollars)         
For the Years Ended December 31, 2019  2018  2017 
          
          
Net loss $(5,952,875) $(16,322,779) $(12,797,797)
             
Other comprehensive income (loss) - net of income taxes            
Exchange differences on translating foreign operations, continuing operations  3,109   (543,557)  362,679 
Exchange differences on translating foreign operations, discontinued operations  171,690   218,675   (33,194)
Comprehensive loss $(5,778,076) $(16,647,661) $(12,468,312)

The accompanying notes are an integral part of these consolidated financial statements.Page 3

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY         
(Expressed in US Dollars)         
          
For the Years Ended December 31, 2019  2018  2017 
Share Capital            
Beginning balance $112,028,194  $103,616,221  $103,357,862 
Funds from the exercise of stock options  60,028   87,974   123,528 
Fair value of stock options exercised  55,950   82,330   134,831 
Funds from the exercise of warrants and compensation warrants  -   1,028,471   - 
Fair value of warrants and compensation warrants exercised  -   447,270   - 
Common shares issued on public offering  -   10,663,548   - 
Share issue costs  -   (1,131,990)  - 
Fair value of warrants issued on public offering  -   (2,286,426)  - 
Fair value of compensation options issued to brokers  -   (479,204)  - 
December 31,  112,144,172   112,028,194   103,616,221 
Equity Component of convertible debentures            
Beginning balance  -   -   - 
Fair value of equity component of convertible debentures  627,511   -   - 
December 31,  627,511   -   - 
Warrants            
Beginning balance  8,303,738   5,985,378   2,013,747 
Fair value of warrants issued in conjunction with of debt financing  221,620   -   - 
Fair value of warrants issued on public offering  -   2,286,426   

5,985,378

 
Fair value of compensation options issued to brokers  -   479,204   - 
Fair value of warrants and compensation warrants exercised  -   (447,270)  

(901,417

)
Fair value of expired warrants  -   -   (1,112,330)
December 31,  8,525,358   8,303,738   5,985,378 
Contributed Surplus            
Beginning balance  36,042,754   32,102,967   29,062,874 
Stock-based compensation  2,812,533   4,022,117   3,174,924 
Fair value of stock options exercised  (55,950)  (82,330)  (134,831)
December 31,  38,799,337   36,042,754   32,102,967 
Accumulated Other Comprehensive Loss            
Beginning balance  (2,083,514)  (1,758,632)  (2,088,117)
Other comprehensive income (loss) attributable to common shareholders - translation adjustment  174,799   (324,882)  329,485 
December 31,  (1,908,715)  (2,083,514)  (1,758,632)
Deficit            
Beginning balance  (133,195,932)  (116,873,153)  (104,075,356)
Net loss  (5,952,875)  (16,322,779)  (12,797,797)
December 31,  (139,148,807)  (133,195,932)  (116,873,153)
Total Shareholders' Equity $19,038,856  $21,095,240  $23,072,781 

The accompanying notes are an integral part of these consolidated financial statements.Page 4

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS         
(Expressed in US Dollars)         
For the Years Ended December 31, 2019  2018  2017 
          
CASH AND CASH EQUIVALENTS (USED IN) PROVIDED BY:            
OPERATING ACTIVITIES            
Net loss $(5,952,875) $(16,322,779) $(12,797,797)
Discontinued operations, net of tax  (5,481,757)  7,900,662   4,888,946 
Net loss, continuing operations  (11,434,632)  (8,422,117)  (7,908,851)
Adjustments for:            
Depreciation of property and equipment (Note 7)  166,342   96,452   128,283 
Amortization of patents and licenses (Note 8)  61,671   56,792   53,969 
Amortization of debt issuance cost (Note 12)  372,340   -   - 
Amortization of right of use asset (Note 9)  15,683   -   - 
Impairment of long lived assets (Notes 10 and 24)  1,764,459   -   - 
Accretion of debt discount on convertible debentures (Note 12)  280,829   -   - 
Stock-based compensation (Note 15)  2,888,141   3,602,879   2,958,358 
Income tax recovery (Notes 25)  (292,740)  -   - 
   (6,177,907)  (4,665,994)  (4,768,241)
Net change in non-cash working capital accounts:            
Prepaid and other current assets (Note 5)  (685,667)  (75,855)  78,011 
Accounts payable and accrued liabilities (Note 11)  420,457   244,054   (544,809)
Cash flows from operating activities, continuing operations  (6,443,117)  (4,497,795)  (5,235,039)
Cash flows from operating activities, discontinued operations  (2,951,104)  (4,790,793)  (3,928,651)
   (9,394,221)  (9,288,588)  (9,163,690)
INVESTING ACTIVITIES            
Purchase of property and equipment (Note 7)  (445,678)  -   (57,023)
Purchase of patents and licenses (Note 8)  (65,806)  (67,608)  (41,728)
Proceeds from the sale of short-term investments  -   -   589,275 
Cash flows from investing activities, continuing operations  (511,484)  (67,608)  490,524 
Cash flow from investing activities, discontinued operations  5,908,623  (3,467,992)  (931,589)
   5,397,139   (3,535,600)  (441,065)
FINANCING ACTIVITIES            
Proceeds from convertible debentures, net of issue costs paid in cash (Note 12)  3,352,849   -   - 
Proceeds from loan payable and promissory note (Note 12)  4,000,000   -   - 
Repayment of loan payable and promissory note (Note 12)  (4,000,000)  -   - 
Issue of common shares for cash, net of issue costs (Note 13)  60,028   10,648,003   123,528 
Payment of lease liability (Note 9)  (19,162)  -   - 
Cash flows from financing activities, continuing operations  3,393,715   10,648,003   123,528 
Cash flow from financing activities, discontinued operations  (258,460)  -   - 
   3,135,255   10,648,003   123,528 
Effect of exchange rate on cash, continuing operations  (263,902)  (256,915)  144,761 
Effect of exchange rate on cash, discontinued operations  (14,010)  26,490   (65,338)
Effect of exchange rate on cash  (277,912)  (230,425)  79,423 
Net change in cash and cash equivalents, continuing operations  (3,824,788)  5,825,685   (4,476,226)
Net change in cash and cash equivalents, discontinued operations  2,685,049   (8,232,295)  (4,925,578)
Cash and cash equivalents, beginning of year  2,567,868   4,974,478   14,376,282 
             
Cash and cash equivalents, end of year $1,428,129  $2,567,868  $4,974,478 
             
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES            
Purchase of property and equipment financed through accounts payable $-  $250,160  $- 

The accompanying notes are an integral part of these consolidated financial statements.

Page 5

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

1.DESCRIPTION OF BUSINESS

 

POET Technologies Inc. is incorporated in the Province of Ontario. POET Technologies Inc. and its subsidiaries (the "Company"“Company”) are developersdesign and manufacturers of optical source productsdevelop the POET Optical Interposer and photonic integrated devicesPhotonic Integrated Circuits for the sensing, datacomdata center and telecomtele-communications markets. The Company'sCompany’s head office is located at 120 Eglinton Avenue East, Suite 1107, Toronto, Ontario, Canada M4P 1E2. These audited consolidated financial statements of the Company were approved by the Board of Directors of the Company on April 28, 2020.

March 25, 2021.

 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

These consolidated financial statements of the Company and its subsidiaries were prepared in accordance with

International Financial Reporting Standards ("IFRS"(“IFRS”), as issued by the International Accounting Standards Board ("IASB"(“IASB”).

 

The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below:

 

Basis of presentation

These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries; ODIS Inc. ("ODIS"(“ODIS”), Opel Solar Inc. ("OPEL"(“OPEL”), BB Photonics Inc., (“BB Photonics UK Limited (collectively "BB Photonics"Photonics”) and, POET Technologies Pte Ltd. ("PTS"(“PTS”) and POET Optoelectronics Shenzhen Co., Ltd (“POET Shenzhen”). They also include the accounts of DenseLight Semiconductor Pte Ltd. ("DenseLight"(“DenseLight”) up-to November 8, 2019. All intercompany balances and transactions have been eliminated on consolidation.

 

On November 8, 2019, the Company sold 100% of the issued and outstanding shares of DenseLight for $26,000,000. The Company received $8,000,000 upon the consummation of the sale. The Company expects to receive the remaining $18,000,000 over three tranches, with $4,750,000 received on February 14, 2020 and $8,250,000 received on March 30, 2020. The remaining $5,000,000 is expected to be received on or before May 31, 2020. Shares were placed into escrow in the name of the Buyer, to be released to the Buyer upon receipt of the remaining payments. The Buyer assumed control of DenseLight on November 8, 2019 and will be responsible for all operations of DenseLight thence-forth. Upon closing, the Company recognized a gain on the sale of $8,707,280. The Company received an additional $2,000,000, in excess of the sale proceeds, with the most recently paid two tranches which was immediately paid to Oak Capital on behalf of the Buyer for due diligence, legal and other expenses.Business combinations

 

Page 6

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Business combinations

Acquisitions of businesses are accounted for using the acquisition method. The acquisition cost is measured at the acquisition date at the fair value of the consideration transferred, including all contingent consideration.

 

Subsequent changes in contingent consideration are accounted for through the consolidated statements of operations and deficit and consolidated statements of comprehensive loss in accordance with the applicable standards.

 

Goodwill arising on acquisition is initially measured at cost, being the difference between the fair value of the consideration transferred including the recognized amount of any non-controlling interest in the acquiree and the net recognized amount (generally fair value) of the identifiable assets and liabilities assumed at the acquisition date. If the net of the amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer’s previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of operations and deficit as a bargain purchase gain.

 

Acquisition-related costs, other than those that are associated with the issue of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred.

 

Page 6

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Foreign currency translation

These consolidated financial statements are presented in U.S. dollars ("USD"(“USD”), which is the Company'sCompany’s presentation currency.

 

Items included in the financial statements of each of the Company'sCompany’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"“functional currency”). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statement of operations and deficit.

 

Assets and liabilities of entities with functional currencies other than U.S. dollars are translated into the presentation currency at the year end rates of exchange, and the results of their operations are translated at average rates of exchange for the year. The resulting translation adjustments are included in accumulated other comprehensive loss in shareholders'shareholders’ equity. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive loss. Elements of equity are translated at historical rates.

 

Financial instruments

IFRS 9 introduced new classification and measurement models for financial assets. The investment classifications held-to-maturity and available-for-sale are no longer used and financial assets at fair value through other comprehensive income ("FVTOCI"(“FVTOCI”) were introduced. Financial assets held with an objective to hold assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest are measured at amortised cost using the effective interest method. Debt investments held with an objective to hold both assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset on the basis of fair value are measured at FVTOCI. All other financial assets are classified and measured at fair value through profit or loss ("FVTPL"(“FVTPL”). Financial liabilities are classified as either FVTPL or other financial liabilities, and the portion of the change in fair value that relates to the Company'sCompany’s credit risk is presented in other comprehensive income (loss). Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in net income (loss). Other financial liabilities are subsequently measured at amortised cost using the effective interest method.

Page 7

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL, are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in consolidated net income (loss).

 

Derecognition

 

Financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability.

 

Page 7

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Financial liabilities

A financial liability is derecognized from the balance sheet when it is extinguished, that is, when the obligation specified in the contract is either discharged, cancelled or expires. Where there has been an exchange between an existing borrower and lender of debt instruments with substantially different terms, or there has been a substantial modification of the terms of an existing financial liability, this transaction is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. A gain or loss from extinguishment of the original financial liability is recognized in profit or loss.

The Company'sCompany’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities.

 

The following table outlines the classification of financial instruments under IAS 39 and the revised classification on the adoption of IFRS 9:

 

 Original classificationNew classification
 under IAS 39under IFRS 9
Financial Assets  
Cash and cash equivalentsLoans and receivablesAmortized cost
Short-term investmentsFVTPLAmortized cost
Accounts receivableLoans and receivablesAmortized cost

Financial Liabilities  
Financial Liabilities  
Accounts payable and accrued liabilitiesAmortized costsAmortized cost
Convertible debenturesAmortized cost
Covid-19 government support loansAmortized cost

 

Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is measured at fair value on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the total carrying value of the compound instrument to derive the equity component. The debt component is subsequently measured at amortized cost using the effective interest rate method. Interest expense based on the coupon rate of the debenture and the accretion of the liability component to the amount that will be payable on redemption are recognized through profit or loss as a finance cost.

Page 8

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Cash and cash equivalents

Cash and cash equivalents consist of cash in current accounts of $722,894 (2019 - $1,278,129, (20182018 - $2,267,868, 2017- $4,974,478)$2,267,868) and funds invested in US Term Deposits of $6,150,000 (2019 - $150,000, (20182018 - $300,000, 2017 - nil)$300,000) earning interest at 1.31% and maturing in less than 90 days.

 

Cash and cash equivalents include restricted funds of $184,569 (2019 - $93,800, (20182018 - $218,888, 2017 - nil)$218,888) which serves as a bank guarantee for the purchase of certain equipment. A bank guarantee was discharged in 2020 and a new bank guarantee was put in place. The bank guarantee is reduced on a monthly basis by $14,197 (2019 - $10,424, 2018 - $10,424) which is the amount paid monthly in settlement of the outstanding balance on the equipment.

 

Accounts receivable

Accounts receivable are amounts due from customers from the sale of products or services in the ordinary course of business. Accounts receivables are classified as current (on the consolidated statements of financial position) if payment is due within one year of the reporting period date, and are initially recognized at fair value and subsequently measured at amortized cost.

 

Page 8

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

In determining a default provision, the Company utilizes a provision matrix, as permitted under the simplified approach to measure expected credit losses. In doing so management considered historical credit losses, forward-looking factors specific to the Company'sCompany’s debtors and other macro-economic factors to arrive at expected default rates. The default rates are then applied to the Company'sCompany’s aging to determine expected credit losses. The carrying amount of trade receivables is reduced by the expected credit losses. If the financial conditions of these customers were to deteriorate and the Company determines that no recovery of a trade receivable is possible, the amount is deemed irrecoverable and subsequently written-off. Accounts receivable at December 31, 2018 and 2017 related to revenue earned by DenseLight. DenseLight was sold on November 8, 2019 (see Note 23).

 

Inventory

Inventory consists of raw material inventory, work in process, and finished goods and are recorded at the lower of cost and net realizable value. Cost is determined on a first in first out basis and includes all costs of purchase, costs of conversion and other costs incurred in bringing the inventory to its present condition.

 

An assessment is made of the net realizable value of inventory at each reporting period. Net realizable value is the estimated selling price less the estimated cost of completion and the estimated costs necessary to make the sale. When circumstances that previously caused inventories to be written down no longer exist or when there is clear evidence of an increase in net realizable value because of changed economic circumstances, the amount of any write down previously recorded is reversed so that the new carrying amount is the lower of the cost and the revised net realizable value. Raw materials are not written down unless the goods in which they are incorporated are expected to be sold for less than cost, in which case, they are written down by reference to replacement cost of the raw materials, as this is the best indicator of net realizable value. Inventory at December 31, 2018 and 2017 related to inventory held by DenseLight. DenseLight was sold on November 8, 2019 (see Note 23).

 

Property and equipment

Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives:

 

 Machinery and equipmentStraight Line, 5 years
 Leasehold improvementsStraight Line, 5 years or life of the lease, whichever is less
 Office equipmentStraight Line, 3 - 5 years

Page 9

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Patents and licenses

Patents and licenses are recorded at cost and amortized on a straight line basis over 12 years. Ongoing maintenance costs are expensed as incurred.

 

Impairment of long-lived assets

The Company’s tangible and intangible assets are reviewed for indications of impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. An assessment is made at each reporting date whether there is any indication that an asset may be impaired.

 

An impairment loss is recognized when the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognized in profit and loss for the year. The recoverable amount is the greater of the asset’s fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit ("CGU"(“CGU”) to which the asset belongs.

Page 9

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

An impairment loss is reversed if there is an indication that there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. The Company reported anno impairment loss of $714,000 for the year ended December 31, 2019 (20182020 (2019 - nil, 2017$714,000, 2018 - nil) (Note 10).

 

Goodwill

Goodwill represents the excess of the cost of an acquired business over the fair value of the identifiable assets acquired net of liabilities assumed. Goodwill is measured at cost less accumulated impairment losses and is not amortized. Goodwill is tested for impairment on an annual basis or whenever facts or circumstances indicate that the carrying amount may exceed its recoverable amount.

 

The Company performedperforms its annual test for goodwill impairment at December 31, 2019.annually in the fourth quarter. The Company utilized a five-year cash flow forecast using the annual budget approved by the Board of Directors as a basis for such forecasts. Cash flow forecasts beyond that of the budget were prepared using a stable growth rate for future periods. These forecasts were based on historical data and future trends expected by the Company. The Company'sCompany’s valuation model also takes into account working capital and capital investments required to maintain the condition of the assets. Forecasted cash flows were discounted using an after-tax rate of 30%.

 

Based on the impairment tests, the value in-use of the CGU to which goodwill is applicable is less than the carrying amount. As a result goodwill of $1,050,459 was impaired in the current year.2019. No provision for impairment of goodwill was made in 20182020 or 20172018 (Note 24).

 

Income taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income taxes are provided on differences between the financial reporting and income tax bases of assets and liabilities and on income tax losses available to be carried forward to future years for tax purposes. Deferred income taxes are measured using the substantively enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are only recognized if the amount is expected to be realized in the future.

Page 10

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Revenue recognition

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer.

 

Sale of goods

Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured.

 

Service revenue

The Company provides contract services, primarily in the form of non-recurring revenue ("NRE"(“NRE”) where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method.

 

Page 10

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars) 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Other income

Interest income

Interest income on cash is recognized as earned using the effective interest method.

 

Research and Development Credits

Through DenseLight, the Company was eligible to receive cash credits for certain qualifying research and development expenses based on actual spending over a three year period, with an expectation that the credits willwould not exceed a certain dollar value over a three year period. Recoverable amounts at December 31, 2018 and 2017 related to expenditures at DenseLight. RecoverableThere was no recoverable amount at December 31, 2020 or 2019 was nil because the Company sold DenseLight on November 8, 2019.

 

Wage subsidies

Wages subsidies received from the Singaporean government are netted against payroll costs on the consolidated statements of operations and deficit.

Intangible assets

Research and development costs

Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the Company believes a development project meets IFRS criteria as set out in IAS 38, Intangible Assets, for deferral and amortization. IAS 38 requires all research costs be charged to expense while development costs are capitalised only after technical and commercial feasibility of the asset for sale or use have been established. This means that the entity must intend and be able to complete the intangible asset and either use it or sell it and be able to demonstrate how the asset will generate future economic benefits. Development costs are tested for impairment whenever events or changes indicate that its carrying amount may not be recoverable.

 

In-Process Research and Development

Under IFRS, in-process research and development ("(“IPR&D"&D”) acquired in a business combination that meets the definition of an intangible asset is capitalized with amortization commencing when the asset is ready for use (i.e., when development is complete). The Company acquired $714,000 of IPR&D when it acquired BB Photonics Inc. in 2016. During 2019, management observed indicators that suggested that IPR&D may be impaired. IPR&D acquired with BB Photonics was no longer useable with the novel POET Interposer platform. BB Photonics IPR&D would not generate sufficient cash flow to support its value in use. Management completed an assessment of IPR&D and determined that the amount of $714,000 was impaired. An impairment loss of $714,000 was recorded during the year ended December 31, 2019. No impairment was recorded in 20182020 or 20172018 (Note 10).

Page 11

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Customer relationships

Intangible assets include customer relationships acquired with the acquisition of DenseLight. Customer relationships is an externally acquired intangible asset and is measured at cost less accumulated amortization and any accumulated impairment losses. Customer relationships are amortized on a straight-line basis over their estimated useful lives and is tested for impairment whenever events or changes indicate that their carrying amount may not be recoverable. The useful life of customer relationships was determined to be 5 years. Customer relations was nil at December 31, 2020 and 2019 as because the asset was disposed of with the sale of DenseLight on November 8, 2019.

 

Page 11

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Stock-based compensation

Stock options and warrants awarded to non employees are measured using the fair value of the goods or services received unless that fair value cannot be estimated reliably, in which case measurement is based on the fair value of the stock options. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option pricing model with assumptions applicable at the date of grant.

 

Income (loss) per share

Basic income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the year. Diluted income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the year after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method.

 

3.RECENT ACCOUNTING PRONOUNCEMENTSRECEIVABLE FROM THE SALE OF DISCONTINUED OPERATIONS

 

Recently adopted accounting policy

IFRS 16, Leases (“IFRS 16”) sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract, the customer (lessee) and the supplier (lessor). This replaces IAS 17, Leases (“IAS 17”) and related Interpretations. IFRS 16 provides revised guidance on identifying a lease and for separating lease and non-lease components of a contract. IFRS 16 introduces a single accounting model for all lessees and requires a lessee to recognize right of use assets and lease liabilities for leases with terms of more than 12 months, unless the underlying asset is of low value, and depreciation of lease assets is reported separately from interest on lease liabilities in the income statement. Under IFRS 16, lessor accounting for operating and finance leases will remain substantially unchanged. IFRS 16 is effective for annual periods beginning on or after January 1, 2019, with earlier application permitted for entities that apply IFRS 15, Revenue from Contracts with Customers. The Company adopted this new standard using the modified retrospective method on January 1, 2019. The adoption of IFRS 16, resulted in a right of use asset and liability of $1,127,534. The carrying value of the right of use asset and lease liability relating to Denselight were disposed of upon the sale of DenseLight onOn November 8, 2019, (notes 9the Company sold 100% of the issued and 23)outstanding shares of DenseLight for $26,000,000. The Company received $8,000,000 upon the consummation of the sale with the remaining $18,000,000 expected over three tranche payments in 2020. Payments received in the first quarter were as follows: $4,750,000 received on February 14, 2020 and $8,250,000 received on March 30, 2020.

The Company received payments of $1,500,000 and $1,000,000 on June 29, 2020 and July 3, 2020 respectively. After taking into consideration the length of time it had taken the Buyer to make the foregoing payments and the Company’s expectations regarding the likelihood of receiving an additional payment, the Company determined that it was in its best interest to accept partial payments as final payment on the Company’s receivable. As a result, the Company recognized a credit loss of $2,500,000 during the year ended December 31, 2020 (nil - 2019 and nil - 2018).

 

4.ACCOUNTS RECEIVABLE

 

The carrying amounts of accounts receivable approximate their fair value and are originally denominated in Singapore dollars before conversion to US dollars at December 31:

 

    2019  2018  2017 
Product sales United States dollar $-  $713,744  $493,925 
Product sales Singapore dollar  -   273,815   - 
Loss allowance    -   (40,615)  - 
    $-  $946,944  $493,925 

Page 12

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

4.ACCOUNTS RECEIVABLE (Continued)
    2020  2019  2018 
            
Product sales United States dollar $-  $-  $713,744 
Product sales Singapore dollar  -   -   273,815 
Loss allowance    -   -   (40,615)
               
    $-  $-  $946,944 

 

In determining the recoverability of a trade receivable, the Company considers any change in the credit quality of the trade receivable from the date credit was initially granted up to the reporting date. The trade receivables that are neither past due nor impaired relates to customers that the company has assessed to be creditworthy based on the credit evaluation process performed by management which considers both customers'customers’ overall credit profile and its payment history with the Company. The loss allowance is determined in accordance IFRS 9 (Note 18)20). Trade receivables at December 31, 2018 and 2017 related to DenseLight. Trade receivable isreceivables were nil at December 31, 2020 and 2019 because DenseLight was sold on November 8, 2019.

 

5.Page 12

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

5.PREPAIDS AND OTHER CURRENT ASSETS

 

The following table reflects the details of prepaids and other current assets at December 31:

 

 2019  2018 2017  2020  2019 2018 
              
Sales tax recoverable and other current assets $81,265  $85,658  $119,482  $122,353  $81,265  $85,658 
Research and development credit  -   1,905,593   1,287,539   -   -   1,905,593 
Security deposits on leased properties  -   233,983   228,170   -   -   233,983 
Prepaid expenses  750,000   711,385   322,536   496,364   750,000   711,385 
 $831,265  $2,936,619  $1,957,727             
 $618,717  $831,265  $2,936,619 

 

Research and development credit, security depositdeposits on leased properties and certain prepaid expenses were disposed of during the year upon the sale of DenseLight.

DenseLight on November 8, 2019.

 

6.INVENTORY

 

The following table reflects the details of inventory at December 31:

 

  2019  2018  2017 
          
Raw materials $-  $98,370  $112,768 
Finished goods  -   212,361   260,105 
Work in process  -   126,102   151,709 
  $-  $436,833  $524,582 

In 2017, the Company recorded an inventory write-down of $353,476. Raw materials related to products under development represented the most significant portion of the write-down.

  2020  2019  2018 
          
Raw materials $-  $-  $98,370 
Finished goods  -   -   212,361 
Work in process  -   -   126,102 
             
  $-  $-  $436,833 

 

The Company disposed of its inventory upon the sale of DenseLight on November 8, 2019.

 

7.PROPERTY AND EQUIPMENT

 

 Equipment not ready for Leasehold Machinery and Office   
 Equipment not Leasehold Machinery and Office    use improvements equipment equipment Total 
 ready for use improvements equipment equipment Total            
Cost                               
Balance, January 1, 2017 $602,830  $667,342  $9,734,885  $314,817  $11,319,874 
Additions  806,182   -   113,433   50,182   969,797 
Reclassification  (874,371)  -   874,371   -   - 
Effect of changes in foreign exchange rates  46,433   -   72,779   8,914   128,126 
Balance, December 31, 2017  581,074   667,342   10,795,468   373,913   12,417,797 
Balance, January 1, 2018 $581,074  $667,342  $10,795,468  $373,913  $12,417,797 
Additions  3,667,894   -   -   50,258   3,718,152   3,667,894   -   -   50,258   3,718,152 
Reclassification (1)  (1,086,895)  -   881,221   202,674   (3,000)  (1,086,895)  -   881,221   202,674   (3,000)
Impairment and disposals (1)  -   -   (611,875)  (3,665)  (615,540)  -   -   (611,875)  (3,665)  (615,540)
Effect of changes in foreign exchange rates  (19,920)  -   (46,829)  (1,739)  (68,488)  (19,920)  -   (46,829)  (1,739)  (68,488)
Balance,December 31, 2018  3,142,153   667,342   11,017,985   621,441   15,448,921 
                    
Balance, December 31, 2018  3,142,153   667,342   11,017,985   621,441   15,448,921 
Additions  1,986,210   -   39,260   19,480   2,044,950   1,986,210   -   39,260   19,480   2,044,950 
Disposals (2)  (4,388,762)  (667,342)  (8,198,519)  (555,688)  (13,810,311)  (4,388,762)  (667,342)  (8,198,519)  (555,688)  (13,810,311)
Effect of changes in foreign exchange rates  24,741   -   14,529   -   39,270   24,741   -   14,529   -   39,270 
Balance, December 31, 2019 $764,342  $-  $2,873,255  $85,233  $3,722,830 
                    
Balance,December 31, 2019  764,342   -   2,873,255   85,233   3,722,830 
Additions  888,726   68,961   525,685   38,416   1,521,788 
Reclassification  (519,366)  -   516,111   3,255   - 
Disposals (3)  (897,727)  -   -   -   (897,727)
Effect of changes in foreign exchange rates  (8,828)  2,967   79,606   1,281   75,026 
                    
Balance, December 31, 2020 $227,147  $71,928  $3,994,657  $128,185  $4,421,917 

Page 13

POET TECHNOLOGIES INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

7.PROPERTY AND EQUIPMENT (Continued)

 

Accumulated Depreciation                               
Balance, January 1, 2017  -   83,189   1,808,308   64,167   1,955,664 
Balance, January 1, 2018  -   216,688   3,665,782   257,157   4,139,627 
Depreciation for the year  -   133,499   1,857,474   192,990   2,183,963   -   133,809   2,201,133   133,662   2,468,604 
Balance, December 31, 2017  -   216,688   3,665,782   257,157   4,139,627 
Depreciation for the year  -   133,809   2,201,133   133,662   2,468,604 
Impairment and disposals (1)  -   -   (455,158)  (3,665)  (458,823)
Impairment and disposals (1)(2)  -   -   (455,158)  (3,665)  (458,823)
                    
Balance, December 31, 2018  -   350,497   5,411,757   387,154   6,149,408   -   350,497   5,411,757   387,154   6,149,408 
Depreciation for the year  -   -   144,337   22,005   166,342   -   -   144,337   22,005   166,342 
Disposals (2)  -   (350,497)  (5,044,288)  (341,195)  (5,735,980)
Impairment and disposals (2)  -   (350,497)  (5,044,288)  (341,195)  (5,735,980)
                    
Balance, December 31, 2019  -   -   511,806   67,964   579,770   -   -   511,806   67,964   579,770 
Depreciation for the year  -   10,332   609,803   11,128   631,263 
Effect of changes in foreign exchange rates  -   445   24,405   280   25,130 
                    
Balance, December 31, 2020  -   10,777   1,146,014   79,372   1,236,163 
                                        
Carrying Amounts                                        
At December 31, 2017 $581,074  $450,654  $7,129,686  $116,756  $8,278,170 
At December 31, 2018 $3,142,153  $316,845  $5,606,228  $234,287  $9,299,513  $3,142,153  $316,845  $5,606,228  $234,287  $9,299,513 
                    
At December 31, 2019 $764,342  $-  $2,361,449  $17,269  $3,143,060  $764,342  $-  $2,361,449  $17,269  $3,143,060 
                    
At December 31, 2020 $227,147  $61,151  $2,848,643  $48,813  $3,185,754 

 

(1)(1)During 2018, $3,000 relating to certain property and equipment were reclassified to non-current assets held for sale and was sold in December 2018 while $156,717 was recorded as an impairment loss and was included in discontinued operations.

(2)
(2)On November 8, 2019, the Company disposed of property and equipment used in the operations DenseLight.
(3)During 2020, the Company settled certain R&D expenses by transferring $897,727 worth of equipment to the supplier. The equipment was initially installed in the fabrication facility of the supplier who provided discounted R&D services to the Company. The equipment will be used by the supplier for volume production primarily for the benefit of the Company.

 

8.PATENTS AND LICENSES

Cost    
Balance, January 1, 2018 $670,430 
Additions  67,608 
Effect of changes in foreign exchange rates  (352)
     
Balance, December 31, 2018  737,686 
Additions  77,037 
Disposals (1)  (29,696)
     
Balance, December 31, 2019  785,027 
Additions  52,075 
     
Balance, December 31, 2020  837,102 
     
Accumulated Amortization    
Balance, January 1, 2018  214,180 
Amortization  56,792 
     
Balance, December 31, 2018  270,972 
Amortization  61,671 
     
Balance, December 31, 2019  332,643 
Amortization  65,782 
     
Balance, December 31, 2020  398,425 

8.Page 14

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

8.PATENTS AND LICENSES (Continued)

 

Cost   
Balance, January 1, 2017 $609,887 
Additions  60,543 
Balance, December 31, 2017  670,430 
Additions  67,608 
Effect of changes in foreign exchange rates  (352)
Balance, December 31, 2018  737,686 
Additions  77,037 
Disposals (1)  (29,696)
Balance, December 31, 2019  785,027 
     
Accumulated Amortization    
Balance, January 1, 2017  160,211 
Amortization  53,969 
Balance, December 31, 2017  214,180 
Amortization  56,792 
Balance, December 31, 2018  270,972 
Amortization  61,671 
Balance, December 31, 2019  332,643 
     
Carrying Amounts    
At December 31, 2017 $456,250 
At December 31, 2018 $466,714 
At December 31, 2019 $452,384 
Carrying Amounts   
    
At December 31, 2018 $466,714 
     
At December 31, 2019 $452,384 
     
At December 31, 2020 $438,677 

 

(1)(1)On November 8, 2019, the Company disposed of certain patents unrelated to the Company'sCompany’s technology on the sale of DenseLight.

Page 14

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

9.RIGHT OF USE ASSET AND LEASE LIABILITY

 

On January 1, 2019, the Company adopted IFRS, 16 Leases. Upon adoption of IFRS 16, the Company recognized a lease liability and right of use asset relating to new leases entered into on February 15, 2019 related to DenseLight, and November 1, 2019 related to PTS. The lease liability was measured at the present value of the remaining lease payments, discounted using the Company'sCompany’s incremental borrowing rate of 12%. During 2020, the Company modified its lease resulting in reducing the space it leased for the operations at PTS. The Company recognized a gain of $786 on the lease modification which is included in selling, general and marketing on the consolidated statements of operations and deficit.

 

Right of use asset Building 
    
Cost    
Balance, January 1, 2019 $- 
Additions  1,127,534 
Disposal (1)  (892,300)
Effect of changes in foreign exchange rates  2,966 
     
Balance, December 31, 2019  238,200 
Additions  465,068 
Lease modification  (47,939)
Effect of changes in foreign exchange rates  (2,097)
     
Balance, December 31, 2020 $653,232 
     
Accumulated Amortization    
Balance, January 1, 2019  - 
Amortization  15,683 
     
Balance, December 31, 2019  15,683 
Amortization  116,057 
Effect of changes in foreign exchange rates  806 
     
Balance, December 31, 2020  132,546 
Carrying Amounts    
At December 31, 2019 $222,517 
     
At December 31, 2020 $520,686 

Right of use asset Building 
Cost   
Balance, January 1, 2019 $- 
Additions  1,127,534 
Disposal (1)  (892,300)
Effect of changes in foreign exchange rates  2,966 
Balance, December 31, 2019  238,200 
     
Accumulated Amortization    
Balance, January 1, 2019  - 
Amortization  15,683 
Balance, December 31, 2019  15,683 
Carrying Amounts    
At December 31, 2019 $222,517 
     
Lease liability    
Balance, January 1, 2019 $- 
Additions  1,127,534 
Interest expense  4,705 
Interest included in discontinued operations  74,494 
Lease payments  (19,162)
Lease payments included in discontinued operations  (258,460)
Disposal (1)  (695,733)
Effect of changes in foreign exchange rates  (9,620)
Balance, December 31, 2019 $223,758 
Page 15

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

(1)9.RIGHT OF USE ASSET AND LEASE LIABILITY (Continued)

Lease liability   
    
Balance, January 1, 2019 $- 
Additions  1,127,534 
Interest expense  4,705 
Interest included in discontinued operations  74,494 
Lease payments  (19,162)
Lease payments included in discontinued operations  (258,460)
Disposal (1)  (695,733)
Effect of changes in foreign exchange rates  (9,620)
     
Balance, December 31, 2019  223,758 
Interest expense  44,655 
Lease modification  (48,725)
Additions  452,385 
Lease payments  (144,142)
Effect of changes in foreign exchange rates  4,066 
     
Balance, December 31, 2020 $531,997 

(1)The Company disposed of $892,000 of right of use asset and $695,733 of lease liability on November 8, 2019 with the sale of DenseLight on November 8, 2019 (Note 23).

10.INTANGIBLE ASSETS

 

10.INTANGIBLE ASSETS

     Customer    
  Technology  Relationships  Total 
Cost         
Balance, December 31, 2017 and 2018 $714,000  $186,131  $900,131 
Impairment  (714,000)  -   (714,000)
Disposals (1)  -   (186,131)  (186,131)
Balance, December 31, 2019  -   -   - 
             
Accumulated Amortization            
Balance, January 1, 2017  -   23,266   23,266 
Amortization for the year  -   37,228   37,228 
Balance, December 31, 2017  -   60,494   60,494 
Amortization for the year  -   37,228   37,228 
Balance, December 31, 2018  -   97,722   97,722 
Disposals (1)  -   (97,722)  (97,722)
Balance, December 31, 2019  -   -   - 

Page 15

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

    Customer    
  Technology  Relationships  Total 
          
Cost            
Balance, January 1, 2018 and December 31, 2018 $714,000  $186,131  $900,131 
Impairment  (714,000)  -   (714,000)
Disposals (1)  -   (186,131)  (186,131)
             
Balance, December 31, 2019 and 2020  -   -   - 
             
Accumulated Amortization            
Balance, January 1, 2018 and December 31, 2018  -   97,722   97,722 
Disposals (1)  -   (97,722)  (97,722)
             
Balance, December 31, 2019 and 2020  -   -   - 
             
Carrying Amounts            
At December 31, 2018 $714,000  $88,409  $802,409 
             
At December 31, 2019 $-  $-  $- 
             
At December 31, 2020 $-  $-  $- 

 

10.INTANGIBLE ASSETS (Continued)

Carrying Amounts         
At December 31, 2017 $714,000  $125,637  $839,637 
At December 31, 2018 $714,000  $88,409  $802,409 
At December 31, 2019 $-  $-  $- 

(1)The Company disposed of its customer relationships intangible assets and related amortization on November 8, 2019 with the sale of DenseLight (Note 23).

 

11.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities at December 31 was as follows:         
  2020  2019  2018 
          
Trade payables $1,603,284  $1,507,644  $2,269,845 
Payroll related liabilities  60,455   44,677   595,720 
Accrued liabilities  66,622   173,387   174,857 
             
  $1,730,361  $1,725,708  $3,040,422 

Accounts payable and accrued liabilities at December 31 was as follows:

Page 16

POET TECHNOLOGIES INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

  2019  2018  2017 
Trade payables $1,507,644  $2,269,845  $504,229 
Payroll related liabilities  44,677   595,720   112,913 
Accrued liabilities  173,387   174,857   193,451 
  $1,725,708  $3,040,422  $810,593 

12.CONVERTIBLE DEBENTURES, LOAN PAYABLE AND PROMISSORY NOTE

 

On April 1, 2019 the Company announced that it arranged for certain financing required to bridge the Company up to the sale of its DenseLight subsidiary.

 

Convertible Debentures

The first component of the financing consists of the issuance of up to $10.5 million (CAD$14 million) of unsecured convertible debentures (the “Convertible Debentures”) of the Company. The Convertible Debentures were sold in multiple tranches, on a brokered private placement basis through the Company’s financial advisors, IBK Capital. During the yearIn 2019, the Company closed five tranches of the private placement of the Convertible Debentures that raised gross proceeds of $3,729,921 (CAD$4,988,292). The Convertible Debentures, bear interest at 12% per annum, compounded annually with 1% payable at the beginning of each month and mature two years from the date of issue. The Company paid $377,072 (CAD$499,462) in brokerage fees and other costs related to the closing of these five tranches.

 

The Convertible Debentures are convertible at the option of the holders thereof into units at any time after October 31, 2019 at a conversion price of CAD$0.40 per unit for a total 12,470,73012,457,500 units of the Company. Each unit will consist of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share of the Company at a price of CAD$0.50 per share for a period of twofour years from the date upon which the convertible debenture is converted into units.issued. Upon completing the sale of DenseLight, holders of Convertible Debentures will have the right to cause the Company to repurchase the Convertible Debentures at face value, subject to certain restrictions. The Convertible Debentures are governed by a trust indenture between the Company and TSX Trust Company as trustee.

 

Insiders of the Company subscribed for 14.3% or $535,000 (CAD$710,000) of the Convertible Debentures, including the Company’s board of directors and senior management team. Insiders of IBK Capital subscribed for 4% or $146,000 (CAD$200,000) of the Convertible Debentures.

 

IAS 32 Financial Instruments: Presentation define these debt securities as compound financial instruments made up of both a liability component and an equity component. The debt componentscomponent of the Convertible Debentures were fair valued using effective discount rates ranging from 28.74% to 29.71% which the Company determined would be the interest rate of the debts without a conversion feature. The difference between the fair value of the debt component and the loan is allocated to the equity component and is included in shareholders'shareholders’ equity.

Page 16

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

12.CONVERTIBLE DEBENTURES, LOAN PAYABLE AND PROMISSORY NOTE (Continued)

 

Because the Convertible Debentures are denominated in Canadian dollars and the conversion price is also denominated in Canadian dollars, the number of equity instruments that would be issued upon exercise of the convertible debentures are fixed. As a result, the equity component of the convertible debentures will not be periodically remeasured.

 

During 2020, holders of certain convertible debentures converted $369,545 (2019 - nil) worth of convertible debentures into 1,235,000 units of the Company.

The following table reflects the details of convertible debentures:debentures at December 31, 2020:

 

Convertible Debentures Loan  Equity Component  Accretion  Debt Component 
             
Issued April 3, 2019 (net of issue costs) $1,293,519  $(242,004) $338,988  $1,390,503 
Issued May 3, 2019 (net of issue costs)  806,893   (151,842)  218,159   873,210 
Issued June 3, 2019 (net of issue costs)  496,995   (93,278)  117,481   521,198 
Issued August 2, 2019 (net of issue costs)  290,365   (54,978)  62,683   298,070 
Issued September 19, 2019 (net of issue costs)  122,965   (23,019)  22,905   122,851 
Effect of foreign exchange rate changes  -   -   -   135,414 
                 
Balance December 31, 2020 $3,010,737  $(565,121) $760,216  $3,341,246 

Convertible Debentures Loan  Equity Component  Accretion  Debt Component 
Issued April 3, 2019 (net of issue costs) $1,293,519  $(242,004) $128,240  $1,179,755 
Issued May 3, 2019 (net of issue costs)  979,256   (183,317)  84,708   880,647 
Issued June 3, 2019 (net of issue costs)  582,356   (109,017)  42,855   516,194 
Issued August 2, 2019 (net of issue costs)  374,753   (70,154)  19,690   324,289 
Issued September 19, 2019 (net of issue costs)  122,965   (23,019)  5,336   105,282 
Effect of foreign exchange rate changes  -   -   -   82,866 
Balance December 31, 2019 $3,352,849  $(627,511) $280,829  $3,089,033 
Page 17

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

12.CONVERTIBLE DEBENTURES, LOAN PAYABLE AND PROMISSORY NOTE (Continued)

The following table reflects the details of convertible debentures at December 31, 2019:

Convertible Debentures Loan  Equity Component  Accretion  Debt Component 
             
Issued April 3, 2019 (net of issue costs ) $1,293,519  $(242,004) $128,240  $1,179,755 
Issued May 3, 2019 (net of issue costs)  979,256   (183,317)  84,708   880,647 
Issued June 3, 2019 (net of issue costs)  582,356   (109,017)  42,855   516,194 
Issued August 2, 2019 (net of issue costs)  374,753   (70,154)  19,690   324,289 
Issued September 19, 2019 (net of issue costs)  122,965   (23,019)  5,336   105,282 
Effect of foreign exchange rate changes  -   -   -   82,866 
                 
Balance December 31, 2019 $3,352,849  $(627,511) $280,829  $3,089,033 

Loan Payable and Promissory Note

The second component of the financing in 2019 consisted of a credit facility (the “Bridge Loan”) provided by Espresso Capital Ltd which granted the Company access to a maximum $5,000,000. The Company signed the loan documents on April 18, 2019 and was advanced $3,100,000 shortly thereafter.

 

Funds drawn on the Credit Facility bearbore interest at a rate of 17.25% per annum (the "Interest Rate"“Interest Rate”), calculated daily from the date of each advance until the earlier of the due date of each such advance, if any, and December 31, 2019 (the "Maturity Date"“Maturity Date”). The Interest Rate iswas comprised of 15% cash interest and 2.25% deferred interest. Per the agreement, the interest rate was retroactively increased to 19.25% because the Company did not consummate the sale of Denselight by October 15, 2019.

 

TheIn 2019, the Company paid $147,077 in costs related to the Bridge Loan. Additionally, the Company issued to Espresso Capital Ltd, warrants for the purchase of 3,289,500 common shares at a price of CAD$0.35 per share. The Warrants expire on April 18, 2020. The fair value of the warrants was estimated on the date of issue using the Black-Scholes option pricing model with the following assumptions: volatility of 78.91%, interest rate of 1.62% and an expected life of 1 year. The estimated fair value assigned to the warrants was $221,620. The total cost of $368,697 along with the foreign exchange impact of $3,543 was deferred and charged against the Bridge Loan and subsequently amortized over the life of the Bridge Loan. The Bridge loan was repaid on November 8, 2019.

 

Additionally, on August 30, 2019, the Company signed a term promissory note (the "Promissory Note"“Promissory Note”) for up-to $1,000,000 with Century Prosper Investment Corporation (the "Lender"“Lender”). The Promissory Note bearsbore interest at 15% per annum. The Promissory Note and accrued interest arewere repayable on the six-month anniversary of each advance. At the option of the Lender, the advances and accrued interest may be repaid in full five days after the sale of the Company'sCompany’s DenseLight subsidiary. The Company was advanced $900,000 in 2019 on this Promissory Note. The $900,000 advance and related interest of $17,160 were repaid on November 8, 2019.

 

Page 1718

POET TECHNOLOGIES INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

13.SHARE CAPITAL

 

 (a)AUTHORIZED

Unlimited number of common shares

One special voting share

Unlimited number of common shares
One special voting share
(b)COMMON SHARES ISSUED

 

 Number of    Number of   
 Shares Amount  Shares Amount 
          
Balance, January 1, 2017  259,333,853  $103,357,862 
Funds from the exercise of stock options  685,000   123,528 
Fair value of stock options exercised  -   134,831 
        
Balance, December 31, 2017  260,018,853   103,616,221 
Balance, January 1, 2018  260,018,853  $103,616,221 
Common shares issued on public offering  25,090,700   10,663,548   25,090,700   10,663,548 
Share issue costs  -   (1,131,990)  -   (1,131,990)
Fair value of warrants issued on public offering  -   (2,286,426)  -   (2,286,426)
Fair value of compensation options issued to brokers  -   (479,204)  -   (479,204)
Funds from the exercise of stock options  372,250   87,974   372,250   87,974 
Fair value of stock options exercised  -   82,330   -   82,330 
Funds from the exercise of warrants and compensation warrants  2,600,500   1,028,471   2,600,500   1,028,471 
Fair value of warrants and compensation warrants exercised  -   447,270   -   447,270 
                
Balance, December 31, 2018  288,082,303   112,028,194   288,082,303   112,028,194 
Funds from the exercise of stock options  281,250   60,028   281,250   60,028 
Fair value of stock options exercised  -   55,950   -   55,950 
        
Balance, December 31, 2019  288,363,553  $112,144,172   288,363,553   112,144,172 
Funds from the exercise of stock options  3,302,835   794,808 
Fair value of stock options exercised  -   768,356 
Funds from the exercise of warrants  744,000   293,642 
Fair value of exercised warrants (Notes 12 and 13)  -   127,964 
Issued on the conversion of convertible debentures (Note 12)  1,235,000   369,545 
Fair value of warrants issued on conversion of convertible debentures  -   (146,858)
Exercise of warrants issued in conjunction with debt financing  942,448   221,620 
Shares issued to settle accounts payable  30,268   13,011 
        
Balance, December 31, 2020  294,618,104  $114,586,260 

 

On March 21, 2018, the Company completed a brokered "bought deal"“bought deal” public offering of 25,090,700 units at a price of $0.425 (CAD$0.55) per unit for gross proceeds of $10,663,548 (CAD$13,799,885). Each unit consists of one common share and one-half common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $0.58 (CAD$0.75) per share until March 21, 2020. The broker was paid a cash commission of $639,813 (6%) of the gross proceeds and received 1,505,442 compensation options. Each compensation option is exercisable into one compensation unit of the Company at a price of $0.425 (CAD$0.55) per compensation unit until March 21, 2020 with each compensation unit comprising one common share and one-half compensation share purchase warrant. Each whole compensation share purchase warrant entitles the broker to purchase one common share of the Company at a price of $0.425 (CAD$0.55) per share until March 21, 2020. The Company paid an additional $492,177 in other costs related to this financing.

 

Certain management participated in the “bought-deal” public offering, by acquiring 281,000 units at a price of $0.425 (CAD$0.55) per unit for gross proceeds of $119,425 (CAD$154,550).

 

Page 19

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

13.SHARE CAPITAL (Continued)

The fair value of the share purchase warrants and compensation options was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 1.86%, volatility of 94.77%, and estimated life of 2 years. The estimated fair values assigned to the warrants and compensation options were $2,286,426 and $479,204, respectively.

During 2020, holders of certain convertible debentures converted $369,545 worth of convertible debentures into 1,235,000 units of the Company. Each unit consists of one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share of the Company at a price of $0.38 (CAD$0.50) per share for a period of four years from the date upon which the convertible debenture was issued.

 

The fair value of the share purchase warrants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 1.32%, volatility of 76.55%, and estimated life of 2 years. The estimated fair value assigned to the warrants was $146,858.

Page 18

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

During 2020, the Company engaged with a firm to assist with its shareholder communications strategy. The terms of the agreement require the Company to issue common shares at certain pre-determined dates in statisfaction of past services rendered. The Company settled $13,011 in accounts payable related to past services rendered under this agreement by issuing 30,268 common shares at a price of $0.43 (CAD$0.56) per share to the firm.

 

14.WARRANTS AND COMPENSATION OPTIONS

 

The following table reflects the continuity of warrants:warrants and compensation options:

 

  Historical  Number of    
  Average Exercise  

Warrants/

Compensation

  Historical 
  Price  options  Fair value 
          
Balance, January 1, 2018 $0.39   34,800,000  $5,985,378 
Fair value of warrants issued on public offering  0.58   12,545,350   2,286,426 
Historical fair value assigned to warrants exercised  0.39   (2,600,500)  (447,270)
Fair value of compensation options issued to brokers  0.43   1,505,442   479,204 
             
Balance, December 31, 2018  0.44   46,250,292   8,303,738 
Fair value of warrants issued as cost of debt financing  0.27   3,289,500   221,620 
             
Balance, December 31, 2019  0.43   49,539,792   8,525,358 
Fair value of warrants issued on conversion of convertible debentures (Notes 12 and 13)  0.38   1,235,000   146,858 
Fair value of expired compensation options issued to brokers  0.43   (1,505,442)  (479,204)
Fair value related to the exercise of warrants issued as cost            
of debt financing (1)  0.27   (3,289,500)  (221,620)
Fair value of expired warrants issued on public offering  0.58   (12,545,350)  (2,286,426)
Historical fair value assigned to warrants exercised  0.39   (744,000)  (127,964)
             
Balance, December 31, 2020 $0.39   32,690,500  $5,557,002 

(1)These warrants had a cashless exercise feature. The warrant holder utilized the cashless exercise feature to exercise the warrants, which resulted in the Company issuing 942,448 common shares to the warrant holders.

  Historical  Number of    
  Average Exercise  Warrants/  Historical 
  Price  Compensation options  Fair value 
          
Balance, January 1, 2017 $0.79   8,369,233  $2,013,747 
Warrants issued  0.39   34,800,000   5,985,378 
Warrants and compensation warrants exercised  (0.51)  (3,794,412)  (901,417)
Expired  (1.02)  (4,574,821)  (1,112,330)
Balance, December 31, 2017  0.39   34,800,000   5,985,378 
Fair value of warrants issued on public offering  0.58   12,545,350   2,286,426 
Historical fair value assigned to warrants exercised  0.39   (2,600,500)  (447,270)
Fair value of compensation options issued to brokers  0.43   1,505,442   479,204 
Balance, December 31, 2018  0.44   46,250,292   8,303,738 
Fair value of warrants issued as cost of debt financing  0.27   3,289,500   221,620 
Balance, December 31, 2019 $0.43   49,539,792  $8,525,358 
Page 20

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

15.STOCK OPTIONS AND CONTRIBUTED SURPLUS

 

Stock Options

On June 21, 2018,August 26, 2020, shareholders of the Company approved amendments to the Company'sCompany’s fixed 20% stock option plan (as amended, previously referred to as the "2016 plan"“2018 plan”, now referred to as the "2018 Plan"“2020 Plan”). Under the 20182020 Plan, the board of directors may grant options to acquire common shares of the Company to qualified directors, officers, employees and consultants. The 20182020 Plan provides that the number of common shares issuable pursuant to options granted under the 20182020 Plan and pursuant to other previously granted options is limited to 57,611,36058,538,554 (the “Number Reserved”). Any subsequent increase in the Number Reserved must be approved by shareholders of the Company and cannot, at the time of the increase, exceed 20% of the number of issued and outstanding shares. The stock options vest in accordance with the policies determined by the Board of Directors from time to time consistent with the provisions of the 20182020 Plan which grants discretion to the Board of Directors.

 

Stock option transactions and the number of stock options outstanding were as follows:

 

   Historical    Historical 
   Weighted Average    Weighted Average 
 Number of Exercise  Number of Exercise 
 Options Price  Options Price 
          
Balance, January 1, 2017  23,805,500  $0.96 
Balance, January 1, 2018  33,090,291  $0.68 
Expired/cancelled  (5,455,209)  0.73   (1,944,791)  0.74 
Exercised  (685,000)  0.19   (372,250)  0.26 
Granted  15,425,000   0.24   13,690,479   0.34 
Balance, December 31, 2017  33,090,291   0.68 
Expired/cancelled  (1,944,791)  0.74 
Exercised  (372,250)  0.26 
Granted  13,690,479   0.34 
        
Balance, December 31, 2018  44,463,729   0.58   44,463,729   0.58 
Expired/cancelled (1)  (8,707,811)  0.90   (8,707,811)  0.90 
Exercised  (281,250)  0.22   (281,250)  0.22 
Granted  17,785,670   0.27   17,785,670   0.27 
        
Balance, December 31, 2019  53,260,338  $0.43   53,260,338   0.43 
Expired/cancelled  (8,287,937)  1.02 
Exercised  (3,302,835)  0.24 
Granted  9,474,926   0.36 
        
Balance, December 31, 2020  51,144,492  $0.33 

 

(1)(1)2,277,186 cancelled options related to staff employed at DenseLight

Page 19

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

15.STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued)

 

During the year ended December 31, 2019,2020, the Company recorded stock-based compensation of $3,612,945 (2019 - $2,888,141, (20182018 - $3,602,879, 2017 - $2,958,358)$3,602,879) relating to stock options that vested during the year. The stock-based compensation applicable to employees of DenseLight in the amount of $(75,608) (2018nil (2019 - $419,238, 2017$(75,608), 2018 - 216,566)$419,238) has been allocated to discontinued operations (see note 23).

 

The stock options granted were valued using the Black-Scholes option pricing model using the following assumptions:

 

 2019 2018 2017 2020  2019 2018 
                
Weighted average exercise price  $0.27   $0.34   $0.24  $0.36  $0.27  $0.34 
Weighted average risk-free interest rate  1.57%   2.17%   1.87%   0.52% - 1.52%  1.57%  2.17%
Weighted average dividend yield  0%   0%   0%   0%  0%  0%
Weighted average volatility  95.48%   103.47%   102.73%   94.77%  95.48%  103.47%
Weighted average estimated life (in years)  10   10   10 
Weighted average estimated life  10 years   10 years   10 years 
Weighted average share price  $0.27   $0.34   $0.24  $0.36  $0.27  $0.34 
Share price on the various grant dates: $0.24-$0.28 $0.18-$0.40 $0.21-$0.32 $0.22 - $0.39  $0.24 - $0.28  $0.18 - $0.40 
Weighted average fair value  $0.24   $0.30   $0.22  $0.30  $0.24  $0.30 

 

The underlying expected volatility was determined by reference to the Company'sCompany’s historical share price movements, its dividend policy and dividend yield and past experience relating to the expected life of granted stock options.

 

Page 21

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

15.STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued)

The weighted average remaining contractual life and weighted average exercise price of options outstanding and of options exercisable as at December 31, 20192020 are as follows:

 

  Options Outstanding Options Exercisable 
       Historical  Weighted     Historical 
       Weighted  Average     Weighted 
       Average  Remaining     Average 
Exercise Number  Exercise  Contractual  Number  Exercise 
Range Outstanding  Price  Life (years)  Exercisable  Price 
$0.11-$0.20  693,750  $0.19   6.14   693,750  $0.19 
$0.21-$0.24  9,020,313  $0.22   7.63   6,887,501  $0.22 
$0.25-$0.29  10,888,259  $0.25   9.18   3,504,188  $0.25 
$0.30-$0.86  24,844,766  $0.35   8.38   9,542,718  $0.40 
$0.87-$1.64  7,813,250  $1.13   0.57   7,789,813  $1.13 
   53,260,338  $0.43   7.24   28,417,970  $0.53 

Contributed Surplus

The following table reflects the continuity of contributed surplus:

  Amount 
Balance, January 1, 2017 $29,062,874 
Stock-based compensation  3,174,924 
Fair value of stock options exercised  (134,831)
Balance, December 31, 2017  32,102,967 
Stock-based compensation  4,022,117 
Fair value of stock options exercised  (82,330)
Balance, December 31, 2018  36,042,754 
Stock-based compensation  2,812,533 
Fair value of stock options exercised  (55,950)
Balance, December 31, 2019 $38,799,337 

Page 20

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

Options Outstanding  Options Exercisable 
                 
      Historical  Weighted     Historical 
      Weighted  Average     Weighted 
      Average  Remaining     Average 
Exercise  Number  Exercise  Contractual  Number  Exercise 
Range  Outstanding  Price  Life (years)  Exercisable  Price 
                 
$0.11 - $0.20   496,750  $0.18   6.72   496,750  $0.18 
$0.21 - $0.24   9,226,250  $0.22   7.14   6,624,688  $0.22 
$0.25 - $0.29   10,270,238  $0.26   8.37   4,201,176  $0.26 
$0.30 - $0.86   31,026,254  $0.35   7.88   16,750,991  $0.36 
$0.87 - $1.64   125,000  $0.92   0.92   125,000  $0.92 
                       
     51,144,492  $0.31   7.82   28,198,605  $0.31 

 

16.INCOME (LOSS) PER SHARE

 

 2020  2019 2018 
 2019  2018 2017        
Numerator                   
Net loss from continuing operations $(11,434,632) $(8,422,117) $(7,908,851) $(18,169,070) $(11,434,632) $(8,422,117)
Net income (loss) from discontinued operations $5,481,757  $(7,900,662) $(4,888,946) $-  $5,481,757   (7,900,662)
            
Net loss $(5,952,875) $(16,322,779) $(12,797,797) $(18,169,070) $(5,952,875) $(16,322,779)
            
Denominator                        
Weighted average number of common shares outstanding  288,216,378   282,098,432   259,771,793   291,696,534   288,216,378   282,098,432 
Weighted average number of common shares outstanding - diluted  288,216,378   282,098,432   259,771,793   291,696,534   288,216,378   282,098,432 
Basic and diluted loss per share, continuing operations $(0.04) $(0.03) $(0.03)
Basic and diluted income (loss) per share, discontinued operations $0.02  $(0.03) $(0.02)
            
Basic and diluted loss per share, continuing            
operations $(0.06) $(0.04) $(0.03)
Basic and diluted income (loss) per share, discontinued            
operations $-  $0.02  $(0.03)
                        
Basic and diluted loss per share $(0.02) $(0.06) $(0.05) $(0.06) $(0.02) $(0.06)

 

The effect of common share purchase options, warrants, compensation warrants and shares to be issued on the net loss in 2020, 2019 2018 and 20172018 is not reflected as they are anti-dilutive.

 

17.COMMITMENTS AND CONTINGENCIES

 

The Company has operating leases on threefour facilities; head office located in Toronto, Canada, design and testing operations located in Allentown, Pennsylvania (formerly in San Jose, CaliforniaCalifornia) and operating facilities located in Singapore.Singapore and China. The Company'sCompany’s design and testing operations terminated a lease on January 31, 2020. A new lease was initiated on April 1, 2020 and expires on March 31, 2025. The lease on the Company'sCompany’s operating facilities in Singapore was initiated on November 1, 2019 and expires April 30, 2022. The lease on the Company’s operating facilities in China was initiated in November 19, 2020 and expires on November 18, 2023. As at December 31, 2019,2020, the Company'sCompany’s head office was on a month to month lease term.

Page 22

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

17.COMMITMENTS AND CONTINGENCIES (Continued)

 

Remaining annual lease payments to the lease expiration dates are as follows:

 

2020 $170,759 
2021 and beyond  494,732 
  $665,491 
2021 $238,002 
2022 and beyond  441,450 
     
  $679,452 

 

18.RELATED PARTY TRANSACTIONS

 

Compensation to key management personnel were as follows:

 

 2019  2018 2017  2020  2019 2018 
              
Salaries $1,251,277  $1,216,250  $932,133  $1,501,058  $1,251,277  $1,216,250 
Share-based payments (1)  2,135,579   2,449,683   2,110,773   2,144,930   2,135,579   2,449,683 
            
Total $3,386,856  $3,665,933  $3,042,906  $3,645,988  $3,386,856  $3,665,933 

 

(1)Share-based payments are the fair value of options granted to key management personnel and expensed during the various years as calculated using the Black-Scholes model.

(1) Share-based payments are the fair value of options granted to key management personnel and expensed during the various years as calculated using the Black-Scholes model.

 

All transactions with related parties have occurred in the normal course of operations and are measured at the exchange amounts, which are the amounts of consideration established and agreed to by the related parties.

Page 21

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

19.SEGMENT INFORMATION

 

The Company and its subsidiaries operate in a single segment; the design, manufacture and sale of semi-conductor products and services for commercial applications. The Company’s operating and reporting segment reflects the management reporting structure of the organization and the manner in which the chief operating decision maker regularly assesses information for decision making purposes, including the allocation of resources. A summary of the Company'sCompany’s operations is below:

 

OPEL, ODIS, POET Shenzhen and PTS

OPEL, ODIS, POET Shenzhen and PTS are the developers of the POET platform semiconductor process IP for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single die.

 

BB Photonics

BB Photonics develops photonic integrated components for the datacom and telecom markets utilizing embedded dielectric technology that enables the low-cost integration of active and passive devices into photonic integrated circuits.

 

On a consolidated basis, the Company operates geographically in Singapore, China (collectively “Asia”), the United States and Canada. Geographical information is as follows:

 

 2019 
         
20202020
As of December 31, Singapore US Canada Consolidated  Asia US Canada Consolidated 
Current assets $86,849  $22,523  $20,150,022  $20,259,394  $304,450  $69,874  $7,117,287  $7,491,611 
Property and equipment  3,055,906   87,154   -   3,143,060   2,982,496   203,258   -   3,185,754 
Patents and licenses  -   452,384   -   452,384   -   438,677   -   438,677 
Right of use asset  222,517   -   -   222,517   289,542   231,144   -   520,686 
Total Assets $3,365,272  $562,061  $20,150,022  $24,077,355  $3,576,488  $942,953  $7,117,287  $11,636,728 

 

Year Ended December 31, Singapore  US  Canada  Consolidate 
Selling, marketing and administration $217,416  $5,126,260  $1,353,711  $6,697,387 
Research and development  218,900   107,161   1,757,754   2,083,815 
Impairment of long lived assets  -   -   1,764,459   1,764,459 
Interest expense  4,705   -   815,206   819,911 
Amortization of debt issuance costs  -   -   372,340   372,340 
Other income including interest income  -   -   (10,540)  (10,540)
Income taxes  -   (292,740)  -   (292,740)
Net loss from continuing operations, net of taxes  (441,021)  (4,940,681)  (4,288,471)  (11,434,632)
Income from discontinued operations, net of taxes  5,481,757   -   -   5,481,757 
Net income (loss) $5,040,736  $(4,940,681) $(4,288,471) $(5,952,875)

  2018 
             
As of December 31, Singapore  US  Canada  Consolidated 
Current assets $4,283,008  $302,405  $2,302,851  $6,888,264 
Property and equipment  9,136,694   162,819   -   9,299,513 
Patents and licenses  18,464   448,250   -   466,714 
Goodwill and intangible assets  6,718,953   1,764,459   -   8,483,412 
Total Assets $20,157,119  $2,677,933  $2,302,851  $25,137,903 
Page 23

Page 22

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars) 

 

19.SEGMENT INFORMATION (Continued)

 

Year Ended December 31, Asia  US  Canada  Consolidated 
Selling, marketing and administration $1,182,054  $5,495,161  $1,460,783  $8,137,998 
Research and development  3,269,873   1,447,729   1,916,715   6,634,317 
Interest expense  20,181   24,474   893,248   937,903 
Credit loss on receivable from the sale of discontinued operation  -   -   2,500,000   2,500,000 
Other income, including interest  -   -   (41,148)  (41,148)
                 
Net loss $(4,472,108) $(6,967,364) $(6,729,598) $(18,169,070)

  2019 
As of December 31, Asia  US  Canada  Consolidated 
Current assets $86,849  $22,523  $20,150,022  $20,259,394 
Property and equipment  3,055,906   87,154   -   3,143,060 
Patents and licenses  -   452,384   -   452,384 
Right of use asset  222,517   -   -   222,517 
                 
Total Assets $3,365,272  $562,061  $20,150,022  $24,077,355 

The Year Ended December 31, Asia  US  Canada  Consolidated 
Selling, marketing and administration $217,416  $5,126,260  $1,353,711  $6,697,387 
Research and development  218,900   107,161   1,757,754   2,083,815 
Impairment of long lived assets  -   -   1,764,459   1,764,459 
Interest expense  4,705   -   815,206   819,911 
Amortization of debt issuance costs  -   -   372,340   372,340 
Other income, including interest  -   -   (10,540)  (10,540)
Income tax recovery  -   (292,740)  -   (292,740)
                 
Net loss from continuing operations  (441,021)  (4,940,681)  (6,052,930)  (11,434,632)
Income from discontinued operations, net of taxes  5,481,757   -   -   5,481,757 
                 
Net income (loss) $5,040,736  $(4,940,681) $(6,052,930) $(5,952,875)

  2018 
As of December 31, Asia  US  Canada  Consolidated 
Current assets $4,283,008  $302,405  $2,302,851  $6,888,264 
Property and equipment  9,136,694   162,819   -   9,299,513 
Patents and licenses  18,464   448,250   -   466,714 
Goodwill and intangible assets  6,718,953   1,764,459   -   8,483,412 
                 
Total Assets $20,157,119  $2,677,933  $2,302,851  $25,137,903 

Year Ended December 31, Singapore  US  Canada  Consolidated 
Selling, marketing and administration $-  $5,169,619  $1,004,256  $6,173,875 
Research and development  -   1,715,154   547,322   2,262,476 
Other income including interest  -   -   (14,234)  (14,234)
Net loss from continuing operations  -   (6,884,773)  (1,537,344)  (8,422,117)
Loss from discontinued operations, net of taxes  (7,900,662)  -   -   (7,900,662)
Net loss $(7,900,662) $(6,884,773) $(1,537,344) $(16,322,779)
Page 24

 

  2017 
             
As of December 31, Singapore  US  Canada  Consolidated 
Current assets $3,190,298  $4,621,318  $139,096  $7,950,712 
Property and equipment  8,018,900   259,270   -   8,278,170 
Patents and licenses  18,816   437,434   -   456,250 
Goodwill and intangible assets  6,756,181   1,764,459   -   8,520,640 
Total Assets $17,984,195  $7,082,481  $139,096  $25,205,772 

POET TECHNOLOGIES INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

The Year Ended December 31, Singapore  US  Canada  Consolidated 
Selling, marketing and administration $-  $4,837,859  $1,049,850  $5,887,709 
Research and development  -   1,719,734   319,687   2,039,421 
Other income including interest  -   -   (18,279)  (18,279)
Net loss from continuing operations  -   (6,557,593)  (1,351,258)  (7,908,851)
Loss from discontinued operations, net of taxes  (4,888,946)  -   -   (4,888,946)
Net loss $(4,888,946) $(6,557,593) $(1,351,258) $(12,797,797)

19.SEGMENT INFORMATION (Continued)

Year Ended December 31, Asia  US  Canada  Consolidated 
Selling, marketing and administration $-  $5,169,619  $1,004,256  $6,173,875 
Research and development  -   1,715,154   547,322   2,262,476 
Other income, including interest  -   -   (14,234)  (14,234)
                 
Net loss from continuing operations  -   (6,884,773)  (1,537,344)  (8,422,117)
Loss from discontinued operations, net of taxes  (7,900,662)  -   -   (7,900,662)
                 
Net loss $(7,900,662) $(6,884,773) $(1,537,344) $(16,322,779)

20.FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

 

The Company'sCompany’s financial instruments consist of cash and cash equivalents, accounts receivable, receivable from the sale of discontinued operations, convertible debentures, and accounts payable and accrued liabilities. Unless otherwise noted, it is management'smanagement’s opinion that the Company is not exposed to significant interest risk arising from these financial instruments. The Company estimates that the fair value of these instruments approximates fair value due to their short term nature.

 

The Company has classified financial assets and (liabilities) as follows at December 31:

 

  2019  2018  2017 
          
Fair value through profit or loss, measured at amortized cost:            
Cash and cash equivalents $1,428,129  $2,567,868  $4,974,478 
Accounts receivable, measured at amortized cost:            
Accounts receivable $-  $946,944  $493,925 
Receivable from the sale of discontinued operations $18,000,000   -  $- 
Other liabilities, measured at amortized cost:            
Accounts payable and accrued liabilities $(1,725,708) $(3,040,422) $(810,593)
Convertible debentures $(3,089,033) $-  $- 

Page 23

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

20.FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)
  2020  2019  2018 
          
Fair value through profit or loss, measured at amortized cost:            
Cash and cash equivalents $6,872,894  $1,428,129  $2,567,868 
Accounts receivable, measured at amortized cost:            
Accounts receivable $-  $-  $946,944 
Receivable from the sale of discontinued operations $-  $18,000,000  $- 
Other liabilities, measured at amortized cost:            
Accounts payable and accrued liabilities $(1,730,361) $(1,725,708) $(3,040,422)
Convertible debentures $(3,341,246) $(3,089,033) $- 
Covid-19 government support loans $(218,151) $-  $- 

 

Credit Risk

The Company is exposed to credit risk associated with its accounts receivable. The Company has accounts receivable from both governmental and non-governmental agencies. Credit risk is minimized substantially by ensuring the credit worthiness of the entities with which it carries on business. Credit terms are provided on a case by case basis. The Company has not experienced any significant instances of non-payment from its customers.

 

The Company'sCompany’s accounts receivable ageing at December 31 was as follows:

 

  2020  2019  2018 
          
Current $-  $-  $892,343 
31 - 60 days  -   -   34,331 
61 - 90 days  -   -   60,885 
> 90 days  -   -   - 
Expected credit losses (1)  -   -   (40,615)
  $-  $-  $946,944 

  2019  2018  2017 
          
Current $-  $892,343  $330,731 
31 - 60 days  -   34,331   56,094 
61 - 90 days  -   60,885   - 
> 90 days  -   -   107,100 
Expected credit losses (1)  -   (40,615)  - 
  $-  $946,944  $493,925 
Page 25

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

(1)20.The Company applies IFRS 9 simplified approach to measuring expected credit losses using a lifetime expected credit loss allowance for trade receivables.FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

 

(1) The Company applies IFRS 9 simplified approach to measuring expected credit losses using a lifetime expected credit loss allowance for trade receivables.

Exchange Rate Risk

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk with the Canadian and Singapore dollar. A 10% change in the Canadian and Singapore dollar would increase or decrease other comprehensive loss by $290,950.$229,088.

 

Liquidity Risk

The Company currently does not maintain credit facilities. The Company'sCompany’s existing cash and cash resources are considered sufficient to fund operating and investing activities beyond one year from the issuance of these consolidated financial statements. The Company may, however, need to seek additional financing in the future.

 

21.CAPITAL MANAGEMENT

 

In the management of capital, the Company includes shareholders'shareholders’ equity (excluding accumulated other comprehensive loss and deficit) and cash. The components of capital on December 31, 20192020 were:

 

Cash and cash equivalents and receivable from the sale of discontinued operations $19,428,129 
Shareholders' equity $160,096,378 
Cash and cash equivalents $6,872,894 
Shareholders’ equity $165,116,062 

 

The Company'sCompany’s objective in managing capital is to ensure that financial flexibility is present to increase shareholder value through growth and responding to changes in economic and/or market conditions; to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business and to safeguard the Company’s ability to obtain financing should the need arise.

 

In maintaining its capital, the Company has a strict investment policy which includes investing its surplus capital only in highly liquid, highly rated financial instruments.

 

The Company reviews its capital management approach on an ongoing basis.

Page 2426

POET TECHNOLOGIES INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

22.EXPENSES

 

Research and development costs can be analysed as follows:

 

 2020  2019 2018 
 2019  2018 2017        
Wages and benefits $874,673  $822,258  $703,759  $1,586,900  $874,673  $822,258 
Subcontract fees  834,598   888,566   1,044,936   3,802,919   834,598   888,566 
Stock-based compensation  237,311   395,468   218,896   567,859   237,311   395,468 
Supplies  137,233   156,184   71,830   676,639   137,233   156,184 
 $2,083,815  $2,262,476  $2,039,421             
 $6,634,317  $2,083,815  $2,262,476 

 

Selling, marketing and administration costs can be analysed as follows:

 

Stock-based compensation $2,650,830  $3,207,411  $2,739,462  $3,045,086  $2,650,830  $3,207,411 
Wages and benefits  1,619,719   1,433,286   1,443,656   2,233,449   1,619,719   1,433,286 
Professional fees  1,120,805   735,604   597,865   800,551   1,120,805   735,604 
General expenses  813,951   392,901   598,600   1,188,712   813,951   392,901 
Depreciation and amortization  243,674   153,244   182,252   813,103   243,674   153,244 
Management and consulting fees  154,357   155,169   229,577   -   154,357   155,169 
Rent and facility costs  94,051   96,260   96,297   57,097   94,051   96,260 
 $6,697,387  $6,173,875  $5,887,709             
 $8,137,998  $6,697,387  $6,173,875 

 

23.DISCONTINUED OPERATIONS

On February 3, 2019, management committed to a plan to sell its subsidiary, DenseLight. The decision was taken in line with a strategy to focus on the Company's opportunities related to its Optical Interposer. Management determined that the divestiture of DenseLight would immediately reduce the Company's operating losses and cash burn, while allowing the Company to pursue a "fab-light" strategy with a less capital-intensive business model that is focused on growing the Optical Interposer business through targeted investments in the design, development and sale of vertical market solutions. Consequently, after the plan and prior to the actual sale, all saleable assets and liabilities relating to DenseLight were classified as "Non-current assets held for sale" or "disposal group liabilities". An impairment assessment was done on the assets that were held for sale. It was determined that no assets were impaired either on the date management committed to a plan of sale or on November 8, 2019 when the sale was consummated.

 

On November 8, 2019, the Company sold 100% of the issued and outstanding shares of DenseLight for $26,000,000. The Company received $8,000,000 upon the consummation of the sale. The Company expects to receive the remaining $18,000,000 over three tranches, with $4,750,000 received on February 14, 2020 and $8,250,000 received on March 30, 2020. The remaining $5,000,000 is expected to be received on or before May 31, 2020. Shares were placed into escrow in the name of the Buyer, to be released to the Buyer upon receipt of the remaining payments. The Buyer assumed control of DenseLight on November 8, 2019 and will beis responsible for all operations of DenseLight thence-forth.DenseLight. Upon closing, the Company recognized a gain on the sale of $8,707,280. The sale proceeds were to be paid over multiple tranches. The first tranche payment was recived on November 8, 2019 in the amount of $8,000,000. The second tranche payment was payment was made in two installments, with first paid on February 14, 2020 in the amount of $4,750,000 and the second on March 30, 2020 in the amount of $8,250,000.

The Company received payments of $1,500,000 and $1,000,000 on June 29, 2020 and July 3, 2020 respectively. After taking into consideration the length of time it had taken the Buyer to make the foregoing payments and the Company’s expectations regarding the likelihood of receiving an additional payment, the Company determined that it was in its best interest to accept partial payments as final payment on the Company’s receivable. As a result, the Company recognized a credit loss of $2,500,000 during the year ended December 31, 2020 (nil - 2019 and nil - 2018).

The Company received an additional $2,000,000, in excess of the sale proceeds with the most recently paid two tranches which was immediately paid to Oak Capital on behalf of the Buyer for due diligence, legal and other expenses.

 

Revenue and expenses, and gains and losses relating to the discontinued operations have beenwere removed from the results of continuing operations and are shown as a single line item on the face of the consolidated statementstatements of comprehensive loss.operations and deficit. The operating results of the discontinued operations can be analysed as follows:

 

Page 2527

POET TECHNOLOGIES INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

23.DISCONTINUED OPERATION (Continued)

 

Results of discontinued operations

 

 For the Period From  For the Year Ended For the Period From For the year ended 
 January 1 to November 8,  December 31, January 1 to November 8, December 31, 
 2019 2018  2017  2019 2018 
            
Revenue $4,426,355  $3,888,185  $2,794,044  $4,426,355  $3,888,185 
                    
Cost of revenue  1,201,373   1,475,969   1,342,691   1,201,373   1,475,969 
        
Gross margin  3,224,982   2,412,216   1,451,353   3,224,982   2,412,216 
                    
Operating expenses                    
Research and development  5,677,222   6,430,328   3,403,452   5,677,222   6,430,328 
Selling, marketing and administration  1,950,526   5,515,329   4,983,032   1,950,526   5,515,329 
Interest expense  74,494   -   -   74,494   - 
Impairment loss  -   156,717   -   -   156,717 
Other income  (1,251,737)  (1,491,556)  (1,748,245)  (1,251,737)  (1,491,556)
        
Operating expenses  6,450,505   10,610,818   6,638,239   6,450,505   10,610,818 
        
Loss from discontinued operations  (3,225,523)  (8,198,602)  (5,186,886)  (3,225,523)  (8,198,602)
Gain on sale of discontinued operations, net of taxes  8,707,280   -   -   8,707,280   - 
Income tax recovery  -   (297,940)  (297,940)  -   (297,940)
        
Net income (loss), net of taxes $5,481,757  $(7,900,662) $(4,888,946) $5,481,757  $(7,900,662)

 

Disaggregated Revenues

The Company disaggregates revenue by timing of revenue recognition, that is, at a point in time and revenue over time. Disaggregated revenue is as follows:

 

  For the Period From  For the Year Ended 
  January 1 to November 8,  December 31, 
  2019  2018 
       
Non-contract revenue (at a point in time)(1)(3) $2,092,426  $3,261,518 
Contract revenue (revenue over time)(2)(3)  2,221,429   441,667 
Contract revenue (at a point in time)(2)(3)  112,500   185,000 
         
  $4,426,355  $3,888,185 

(1) Revenue from the sale of products.

(2) Revenue from long-term projects or non-recurring engineering (NRE).

(3) All revenue was generated from the Singapore geographic region.

Revenue Contract Balances

  Contract 
  Receivables  Liabilities 
       
Balance, January 1, 2018 $40,000  $- 
Revenues recognized  626,667   (626,667)
Changes due to payment, fulfillment of performance obligations or other  (606,667)  626,667 

  For the Period From  For the Year Ended
  January 1 to November 8,  December 31,
  2019  2018  2017 
Non-contract revenue (at a point in time)(1)(3) $2,092,426  $3,261,518  $2,714,044 
Contract revenue (revenue over time)(2)(3)  2,221,429   441,667   80,000 
Contract revenue (at a point in time)(2)(3)  112,500   185,000   - 
  $4,426,355  $3,888,185  $2,794,044 
Page 28

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

(1)23.Revenue from the sale of products.
(2)Revenue from long-term projects or non-recurring engineering (NRE).
(3)All revenue was generated from the Singapore geographic region.DISCONTINUED OPERATION (Continued)

 

Revenue Contract Balances

  Contract 
  Receivables  Liabilities 
Opening balance, January 1, 2017 $-  $(20,000)
Revenues recognized  80,000   (60,000)
Changes due to payment, fulfillment of performance obligations or other  (40,000)  80,000 
Balance, December 31, 2017 $40,000  $- 
Revenues recognized  626,667   (626,667)
Changes due to payment, fulfillment of performance obligations or other  (606,667)  626,667 

Page 26

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

23.DISCONTINUED OPERATION (Continued)

  Contract 
  Receivables  Liabilities 
       
Balance, December 31, 2018  60,000   - 
Revenues recognized  2,333,929   (2,333,929)
Changes due to payment, fulfillment of performance obligations or other  (1,293,929)  2,333,929 
         
Balance, November 8, 2019 $1,100,000  $- 

 

Research and development costs included in discontinued operations can be analysed as follows:

 

 For the Period From For the Year Ended 
 For the Period From  For the Year Ended  January 1 to November 8, December 31, 
 January 1 to November 8,  December 31,  2019 2018 
 2019  2018 2017      
Wages and benefits $3,565,076  $3,818,980  $2,135,329  $3,565,076  $3,818,980 
Supplies  1,412,572   2,070,495   1,118,011   1,412,572   2,070,495 
Subcontract fees  728,457   400,000   -   728,457   400,000 
Stock-based compensation  (28,883)  140,853   150,112   (28,883)  140,853 
 $5,677,222  $6,430,328  $3,403,452         
 $5,677,222  $6,430,328 

 

Selling, marketing and administration costs included in discontinued operations can be analysed as follows:

 

Wages and benefits $887,860  $1,034,715  $1,131,322  $887,860  $1,034,715 
Rent and facility costs  604,442   975,467   1,079,635   604,442   975,467 
General expenses  458,465   785,635   585,637   458,465   785,635 
Stock-based compensation  (46,725)  278,385   66,454   (46,725)  278,385 
Professional fees  46,484   31,747   27,076   46,484   31,747 
Depreciation and amortization  -   2,409,380   2,092,908   -   2,409,380 
 $1,950,526  $5,515,329  $4,983,032         
 $1,950,526  $5,515,329 

 

Cash flows from (used in) discontinued operations

 

  2019  2018  2017 
          
CASH (USED IN) PROVIDED BY:            
             
OPERATING ACTIVITIES            
             
Net loss $5,481,757  $(7,900,662) $(4,888,946)
Adjustments for:            
Depreciation of property and equipment  -   2,372,152   2,055,680 
Gain on sale of discontinued operations  (8,707,280)  -   - 
Amortization of intangibles  -   37,228   37,228 
Interest expense  74,494   -   - 
Impairment loss  -   156,717   - 
Stock-based compensation  (75,608)  419,238   216,566 
Income tax recovery  -   (297,940)  (297,940)
Deferred rent  (1,825)  (21,992)  - 
Expected credit loss  -   40,615   - 
             
   (3,228,462)  (5,194,644)  (2,877,412)

  2019  2018 
       
CASH (USED IN) PROVIDED BY:        
OPERATING ACTIVITIES        
Net income (loss) $5,481,757  $(7,900,662)
Adjustments for:        
Depreciation of property and equipment  -   2,372,152 
Gain on sale of discontinued operations  (8,707,280)  - 
Amortization of intangibles  -   37,228 
Interest expense  74,494   - 
Impairment loss  -   156,717 
Stock-based compensation  (75,608)  419,238 
Income tax recovery  -   (297,940)
Deferred rent  (1,825)  (21,992)
Expected credit loss  -   40,615 
         
   (3,228,462)  (5,194,644)

 

Page 2729

POET TECHNOLOGIES INC.

 

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

23.DISCONTINUED OPERATION (Continued)

 

23.DISCONTINUED OPERATION (Continued)

Net change in non-cash working capital accounts:               
Accounts receivable  584,902   (508,093)  (171,257)  584,902   (508,093)
Prepaid and other current assets  497,259   (949,401)  (927,685)  497,259   (949,401)
Inventory  (334,425)  78,733   663,992   (334,425)  78,733 
Accounts payable and accrued liabilities  (470,378)  1,782,612   (616,289)  (470,378)  1,782,612 
Cash flows from operating activities  (2,951,104)  (4,790,793)  (3,928,651)
        
Cash flows provided by (used in) operating activities  (2,951,104)  (4,790,793)
                    
INVESTING ACTIVITIES                    
Proceeds from the sale of discontinued operations, net of cash given up (1)  7,519,126   -   - 
Proceeds from the sale of discontinued operations, net of cash        
given up (1)  7,519,126   - 
Purchase of property and equipment (Note 7)  (1,599,272)  (3,467,992)  (912,774)  (1,599,272)  (3,467,992)
Purchase of patents and licenses (Note 8)  (11,231)  -   (18,815)  (11,231)  - 
        
Cash flows from investing activities  5,908,623  (3,467,992)  (931,589)  5,908,623   (3,467,992)
        
FINANCING ACTIVITIES                    
Payment of lease liability (Note 9)  (258,460)  -   -   (258,460)  - 
        
Cash flows from financing activities  (258,460)  -   -   (258,460)  - 
        
EFFECT OF EXCHANGE RATE CHANGES ON CASH  (14,010)  26,490   (65,338)  (14,010)  26,490 
        
NET CHANGE IN CASH $2,685,049 $(8,232,295) $(4,925,578) $2,685,049  $(8,232,295)

 

Effect of Disposal on the Financial Position of the Group

 

Accounts receivable $396,037 
Prepaid and other current assets  2,303,014 
Inventory  774,404 
Property and equipment  8,424,638 
Right of use asset  880,577 
Patents  29,696 
Goodwill and customer list  6,718,953 
Trade payables  (1,312,053)
Lease Liability  (695,733)
Deferred tax liability  (707,687)
     
Net assets disposed $16,811,846 
     
(1) Consideration received in cash $8,000,000 
(1) Cash given up  (480,874)
Consideration receivable  18,000,000 
     
Net inflows $25,519,126 

Page 28

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

24.Page 30

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

24.GOODWILL AND DEFERRED TAX LIABILITY

 

On May 11 and June 22, 2016 the Company acquired DenseLight and BB photonics for $10,500,000 and $1,550,000 respectively. The all stock purchases were accomplished with the issuance of 13,611,150 common shares and 1,996,090 common shares of the Company at a price of $0.7714 and $0.777 per share, respectively. The purchase price in both acquisitions exceeded the net assets acquired which resulted in the difference being accounted for as goodwill on the consolidated statements of financial position.

 

The continuity of goodwill is as follows:

 

 DenseLight BB Photonics Total  DenseLight BB Photonics Total 
Balance, December 31, 2017 and 2018 $6,630,544  $1,050,459  $7,681,003 
       
Balance January 1, 2018 and December 31, 2018 $6,630,544  $1,050,459  $7,681,003 
Impairment  -   (1,050,459)  (1,050,459)  -   (1,050,459)  (1,050,459)
Disposed on the sale of DenseLight  (6,630,544)  -   (6,630,544)  (6,630,544)  -   (6,630,544)
Balance, December 31, 2019 $-  $-  $- 
            
Balance, December 31, 2019 and 2020 $-  $-  $- 

 

Deferred tax liability was created on the date of purchase for both DenseLight and BB Photonics. The following is a continuity of deferred tax liability.

 

 DenseLight BB Photonics Total  DenseLight BB Photonics Total 
Balance, January 1, 2017 $1,303,567  $292,740  $1,596,307 
       
Balance, January 1, 2018 $1,005,627  $292,740  $1,298,367 
Tax effect of amortization  (297,940)  -   (297,940)  (297,940)  -   (297,940)
Balance, December 31, 2017  1,005,627   292,740   1,298,367 
Tax effect of amortization  (297,940)  -   (297,940)
            
Balance, December 31, 2018  707,687   292,740   1,000,427   707,687   292,740   1,000,427 
Tax effect of Impairment  -   (292,740)  (292,740)  -   (292,740)  (292,740)
Disposed on the sale of DenseLight  (707,687)  -   (707,687)  (707,687)  -   (707,687)
Balance, December 31, 2019 $-  $-  $- 
            
Balance, December 31, 2019 and 2020 $-  $-  $- 

 

Included in the sale of DenseLight on November 8, 2019 was $6,630,544 of goodwill and $707,687 of deferred liability.

 

25.INCOME TAXES

 

The following table reconciles the expected income tax recovery at the Canadian statutory income tax rate of 26.5% for 2019 (20182020 (2019 - 26.5%, 20172018 - 26.5%) to the amounts recognized in operations.

 

For the Year Ended December 31, 2020  2019  2018 
          
Net loss, continuing operations $(18,169,070) $(11,727,372) $(8,422,117)
Net income (loss), discontinued operations  -   5,481,757   (8,198,602)
             
Net loss before taxes $(18,169,070) $(6,245,615) $(16,620,719)
             
Expected current income tax recovery  4,814,804   1,655,088   4,404,491 
Deferred tax recovery (2)  -   292,740   297,940 
             
   4,814,804   1,947,828   4,702,431 

For the Year Ended December 31, 2019  2018  2017 
          
Net loss, continuing operations $(11,727,372) $(8,422,117) $(7,908,851)
Net income (loss), discontinued operations  5,481,757   (8,198,602)  (5,186,886)
Net loss before taxes $(6,245,615) $(16,620,719) $(13,095,737)
             
Expected current income tax recovery  1,655,088   4,404,491   3,470,370 
Deferred tax recovery (2)  292,740   297,940   297,940 
   1,947,828   4,702,431   3,768,310 
Page 31

Page 29

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

25.INCOME TAXES (Continued)

 

For the Year Ended December 31, 2020  2019  2018 
          
Adjustments to income tax recovery:            
             
Amounts not deductible for tax purposes $(957,400) $(1,212,900) $(1,065,900)
Other non-deductible items  (137,000)  (173,000)  (509,900)
Other deductible items  115,000   216,000   77,000 
Non-taxable gain  -   2,307,000   - 
Foreign tax differential  (221,000)  591,000   (592,000)
Non-recognizable permanent capital loss  -   (1,175,000)  - 
Unusable foreign tax recoveries (1)  -   (7,040,081)  - 
Unrecognized tax recovered (losses)  (3,614,404)  4,831,893   (2,313,691)
             
Income tax recovery recognized (2) $-  $292,740  $297,940 

 

25.INCOME TAXES (Continued)

(1) Deferred tax assets applicable to DenseLight and no longer available to the Company.

 

For the Year Ended December 31, 2019  2018  2017 
          
Adjustments to income tax recovery:            
             
Amounts not deductible for tax purposes $(1,212,900) $(1,065,900) $(841,000)
Other non-deductible items  (173,000)  (509,900)  (463,000)
Deductible share and debt issuance costs  216,000   77,000   94,000 
Non-taxable gain  2,307,000   -   - 
Impact of US statutory income tax rate change (1)  -   -   (9,472,000)
Foreign tax differential  591,000   (592,000)  (69,000)
Non-recognizable permanent capital loss  (1,175,000)  -   - 
Unusable foreign tax recoveries (3)  (7,040,081)  -   - 
Unrecognized tax recovered (losses)  4,831,893   (2,313,691)  7,280,630 
Income tax recovery recognized (2) $292,740  $297,940  $297,940 

(2) Deferred tax recovery and income tax recovery recognized for 2018 and 2017 are included Income (loss) from discontinued operations, net of taxes on the consolidated statements of operations and deficit.

(1)Due to the reduction of US corporate tax rates from 35% to 21%, the Company will not be able to apply $9,472,000 against any future US taxes payable.

(2)Deferred tax recovery and income tax recovery recognized for 2018 and 2017 are included Income (loss) from discontinued operations, net of taxes on the consolidated statements of operations and deficit.

(3)Deferred tax assets applicable to DenseLight and no longer available to the Company.

 

The following table reflects future income tax assets at December 31:

 

 2020  2019 2018 
 2019  2018 2017        
Resource assets $1,024,271  $1,024,271  $1,024,271  $1,024,271  $1,024,271  $1,024,271 
Gross unamortized share issue costs  385,000   669,000   705,351   325,600   385,000   669,000 
Canadian non-capital losses  16,545,000   12,431,000   11,100,672   22,969,000   16,545,000   12,431,000 
Canadian capital losses  4,432,500   -   -   4,432,532   4,432,500   - 
US non-capital losses  75,060,000   71,594,000   67,654,438   78,829,000   75,060,000   71,594,000 
Singapore non-capital losses  378,000   46,894,000   43,671,200   3,753,000   378,000   46,894,000 
  97,824,771   132,612,271   124,155,932             
  111,333,403   97,824,771   132,612,271 
Unrecognized deferred tax assets  (97,824,771)  (132,612,271)  (124,155,932)  (111,333,403)  (97,824,771)  (132,612,271)
            
Deferred income tax assets recognized $-  $-  $-  $-  $-  $- 

 

In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carry forward related to the BB Photonics acquisition in 2016 of approximately $928,000 could be subject to annual limitation since there was greater than 50% ownership change.

26.COVID-19 GOVERNMENT SUPPORT LOANS

In March 2020, the United States Congress passed the Paycheck Protection Program (“PPP”), authorizing loans to small businesses for use in paying employees that they continue to employ throughout the COVID-19 pandemic and for rent, utilities and interest on mortgages. Loans obtained through the PPP are eligible to be forgiven as long as the proceeds are used for qualifying purposes and certain other conditions are met. On May 3, 2020, the Company received a loan in the amount of $186,747 through the PPP. Management expects that the entire loan will be used for payroll, utilities and interest; therefore, management anticipates that the loan will be substantially forgiven. To the extent it is not forgiven, the Company would be required to repay that portion at an interest rate of 1% over a period of two years, beginning July 2021 with a final installment in May 2022. The Company may prepay the PPP loan at any time prior to maturity with no penalty.

 

26.SUBSEQUENT EVENTSPage 32

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

26.COVID-19 GOVERNMENT SUPPORT LOANS (Continued)

 

On February 14,April 9, 2020, and March 30,the Canadian government launched the Canada Emergency Business Account (“CEBA”) which is intended to support businesses during COVID-19 by providing interest free financing of up to $31,404 (CA$40,000) until December 31, 2022. If 75% of the loan is repaid by December 31, 2022, the loan recipient will be eligible for a loan forgiveness of the remaining 25% of the amount loaned. On April 15, 2020, the Company collected $4,750,000received a loan in the amount of $31,404 through the CEBA. If the loan has not been repaid by December 31, 2022, the outstanding amount will be automatically extended for an additional three years at 5% interest per annum payable monthly and $8,250,000 respectivelymaturing on December 31, 2025. The Company expects to repay 75% of the amount borrowed prior to December 31, 2022.

27.FORMATION OF JOINT VENTURE

On October 22, 2020, the Company signed a Joint Venture Agreement (“JVA”) with Sanan IC to manufacture cost-effective, high-performance optical engines based on POET’s proprietary CMOS compatible Optical Interposer platform technology. In conjunction with the signing of the JVA, Sanan IC and the Company formed a joint venture company, Super Photonics Xiamen Co., Ltd. (“JVC”). The JVC will assemble, test, package and sell optical engines, a primary component of optical transceivers that transmit data between switches and severs in data centers and between data centers and metro areas.

28.SUBSEQUENT EVENTS

On February 11, 2021, the Company completed a brokered private placement offering of 17,647,200 units at a price of $0.67 (CAD$0.85) per unit for gross proceeds of $11,811,118 (CAD$15,000,120). Each unit consists of one common share and one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $0.90 (CAD$1.15) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company’s average stock price exceeds $1.81 (CAD$2.30) for a cumulative $13,000,000 representing two tranchesperiod of an agreed three tranche payment plan for10 consecutive trading days. The broker was paid a cash commission of $708,667 (CAD$900,007) equating to 6% of the outstanding balance due from DL Shanghaigross proceeds and received 1,058,832 broker warrants. Each broker warrant is exercisable into one common share of the Company at a price of $0.67 (CAD$0.85) per broker warrant until February 11, 2023.

In addition to funds received from the salebrokered private placement, subsequent to December 31, 2020 the Company received $8,441,240 (CAD$10,714,953) from the exercise of DenseLight.stock options and warrants. The escrow agent transferred additionalCompany also improved its liquidity by $1,709,526 (CAD$2,170,000) through the conversion of convertible debentures into common shares from escrow to the Buyer. The Buyer now directly holds a cumulative 81% of the shares of DenseLight. The Company collected an additional $2,000,000, in excess of the sale proceeds, which was immediately paid to Oak Capital on behalf of the DL Shanghai for due diligence, legal and other expenses.

Company.

 

Page 33

 

Page 30